{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "tKF4tEGbLdnp"
      },
      "source": [
        "# **1 Data Cleaning and Preprocessing**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "BonhBIbnAEeD"
      },
      "outputs": [],
      "source": [
        "import pandas as pd\n",
        "import re\n",
        "from dateutil import parser"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 2,
      "metadata": {
        "id": "teHTP_mFDuHw",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "7b937718-34f4-408e-ce82-9b7108a37e20"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Mounted at /content/drive\n"
          ]
        }
      ],
      "source": [
        "from google.colab import drive\n",
        "drive.mount('/content/drive')"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "Sqpz9uMiAUO9"
      },
      "outputs": [],
      "source": [
        "try:\n",
        "  df=pd.read_pickle(\"/content/drive/MyDrive/Earnings call prediction/motley-fool-data.pkl\")\n",
        "except Exception as e:\n",
        "  print(f\"Error : {e}\")\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "hh41-z_vFJGN"
      },
      "outputs": [],
      "source": [
        "df.columns"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "DRu3f7rmGvo8"
      },
      "outputs": [],
      "source": [
        "print(f\"Data shape: {df.shape}\")\n",
        "df.head(5)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "CU9xOA_rG008"
      },
      "outputs": [],
      "source": [
        "def parse_date(date_str):\n",
        "  try:\n",
        "    clean_str=re.sub(r\"\\sE[DS]?T\",\"\",str(date_str))\n",
        "    return parser.parse(clean_str)\n",
        "  except:\n",
        "    return None\n",
        "df[\"Timestamp\"]=df[\"date\"].apply(parse_date)\n",
        "df.head(10)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "q5z63aRaIRE4"
      },
      "outputs": [],
      "source": [
        "df=df.dropna(subset=[\"Timestamp\"])\n",
        "df.shape"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "3saAIqfnIf2O"
      },
      "outputs": [],
      "source": [
        "df[\"Date_only\"]=df[\"Timestamp\"].dt.normalize()\n",
        "df.head(5)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "9I_YLNvEIyiB"
      },
      "outputs": [],
      "source": [
        "def clean_transcript(text):\n",
        "  if not isinstance(text,str):\n",
        "    return \"\"\n",
        "  text = re.sub(r'(Prepared Remarks:|Questions and Answers:)', '', text, flags=re.IGNORECASE)   #headers-Prepared remarks, Q&A\n",
        "  text = re.sub(r'Operator\\n.*?\\n', '', text, flags=re.IGNORECASE)   #operator word\n",
        "  text = re.sub(r'\\s+', ' ', text).strip()  #extra whitespace\n",
        "  return text\n",
        "df[\"Clean_Text\"]=df['transcript'].apply(clean_transcript)\n",
        "df[\"word_count\"]=df[\"Clean_Text\"].apply(lambda x: len(str(x).split()))\n",
        "df=df[df[\"word_count\"]>100]      #keeping text word count >100, deleting short or cancelled calls\n",
        "output_path=\"/content/drive/MyDrive/Earnings call prediction/cleaned_transcripts.pkl\"\n",
        "df.to_pickle(output_path)\n",
        "print(df.shape)\n",
        "df.head(5)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "LFUiIBdcNCXQ"
      },
      "source": [
        "# **2 Stock Price Reaction**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "NpU16VIlNpcj"
      },
      "outputs": [],
      "source": [
        "!pip install yfinance"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "ik9M46w5NAmD"
      },
      "outputs": [],
      "source": [
        "import yfinance as yf\n",
        "from datetime import timedelta\n",
        "import time\n",
        "import pandas as pd"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "mv3giUuqgFuF"
      },
      "outputs": [],
      "source": [
        "df=pd.read_pickle(\"/content/drive/MyDrive/Earnings call prediction/cleaned_transcripts.pkl\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "e-rNu-aBSSOK"
      },
      "outputs": [],
      "source": [
        "earliest_date = df['Date_only'].min()\n",
        "print(f\"Earliest Transcript Date found: {earliest_date}\")\n",
        "start_date_dynamic=(earliest_date-pd.Timedelta(days=30)).strftime(\"%Y-%m-%d\")\n",
        "print(f\"Fetching stock history from: {start_date_dynamic}\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "R9aBoDk8pyWv"
      },
      "outputs": [],
      "source": [
        "def clean_ticker(ticker_str):\n",
        "  t=str(ticker_str).upper().strip()\n",
        "  if \":\" in t:    #if ticker is NASDAQ:AAPL\n",
        "    t=t.split(\":\")[1].strip()\n",
        "  t=t.replace(\"$\",\"\")\n",
        "  return t\n",
        "df[\"ticker_clean\"]=df['ticker'].apply(clean_ticker)\n",
        "print(f\"unique tickers: {df[\"ticker_clean\"].unique().tolist()}\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "Fw9ZdtZDgjGQ"
      },
      "outputs": [],
      "source": [
        "# This uses 'regex=False' to search for the literal '$' character\n",
        "print(f\"Number of rows in 'ticker_clean' still containing '$': {df['ticker_clean'].str.contains('$', regex=False).sum()}\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "6pSH-mDVLZ69"
      },
      "outputs": [],
      "source": [
        "price_data={}\n",
        "def get_price_reaction(row):\n",
        "  ticker=row[\"ticker_clean\"]\n",
        "  call_date=row[\"Date_only\"]\n",
        "  if not ticker or not isinstance(ticker, str): return None\n",
        "  if ticker not in price_data:\n",
        "    try:\n",
        "      stock=yf.Ticker(ticker)\n",
        "      hist=stock.history(start=start_date_dynamic,end=None)\n",
        "      if hist.empty:\n",
        "        price_data[ticker] = None\n",
        "        return None\n",
        "      hist.index=hist.index.tz_localize(None)\n",
        "      price_data[ticker]=hist\n",
        "    except Exception as e:\n",
        "      print(f\"Error on: {ticker} Error:{e}\")\n",
        "      price_data[ticker]=None\n",
        "      return None\n",
        "  hist=price_data[ticker]\n",
        "  if hist is None or hist.empty:\n",
        "    return None\n",
        "  try:\n",
        "    if call_date<hist.index.min() or call_date>hist.index.max():\n",
        "      return None\n",
        "    idx=hist.index.get_indexer([call_date],method=\"nearest\")[0]\n",
        "    if idx+1>=len(hist):\n",
        "      return None\n",
        "    day_0=hist.iloc[idx]\n",
        "    day_1=hist.iloc[idx+1]\n",
        "    price_change=(day_1[\"Close\"]-day_0[\"Open\"])/day_0[\"Open\"]\n",
        "    return price_change\n",
        "  except Exception:\n",
        "    return None\n",
        "\n",
        "print(f\"Fetching data\")\n",
        "df[\"Price_change\"]=df.apply(get_price_reaction,axis=1)\n",
        "df.head(5)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "2bde119b"
      },
      "outputs": [],
      "source": [
        "num_failed_fetches = df['Price_change'].isnull().sum()\n",
        "print(f\"Number of rows where Price_change could not be fetched: {num_failed_fetches}\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "b9f02dba"
      },
      "outputs": [],
      "source": [
        "df_cleaned = df.dropna(subset=['Price_change']).copy()\n",
        "print(f\"New DataFrame shape after dropping rows: {df_cleaned.shape}\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "ACqmM85FXOoQ"
      },
      "outputs": [],
      "source": [
        "df.head(5)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "mMhRZ6YSj7ZB"
      },
      "outputs": [],
      "source": [
        "original_df_path=\"/content/drive/MyDrive/Earnings call prediction/original_stock_price_reaction.csv\"\n",
        "final_df_path=\"/content/drive/MyDrive/Earnings call prediction/cleaned_stock_price_reaction.csv\"   #for model training\n",
        "df.to_csv(original_df_path,index=False)\n",
        "df_cleaned.to_csv(final_df_path,index=False)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "zuS6wSXGmeEO"
      },
      "source": [
        "# **3 Exploratory Data Analysis**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "nzQlDQ3MmRUJ"
      },
      "outputs": [],
      "source": [
        "import pandas as pd\n",
        "import numpy as np"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "IEAO02orm_er"
      },
      "outputs": [],
      "source": [
        "df_analysis=pd.read_csv(\"/content/drive/MyDrive/Earnings call prediction/cleaned_stock_price_reaction.csv\")\n",
        "df_analysis.head(5)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "8ioyN99unPEw"
      },
      "outputs": [],
      "source": [
        "print(df_analysis.shape)\n",
        "df_analysis.columns"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "t0EntZ3Hnae7"
      },
      "outputs": [],
      "source": [
        "df_analysis['Price_change'].describe()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "JxAudB0xn6Rb"
      },
      "outputs": [],
      "source": [
        "extreme_gain_count=df_analysis[df_analysis[\"Price_change\"]>0.1].shape[0]\n",
        "extreme_loss_count=df_analysis[df_analysis[\"Price_change\"]<-0.1].shape[0]\n",
        "print(f\"No. of Earning calls resulting extreme gain : {extreme_gain_count}\")\n",
        "print(f\"No. of Earning calls resulting extreme loss : {extreme_loss_count}\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "1Y1jm2ckqK5l"
      },
      "outputs": [],
      "source": [
        "import matplotlib.pyplot as plt\n",
        "import seaborn as sns"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "IeN0RDxbqQ8Y"
      },
      "outputs": [],
      "source": [
        "CURRENT_THRESHOLD = 0.10\n",
        "LOWER_THRESHOLD = 0.05\n",
        "\n",
        "plt.figure(figsize=(12,6))\n",
        "sns.histplot(df_analysis[\"Price_change\"],bins=100,kde=True,edgecolor=\"none\",color=\"skyblue\",alpha=0.7)\n",
        "plt.axvline(CURRENT_THRESHOLD,color=\"red\",linestyle=\"--\",linewidth=2,label=f\"+{CURRENT_THRESHOLD*100:.0f}% Threshold (10%)\")\n",
        "plt.axvline(-CURRENT_THRESHOLD,color=\"red\",linestyle=\"--\",linewidth=2,label=f\"-{CURRENT_THRESHOLD*100:.0f}% Threshold (10%)\")\n",
        "\n",
        "plt.axvline(LOWER_THRESHOLD,color=\"green\",linestyle=\":\",linewidth=1,label=f\"+{LOWER_THRESHOLD*100:.0f}% Test Threshold (5%)\")\n",
        "plt.axvline(-LOWER_THRESHOLD,color=\"green\",linestyle=\":\",linewidth=1,label=f\"-{LOWER_THRESHOLD*100:.0f}% Test Threshold (5%)\")\n",
        "\n",
        "plt.title(\"Distribution of Price change day0 open to day 1 close\",fontsize=16)\n",
        "plt.xlabel(\"Price_change (in decimal)\",fontsize=12)\n",
        "plt.ylabel(\"Frequency\",fontsize=12)\n",
        "plt.grid(axis=\"y\",alpha=0.5)\n",
        "plt.legend()\n",
        "plt.show()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "rfYBvmR6Y2-a"
      },
      "outputs": [],
      "source": [
        "THRESHOLD=0.05\n",
        "conditions=[(df_analysis[\"Price_change\"]>=THRESHOLD), (df_analysis[\"Price_change\"]<=-THRESHOLD)]\n",
        "values=[\"Gain\",\"Loss\"]\n",
        "df_analysis[\"Target_Class\"]=np.select(condlist=conditions,choicelist=values,default=\"Neutral\")\n",
        "print(\"Target_Class column created\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "75eKJ98_aLdf"
      },
      "outputs": [],
      "source": [
        "class_distribution_counts=df_analysis['Target_Class'].value_counts()\n",
        "class_distribution_percent=class_distribution_counts.apply(lambda x:f\"{(x/class_distribution_counts.sum())*100:2f}%\")\n",
        "print(f\"class_distribution_counts are {class_distribution_counts}\")\n",
        "print(f\"Class distribution percentage are {class_distribution_percent}\")"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "dpdi2MjEcShg"
      },
      "source": [
        "# **4 Feature Engineering**"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "H0whx68RdZ-A"
      },
      "source": [
        "**Temporal Features**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "YcHKXEyrcmFv"
      },
      "outputs": [],
      "source": [
        "df_analysis['Date_only']=pd.to_datetime(df_analysis[\"Date_only\"])\n",
        "df_analysis[\"DateOfWeek\"]=df_analysis[\"Date_only\"].dt.day_of_week\n",
        "df_analysis[\"Month\"]=df_analysis[\"Date_only\"].dt.month\n",
        "df_analysis[\"Quarter\"]=df_analysis[\"Date_only\"].dt.quarter"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "sV8psN1T0tCa"
      },
      "source": [
        "**bold text**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "646uLoOidkel"
      },
      "outputs": [],
      "source": [
        "!pip install category_encoders\n",
        "from category_encoders import TargetEncoder\n",
        "\n",
        "df_analysis[\"Target_gain_flag\"]=(df_analysis[\"Target_Class\"]==\"Gain\").astype(int)\n",
        "encoder=TargetEncoder(cols=[\"ticker_clean\"])\n",
        "df_analysis[\"Ticker_gain_prob\"]=encoder.fit_transform(df_analysis[\"ticker_clean\"],df_analysis[\"Target_gain_flag\"])\n",
        "\n",
        "df_analysis[\"Target_loss_flag\"]=(df_analysis[\"Target_Class\"]==\"Loss\").astype(int)\n",
        "encoder=TargetEncoder(cols=[\"ticker_clean\"])\n",
        "df_analysis[\"Ticker_loss_prob\"]=encoder.fit_transform(df_analysis[\"ticker_clean\"],df_analysis[\"Target_loss_flag\"])\n",
        "df_analysis.head(5)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "zFQvAHjVhMGC"
      },
      "outputs": [],
      "source": [
        "df_analysis.drop(columns=[\"Target_gain_flag\",\"Target_loss_flag\",\"ticker_clean\"],inplace=True)\n",
        "df_analysis.head(5)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "WIc_YdaNotVA"
      },
      "outputs": [],
      "source": [
        "path=\"/content/drive/MyDrive/Earnings call prediction/final_dataframe_after_FE.csv\"\n",
        "df_analysis.to_csv(path)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "adUtpKgg0iJo"
      },
      "source": [
        "**Sentiment scores**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 1,
      "metadata": {
        "id": "ELUs2zvf0dDG"
      },
      "outputs": [],
      "source": [
        "import pandas as pd\n",
        "import numpy as np"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 2,
      "metadata": {
        "id": "K5Jt4NFj0VFP"
      },
      "outputs": [],
      "source": [
        "df_analysis=pd.read_csv(\"/content/drive/MyDrive/Earnings Call Prediction/final_dataframe_after_FE.csv\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 3,
      "metadata": {
        "id": "u0E71rE-ltm_",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000,
          "referenced_widgets": [
            "e96c58d8348645f4beb6d3a2c2e60c3a",
            "81cd2bfe800e4ea9a3abf8e57f50e032",
            "2864e3bbf8b54e6c9ca0da602e4f4ebd",
            "187aafbcb3ab4561ba717cea3af54c63",
            "130cfb6d4d87487c9c1aa5ea54644be9",
            "7112badf528a4bdea60a25064fb2cd5e",
            "bb55b537c03a4a43ab98dda45e8c5f79",
            "04779e4827774f58b58a579d0f779b01",
            "9002657615ce465f9e55d076e27defd0",
            "962093db2760463786e5a86a96d255a8",
            "71de8006d55c406c9222ad3f8dcecb14"
          ]
        },
        "outputId": "bf936ef1-379e-487a-da05-d87af628b36b"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: transformers in /usr/local/lib/python3.12/dist-packages (4.57.2)\n",
            "Requirement already satisfied: torch in /usr/local/lib/python3.12/dist-packages (2.9.0+cpu)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.12/dist-packages (4.67.1)\n",
            "Requirement already satisfied: filelock in /usr/local/lib/python3.12/dist-packages (from transformers) (3.20.0)\n",
            "Requirement already satisfied: huggingface-hub<1.0,>=0.34.0 in /usr/local/lib/python3.12/dist-packages (from transformers) (0.36.0)\n",
            "Requirement already satisfied: numpy>=1.17 in /usr/local/lib/python3.12/dist-packages (from transformers) (2.0.2)\n",
            "Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.12/dist-packages (from transformers) (25.0)\n",
            "Requirement already satisfied: pyyaml>=5.1 in /usr/local/lib/python3.12/dist-packages (from transformers) (6.0.3)\n",
            "Requirement already satisfied: regex!=2019.12.17 in /usr/local/lib/python3.12/dist-packages (from transformers) (2025.11.3)\n",
            "Requirement already satisfied: requests in /usr/local/lib/python3.12/dist-packages (from transformers) (2.32.4)\n",
            "Requirement already satisfied: tokenizers<=0.23.0,>=0.22.0 in /usr/local/lib/python3.12/dist-packages (from transformers) (0.22.1)\n",
            "Requirement already satisfied: safetensors>=0.4.3 in /usr/local/lib/python3.12/dist-packages (from transformers) (0.7.0)\n",
            "Requirement already satisfied: typing-extensions>=4.10.0 in /usr/local/lib/python3.12/dist-packages (from torch) (4.15.0)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.12/dist-packages (from torch) (75.2.0)\n",
            "Requirement already satisfied: sympy>=1.13.3 in /usr/local/lib/python3.12/dist-packages (from torch) (1.14.0)\n",
            "Requirement already satisfied: networkx>=2.5.1 in /usr/local/lib/python3.12/dist-packages (from torch) (3.6)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.12/dist-packages (from torch) (3.1.6)\n",
            "Requirement already satisfied: fsspec>=0.8.5 in /usr/local/lib/python3.12/dist-packages (from torch) (2025.10.0)\n",
            "Requirement already satisfied: hf-xet<2.0.0,>=1.1.3 in /usr/local/lib/python3.12/dist-packages (from huggingface-hub<1.0,>=0.34.0->transformers) (1.2.0)\n",
            "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /usr/local/lib/python3.12/dist-packages (from sympy>=1.13.3->torch) (1.3.0)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.12/dist-packages (from jinja2->torch) (3.0.3)\n",
            "Requirement already satisfied: charset_normalizer<4,>=2 in /usr/local/lib/python3.12/dist-packages (from requests->transformers) (3.4.4)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.12/dist-packages (from requests->transformers) (3.11)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.12/dist-packages (from requests->transformers) (2.5.0)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.12/dist-packages (from requests->transformers) (2025.11.12)\n",
            "Looking in links: https://storage.googleapis.com/libtpu-releases/index.html\n",
            "Requirement already satisfied: torch==2.9.0 in /usr/local/lib/python3.12/dist-packages (2.9.0+cpu)\n",
            "Requirement already satisfied: torch_xla==2.9.0 in /usr/local/lib/python3.12/dist-packages (from torch_xla[tpu]==2.9.0) (2.9.0)\n",
            "Requirement already satisfied: filelock in /usr/local/lib/python3.12/dist-packages (from torch==2.9.0) (3.20.0)\n",
            "Requirement already satisfied: typing-extensions>=4.10.0 in /usr/local/lib/python3.12/dist-packages (from torch==2.9.0) (4.15.0)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.12/dist-packages (from torch==2.9.0) (75.2.0)\n",
            "Requirement already satisfied: sympy>=1.13.3 in /usr/local/lib/python3.12/dist-packages (from torch==2.9.0) (1.14.0)\n",
            "Requirement already satisfied: networkx>=2.5.1 in /usr/local/lib/python3.12/dist-packages (from torch==2.9.0) (3.6)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.12/dist-packages (from torch==2.9.0) (3.1.6)\n",
            "Requirement already satisfied: fsspec>=0.8.5 in /usr/local/lib/python3.12/dist-packages (from torch==2.9.0) (2025.10.0)\n",
            "Requirement already satisfied: absl-py>=1.0.0 in /usr/local/lib/python3.12/dist-packages (from torch_xla==2.9.0->torch_xla[tpu]==2.9.0) (1.4.0)\n",
            "Requirement already satisfied: numpy in /usr/local/lib/python3.12/dist-packages (from torch_xla==2.9.0->torch_xla[tpu]==2.9.0) (2.0.2)\n",
            "Requirement already satisfied: pyyaml in /usr/local/lib/python3.12/dist-packages (from torch_xla==2.9.0->torch_xla[tpu]==2.9.0) (6.0.3)\n",
            "Requirement already satisfied: requests in /usr/local/lib/python3.12/dist-packages (from torch_xla==2.9.0->torch_xla[tpu]==2.9.0) (2.32.4)\n",
            "Requirement already satisfied: libtpu==0.0.21 in /usr/local/lib/python3.12/dist-packages (from torch_xla[tpu]==2.9.0) (0.0.21)\n",
            "Requirement already satisfied: tpu-info in /usr/local/lib/python3.12/dist-packages (from torch_xla[tpu]==2.9.0) (0.2.2)\n",
            "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /usr/local/lib/python3.12/dist-packages (from sympy>=1.13.3->torch==2.9.0) (1.3.0)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.12/dist-packages (from jinja2->torch==2.9.0) (3.0.3)\n",
            "Requirement already satisfied: charset_normalizer<4,>=2 in /usr/local/lib/python3.12/dist-packages (from requests->torch_xla==2.9.0->torch_xla[tpu]==2.9.0) (3.4.4)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.12/dist-packages (from requests->torch_xla==2.9.0->torch_xla[tpu]==2.9.0) (3.11)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.12/dist-packages (from requests->torch_xla==2.9.0->torch_xla[tpu]==2.9.0) (2.5.0)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.12/dist-packages (from requests->torch_xla==2.9.0->torch_xla[tpu]==2.9.0) (2025.11.12)\n",
            "Requirement already satisfied: grpcio>=1.65.5 in /usr/local/lib/python3.12/dist-packages (from tpu-info->torch_xla[tpu]==2.9.0) (1.76.0)\n",
            "Requirement already satisfied: protobuf in /usr/local/lib/python3.12/dist-packages (from tpu-info->torch_xla[tpu]==2.9.0) (6.33.1)\n",
            "Requirement already satisfied: rich in /usr/local/lib/python3.12/dist-packages (from tpu-info->torch_xla[tpu]==2.9.0) (14.2.0)\n",
            "Requirement already satisfied: markdown-it-py>=2.2.0 in /usr/local/lib/python3.12/dist-packages (from rich->tpu-info->torch_xla[tpu]==2.9.0) (4.0.0)\n",
            "Requirement already satisfied: pygments<3.0.0,>=2.13.0 in /usr/local/lib/python3.12/dist-packages (from rich->tpu-info->torch_xla[tpu]==2.9.0) (2.19.2)\n",
            "Requirement already satisfied: mdurl~=0.1 in /usr/local/lib/python3.12/dist-packages (from markdown-it-py>=2.2.0->rich->tpu-info->torch_xla[tpu]==2.9.0) (0.1.2)\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/tmp/ipython-input-1725248875.py:5: DeprecationWarning: Use torch_xla.device instead\n",
            "  device = xm.xla_device()\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "TPU device connected: xla:0\n",
            "\n",
            "Example computation on TPU: tensor([[ 0.3355, -1.4628, -3.2610],\n",
            "        [-1.4656,  0.3196, -2.8766],\n",
            "        [ 0.8667, -1.5060,  0.7125]], device='xla:0')\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.12/dist-packages/jax/_src/cloud_tpu_init.py:86: UserWarning: Transparent hugepages are not enabled. TPU runtime startup and shutdown time should be significantly improved on TPU v5e and newer. If not already set, you may need to enable transparent hugepages in your VM image (sudo sh -c \"echo always > /sys/kernel/mm/transparent_hugepage/enabled\")\n",
            "  warnings.warn(\n",
            "/usr/local/lib/python3.12/dist-packages/huggingface_hub/utils/_auth.py:94: UserWarning: \n",
            "The secret `HF_TOKEN` does not exist in your Colab secrets.\n",
            "To authenticate with the Hugging Face Hub, create a token in your settings tab (https://huggingface.co/settings/tokens), set it as secret in your Google Colab and restart your session.\n",
            "You will be able to reuse this secret in all of your notebooks.\n",
            "Please note that authentication is recommended but still optional to access public models or datasets.\n",
            "  warnings.warn(\n",
            "Device set to use xla:0\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Starting inference on 15055 rows...\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.12/dist-packages/transformers/pipelines/text_classification.py:111: UserWarning: `return_all_scores` is now deprecated,  if want a similar functionality use `top_k=None` instead of `return_all_scores=True` or `top_k=1` instead of `return_all_scores=False`.\n",
            "  warnings.warn(\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "  0%|          | 0/471 [00:00<?, ?it/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "e96c58d8348645f4beb6d3a2c2e60c3a"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Success! FinBERT scores added.\n"
          ]
        }
      ],
      "source": [
        "!pip install transformers torch tqdm\n",
        "! pip install torch==2.9.0 'torch_xla[tpu]==2.9.0' -f https://storage.googleapis.com/libtpu-releases/index.html\n",
        "import torch_xla.core.xla_model as xm\n",
        "import torch\n",
        "device = xm.xla_device()\n",
        "print(\"TPU device connected:\", device)\n",
        "t1 = torch.randn(3, 3, device=device)\n",
        "t2 = torch.randn(3, 3, device=device)\n",
        "print(\"\\nExample computation on TPU:\", t1 + t2)\n",
        "\n",
        "import torch\n",
        "from transformers import pipeline\n",
        "from tqdm.auto import tqdm\n",
        "import pandas as pd\n",
        "\n",
        "classifier = pipeline(\"text-classification\", model=\"ProsusAI/finbert\", return_all_scores=True, device=device)\n",
        "\n",
        "# Preparing Data\n",
        "texts = df_analysis['Clean_Text'].astype(str).tolist()\n",
        "batch_size = 32\n",
        "results = []\n",
        "\n",
        "print(f\"Starting inference on {len(texts)} rows...\")\n",
        "for i in tqdm(range(0, len(texts), batch_size)):\n",
        "  batch = texts[i : i + batch_size]\n",
        "  batch_results = classifier(batch, truncation=True, max_length=512)\n",
        "  results.extend(batch_results)\n",
        "\n",
        "# Parsing Results into Columns. FinBERT outputs a list of dictionaries. Mapping them to columns\n",
        "pos_scores = []\n",
        "neg_scores = []\n",
        "neu_scores = []\n",
        "\n",
        "for row_result in results:\n",
        "  scores_dict = {item['label']: item['score'] for item in row_result}\n",
        "  pos_scores.append(scores_dict.get('positive', 0))\n",
        "  neg_scores.append(scores_dict.get('negative', 0))\n",
        "  neu_scores.append(scores_dict.get('neutral', 0))\n",
        "\n",
        "#Adding to DataFrame\n",
        "df_analysis['FinBERT_Positive'] = pos_scores\n",
        "df_analysis['FinBERT_Negative'] = neg_scores\n",
        "df_analysis['FinBERT_Neutral'] = neu_scores\n",
        "\n",
        "df_analysis.drop(columns=['Clean_Text'], inplace=True)\n",
        "\n",
        "print(\"Success! FinBERT scores added.\")"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_analysis.head(5)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 677
        },
        "id": "Ncg3LMKGH8xw",
        "outputId": "d700ef44-d129-4bda-e4b8-eae2c9f47bf6"
      },
      "execution_count": 4,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "   Unnamed: 0                        date      exchange        q ticker  \\\n",
              "0           0  Aug 27, 2020, 9:00 p.m. ET  NASDAQ: BILI  2020-Q2   BILI   \n",
              "1           1  Jul 30, 2020, 4:30 p.m. ET     NYSE: GFF  2020-Q3    GFF   \n",
              "2           2  Oct 23, 2019, 5:00 p.m. ET  NASDAQ: LRCX  2020-Q1   LRCX   \n",
              "3           3  Nov 6, 2019, 12:00 p.m. ET  NASDAQ: BBSI  2019-Q3   BBSI   \n",
              "4           4   Aug 7, 2019, 8:30 a.m. ET  NASDAQ: CSTE  2019-Q2   CSTE   \n",
              "\n",
              "                                          transcript            Timestamp  \\\n",
              "0  Prepared Remarks:\\nOperator\\nGood day, and wel...  2020-08-27 21:00:00   \n",
              "1  Prepared Remarks:\\nOperator\\nThank you for sta...  2020-07-30 16:30:00   \n",
              "2  Prepared Remarks:\\nOperator\\nGood day and welc...  2019-10-23 17:00:00   \n",
              "3  Prepared Remarks:\\nOperator\\nGood day, everyon...  2019-11-06 12:00:00   \n",
              "4  Prepared Remarks:\\nOperator\\nGreetings and wel...  2019-08-07 08:30:00   \n",
              "\n",
              "    Date_only  word_count  Price_change Target_Class  DateOfWeek  Month  \\\n",
              "0  2020-08-27        5623      0.035078      Neutral           3      8   \n",
              "1  2020-07-30        4755      0.116154         Gain           3      7   \n",
              "2  2019-10-23        8917      0.142022         Gain           2     10   \n",
              "3  2019-11-06        8286      0.029891      Neutral           2     11   \n",
              "4  2019-08-07        4611      0.249623         Gain           2      8   \n",
              "\n",
              "   Quarter  Ticker_gain_prob  Ticker_loss_prob  FinBERT_Positive  \\\n",
              "0        3          0.134823          0.215544          0.146988   \n",
              "1        3          0.210214          0.212302          0.910005   \n",
              "2        4          0.261479          0.176718          0.878131   \n",
              "3        4          0.210214          0.181707          0.727205   \n",
              "4        3          0.253273          0.199769          0.755221   \n",
              "\n",
              "   FinBERT_Negative  FinBERT_Neutral  \n",
              "0          0.012653         0.840358  \n",
              "1          0.010605         0.079389  \n",
              "2          0.012376         0.109493  \n",
              "3          0.122016         0.150779  \n",
              "4          0.136653         0.108126  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-0a3d52aa-2c11-43a9-9b54-be4fa1b2a115\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Unnamed: 0</th>\n",
              "      <th>date</th>\n",
              "      <th>exchange</th>\n",
              "      <th>q</th>\n",
              "      <th>ticker</th>\n",
              "      <th>transcript</th>\n",
              "      <th>Timestamp</th>\n",
              "      <th>Date_only</th>\n",
              "      <th>word_count</th>\n",
              "      <th>Price_change</th>\n",
              "      <th>Target_Class</th>\n",
              "      <th>DateOfWeek</th>\n",
              "      <th>Month</th>\n",
              "      <th>Quarter</th>\n",
              "      <th>Ticker_gain_prob</th>\n",
              "      <th>Ticker_loss_prob</th>\n",
              "      <th>FinBERT_Positive</th>\n",
              "      <th>FinBERT_Negative</th>\n",
              "      <th>FinBERT_Neutral</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>0</td>\n",
              "      <td>Aug 27, 2020, 9:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BILI</td>\n",
              "      <td>2020-Q2</td>\n",
              "      <td>BILI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, and wel...</td>\n",
              "      <td>2020-08-27 21:00:00</td>\n",
              "      <td>2020-08-27</td>\n",
              "      <td>5623</td>\n",
              "      <td>0.035078</td>\n",
              "      <td>Neutral</td>\n",
              "      <td>3</td>\n",
              "      <td>8</td>\n",
              "      <td>3</td>\n",
              "      <td>0.134823</td>\n",
              "      <td>0.215544</td>\n",
              "      <td>0.146988</td>\n",
              "      <td>0.012653</td>\n",
              "      <td>0.840358</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>1</td>\n",
              "      <td>Jul 30, 2020, 4:30 p.m. ET</td>\n",
              "      <td>NYSE: GFF</td>\n",
              "      <td>2020-Q3</td>\n",
              "      <td>GFF</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nThank you for sta...</td>\n",
              "      <td>2020-07-30 16:30:00</td>\n",
              "      <td>2020-07-30</td>\n",
              "      <td>4755</td>\n",
              "      <td>0.116154</td>\n",
              "      <td>Gain</td>\n",
              "      <td>3</td>\n",
              "      <td>7</td>\n",
              "      <td>3</td>\n",
              "      <td>0.210214</td>\n",
              "      <td>0.212302</td>\n",
              "      <td>0.910005</td>\n",
              "      <td>0.010605</td>\n",
              "      <td>0.079389</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>2</td>\n",
              "      <td>Oct 23, 2019, 5:00 p.m. ET</td>\n",
              "      <td>NASDAQ: LRCX</td>\n",
              "      <td>2020-Q1</td>\n",
              "      <td>LRCX</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day and welc...</td>\n",
              "      <td>2019-10-23 17:00:00</td>\n",
              "      <td>2019-10-23</td>\n",
              "      <td>8917</td>\n",
              "      <td>0.142022</td>\n",
              "      <td>Gain</td>\n",
              "      <td>2</td>\n",
              "      <td>10</td>\n",
              "      <td>4</td>\n",
              "      <td>0.261479</td>\n",
              "      <td>0.176718</td>\n",
              "      <td>0.878131</td>\n",
              "      <td>0.012376</td>\n",
              "      <td>0.109493</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>3</td>\n",
              "      <td>Nov 6, 2019, 12:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BBSI</td>\n",
              "      <td>2019-Q3</td>\n",
              "      <td>BBSI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, everyon...</td>\n",
              "      <td>2019-11-06 12:00:00</td>\n",
              "      <td>2019-11-06</td>\n",
              "      <td>8286</td>\n",
              "      <td>0.029891</td>\n",
              "      <td>Neutral</td>\n",
              "      <td>2</td>\n",
              "      <td>11</td>\n",
              "      <td>4</td>\n",
              "      <td>0.210214</td>\n",
              "      <td>0.181707</td>\n",
              "      <td>0.727205</td>\n",
              "      <td>0.122016</td>\n",
              "      <td>0.150779</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>4</td>\n",
              "      <td>Aug 7, 2019, 8:30 a.m. ET</td>\n",
              "      <td>NASDAQ: CSTE</td>\n",
              "      <td>2019-Q2</td>\n",
              "      <td>CSTE</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGreetings and wel...</td>\n",
              "      <td>2019-08-07 08:30:00</td>\n",
              "      <td>2019-08-07</td>\n",
              "      <td>4611</td>\n",
              "      <td>0.249623</td>\n",
              "      <td>Gain</td>\n",
              "      <td>2</td>\n",
              "      <td>8</td>\n",
              "      <td>3</td>\n",
              "      <td>0.253273</td>\n",
              "      <td>0.199769</td>\n",
              "      <td>0.755221</td>\n",
              "      <td>0.136653</td>\n",
              "      <td>0.108126</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-0a3d52aa-2c11-43a9-9b54-be4fa1b2a115')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-0a3d52aa-2c11-43a9-9b54-be4fa1b2a115 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-0a3d52aa-2c11-43a9-9b54-be4fa1b2a115');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-60a83922-f51e-4c5d-ac68-d0d86c7b7388\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-60a83922-f51e-4c5d-ac68-d0d86c7b7388')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-60a83922-f51e-4c5d-ac68-d0d86c7b7388 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df_analysis",
              "summary": "{\n  \"name\": \"df_analysis\",\n  \"rows\": 15055,\n  \"fields\": [\n    {\n      \"column\": \"Unnamed: 0\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 4346,\n        \"min\": 0,\n        \"max\": 15054,\n        \"num_unique_values\": 15055,\n        \"samples\": [\n          13726,\n          12694,\n          12017\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"date\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 5142,\n        \"samples\": [\n          \"May 19, 2022, 11:00 a.m. ET\",\n          \"Oct 25, 2021, 3:30 p.m. ET\",\n          \"May 30, 2019, 3:00 p.m. ET\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"exchange\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2272,\n        \"samples\": [\n          \"NASDAQ: EGRX\",\n          \"NYSE: ASB\",\n          \"NYSE: HLF\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"q\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 19,\n        \"samples\": [\n          \"2020-Q2\",\n          \"2021-Q2\",\n          \"2021-Q4\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2271,\n        \"samples\": [\n          \"EGRX\",\n          \"ES\",\n          \"APD\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"transcript\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 14122,\n        \"samples\": [\n          \"Prepared Remarks:\\nOperator\\nLadies and gentlemen, thank you for standing by, and welcome to Sangamo Therapeutics Inc Q3 2020 webcast. [Operator Instructions] After the speaker presentation there will be a question and answer session. [Operator Instructions]\\nI would now like to hand the conference over to your host head of Corporate Communications McDavid Stilwell, please go ahead.\\nMcDavid Stilwell -- Head of Corporate Communications\\nGood afternoon. And thank you for joining us today. With me this afternoon on this call are several members of the same demo executive leadership team, including Sandy Macrae, Chief Executive Officer. Sung Lee Chief Financial Officer, Mark McClung, Chief Business Officer, Jason Fontenot, Interim Head of Research and Bettina Cockroft Chief Medical Officer. Slides from our corporate presentation can be found at our website, sangamo.com, under the Investors and Media section in the Events and Presentations page. This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to, statements relating to our pipeline of genomic medicine product candidates; our ability to develop, obtain regulatory approvals for and commercialize therapies to treat certain diseases and the timing, availability and cost of such therapies; plans and time lines for Sangamo and to conduct clinical trials and share clinical data and the potential for data to demonstrate clinical benefit to patients; the potential to use certain technologies to develop AR therapies, our collaboration strategy and the potential to earn fees, milestone payments and royalties from our collaboration; plans and time lines for building and opening manufacturing facilities, the effects of the evolving COVID-19 pandemic; the anticipated benefits of our organizational changes; our expectations regarding our financial performance and resources and other statements that are not historical fact. Actual results may differ substantially from what we discuss today.\\nIn addition, these statements are not guarantees of future performance and are subject to certain risks and uncertainties that are discussed in documents that we file with the securities and Exchange Commission, specifically in our quarterly report on Form 10-Q for the quarter ended September 30, 2020. The forward-looking statements stated today are made as of this date, and we undertake no duty to update such information, except as required under applicable law. On this call, we discuss a non-GAAP financial measure. We believe this measure is helpful in understanding our past financial performance and our potential future results. This is not meant to be considered in isolation or as a substitute for the comparable GAAP measure. The comparable GAAP measures and reconciliations of GAAP to the non-GAAP measures discussed on this call are included in today's press release, which is available on our website.\\nNow, I'd like to turn the call over to our CEO, Sandy Macrae.\\nSandy Macrae -- Chief Executive Officer\\nThank you, and good afternoon to everyone on the call. This quarter. We advanced our r&d activities as we continue to adapt to the conditions brought on by the evolving Covid-19 pandemic. We are moving forward on clinical execution. And we're optimistic we're plans to continue to doors patients and initiate new trials. We also completed our research activities associated with our als control collaboration with slide and are continuing to move our research projects with Biogen and Novartis forward and are progressing and work with our other partners. Pfizer has dosed the first participant in the phase three of fine study of JIRA tokujin, fetal Purbeck or SP five to five or investigational gene therapy for Haemophilia a patients. This event triggered a $13 million milestone achievement for sango, which we expect to receive in the current quarter, further strengthening our cash position. Pfizer previously communicated that they expect a pivotal data readout from the final study in 2022. During the mid September investor day, Pfizer provided an update from the phase one to alter study showing encouraging data garnering tolerability clinically meaningful factor levels, bleeding rates and factor use in the highest dose cohort up to 85 weeks in the longest treated patients. Pfizer and sanken will believe that these data support a potentially differentiated Haemophilia a gene therapy product candidate in August and September, in close collaboration with principal investigators monitoring safe conditions for patients with the within the context of COVID-19 single dose the first two patients in the phase one two star study evaluating STM 20 gene therapy in Fabry disease. Those are the first cohort of this study is no complete. And enrollment is ongoing for Cohort Two.\\nWe expect to share data on this study by the end of next year. During the quarter, we received additional regulatory approvals for the first in human Phase One Two clinical study evaluating car regulatory T cell or car t reg, candidate tx 200 and kidney transplantation. We believe we are on track to initiate the study next year. initiating the study may allow us to be the first company to explore the potential of car T cells in humans. We are hopeful that this will provide broader proof of concept for genetically engineered cell therapy using T rex beyond transplantation. We intend to further evaluate current T Rex, including zinc finger nucleases edited allergenic t reg therapies in autoimmune diseases with high unmet medical need. Also, this quarter we completed our research activities associated with our ongoing Pfizer collaboration to develop gene regulation therapy. Using zinc finger technology for the treatment of C nine or 72 related als in this program are safe finger proteins are designed to selectively target disease alio repeats a remarkable demonstration. Yet another way our versatile technology may be able to have a disease modifying impact on challenging CNS diseases. We recently earned a 5 million milestone payment from Pfizer so stay with this program, which we expect to receive later this quarter. It is a testament to our r&d momentum. We look forward to continue to work closely with Pfizer to support their research and development in this program.\\nWith that, I will turn the call over to our chief medical officer Bettina, who will provide additional details on our clinical accomplishments.\\nBettina Cockroft -- Senior Vice President and Chief Medical Officer\\nGood afternoon. As Sandy mentioned, our clinical operations have adapted to the challenges of the evolving covid 19 pandemic. And we are pleased with our progress in executing on our partner and wholly owned programs. Pfizer those the first patient in the assigned study of director gene fetal Popovic or SB five to five, our first acid in a registrational trial. A fine is a global phase three open label multicenter single arm study evaluating the efficacy and safety of SB five to five. in patients with moderately severe to severe Haemophilia a. The primary endpoint is annualized bleeding rates or APR through 12 months following treatment. This will be compared to ABR while in fact eight Replacement Therapy collected in the phase three lead and study, which will provide a baseline for phase three study participants. The secondary endpoints include factor eight activity level after the onset of steady state over 12 months. Participants will be analyzed throughout the five year study period following the single infusion to further assess your ability of efficacy and safety.\\nFive has shared updated phase one two data at a Pfizer investor events in September, which demonstrated that sb 525 was generally well tolerated. Each of the five patients in the high dose cohort sustained a clinically meaningful level effect great activity without leads or the need for prophylactic factor up to 85 weeks for the longest treated patient. Both companies are encouraged by these results and plan to present further follow up data from the altia study in the next few months. When all five patients in the 313 vector genomes per kilogram dose cohort have been followed for at least one year. We have those the first two patients comprising the first cohort in the phase one to start study evaluating SPSS 20 in Fabry disease. The goal of this gene therapy candidate is to provide a predictable and durable expression of the alpha gal a enzyme, which is deficient and Fabry disease due to mutations in the GLA gene, resulting in the accumulation of the substrates GP three, and it's soluble derivative lyso Gp three. This can cause challenging symptoms and morbidities including impaired renal and cardiac function, pain and gastrointestinal symptoms. The star trial is a multicenter open label those ranging study evaluating the safety and tolerability of St. 920 and classical Fabry patients 18 years and older study participants will receive a single intravenous infusion of St. 920, followed by one year of observation and monitoring of clinical endpoints, such as alpha gelei activity and assessment of GB three and laser GB three levels. A long term follow up study will allow patients to be monitored for an additional four years. enrollment for the second cohort is ongoing. We expect that data will be shared toward the end of 2021 after we have identified adults code for cohort expansion.\\nWe believe that sc 920 offers a potentially differentiated treatment for Fabry disease, with the potential to deliver efficacy with preserved renal function and reduced cardiac morbidity and neuropathy. preclinical studies evaluating STI 20 demonstrated strong expression of alpha Galle and G v3 substrate reduction across tissue types. As delivered directed gene therapy, Sc 920 is delivered by a one time intravenous infusion that does not require any preconditioning regimen for patients. We are also working closely with our oncology collaborator Kate Gilliard company, as it advances code 037 and allergenic and PCV 19 Carty therapy into clinical trial tight expects to submit an investigational new drug application by the end of 2020 and to initiate a clinical trial evaluating kite 037 in 2021.Throughout the third quarter, we have continued to receive additional regulatory approvals that support the phase one to steadfast clinical study evaluating the first inhuman car t reg cell therapy tx 200 in HLA to mismatched renal transplantation, we expect to initiate the study next year. The goal for this study is the prevention of transplant rejection through the engineering of T regs to express an HLA to kemmerich antigen receptor or car, allowing them to localize to the renal graft and activate upon recognition of the HLA to antigen. The Carty regs may prevent immune mediated rejection through the inhibition and modulation of inflammatory immune cells and the release of anti inflammatory cytokines to induce a tolerogenic environment within the preclinical data supporting the steadfast study presented last month showed that the TX 200 HLA to Carty regs efficiently prevented rejection in both graft versus host disease and skin transplantation model.\\nThey were also shown to be safe and well tolerated in our in vivo studies. Similar to other genetically engineered cell therapy approaches, patients will undergo a Luca phoresis procedure from which their t reg cells will be isolated and engineered then cryopreserved. The HLA to negative patient will subsequently undergo transplantation surgery and following a recovery period will receive their personalized pX 200 drug candidate.As a result of this detailed process, we expect those patients will occur several months after their enrollment. recent publications show that the regulatory cell therapy space is gaining momentum and excitement in the scientific community. In particular, the one study a large international clinical study gathering seven investigator led trials across five countries showed that immune regulatory cell therapy as a whole were safe, and that immune cell therapy is a potentially useful therapeutic approach in renal transplant recipients allowing immune cell composition restoration to normal healthy level of minimization of the burden of general immune suppression. This is very promising and supports our plan to evaluate Carty regs in renal transplant patient populations.\\nWill now turn the call over to some for an overview of the financial results.\\nSung Lee -- Executive Vice President and Chief Financial Officer\\nThank you, Bettina and good afternoon everyone. We're pleased to share our financial results for the third quarter of 2020. We reported a net loss of $1.6 million, or one cent per share compared to a net loss of $27.3 million or 24 cents per share for the same period in 2019. total revenues were $57.8 million, compared to $22 million for the same period in 2019. The increase was primarily attributable to a $30 million milestone achieved. For SP five to five or Haemophilia, a candidate partnered with Pfizer, and a $5 million milestone achieved for our C nine or 72 collaboration with Pfizer. Turning to expensive non GAAP operating expenses, which include stock based compensation expense were $54.8 million, compared to $46.5 million for the same period in 2019. The increase in operating expense reflects our headcount growth and facilities expansion to support the advancement of our therapeutic pipeline, and manufacturing capabilities.\\nThese increases were partially offset by a decrease in clinical and manufacturing supply expenses. Moving to the balance sheet, we ended the quarter with $695 million in cash, cash equivalents and marketable securities. This balance includes the $75 million upfront license fee payment received from Novartis. Additionally, in the current quarter, we expect to receive the $35 million milestone payments from Pfizer mentioned earlier. We believe our balance sheet remains strong and will allow us to reach several important r&d milestones, including the potential filing of the Vla for sp 525. For hemophilia a. Turning to 2024 year guides, we're updating our financial guidance for non GAAP operating expenses, which exclude estimated stock compensation expense of $25 million from an estimated range of 210 million to $225 million to now be in the estimated range of 210 million to $220 million.\\nI'll now turn it back to Sandy for closing remarks.\\nSandy Macrae -- Chief Executive Officer\\nThank you. So we're focused on clinical execution and building momentum. As we adapt to the conditions of COVID-19 and head toward the end of the year. We're pleased with our progress in clinical operations and with our partner programs. Our strong balance sheet enables us to advance our r&d pipeline. We believe these accomplishments are put single in a strong position to achieve several important milestones and catalysts heading into next year. We believe we remain on track for a V manufacturing facility in Brisbane to be operation at the end of this year, and offeror cell therapy facilities in Brisbane and football to be operational by year end 2021. We anticipate continued enrollment in Pfizer's phase three a fine study with a pivotal data readout expected by Pfizer in 2022. And also expect one year and two year phase one two data presentations over the next year and a half. We expect continued enrollment in the phase one two star study and the data read data readout toward the end of 2021.\\nSanta Fe has guided that the first data readout from the phase one to sickle cell disease study is expected next year. We anticipate presenting pull up sp 400 beta thalassemia data at the same time. And lastly, we expect the clinical trial initiation. So the phase one two first inhuman Carty reg status study will occur in 2021. And Kate expects that this study of allogeneic anti cd 19 Carty product candidate count or three seven will also commence in 2021. We look forward to delivering on these milestones in the coming year.\\nOperator, please open the line for questions.\\nQuestions and Answers:\\nOperator\\n[Operator Instructions] Our first question comes from the line of Geoff Meacham With Bank of America.\\nGeoff Meacham -- Bank of America -- Analyst\\nHey guys, thanks for the question and congrats on all the pipeline progress. I had a couple on the first one is on the Haemophilia a study just with the 12 month analyze bleed rate endpoint, I want to kind of get your feedback on on what FDA is, is looking for just relative to, you know, the feedback that biomarin received. And that's obviously subject of a lot of investor conversations of late. And then the second question is just a broader one on the strategy for the car t regs just wanted to maybe give us a little bit more, you know, context for, you know, how you see that differentiating and maybe what successes you see what the best probability of success, you see, and, and for example, solid tumors versus the liquid tumor say. Thank you.\\nSandy Macrae -- Chief Executive Officer\\nThank you for your questions. On the first one around Haemophilia a, we are limited in what we can see, because this is known Pfizer sounds, we are so pleased with their progress into phase three, with their enthusiasm for the program, and that all the way up and down their organization right up to their CEO, how valuable they see this asset for them. The you can be assured that they will be having regular conversations with the regulatory authorities. And I'm certain that Pfizer will know how to navigate that landscape. As regards to T regs, I'm going to pass over to Jason who is a real expert in this area.\\nGeoff Meacham -- Bank of America -- Analyst\\nAnd Jason, can you talk to us about how you see your T reg strategy?\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nThanks, Sandy. And thanks for the question. Um, so first, I'll start off by by pointing out that our programs and regulatory T cells, engineered regulatory T cells are directed in the autoimmune and inflammatory disease space, these are drugs for cancer. So we're really excited about our engineered regulatory T cell platform and the programs that we're bringing forward. We're excited about the progress and regulatory approvals we've received so far. And about our first inhuman. Carty reg study, Tx 200. We're leaders in this field. And, you know, we're developing and refining our understanding of cartoon t reg biology and rapidly advancing our ability to engineer and manufacture that cell. And our tx 200 study will be the first inhuman test of engineered regulatory T cells of car t regs, and this will be further demonstration of our leadership.\\nThe goal with that study is the prevention of renal transplant rejection in the setting of an MHC mismatch transplant. So this is a setting where and HLA a two negative patient will receive an HLA a two positive kidney transplant. And our therapy is comprised of T regs that are engineered to recognize the a two antigen through a Comerica antigen receptor and that car that will drive the accumulation and activation of the T regs in the renal graft and suppress the rejection of the graft by the patient's immune system. And what's important about that study is that as I mentioned, this is going to be the first test of this therapeutic hypothesis around core t regs. And this study will be important for us to understand the safety and efficacy and the therapeutic potential of car t regs. And we'll be informing programs that we're actively pursuing enlarger autoimmune and inflammatory indications such as multiple sclerosis and Crohn's disease.\\nGeoff Meacham -- Bank of America -- Analyst\\nOkay, great. Thank you.\\nOperator\\nThank you. Our next question comes from the line of Maurice Raycroft with Jefferies.\\nMaurice Raycroft -- Jefferies -- Analyst\\nHi, Everyone, thanks for taking my questions. I had one on the T reg program as well. So I guess for getting the getting that study started. Can you talk more about what factors have led to pushing the study start to 2021? Is it due to COVID or the autologous cell manufacturing process or anything else that you can comment on? And can you talk more about what else needs to be completed before starting the study?\\nSandy Macrae -- Chief Executive Officer\\nMaurice, thank you very much for your question. We are we're very pleased with the progress of the T reg for HLA to mismatch. We're very pleased with the approval From the regulatory authorities, we call for dis epic where COVID is in. In is impacting the hospitals, we will go to the the laboratories, the manufacturing. So there's a general COVID impact, but we are confident that we'll be able to move forward with this program.\\nMaurice Raycroft -- Jefferies -- Analyst\\nAnd from a manufacturing and process development standpoint, is that all figured out? Or is there any other perspective you can provide on that?\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nOne of the reasons that we acquired t excel in 2018, was their understanding of how to look after T Rex, which is different from how people look after T cells. And so we're very pleased with the progress that they've made.\\nMaurice Raycroft -- Jefferies -- Analyst\\nGot it. Okay. And then the other question I had was just on the preamp program that you guys have, which is sort of under the radar, I'm just wondering if you can provide a status update on that program, any timeline, update on that program, and then maybe talk about the strategic importance of that one, as well.\\nSandy Macrae -- Chief Executive Officer\\nJason, can you hear me talk about prions and what we think of them?\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nSure, Sandy, thank you. Um, you know, the prion program is in preclinical development. So I think, you know, we'll be looking forward to sharing updates at the appropriate time. I think that there is a great opportunity there to to demonstrate the power of our platform, similar to the approaches that we're taking with our partners in CNS, both Biogen and Novartis. These are both of these partnerships are driven by by what our partners see in our platform. And the prion program is yet to get another example of that, and we'll be excited to, to talk about it as we move forward. And we've done some of the initial work with the Broad Institute in Boston. And they have a real deep x the group we're working with as a real deep expertise in this. And so we have that biological expertise to match with our technological expertise.\\nMaurice Raycroft -- Jefferies -- Analyst\\nGot it. Thank you for the perspective. Thanks for taking the questions.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nThank you, Marie.\\nOperator\\nThank you. Next question comes from the line of Jim Burchinal with Wells Fargo.\\nJim Burchinal -- Wells Fargo. -- Analyst\\nHi, thanks for taking my question. This is a yen and on for Tim, some perhaps a question on the T reg program as as well. It, Could you confirm whether this is a gene additive product? Because I think it's autologous. So, it you know, the obviously the HLA two is put in with a gene audition approach. So if if you can comment on whether it's a gene edited product, and then for your, you know, future product, the genetic regulatory car T cells. How do you see the issue of persistence? I guess it's for this program, GTX 200, as well. How do you see the issue of persistence? And for renal transplant, would you require long term persistence? And would you explore repeated dosing for your animal genetic programs? Thanks.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nSo thank you for your question. They they're very sensible, scientific questions. And let me try and lay out the path that we've chosen, which is to start with a topic of sorts, we can understand the effectiveness of T regs. And one of the advantages of renal transplant is that the transplanted kidney can be biopsied because it's it's implanted close to the surface. So, we can look at things like persistence which as you can see is an important feature that would be required of any good treatment, we will gradually switch to allergenic and, and we can either develop our genetics, t regs by editing down from healthy donor volunteers, or by studying IPS, C's and other forms of stem cells to develop them up to be T Rex. So this is really at the very cutting edge of regulatory cellular science and we are lucky to have many options as possible to take us into those areas.\\nJim Burchinal -- Wells Fargo. -- Analyst\\nGot it? And a quick follow up in tx 200. Is there a gene editing component?\\nSandy Macrae -- Chief Executive Officer\\nTx 200 isn't a tall Lucas form and therefore doesn't have gene editing component? Jason, I'm correct on that.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nYes, that's correct. tx 200. We introduced the car with a lentivirus for that first, for that first program. But obviously, you know, our platform, one of the one of the assets we have etang. Mo is our platforms ability to do genomic engineering and the T rex are our future future products. And that was why the marriage of sanguine to excel was so sensible. They they brought the TV experience and we brought editing that they read, they needed to take the platform forward.\\nJim Burchinal -- Wells Fargo. -- Analyst\\nGot it, then maybe a question on zinc finger transcription factors. Just wondering about the origin origin of the transcription transcription factor, whether it is Foley Schumann, or is there any synthetic component in those transcript transcription factors? And how do you think how should we think about immunogenicity? Thanks.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nSure, so, so the base components of the zinc finger transcription factors are all human. Obviously, in order to direct those transcription factors to a desired sequence, we have to design a synthetic protein that is specific for a specific sequence in the genome. And, and by nature of the fact that they are fully human, we expect that the immunogenicity should, should be inherently lower. And we haven't made any observations today to suggest that immunogenicity can be a problem.\\nJim Burchinal -- Wells Fargo. -- Analyst\\nGreat, thank you so much for taking the question and congrats on your progress.\\nSandy Macrae -- Chief Executive Officer\\nThank you very much.\\nOperator\\nThank you. And our next question comes from the line of Gena Wang with Barclays.\\nGena Wang -- Barclays -- Analyst\\nThank you for taking my questions. I have three questions. Now. First is regarding Haemophilia a. Just wondering, certainly I know this is already tech transferred to Pfizer given the ball milling experience, phase one two data did not three data dinner had quite different from the least one two. So you know, any thoughts you can share with us regarding your face one two data and regarding. you know, also the phase three data and one hypothesis was the manufacturing part. In essence, you know, this manufacturing Phase One, two is from your side. And now we'll transfer to the Pfizer in any thoughts you can help us understand in terms of our potential predict ability from phase one to data to phase three.\\nAnd then the second question is regarding Pfizer Partner Program, the ALS didn't single protein transcription gene regulation program. So wondering if you can share any color regarding the efficiency from this initial r&d study. And the last question is regarding the February program, you already enrolled second cohort and what will be their determination that you think you reach the optimal cohort that you can extend the cohort regarding the biomarker data like a plasma lecture with GD three, you know, as a reference, Avro showed 30 to 40% further reduction versus the baseline er T. Any thoughts you have regarding what is your boss in order to determine the optimal dose?\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nI'm afraid I may disappoint you in my answers the visor the face two of the ultra study and the progression of of this with Pfizer is really in their hands, no to talk about. And the announced or the abstracts for ash were announced today. And so there'll be talking about that at ash and so I would go to to to wait for those results. The convertibility between phase two and phase three, really we we mustn't see anything until we see the three results. As regards the SR north. All I can tell you is Pfizer very pleased with the product that we produce for them. And they have transferred into their research organization and paid the necessary milestone. As regards fabri, I'm going to pass on to Bettina Bettina. Can you talk about fabri? And what we're looking for and what this study will measure?\\nBettina Cockroft -- Senior Vice President and Chief Medical Officer\\nAbsolutely. So, yes, thank you for the question. So as I've mentioned earlier, we don't the first cohort of two patients, and enrollment is ongoing. And the study goal really is to provide a predictable and durable expression of the alpha Galle enzyme, which is the enzyme deficient in Fabry disease due to mutations in the GLA gene. And so we are going to be measuring this parameter as one of the more more important parameters. But as you point out, we're also looking at substrates. GB, three and Lysa, GB, three, these are the basis of some of the challenges in terms of morbidity in patients with fabri. So we're going to be monitoring all of this data along with other data. Remember, this is first and foremost, the safety and tolerability study to start off with. And we have a safety monitoring committee that will be will be involved in the decisions as we move on to escalate, goes to the optimum dose, think it is, is with the totality of the data, and the data that we are monitoring from other studies with with other products, of course, as well that we will be making our ultimate decisions on the dollars that we bring forward in our cohort expansion.\\nGena Wang -- Barclays -- Analyst\\nOkay, thank you.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nThank you very much for your question.\\nOperator\\nThank you. Our next question comes from the line of Eric Joseph with JPmorgan.\\nEric Joseph -- JPmorgan -- Analyst\\nHi, thanks for taking the question. Maybe just perhaps this cheated. One. I'm curious to get a sense of whether there are? Well, how we should be thinking about the potential for additional, largely wholly owned programs coming for the clinic over the next 12 to 18 months, relative to I guess what we've seen over the past year, a fair amount of, you know, leveraging up the platform through partnering activities.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nNext. Thank you for your question, Eric. Mark, this feels like one for you, please.\\nMark McClung -- Executive Vice President and Chief Business Officer\\nHi, Eric, thanks for the question. You know, so if you take a look at the, the deals that we've done, including those most recently, really the driver of that is is twofold. And in some cases, they've come to us on, you know, obviously in the the charging case intersect and in the couple of the candidates that we had progressing toward the the end. But they came to us with a view taxi, expanding the number of CMS targets that we weren't otherwise considering. So we looked at that as being really an extension of our, our potential pipeline. he second way we sort of took take a look at partnerships is whether they're bringing a specific expertise and the resources necessary to accelerate the products assuming they're successful to patients, and in that particular case, as well as the Novartis case. Both of those really fit those type of criteria. We fully intend and we to to become a genomic medicine company. And we are continually looking to advance wholly owned assets, which we would take into the clinic and I think a good example of that is is what you heard in terms of tx 200 as well as the follow on programs that we're intending to take forward into the clinic for our car t reg programs.\\nEric Joseph -- JPmorgan -- Analyst\\nGot it I guess in addition to T reg, are there certain disease states over targets that you have essentially walled off and are prioritizing for internal development.\\nMark McClung -- Executive Vice President and Chief Business Officer\\nWe'd not disclose that. I mean, we're we're taking a look at, obviously, we've got interest in the autoimmune spaces, as we talked about, with her Carty read programs. And Jason touched on earlier. You know, naturally, we're working heavily within the CNS area with our partners in Biogen and partnership with Novartis. And so, you know, there may be targets that we choose in that particular space, but we've not made any decisions on that as yet. We don't believe you can really stick areas and go after it, we need to let the science drive us toward things that we believe are important to develop for patients.\\nEric Joseph -- JPmorgan -- Analyst\\nGod, that's a tough one. Thanks for taking the question.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nSure.\\nOperator\\nThank you. Our next question comes from the line of Ritu Baral with Cowen.\\nRitu Baral -- Cowen -- Analyst\\nHi, guys, thank you for taking the question. This is while on for two, just two quick questions from me. First, on the star fabri study, are you still seeing impacts from COVID on enrollment? I know you've completed the first cohort, but are all the sites up and running? And then as a quick follow up, regarding the Pfizer collaboration with the ALS program, you know, what are the next steps for the program? Specifically, what's the next opportunity for a milestone to reach is that contingent on them initiating a clinical trial? and unicolor on this would be helpful. Thank you.\\nSandy Macrae -- Chief Executive Officer\\nThank you for your question. We haven't we or Pfizer haven't commented on the LS program and when the mouse ones will come? I would say again, reiterate what I said in the call script. It's a remarkable piece of science to be able to suppress the transcription of one Leal and leave the other one, on touched is why Pfizer, Kim does and we have achieved what they requested of us, and it's move forward to them. So let's hope because it's such a dreadful disease, let's hope it gets to patients as soon as possible. For the Fabry disease, I'm going to refer you to Bettina who will answer that question?\\nBettina Cockroft -- Senior Vice President and Chief Medical Officer\\nYes, and thank you for that question. So on the clinical operations side, I have to say, we have an excellent clinical operations team working very hard on maintaining the relationship with all the sites on during the pandemic, we've also been able to initiate sites qualify other sites as we expand our footprint for the study. Of course, COVID has had an impact worldwide, some regions more than others, we are confident that we can keep going with following the enrollment and dozing of the first two patients to keep going with our enrollment, despite the pandemic at this stage where the the things we've put in place from an operational perspective with home visits with virtual assistants have really helped us make sure that but we, together with the sites manage to to guide the patients through the enrollment and screening procedures to ultimately get us to dosing. Very pleased. I'm very, very pleased with the way the clinical to have navigated. We feel we have a responsibility to do this. Well, to make sure that the patient comes first whether they're being treated for coffered in which case we should not be taking up doctors times. But we've been ready to doors as soon as the window was open. And I think Bettina and her team have done remarkable job together.\\nRitu Baral -- Cowen -- Analyst\\nThank you for the color.\\nOperator\\nThank you. Our next question comes from the line of the Nicole Germino with Securities.\\nNicole Germino -- Securities -- Analyst\\nGood evening, everyone. Hi, thanks for taking my question. On February, given the competition in this space, what is it more specifically about saying the most a decapitated or the promoter that make it differentiated and better than your peers? And how have you made that determination? And then does how does sc 920 impacts the renal and cardiac tissue?\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nSo let me take that one. We are encouraged by the data we've seen from AV six in hemophilia. But until we those patients with Fabry disease, we really can't and shouldn't comment on what it's going to look like. The animal data looks very encouraging. We see supramaximal dozing and supramaximal effect. And in the animal dosing that we recently published, we're able to show benefit to both the heart and the kidney. But I'm, I'm just prudent in telling people to wait and let's see what the clinical results are. Were guiding that will show the clinical results to RCM just next year when the Deus Ex escalation phase is completed.\\nNicole Germino -- Securities -- Analyst\\nOkay, great. Thank you so much.\\nOperator\\nThank you. Next question comes from the line of Boran Wang with Guggenheim securities.\\nBoran Wang -- Guggenheim securities -- Analyst\\nHi, guys, thanks for taking my question. I had to one on PMA and other on the Albuquerque program on him a what's the plan going forward to share data on the Phase One, two, I know you'll have the updated app. But are there any specific time points provide a complete picture of the data and without requiring of all patients require cross that time point. And on the alto Carty program?\\nSandy Macrae -- Chief Executive Officer\\nYeah, we've seen some data, early data from other Allo programs from allergy and CRISPR. No any thoughts on the initial data generated so far, and any kind of learnings you can take, especially given some of the deaths we've seen in those trials? So let me do the humane and then passes to Jason to comment on aloe. So the I'm gonna say again, why piercing through Pfizer will are in control of the release of data on hemophilia. The there is an abstract has been accepted for ash and they will use whatever conference schedule in the future to continue to demonstrate the benefit to patients or reduce absent bleeding events and no requirement for factor. Jason, can you talk about the allergy alginate question, please.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nSure. Thank you, Sandy. So I believe that you're referring to aloe Carty programs in in oncology and not we have a partnership with Gilead to support their allogeneic Carty programs. kite has has guided that we're expecting to begin the studies on on their alpha genetics cd 19 targeted Carty therapy next year. And we believe that the data that we've seen so far from from others are consistent with, with these with these therapies having real therapeutic potential and we're excited about it and and we're excited to see Kai get the get the therapies into patients.\\nBoran Wang -- Guggenheim securities -- Analyst\\nOkay, thank you.\\nOperator\\nThank you. I will now turn the call back over to head of corporate communications. Sandy Macrae for any further remarks.\\nSandy Macrae -- Chief Executive Officer\\nThank you once again for joining us today and for your questions. We look forward to keeping you updated on our future developments.\\nOperator\\n[Operator Closing Remarks]\\nDuration: 49 minutes\\nCall participants:\\nMcDavid Stilwell -- Head of Corporate Communications\\nSandy Macrae -- Chief Executive Officer\\nBettina Cockroft -- Senior Vice President and Chief Medical Officer\\nSung Lee -- Executive Vice President and Chief Financial Officer\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nMark McClung -- Executive Vice President and Chief Business Officer\\nGeoff Meacham -- Bank of America -- Analyst\\nMaurice Raycroft -- Jefferies -- Analyst\\nJim Burchinal -- Wells Fargo. -- Analyst\\nGena Wang -- Barclays -- Analyst\\nEric Joseph -- JPmorgan -- Analyst\\nRitu Baral -- Cowen -- Analyst\\nNicole Germino -- Securities -- Analyst\\nBoran Wang -- Guggenheim securities -- Analyst\\nMore SGMO analysis\\nAll earnings call transcripts\\n\\n\\n\\n\\n\",\n          \"Prepared Remarks:\\nOperator\\nGood morning, and thank you for standing by. Welcome to today's International Paper's First Quarter 2021 Investor Earnings Day Conference Call. [Operator Instructions]\\nI'd now like to turn today's conference call over to Guillermo Gutierrez, Vice President, Investor Relations.\\nGuillermo Gutierrez -- Vice President of Investor Relations\\nThank you, Maria. Good morning, and thank you for joining International Paper's First Quarter 2021 Earnings Call. Our speakers this morning are Mark Sutton, Chairman and Chief Executive Officer; and Tim Nicholls, Senior Vice President and Chief Financial Officer. There's important information at the beginning of our presentation on Slide two, including certain legal disclaimers. For example, during this call, we will make forward-looking statements that are subject to risks and uncertainties, including the impact of COVID-19. We will also present certain non-U.S. GAAP financial information.\\nA reconciliation of those figures to U.S. GAAP financial measures is available on our website. Our website also contains copies of our first quarter 2021 earnings press release and today's presentation slides. Relative to the Ilim joint venture and Graphic Packaging investment, Slide two provides context around the financial information and measures presented on those entities.\\nI will now turn the call over to Mark Sutton.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nThank you, Guillermo, and good morning, everyone. We will begin our discussion on Slide three. International Paper delivered solid earnings and strong cash generation in the first quarter. Our mill and converting system performed well to mitigate the significant impact of the winter storm and support a strong customer demand across all of our packaging channels. Input costs and transportation were a headwind in the first quarter, especially for energy, which was impacted by the duration of the severe cold temperatures in the Southern U.S.\\nWe see momentum building, continuing to build across our three businesses with very strong demand for corrugated packaging and containerboard and solid demand for absorbent pulp. And in papers, we're seeing an improved supply demand backdrop in all of our key geographies. Our capital allocation in the first quarter, we repaid $108 million of debt and we returned $331 million to shareholders, including $129 million of share repurchases. Our performance again demonstrates the agility and resilience of International Paper to perform well across many different circumstances.\\nWe're passing the 1-year mark of the global pandemic, and I could not be any prouder of the commitment of our employees to take care of each other and take care of our customers. The vast majority of our 48,000 team members work in our mills and conversion plants each and every day, and their health and safety remains our most important responsibility. We also made solid progress on the spin-off of our Printing Papers business, which we expect to complete late in the third quarter this year. Our team is also making strong progress to develop and deliver multiple streams of earnings initiatives to achieve the $350 million to $400 million in incremental earnings and accelerated growth by the end of 2023.\\nAs we work to build a better IP, we remain laser-focused on delivering superior solutions to our customers, executing well and meeting our commitments to our shareowners and our other stakeholders. Turning now to Slide four, which shows our first quarter results. We delivered EBITDA of $730 million and free cash flow of $423 million despite the $80 million pre-tax earnings impact from the winter storm in the Southern U.S. Revenue increased by more than $100 million sequentially, primarily driven by price realization in our Packaging and Global Cellulose Fibers businesses. And again, free cash flow is strong with a continued focus on running our businesses well, controlling our cost and actively managing our working capital.\\nNow I'll turn it over to Tim, who will cover our business performance and our second quarter outlook. Tim?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nThank you, Mark, and good morning. I'll start with the quarter-over-quarter earnings bridge on Slide five. First quarter operating earnings were $0.76. The winter storm impacted pre-tax earnings by $80 million or a $0.15 impact to operating EPS. We're still in the very early stages of the insurance process and do not have a recovery estimate at this time. Looking at the bridge, price/mix was strong driven by prior period price flow-through and packaging and cellulose fibers. Volume was essentially flat with continued strong demand for corrugated packaging and absorbent pulp.\\nOverall papers volume continues to recover even though we saw the expected seasonal decline for papers in Brazil in the first quarter. Operations and costs were favorable. Mill and box system performance was solid and helped mitigate the impact of the winter storm, which was a cost headwind of $55 million to operations. Maintenance costs increased sequentially, and we expect to complete about 65% of our maintenance outages in the first half of the year. Input costs were unfavorable, which included a $20 million cost impact from the storm, mostly for energy and raw materials such as starch and adhesives.\\nOverall, we're seeing higher costs for recovered fiber, energy, chemicals and distribution, which we expect to continue in the second quarter. Transportation conditions are challenging, and we're experiencing significant rail, truck and ocean transportation congestion. Higher corporate expenses were driven by a noncash foreign exchange loss on intercompany loans, and lower equity earnings are partly attributed to the reduced ownership position in GPK. Turning to the segments, and starting with Industrial Packaging on Slide six. We continue to see strong demand across all of our channels, including box, sheets and containerboard.\\nFor the quarter, volume was essentially flat. We lost 145,000 tons of containerboard production due to the winter storm. Although our mills and box plants in the region recovered quickly, the storm did impact sales in the quarter. We had nearly 30 box plants in Texas, Louisiana and Mississippi affected by the storm, which impacted our box shipments in the quarter. Price and mix was strong. Our November increase is essentially implemented fully with the $131 million first quarter realization. And I would add, this is one of the fastest implementations that we've seen.\\nOperations and cost includes about $55 million impact from the winter storm, about half of which is due to unabsorbed fixed costs and the balance is related to repairs and higher distribution costs. Overall, mill and box plant performance was solid, and we leveraged our system to support strong customer demand across all of our channels. Maintenance outage costs increased sequentially. We did defer about $30 million of maintenance outages from the first to the second quarter due to the significant production loss resulting from the winter storm. We expect to complete about 75% of our planned maintenance outages for packaging in the first half of the year.\\nInput costs were a significant headwind in the quarter, including about $20 million related to the winter storm due to higher energy, distribution and raw materials in our mill system and box plants. Higher recovered fiber costs were another significant headwind in the quarter. We expect continued cost pressure for recovered fiber, energy distribution in the second quarter, and we're still seeing the lingering effects in certain chemicals produced in Texas and Louisiana as suppliers recover from the winter storm. Turning to Slide eight.\\nAs we enter the second quarter, we're seeing continued strong demand across all of our channels. U.S. and export containerboard demand is strong with low inventories in all regions. Our first quarter shipments were impacted by the significant production loss resulting from the storm. We're working with our customers to recover from extensive backlogs. In our U.S. box system demand remains robust as more states start lifting restrictions. E-commerce, again grew at a strong double-digit pace in the first quarter, and we believe the majority of the accelerated consumer adoption in this channel is permanent.\\nWith states starting to reopen, we're also seeing improved demand in segments with greater exposure to restaurant and foodservice channels, such as produce and protein, although we're still not back to pre-COVID levels. Nondurables, excluding food and beverage, represents about 30% of U.S. box demand across a wide range of consumer and industrial products. This segment is benefiting from strong consumer demand in the broad manufacturing sector recovery. And lastly, demand for durable goods, which had the immediate pullback due to COVID is benefiting from a healthy housing market.\\nWe're well positioned and have the scale and footprint to serve just about every corrugated segment in a meaningful way, and our packaging team continues to focus on delivering superior packaging solutions to help our customers succeed. Turning to Slide eight. I'll provide an update on the progress we're making in our EMEA packaging business. Our objective is to bring this business back to sustainable mid-teen margins and generate returns above our cost of capital. We're well on our way to achieving our goal. In the first quarter, we improved adjusted EBITDA by nearly $20 million compared with last year.\\nThe Madrid mill is fully ramped, and we have more integration and cost opportunities available. We're integrating our world-class lightweight recycled containerboard with our box network in Southern Europe to provide customers with a broader array of packaging solutions. We've improved our footprint in the Iberian Peninsula through selective acquisitions, including two box plants in Spain acquired at the end of the first quarter. These acquisitions provide additional integration opportunities with the Madrid mill. And more importantly, they enhance our commercial capabilities in the region. We continue to make progress with our box system performance and have more opportunity ahead.\\nAll our plants have clear commercial and operational plans, and we're leveraging the skills and resources from across the company to deliver on our commitments.\\nThe map on the slide shows our packaging footprint in Europe after the sale of our Turkey packaging business, which we expect to close in the second quarter. After the sale, the EMEA packaging business will have two recycled containerboard mills, 21 box plants and two sheet plants. And again, our commitment is to bring this business to sustainable returns above our cost of capital. Moving to Global Cellulose Fibers on Slide nine.\\nPrice and mix was favorable with price realization accelerating across all pulp segments in the first quarter. Volume was moderately lower due to the shipping delays related to port congestion. Demand for fluff is solid and we have healthy backlogs. Operations and costs improved sequentially, driven by the nonrepeat of the $20 million write-off in the fourth quarter as well as solid operations and good cost management. These improvements were partially offset by about $10 million of higher seasonal energy consumption and an FX loss at our mill in Canada.\\nMaintenance outage costs decreased as expected, and input costs increased due to higher wood costs in the Mid-Atlantic region as well as higher energy costs. Demand improved as we entered the year and the end-use demand signals for absorbent hygiene products is healthy. Turning to Printing Papers on Slide 10. Our business -- our papers business has demonstrated outstanding resilience throughout the past year. Our performance reflects the talent and commitment of our team, the scale and capabilities of our global footprint and the strength of our highly valued brands.\\nWe continue to see steady recovery in demand across all regions, which we expect will accelerate with broader return to office and return-to-school activity. I'd also add that we've seen significant improvement in supply demand dynamics both within the U.S. and outside the U.S. Looking at our first quarter performance, price and mix was stable across the segment. Volume decreased sequentially due to the lower seasonal demand in Brazil and Russia as expected. It also meant that the export supply chains are stretched in most regions. Operations and costs improved on solid operations and good cost management, as well as a favorable FX in Brazil of about $10 million.\\nFixed cost absorption improved with economic downtime decreasing by 40,000 tons sequentially across the system. Maintenance outages increased modestly, as expected, and input costs increased primarily due to higher wood and energy costs in North America. Looking at Ilim on Slide 11. The joint venture delivered $49 million in equity earnings in the first quarter with an EBITDA margin of nearly 35%, driven by higher average pricing. Volume decreased sequentially, primarily due to fewer shipping days because of the Chinese New Year, as well as the impact of tight shipping capacity in China. Underlying demand remained strong as we enter the second quarter.\\nAnd lastly, in April, we saved a $144 million dividend payment from Ilim, which is $44 million higher than the estimate we provided last quarter. Now we can turn to the outlook on Slide 12, and starting with Industrial Packaging. We expect price and mix to improve by $75 million on realization of our March 2021 price increase. Volume is expected to decrease by $10 million on lower seasonal demand in Spain and Morocco as the citrus season winds down. Operations and costs are expected to improve by $15 million, with the full recovery of the winter storm impact partially offset by higher incentive compensation accruals related to a stronger outlook.\\nStaying with Industrial Packaging, maintenance outage expense is expected to increase by $77 million. And input costs are expected to increase by $20 million due to higher OCC, energy, raw materials and distribution costs. In Global Cellulose Fibers, we expect price and mix to increase by $100 million on realization of prior price movements. Volume is expected to increase by $5 million. Operations and costs are expected to decrease earnings by $10 million. Maintenance outage expense is expected to decrease by $10 million, and input costs are expected to be stable. Turning to Printing Papers. We expect price and mix to increase by $25 million.\\nVolume is expected to increase by $5 million. Operations and costs are expected to decrease earnings by $10 million due to the nonrepeat of foreign currency gain in Brazil during the first quarter. Maintenance outage expense is expected to increase by $22 million, and input costs are expected to increase by $5 million. And under equity earnings, you'll see the outlook for our Ilim joint venture. Turning to Slide 13. I want to take a moment to update you on our capital allocation actions in the first quarter. We're committed to maintaining a strong balance sheet. We have no significant near-term maturities. And in the first quarter, we reduced debt by $108 million.\\nWe also returned $331 million to shareholders, including $129 million of share repurchases, which represented about 2.6 million shares at an average price of $50.28. We acquired two box plants in Spain at the end of the first quarter. You can expect M&A to continue to focus primarily on bolt-on opportunities in North America and Europe. And lastly, in the first quarter, we monetized about $400 million of our stake in Graphic Packaging. After that transaction, we now hold about 7.4% ownership in the partnership.\\nAnd with that, I'll turn it back over to Mark.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nThank you, Tim. Turning to Slide 14. As we enter the second quarter, I'm mindful that we're still in the midst of a global pandemic, and there is still significant uncertainty in the geographies and markets that we operate. Having said that, we see momentum building in our three businesses. We continue to see very strong demand for corrugated packaging and containerboard in North America and Europe. We're also seeing solid demand for absorbent pulp with more favorable supply and demand dynamics as paper-grade pulp demand recovers. In Printing Papers, we're seeing a steady recovery in demand.\\nAnd in areas where schools and offices have reopened, we're seeing a step change improvement. Overall, we're seeing a much better supply/demand backdrop. We expect price flow-through from prior price increases across our three businesses. We expect margins to improve, even as we manage through the impact of higher input costs for recovered fiber, energy and transportation. In addition, we expect productivity and other cost initiatives to offset general inflation. All of this contributes to a more favorable outlook for 2021.\\nAnd I'll end our prepared remarks on Slide 15. I just want to take a moment to reflect on what has now been a full year of living and working in a global pandemic environment. When we shared our first quarter performance last year, we talked about all the protocols we quickly put in place to keep our employees and contractors safe so that we could continue taking care of our customers. We stayed diligent about adhering to those protocols, and we will remain steadfast for as long as it takes to get fully and safely past the pandemic.\\nWe continue to operate in this environment with a view toward the short-term and long-term success and sustainability of International Paper for all of our stakeholders, with an unwavering commitment to the health and safety of our employees and contractors, to understanding and taking care of our customers' needs as they also adapt to rapid change, to supporting the critical needs in our communities and to building a better IP for all of our stakeholders.\\nSince the pandemic began, not a day goes by that I don't think about the commitment of our employees, and especially our frontline teams for their ability to adapt well and perform at a high level across circumstances and geographies. And once again, I want to take this time to thank each of our employees for their role in making our company strong and resilient.\\nAnd with that, Tim and I are happy to take your questions.\\nQuestions and Answers:\\nOperator\\nThank you. [Operator Instructions] Our first question comes from the line of Mark Wilde of Bank of Montreal.\\nMark Wilde -- Bank of Montreal -- Analyst\\nGood morning, Mark. Good morning, Tim.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nGood morning.\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nGood morning.\\nMark Wilde -- Bank of Montreal -- Analyst\\nMark, I'm just curious, it does seem like the containerboard business really has accelerated globally, not just containerboard, but corrugated. And that the market is quite tight. And I'm just curious about how that might be impacting your thinking about a potential conversion of that second line down at Selma?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nThat's a good question, Mark. We obviously have looked at that and what product we might need in the future. If you just play out the current conditions, you'd probably look at using some of that from a packaging standpoint sooner. But outside of interruptions like we talked about with the winter storm and one-offs, we have largely the containerboard we need when you look at all of our channels, domestic and our own box, domestic open market and export for what we believe is the foreseeable future. But that's a good option for us in the future. And it depends on the type of grades, whether it's medium or linerboard that we need. One is quicker and less expensive than the other. But it's on our radar screen.\\nWe don't feel the need to immediately do that right now. When we operate well and we don't have interruptions like we had in the first quarter, we feel quite confident in our containerboard quality, type of grade and overall capacity.\\nMark Wilde -- Bank of Montreal -- Analyst\\nOkay. And just as a follow-on, if I could, Mark. I know that both European producers and North American producers have been sort of pulling out of the export market and kind of rechanneling volume to their domestic businesses and domestic customers. I just -- I'm curious about how you think about this in the context of taking care of long-term export customers because I think there's some real concern by converters in places like Latin America that have always relied on imported board.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nYes. It's definitely important to us. IP is probably the largest provider of kraftliner board in Latin America and Europe for long-term customers who use it because it's needed. And that's critically important to us, and we've talked about the importance of our channels to market, especially for kraftliner. Things are very tight right now. Disruptions make that further -- more difficult for the supply chain. I think where we are right now is inventories are very low through the system with our customers and our own processes.\\nAnd we are working individually with each of our customers, I can't speak for others, obviously, to make sure we can provide as much of their needs as possible in the time that they need it. But I think we're looking at a tight supply chain, especially for kraftliner for the foreseeable future.\\nMark Wilde -- Bank of Montreal -- Analyst\\nOkay. Great. I'll turn it over. Thank you, Mark.\\nOperator\\nOur next question comes from the line of George Staphos of Bank of America.\\nGeorge Staphos -- Bank of America -- Analyst\\nHi, everyone. Good morning. Hope you're doing well. Thanks for the details. I guess my first question is really around corrugated volume. And Mark, you mentioned that from what you're seeing and the acceleration from e-commerce, that you think the -- and I'm paraphrasing, the new consumption levels and new usage of corrugated, they're more or less here to stay. You don't intend or don't expect that to recede. So can you tell us why -- what evidence you're seeing that suggests that and how your volumes have looked to the extent that you can comment early in the second quarter?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nSo it's a great question, George. I think one of the things we look at is what our customers look at. And on the e-commerce part of your question, we're seeing really important winning customers, investing more in their capability, putting real dollars and real equipment and real capability and hiring employees. Their data analytics around customer repeat buying and all that gives them confidence to believe that a good portion of this shift to an e-commerce way of retail is permanent. It may not be 100% permanent, but it is the majority of it. So we look for clues from our customers instead of trying to wish it or guess at it.\\nWhat's uncertain is as things return to a more \\\"normal environment\\\", what does traditional retail do? Is it a net loss to e-commerce? Or is it a hybrid? Were there still going to be some normal return to in-store brick-and-mortar type retail, and you can look at a lot of information, studies and listen to company's earnings reports that are in those businesses, and it's hard to conclude from that. So our box volumes in April for our own make box -- the boxes we make, looks -- the trends look like they're continuing from the first quarter.\\nBut I'll remind you, we serve multiple channels. So we're in the box market, whether we make the box, whether we have a long-term strategic partner using our containerboard and making specialty boxes or whether it's a pure open market, and we're seeing those volumes up close to double digit for the overall exposure we have for the North American box market. So it looks like more of the same. We do see some channel shifting, which is good news. We see obviously some foodservice and restaurant supply picking up.\\nWhere that shows up for IP, and we're overweight in this area is fresh food produce, the type of things restaurants buy twice weekly, 3 times weekly basis, which really got hit hard in the pandemic. So we're encouraged by what we're seeing in the demand trends and the segment exposure that we have.\\nGeorge Staphos -- Bank of America -- Analyst\\nThanks, Mark. Just a point of clarification. The close to double-digit reference that you just made, what was that referring to?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nIt's all in channels to market that we look to provide to the U.S. box market. So our vertical channel in our own box business, we have some strategic partnerships where we have either partial ownership or majority ownership downstream in the converting. And usually, that's specialty type products. And then we have just the pure open market where we have long-term arrangements. When we look at the activity and -- that we participate in the U.S. box market, it's really strong.\\nGeorge Staphos -- Bank of America -- Analyst\\nOkay. Thanks for that. My other question, recognizing this was a very different first quarter from a storm and outage standpoint. And clearly, we can understand why you saw such a pickup in energy costs in the quarter. Looking back over time, it looks like IP's consumption of energy has been relatively constant. Are there -- given what we've seen in the last quarter and given that experience, what are the areas that you see where perhaps IP can become even more efficient within its mill network in terms of energy consumption? Thanks, guys, and good luck in the quarter.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nThanks, George. It's a good question. On energy, the main thing we can do on the mill system side is maximize our own make energy in our fully integrated kraftliner mills, where we make anywhere from 75% to 85% of our energy with carbon-neutral biomass. There's more we can do there. Sometimes it takes investment. As you know, what we've done with our capital investment program over the last couple of years is to navigate some strategic projects like Riverdale and then the pandemic and managing our entire liquidity situation. We -- those are the type of projects that you can go back and get later.\\nSometimes, it's unfortunate, but we delay them even though they have really good returns. So we've got more investment we can make. Fuel switching, we've done a lot of to natural gas from other higher-cost fuels. And in the converting plants, we don't make our own energy. So part of it's geographical exposure to the grid, but part of it's energy efficiency through the uses of energy in the plant. Most all of that, where we are now in our company in terms of consumption, most all of that is part of our investment profile. And usually, George, those projects have the highest returns. And we plan to invest -- increase our investments in those areas now that all phases of our financial condition are much stronger.\\nGeorge Staphos -- Bank of America -- Analyst\\nThank you, Mark.\\nOperator\\nOur next question comes from the line of Mark Weintraub of Seaport Global.\\nMark Weintraub -- Seaport Global -- Analyst\\nThank you. First question was you really did have a lot more pricing in the Industrial Packaging business flow-through than I think your original guidance had been. And you mentioned, Tim, that this was one of the fastest pass-throughs or your ability to get price turned out to be very good. Can you give us more color on what happened and what it tells you?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nIt's a difficult question, Mark, because there's so many customers and so many unique commercial agreements. I think the general answer is when you have this type of demand, and a lot of our customers are dealing with multiple supply chain challenges. It's not just the packaging that they get but the other inputs. I think the discussion time about the gray area in every commercial relationship about how fast or how slow, no one loves price increases, obviously. That dynamic just lends itself, so let's get this done and get our material in and get it in as quickly as possible because I've got 17 problems and the box is only one of them.\\nThat's just a general answer. The dynamic out there right now is things are very tight in multiple parts of the supply chain for a lot of our customers. And everything at the final minute of when you implement tends to be a human team in negotiation and it just went faster.\\nMark Weintraub -- Seaport Global -- Analyst\\nGreat. And can you give us a sense -- I recognize that certainly by the end of the quarter, it was all in. Is there still some carryover impact that's included in that $75 million that you're looking for in the second quarter versus the first quarter? Or is that actually genuinely all from the new initiatives?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nYes. It's small, Mark. There's probably just a little bit from the first price increase, but virtually all of it's in. And so we're looking forward now to the March increase implementation.\\nMark Weintraub -- Seaport Global -- Analyst\\nAnd one last one, sort of in the same vein, but in the pulp business, where great to see that, hopefully, second quarter will actually be a little bit in the black. I imagine though, because of the way those contracts are laid out, that even based on the prices -- price increases you've already implemented that there should presumably be more to come in the second half of the year. A, is that valid? And b, do you have pretty -- do you begin to have pretty good visibility on that? Or is that going to be negotiations and conversations yet to come?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nIt's for the -- we gave an outlook. I think the number was $100 million in price in the second quarter. That's as far as we're going to go on that. But we like -- as I said in my closing prepared remarks, we really like the momentum in Cellulose Fibers right now. A big part of that like is the movement in pricing. But I don't want to go out into the third -- or into the third quarter and fourth quarter. But if you just take the confidence we have in the trajectory, I think you can make some conclusions.\\nMark Weintraub -- Seaport Global -- Analyst\\nThank you.\\nOperator\\nOur next question comes from the line of Adam Josephson of KeyBanc.\\nAdam Josephson -- KeyBanc -- Analyst\\nHope you're well. Well, Tim, one question on the guide -- the 2021 momentum building slide. I asked the same basic question on the last call, but -- so everything seems to be getting better as you go through the year. Why not resume providing guidance at this point? I know about all the -- there are many uncertainties, as there always are. So did you -- how much consideration did you get to doing that? And why did you reach the conclusion, at least for now that you don't want to resume doing so?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nYes. It's a good question, Adam. I mean, technically, we don't provide guidance as such. We give an outlook. It's true that in prior periods, we had talked about a full year outlook and expectations sometimes within a range. It's something that we look at every quarter. I think we're -- some of the uncertainty around COVID is -- seems to be diminishing. But I think maybe as we get to the middle of the year, we'll have a better feel for vaccination rates and what's reopening and what's not. And so it was just not enough in our view at this point in time to start talking about full year guidance. But we do have a lot of optimism about how we see the year playing out.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nAdam, this is Mark. Just to add. It's -- look, it's a good question. We have given the investment community, as Tim said, at least an EBITDA range, a couple of other numbers for full year expectations. I think what's missing is that EBITDA number. We did talk about our capital expenditures, for example. But as we get into this year, a full year guidance given in the middle of the year, I think was maybe less valuable than if we would have given at the beginning of the year. Look, I'm an optimistic person. You know me personally, Adam, I am feeling really good about where we are.\\nBut just as soon as I say that, I think about our employees in Poland right now or our employees in Brazil, and they are where we were during the Christmas holidays and in January with pandemic and its effect on their economy and their lives. So I just don't want to get out over our skis and say things that imply this is all behind us only to have to come back and say, what, that was too quick. So I know it's a little frustrating, but we're trying to get this transparent outlook, as Tim walked through methodically all those numbers on the outlook slide. And hopefully, that gives people a sense of the big picture, which is things are really strong and improving.\\nAnd we have, as Tim said, on the capital allocation slide, a balance sheet that's headed very quickly to the low end of our range and good cash generation, flowing cash through the capital allocation framework, dividend share repurchases like we committed to, albeit interrupted for a program not casually. And so that's the message I really want investors to take away and analysts to work with. But your point is well taken. It's information you used to have, but you don't have right now.\\nAdam Josephson -- KeyBanc -- Analyst\\nNo, I really appreciate that, Mark. And just one other question for you on -- back to the e-commerce and the whole box demand issue. You used to talk about the relationship between box demand and GDP, and between box demand and nondurable industrial production. And you have that really good slide in your roadshow handout to that effect. How do you think those relationships have changed, if at all, given this new information you have about the presumed permanence of this e-commerce growth.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nWell, that's a really good question. I know our team is looking at the resiliency of that model that creates that slide you're talking about in our roadshow where we have the nondurable and transportation index and a number of other metrics. I don't know if we've decided that there's a shift in it yet, but I know our team is looking at it. As soon as we have something that we feel good about and that it's legitimate and statistically valid, we like to share that in our investor material, and we'll do that in the future.\\nAdam Josephson -- KeyBanc -- Analyst\\nThanks so much, Mark. Best of luck in the quarter.\\nOperator\\nOur next question comes from the line of Phil Ng of Jefferies.\\nPhil Ng -- Jefferies -- Analyst\\nHey, guys. Appreciating there's a greater lag in the flow-through on pricing. But with fluff pulp prices approaching 2018 levels, and commercial initiatives you guys are implementing, how quickly do you think that earnings power for cellulose to kind of return back to 2018 levels?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nWell, we gave the outlook for the second quarter, and you can look at the trend there on just the pricing comment of $100 million. I think we are in that part of the pulp market dynamic. And we're also trying, as I mentioned multiple times, we're trying to change the business model commercially, primarily on how we go to market and how we interact with our customers so that we put more sustainability and less volatility in the business. And that's a lot of work, about work I can comment on because it's customer-specific, but we feel good about where we are right now. And we think the business can get back to. And then, if we can invest in the cost side, improve upon what numbers you're talking about from '18.\\nPhil Ng -- Jefferies -- Analyst\\nThat's great. I appreciate that color. It seems like a solid game plan. The 145,000 lost tons in containerboard from the winter storms, is your view you would essentially sell pretty much all that? Or would that have been kind of an effort behind to build inventory? The reason I'm asking, I'm just trying to gauge if you view that as pent-up demand for 2Q. And then more broadly, just given how tight things are, do you have bandwidth to kind of supply your customers given how strong demand is right now?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nYes. We're working hand in glove with customers across all of our channels, trying to make sure that we're meeting their needs as quickly as possible. Having said that, it's a challenge. 145,000 tons, a big portion of that was available for sale and ready to go. In some cases, as we go into the second quarter, it's a heavier maintenance outage quarter. And so part of it is preparing for that as well. But definitely missed opportunities on the containerboard side. But as, if not more importantly on the box side, with 30 plants down and significant exposure. So our estimates around that exposure is that the growth that we had in the quarter would be closer to overall industry growth if we haven't had that disruption.\\nPhil Ng -- Jefferies -- Analyst\\nBut you see that demand still there? Or your customers kind of went elsewhere to kind of get supply just given how tight things are?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nWell, some of it's there. Some of them are still working through, as I mentioned in the prepared comments, working through backlogs. All of these channels have different lead times on orders and when customers are expecting them. And so we're working through it customer by customer on that basis.\\nPhil Ng -- Jefferies -- Analyst\\nOkay. Super helpful, guys. Appreciate it.\\nOperator\\nOur next question is from Mark Connelly of Stephens.\\nMark Connelly -- Stephens -- Analyst\\nFollowing on Phil's question. If we remove the storm impact that held back first quarter, is there any reason to think that IP can't match the industry shipments in 2021 or even exceed it? I'm thinking about the outages and the maintenance timing shifts and that sort of stuff. Because obviously, there was a lag or a lag in performance in 4Q too. So I just want to make sure we're not missing anything.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nNo, it's a good question, Mark. There's no reason to believe we can't match or exceed. Now given our size exceeds means some basis points, not multiples. But there's no reason you can't match the market. Fourth quarter, we did have some operational issues, if you recall. And then not an excuse, but this geography and the winter storm matched right on top of us. But no reason you shouldn't expect us to perform at or better than the market.\\nMark Connelly -- Stephens -- Analyst\\nOkay. And -- thank you, that's helpful. Just on EMEA, following on Tim's comments, how does the push to mid-teens margins in EMEA breakout between converting and mill opportunities? I'm just wondering if there's spending opportunities at those mills or if most of the incremental investment and improvement is coming on the converting side.\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nYes. It's a good question, Mark. We think we have additional opportunities, not that so many of them require capital in the mill operations, but just in terms of how we're managing cost as we get fully up the ramp curve and integrated, and it's both mill and supply chain. So we see more opportunity for the mill in Spain. The other mill is a more mature mill that's been there for a while. And so it's probably running at an optimal level. But in Spain, given the integration play, we see more opportunity.\\nMark Connelly -- Stephens -- Analyst\\nSo bringing some of the strengths in the integration that you have in the U.S. over to there. Okay. That's very helpful. Thank you.\\nOperator\\nOur next question comes from the line of Cleve Rueckert of UBS.\\nCleve Rueckert -- UBS -- Analyst\\nHi. Good morning, everybody. Thanks for taking my questions.\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nMorning.\\nCleve Rueckert -- UBS -- Analyst\\nJust first off, I wanted to follow up on the $350 million to $400 million of incremental EBITDA. I think $300 million of that was supposed to be from cost savings. And I realized Q1 was kind of challenging, but I didn't hear an update on how much of that you've achieved to date or how much you expect to achieve this year headed toward that 2023 exit rate?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nYes. Well, you -- we didn't provide one. So we're working through our plans right now, and we're in the process of beginning the implementation of all that. We pointed on the last quarterly call to some of the benefits that we saw coming through, more of the process automation and using data analytics and technology. And as we go through this year, we're looking forward to probably the third quarter where we provide a robust update in terms of all of the plans that are being executed and achievement this year, but also run rate expectations for 2022.\\nCleve Rueckert -- UBS -- Analyst\\nOkay. All right. That's clear. And then, I guess, just a follow-up on the containerboard and corrugated box business. Could you give us just a sense of where your inventories stand, given the disruptions kind of, I guess, where you are today at an inventory level versus where you like to be or where you've been historically on average? And kind of what the trajectory is there on the inventory side given the outages in the second quarter?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nWell, the easy answer is we're lower than we'd like to be. And that's the source of the hand to glove comment Tim just made. So we need to rebuild, while we serve our customers' active demand, we need to be very efficient in rebuilding important roll stock inventories across the wide range of boxes that we have to make. So there's more for us to do. It's not unexpected when you have this type of demand, coupled with the one-off interruption of the storm we talked about and then just the timing of outage schedules. But the good news is we have a really big system, and it's very flexible and it recovers very quickly.\\nSo we feel like we could do it. But our inventories are lower than we would like, all things considered. And the main thing I'm concerned with right now is our ability to support our customers through their dynamic demand changes. And that's what our focus is right now.\\nCleve Rueckert -- UBS -- Analyst\\nThat's clear. I guess just quickly, given what you know about the second quarter, would you expect to be in a position to build inventories?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nEvery effort is going to be made to try to restore inventory levels, but it's a heavy maintenance outage quarter. And so you're triaging and prioritizing and trying to satisfy all of the needs across the channels. So now the good news is, most of the outages are behind us by the time we get to the middle of the year. But these supply chains are very long, and they take a long time to recover.\\nCleve Rueckert -- UBS -- Analyst\\nThat's very clear. Thanks, guys. Appreciate it.\\nOperator\\n[Operator Instructions] Our next question comes from the line of Gabe Hajde of Wells Fargo Securities.\\nGabe Hajde -- Wells Fargo Securities -- Analyst\\nMark, Tim, good morning. I hope you guys are well.\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nMorning.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nMorning, Gabe.\\nGabe Hajde -- Wells Fargo Securities -- Analyst\\nI'm thinking about integration levels in the corrugated operations or Industrial Packaging North America and kind of whether or not you kind of still view this as the right destination? I mean, you have some competitors that are maybe trying to bump that up for different reasons. And I also appreciate that maybe looking back in the rearview mirror, you're kind of playing a little bit more defense and/or kind of making some asset changes along the way. Now you've got some kind of more, I'll call it, disposable cash to go on offense with and you made these two small box plant acquisitions. Is that part of the strategy that maybe get that closer to something, I don't know, 90%? Or you feel good at that 80% level kind of over a longer-term basis?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nYes. So we think what's important about integration is how we go about building it. Our most profitable channel is our North American domestically integrated channel containerboard to box and to the customer. And we want to grow that part of the business by delivering superior solutions on the packaging side to our customers. So that we're building long-term sustainable relationships where we can through small M&A or some of these more creative arrangements that we've started implementing to grow that channel. So higher over time, but done in a very sustainable way.\\nGabe Hajde -- Wells Fargo Securities -- Analyst\\nOkay. And then, I guess, kind of to revisit the cost reduction or the $300 million to $350 million of savings and trying to marry up the comments that you made about Europe. Are those sort of mutual exclusive, meaning the $20 million or so that you saw an improvement in profitability this quarter and I think what you talked about kind of getting back to mid-teens implies maybe another $100 million of improvement in aggregate for European Industrial Packaging. Is that more related to the mill conversion over there and that starting to contribute? Or is that, again, kind of included in that $300 million to $350 million of savings?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nYes. Part of it is included, but it's across commercial, operational supply chain. It's all the things that we touch in terms of delivering a packaging solution to a customer. So we've got improvement plans across all aspects of the business.\\nGabe Hajde -- Wells Fargo Securities -- Analyst\\nThank you, guys.\\nOperator\\nOur next question comes from the line of Paul Quinn of RBC Capital Markets.\\nPaul Quinn -- RBC Capital Markets -- Analyst\\nYes. Thanks very much. Good morning, guys.\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nGood morning.\\nPaul Quinn -- RBC Capital Markets -- Analyst\\nJust had a question on Global Cellulose Fibers. Just when I look at the quarter, I mean, it's an improvement, but it's still a disappointing result, especially when I compare it to your European peers. Where do you see this business being mid-cycle? Can you get up to the profitability of your peers? And when you -- how long do you think that's going to take?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nWell, as I mentioned on the last call, we -- last quarter call, Paul, we see the business improving quarter after quarter after quarter. And we think it'll be in very good shape. I don't have all those European numbers in my head -- off the top of my head, but we think it'll be in very good shape as we leave '21 and head into '22.\\nPaul Quinn -- RBC Capital Markets -- Analyst\\nAlright. That's all I had. Best of luck, guys.\\nOperator\\nOur next question comes from the line of Neel Kumar of Morgan Stanley.\\nNeel Kumar -- Morgan Stanley -- Analyst\\nGreat. Thank you. For corrugated, can you just talk about the cadence of volume growth through the first quarter by month? And then, can you just give us a sense of what you're seeing in terms of box shipments so far in April?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nApril is running very close to maybe a little bit ahead of how we exited the quarter, just looking -- it was pretty steady throughout the quarter -- yes. I mean, it started really strong in January. Now we think a big part of that is our exposure to e-commerce because you not only have the Christmas push around the holidays, but January with returns and in specialty sales and whatnot. It tends to be a strong month as well. But I think it was solid throughout the quarter.\\nNeel Kumar -- Morgan Stanley -- Analyst\\nOkay. That's helpful. And then in terms of your recent asset sales, I was wondering if you can just touch on how you're thinking about allocating proceeds between buybacks versus inorganic and organic investments? And then more generally, where are you in the process of evaluating your portfolio of assets. Could there be additional asset sale announcements? Or is it generally complete at this point?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nWell, when we talked about on the acquisition side is look at what we've been doing for the past couple of years. They've tended to be one-off operations, sometimes 2, bolt-on in nature and filling gaps in capability or exposure that we want. And most of them, to be honest, that's happened in Europe at this point. In terms of the cash coming in, we have a fairly robust capital allocation framework that we have talked about over time, including the strong balance sheet, target ranges of debt. The fact that we're on a path of share repurchases before COVID hit and out of prudence we took a pause last year, but we're back in the market. But the goal is to be thoughtful about the cash coming in and making sure that we're doing everything in our power to maximize value through the actions that we take.\\nOperator\\nAnd our last question comes from the line of Kyle White of Deutsche Bank.\\nKyle White -- Deutsche Bank -- Analyst\\nHey, good morning. Thanks for taking the question. On Global Cellulose Fibers, I just want to talk about the port congestion that you're experiencing and maybe how that is impacting your volumes or your supply chain in that business?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nIt's a good question, Kyle. It's a big issue. We're not losing orders because of it because we're spec-ed in, in a lot of the customers. It's just creating a long, long supply chain. So customers are trying to figure out the new duration between placing an order and actually receiving it and in some cases, trying to get our help to understand whether they should change their order cycle. So there's a lot of order management changes being talked about and figured out between IP as the supplier and our customers. But it affects more than our pulp business.\\nIt affects our export containerboard, and we're even seeing it in our export paper business in Brazil. I don't think there's an immediate fix to it. So it's a velocity mission on the supply chain than it looks like, we're going to have to adapt to for some period of time.\\nKyle White -- Deutsche Bank -- Analyst\\nGot it. That's helpful. And then switching to EMEA Industrial Packaging. Can you guys provide some of your integration rate for just that region and kind of where do you see it going with these recent acquisitions in Spain? And then maybe just a longer-term target for integration there as you continue kind of bolt-ons in that region?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nWe typically don't give a number because it's not as clean. We're integrated on our kraftliner from our U.S. mill system to our European box plants. We have world-class mill. We just started up a couple of years ago in Madrid. That's almost at its full ramp, which is a lot of our high-performance lightweight liner. But we buy most of our medium -- the corrugated medium from the open market. So we typically haven't given an absolute number. But as Tim said, building an integrated model regionally is where we have the most success commercially and on the financial metrics. And so that's kind of the approach we're taking in Europe is regional density.\\nAnd so right now, it's Iberian Peninsula surrounding our new mill and supported with kraftliner from our U.S. system. And then we have some very important suppliers in the European market for grades that we don't make or just that make geographic sense because of grade. So we're still a large customer for some key European containerboard producers and those are long-term relationships.\\nKyle White -- Deutsche Bank -- Analyst\\nGot it. Thank you. Good luck in the quarter.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nThank you. So I appreciate everyone's questions. Again, thank you for your interest in International Paper, and we look forward to talking with you again next quarter.\\nOperator\\n[Operator Closing Remarks]\\nDuration: 90 minutes\\nCall participants:\\nGuillermo Gutierrez -- Vice President of Investor Relations\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nMark Wilde -- Bank of Montreal -- Analyst\\nGeorge Staphos -- Bank of America -- Analyst\\nMark Weintraub -- Seaport Global -- Analyst\\nAdam Josephson -- KeyBanc -- Analyst\\nPhil Ng -- Jefferies -- Analyst\\nMark Connelly -- Stephens -- Analyst\\nCleve Rueckert -- UBS -- Analyst\\nGabe Hajde -- Wells Fargo Securities -- Analyst\\nPaul Quinn -- RBC Capital Markets -- Analyst\\nNeel Kumar -- Morgan Stanley -- Analyst\\nKyle White -- Deutsche Bank -- Analyst\\nMore IP analysis\\nAll earnings call transcripts\\n\\n\\n\\n\\n\",\n          \"Prepared Remarks:\\nOperator\\nWelcome to AxoGen, Inc. Second Quarter 2020 Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.\\nI would now like to turn the conference over to your host, Pete Mariani, AxoGen's Chief Financial Officer. Please begin, Mr. Mariani.\\nPeter J. Mariani -- Chief Financial Officer\\nThank you, Devin, and good afternoon, everyone. Joining me on today's call is Karen Zaderej, AxoGen's Chairman, Chief Executive Officer and President. Karen will begin today's call with an overview of our second quarter performance and an update on the ongoing recovery in our markets, followed by a review of the recent announcement of our RECON study enrollment and our path to a BLA submission. I will then provide an analysis of our second quarter performance, along with a summary of our recently announced debt deal with Oberland capital.\\nToday's call is being broadcast live via webcast, which is available on the Investors section of AxoGen's website. Within an hour following the end of the live call, a replay will be available in the Investors section of the company's website at www.axogeninc.com. Before we get started, I'd like to remind you that during this conference call, the company will make projections and forward-looking statements regarding future events.\\nWe encourage you to review the company's past and future filings with the SEC, including, without limitation, the company's forms 10-K and 10-Q, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements related to the expected impact of COVID-19 on our business, statements regarding product acquisition and/or development, product potential, the regulatory environment, sales and marketing strategies, capital resources or operating performance.\\nAnd with that, I'd like to turn the call over to Karen. Karen?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nThank you, Pete, and good afternoon, everyone. Our total revenue for the quarter was $22.1 million, representing a 17% decline to the prior year period. While COVID-19 had a material negative impact on total revenue, we saw steady improvement across the quarter as our customers reopen their surgical schedules. Our second quarter performance reflects the recovery in our markets that was stronger than we anticipated. As well as the priority that surgeons and hospitals have placed on nerve repair with AxoGen products in the early stages of the recovery. Our recovery also reflects the hard work and creativity of the entire AxoGen team to support our customers and their patients in this difficult environment.\\nThe recovery varied regionally based on the intensity and trends of COVID-19 in local markets. As elective surgeries resumed, we experienced short-term regional surges in nerve repair cases, reflecting the completion of deferred procedures. These recovery surges were typically followed by a return to more normalized levels for the territory. Certain interviews that we conducted confirmed that nearly all surgeons had experienced significant disruption to their practice and a reduction in surgical procedures due to COVID-19, but many surgeons believed that they were already caught up with their current backlog of deferred procedures, while most others believe they would catch up by the end of the summer.\\nIn addition to regional variation, our recovery also varies by nerve repair applications with our core trauma business leading our recovery. The recovery of procedures in our breast and OMF applications as well as our emerging business in the surgical treatment of pain began later in the quarter. Overall, we're encouraged by the execution of our team and the priority hospitals and surgeons are giving to nerve repair with AxoGen products during the recovery. However, we remain measured in our outlook for the remainder of the year as most currently deferred procedures will likely be completed by the end of the summer, and COVID-19 may continue to negatively impact the incidence of trauma, and regional surgical procedure volumes.\\nWe, therefore, expect third and fourth quarter revenue to remain below prior year levels. In the area of sales execution, we continue to strategically focus our sales representatives on extremity trauma and on driving deeper penetration with our existing surgeon customers, although COVID-19 required us to adjust our approach. During April, healthcare facilities broadly restricted vendor access, and we directed our sales team to enter facilities only when requested and necessary. Our sales representatives remained in frequent contact with our customers virtually. And they work together to provide effective case support remotely.\\nWe also used restricted time to provide six weeks of extensive product and skills training for our sales team, which we believe provided the benefits of keeping the sales team positively engaged and improve their ability to support our customers. On May 1, we released our sales team to begin reentering healthcare facilities following local, regional and national guidelines and using contact tracing. While our access to healthcare facilities have improved, the ability to effectively support our customers remotely continues to be an important learned capability that our team has embraced, and we believe our customers have appreciated.\\nWe ended the second quarter with 112 direct sales representatives, an increase of three representatives added early in the quarter. With our slowing of sales headcount expansion this year, we have minimized change and disruption to stabilize our sales territories and provide consistency of support to our customers. Our direct sales channel was supplemented by 19 independent sales agencies who generally cover geographies that are less impacted by COVID-19 during the quarter. These geographies delivered better year-over-year performance than those covered by our direct sales representatives. As a result, the indirect channel represented approximately 15% of our total revenue in the second quarter compared to an approximately 10% in the first quarter.\\nWe had 789 active accounts in the second quarter, an increase of 4% from 752 one year ago and down 4% versus the first quarter. We have always reported our number of active accounts as an average for the quarter. And the significant decrease in the number of orders from accounts in April and early May had a material impact on the average for the second quarter. Our active accounts have continued to increase each month, such that for the three months ending July 31, our average active accounts has increased and is more consistent with our Q1 average of 825.\\nWe were pleased that a large majority of our top surgeons and hospitals continue to use and order AxoGen products for their patients despite the challenges of COVID-19. The top 10% of our active accounts continue to represent approximately 35% of our revenue. Our sales team remains focused on our strategy of going deeper with current certain customers and exited the second quarter well prepared for the second half of the year. We continue to focus on building market awareness of AxoGen and our products despite reduced in-person access to surgeons and restrictions on certain travel to scientific conferences.\\nIn June, we expanded our digital marketing capabilities, allowing us to more fully engage with surgeons electronically. These digital efforts provide an enhanced long-term capability to supplement the efforts of our sales team. And help our sales reps engage with surgeons where access to hospitals remains limited. Our efforts to educate surgeons and develop advocates continued in the second quarter. In March, we canceled the remainder of our 2020 schedule of in-person surgeon and fellows education programs, and we've since developed several virtual education programs led by surgeon experts in nerve repair. In June, we launched an invitation-only program for early career upper extremity surgeons who are passionate about advancing the field of nerve repair. The program is an interactive 6-part series, led by an expert faculty.\\nSimilarly, we launched a surgeon-led extremity trauma webinar series open to all of our surgeon customers. We're also continuing our commitment to educating hand and microsurgery fellows and are launching an updated training program for the second half of 2020. We previously discussed our plans to introduce new products and expand the application of our portfolio into the surgical treatment of pain, focused on symptomatic neuroma. We launched AxoGuard Nerve Cap in February, and are pleased with our early results as we focus on expanding the nerve repair algorithm of our current surgeon customers.\\nNerve Cap, an important addition to our solutions portfolio, designed to protect the peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. With the addition of Nerve Cap, we now have a full portfolio of products for nerve connection, nerve protection and nerve termination. Increasing surgeon adoption of our product portfolio continues to be supported by a large and expanding body of clinical data. We recently announced our RECON clinical study had reached its targeted enrollment of 220 subjects in July.\\nRECON is our Phase III pivotal study supporting our biologics license application, or BLA, which will transition our Avance Nerve Graft from a Section 361 tissue product to a Section 351 biologic products. We're pleased to have reached this important milestone despite a challenging environment for clinical studies, and we appreciate the dedication and commitment of our participating study teams as well as our internal team of clinical professionals. The RECON clinical study protocol requires a one year follow-up assessment with the allowance for an additional three months visit window. With the final subjects enrolled in July of 2020, the last subject is expected to complete the study no later than October of 2021.\\nWe've increased our efforts to support completion of subject follow-up visits during the COVID-19 crisis by implementing an expanded home health visit program to allow follow-up visits to be conducted by a trained healthcare professional outside of the clinic environment and with appropriate safety precautions. We are working closely with our research centers to monitor follow visit windows and minimize any potential disruption. We anticipate providing a preliminary report of trial data in the second quarter of 2022 and expect to file the BLA in 2023. In addition to the completion of enrollment of the RECON study, our RANGER Registry now has over 2,200 nerve injuries enrolled.\\nAnd we expect data from the study to be presented at clinical conferences and published in the second half of the year. Enrollment in our REPOSE study is ongoing. REPOSE is a prospective randomized controlled study evaluating the use of AxoGuard Nerve Cap in the management of painful neuroma as compared to a standard neurectomy procedure. Preliminary outcomes from the pilot phase of the REPOSE study found that at six months, subjects reported meaningful improvements in pain and quality of life scales. We've completed the last subject follow-up visits and data analysis is under way to support our REPOSE study pilot phase manuscript.\\nWhile this is a small pilot study, we remain encouraged by the positive impact reported to date and will continue enrollment of the comparative phase of the study as centers reopen to research subjects. As we noted in our call in May, we've paused enrollment of our Sensation-NOW clinical registry for the remainder of 2020, given the COVID-19-related restrictions in our study centers. We're pleased with the enrollment of 600 subjects in the registry and believe this will create a significant body of evidence around the breast neurotization technique. Similarly, we've paused enrollment in our RETHINK PAIN registry and our Avive ASSIST study.\\nWe continue to monitor the recovery of activities at study centers and will prioritize the potential restart of the clinical programs based on our business needs. We remain committed to providing meaningful and impactful clinical evidence on the utility of our nerve repair portfolio. Despite ongoing COVID-related challenges in the market, we're encouraged by the performance of our AxoGen team to creatively adapt and adjust to these challenges. We've learned new skills in supporting our customers and continue to advance our strategy focused on extremity trauma and driving deeper penetration with our existing surgeon customers. We remain as excited as ever with the opportunity in front of us, and we believe we are well positioned to drive continued growth as we emerge from the pandemic.\\nNow I'll turn it over to Pete for a review of financial highlights. Pete?\\nPeter J. Mariani -- Chief Financial Officer\\nThanks, Karen. Second quarter revenue declined 17% to $22.1 million. Our revenue decline for the quarter was the result of a 19% decrease in unit volume, partially offset by a 2% net benefit from changes in pricing and product mix. Gross profit for the second quarter was $16.5 million compared to $22.5 million in the prior year. Gross margin was 74.7% for Q2 compared to 84.1% in the prior year second quarter. Gross margin was negatively impacted in Q2 as a result of increased period and variance cost, associated with the suspension of tissue processing during the quarter of $1.6 million and increases to inventory reserves.\\nWe began a gradual restart of our tissue processing in June, are continuing that ramp in the third quarter and anticipate that gross margins will return to normalized levels as sales and production levels recover. Total operating expenses in the second quarter declined 18% to $24.8 million compared to $30.1 million in the prior year. Total operating expenses in the second quarter included $2.2 million in noncash stock compensation compared to $2.7 million in the prior year. Sales and marketing expense in the second quarter declined 23% to $14.3 million compared to $18.5 million in the prior year.\\nThis decrease was primarily due to reduced compensation expenses including lower commissions, a reduction in our surgeon education expenses after canceling in-person education programs and lower travel expense as a result of the travel restrictions and canceled programs. As a percentage of total revenue, sales and marketing expense decreased or decreased to 65% for the three months ended June 30, 2020, as compared to 69% for the previous year. Research and development spending in the second quarter decreased 5% to $4.1 million compared to $4.3 million in the prior year.\\nResearch and development costs include product development, including expenses in support of the BLA for the Avance Nerve Graft and clinical research. Product development expenses represented approximately 50% of total R&D in the second quarter compared to 58% in the prior year. While clinical expenses represented the other 50% in the second quarter of 2020 compared to 42% in the prior year. As a percent of total revenues, research and development expenses were 18.4% in Q2 and compared to 16% in the prior year. General and administrative expenses in the second quarter decreased 13% to $6.4 million or 29% of revenue, compared to $7.4 million or 27.6% of revenue in the prior year.\\nHe decrease is primarily related to the reduction in litigation and professional fees as well as lower compensation and travel expenses. Net loss in the second quarter was $8.1 million or $0.20 per share compared to $7 million or $0.18 per share in the prior year. Excluding the impact of noncash stock compensation as well as litigation and related charges, adjusted net loss and net loss per share in Q2 of this year was $5.9 million and $0.15 per share compared to $3.7 million and $0.10 per share in the prior year. Adjusted EBITDA loss in the quarter, which also excludes the impact of stock compensation, litigation and related charges, was $5.7 million compared to an adjusted EBITDA loss of $4.1 million in the prior year.\\nTurning to our balance sheet. The balance of cash, cash equivalents and investments on June 30 was $109.9 million, compared to a balance of $89 million in March of 2020. The net change reflects the receipt of net debt proceeds of $34.7 million, partially offset by capital expenditures totaling $7.7 million and net operating cash burn of $6 million during the quarter. Capital expenditures in the quarter included $6.5 million related to cost incurred for our Dayton biologic processing center prior to the suspension of construction in April, and $1.2 million related to our new office and lab facility in Tampa.\\nWe anticipate completing our new Tampa facility in the third quarter and restarting construction on our Dayton biologics processing center in early 2021. On June 30, we announced a new seven year interest-only financing agreement with Oberland Capital, which provides up to $75 million in total financing commitments with $35 million drawn at close. The second tranche of $15 million can be drawn at the company's option upon achieving two consecutive quarters with revenue of at least $20 million. And this second tranche can also be put to the company at any time by Oberland. The third tranche of $25 million can be drawn by the company or at the company's option upon achieving two consecutive quarters with revenue of $28 million.\\nOberland cannot put third tranche to AxoGen. Under the terms of the agreement, the option to draw both the second and third tranche expires on December 31, 2021. Interest from this facility is calculated a 7.5% plus the greater of LIBOR or 2%, leading to an interest rated closing of 9.5%. An additional quarterly royalty payment calculated on up to $70 million of annual revenue will begin on September 30, 2021. This royalty structure results in approximately 1% per year of additional payment on the outstanding loan amount. We believe the terms of this debt agreement allow us to strengthen our balance sheet and support the completion of the Dayton and Tampa facilities.\\nThe financing provides a manageable and flexible covenant structure, and we believe the interest-only provision for the full seven years provides a sufficient liquidity extension without diluting our shareholders that can support our continued growth through an uncertain environment and as we drive toward long-term profitability. On April 23, we announced a cost mitigation initiative designed to defer and reduce certain expenses and capital expenditures in response to the anticipated reduction of revenue caused by the ongoing COVID-19 pandemic.\\nThis initiative preserved our ability to support customers and patients in the second quarter and through the recovery and put us on a more efficient spending run rate. The initiative included the reduction of executive cash compensation and Board fees by 20%, and reduced cash compensation for all other exempt salary employees by 10% to 15%. We have restored pay levels for most employees as of August, although our officers and the Board have continued with a 20% pay cut for the time being.\\nAdditionally, we were able to defer approximately $25 million to complete our Dayton, Ohio facility for up to a year. While the path and pace of our business recovery continues to be uncertain, we are encouraged by the execution of our team and the trends in our markets that we observed during the second quarter. We also believe that the strength of our balance sheet, our cost-mitigation initiatives and our continued commercial execution will allow us to emerge from this pandemic-related downturn, a stronger, leaner organization and a lot of path to profitability.\\nAnd with that, I'd like to hand the call back over to Karen.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nThank you, Pete. We're encouraged by the performance of our commercial team during the pandemic, and believe that our renewed focus on the core trauma opportunity has supported the pace of our recovery and has positioned us well as we enter the second half of the year and continue to develop the nerve repair market. We believe that the regional surges we experienced as surgical cases reopened indicates that nerve repair with AxoGen products ranks high among surgeon priorities. And provides additional evidence of our products, clinical benefit and value proposition to patients, surgeons and hospitals. At this point, I'd like to open up the line for questions. Devin?\\nQuestions and Answers:\\nOperator\\n[Operator Instructions] Our first question comes from the line of Raj Denhoy with Jefferies. Please proceed with your question.\\nRaj Denhoy -- Jefferies -- Analyst\\nHi, good afternoon.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nGood afternoon, Raj.\\nPeter J. Mariani -- Chief Financial Officer\\nHi, Raj.\\nRaj Denhoy -- Jefferies -- Analyst\\nI wonder if I could start with the revenue lines. Pretty encouraging to see only down, I think it was 17% for the quarter after the negative 70%, I think you talked about in April. And so it does imply that very strong recovery in the second couple of quarters second couple of months of the quarter, but you're still, I guess, pointing to that being mostly recovered procedures as opposed to underlying demand. And so what I'm trying to get at is what is that underlying demand right now? And you did talk about it being still below 2019 levels in the back half of the year. And so maybe you could just ground us in terms of where you think we are on that metric?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nYes. So the recovery in the quarter was both. It was both deferred procedures from the March time period that got rolled over into the Q2 time period as well as current trauma that just happens day-to-day as surgical ORs opened up, surgeons were able to do in real time. And so we saw both of those occurring and driving the demand. We definitely saw a surge or a spike as various regions opened up. And of course, those happened at different times as regions had different time periods of the recovery.\\nAs you can imagine, some of the Northeast recovered either late June or even into July, and other parts of the country started to recover in May, balanced by some of the pullback that we've seen in some of the regions as COVID starts up again. So from a impact to us overall. We feel that incidence overall of trauma is still down somewhat, not as much as it was during the full shutdown, but we believe that the overall incident is somewhat depressed. We believe that from a deferred procedures, actually, many of them were completed in the second quarter.\\nSo those March procedure that didn't happen, got rolled over into March excuse me, in the second quarter. There are some deferred procedures that will still get wrapped up toward the end of summer. But really, we think that, again, given the priority that surgeons placed on nerve repair, they moved those procedures pretty quickly into the OR. And so we won't see a big surge from deferred procedures, but we do see the underlying demand continuing to stabilize.\\nRaj Denhoy -- Jefferies -- Analyst\\nI guess I'm trying to understand at what level? I know you're not giving guidance, and I appreciate that you're operating under a pretty limited information. But is that down 10%? Is it down 20%? What level of lower demand are we talking about at this point? And I appreciate you also have the ability to speak to July. So I don't know if you want to comment on that as well.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nWell, I think we saw good solid trends as we moved into the third quarter and in July. We're encouraged by that. But our and I'll just tell you my hesitation on giving you a depression of the incidence of trauma and the surgical repair of those procedures is because I still don't know what's going to happen regionally around COVID as it resurges in different places. And that's going to affect the trauma rate. And so I really I just I don't feel like it's fair to give you a guidance number because it's going to be based on the resurgence of COVID. The underlying demand for the products remains strong, and surgeons certainly are prioritizing getting those nerve repairs done.\\nRaj Denhoy -- Jefferies -- Analyst\\nUnderstood. On a separate topic, you were, I guess, pretty encouraged by what you're seeing on your transition to more kind of digital or virtual training and even case support efforts. And I guess what I'm asking about is how permanent do you think some of these might be? I mean is something you could see playing out even once COVID ebbs and you can get back into the hospital? Does this represent some potential cost savings for you longer term? And how do you see this playing out over the next couple of years?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nYes. I think that we have learned. We've been really nimble. We've learned some new skills and build some new capabilities. And I'm pretty optimistic that these are permanent additions to our skill sets and capabilities. And so when we think about the remote case coverage, some of the virtual education work that we've developed, and the digital marketing tools that we've developed, we think we're going to keep those in our tool belt for the long term. We think they really are beneficial to us.\\nRaj Denhoy -- Jefferies -- Analyst\\nBut I guess, do those replace things you were doing? Or are those really additive in a sense? I mean is there the potential that you could see a permanent reduction in your selling costs, for instance, from where you were pre COVID?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nYes. I think that they contribute to sales rep productivity and overall commercialization productivity. So I think they are added tools that improve our overall productivity and make us more efficient.\\nRaj Denhoy -- Jefferies -- Analyst\\nOkay, understood. Thank you.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nThanks Raj.\\nOperator\\nOur next question comes from the line of David Turkaly with JMP Securities. Please proceed with your question.\\nDan Stauder -- JMP Securities -- Analyst\\nYes, hi, this is actually Dan Stauder on for Dave. How is it going?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nHi, Dan.\\nPeter J. Mariani -- Chief Financial Officer\\nHi, Dan.\\nDan Stauder -- JMP Securities -- Analyst\\nGreat. It's actually Dan Stauder on for Dave. So I guess just going back to Raj's question. You mentioned that sales consisted of both deferred procedures as well as some current trauma demand. Could you give us any more color on that? How much contributed from both? Was it mainly from recoup cases? Or any amount of detail you can go into that would be great.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nWell, by far, the majority is day-to-day trauma. The deferred cases that rolled in were what was delayed in March. So we saw procedures start to drop in the early part of March, and some of those obviously rolled in and were deferred procedures. But trauma overall in the peak of April, we estimate it was down about 20% and it has come back up from that. Again, it's highly affected by activity and activities affected by COVID and the lockdowns in various regions associated with that. But we've come up materially from where we were at the low point, both in, we believe, the incidence of trauma. As well as patients' willingness to come into either hospitals or surgery centers to get that traumatic injury repaired.\\nDan Stauder -- JMP Securities -- Analyst\\nGreat. And then just a follow-up on that. As different regions reopened, how much of that headwind from the state home orders really waned off? Was it really pretty immaterial in June as construction and other activities we're able to resume? Or do you think that's probably here for the back half as well?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nWe still see high regional variations. It definitely waned across much of the country, but we saw impacts in Texas, in South Florida and Southern California in the June time period, given the incidence of COVID that was happening there. It is tough to tell for us at this point, whether it's the incidence of trauma or whether it's people's willingness to come or ability to come in to get surgery completed. But that's counterbalanced by the opening up of places in the Northeast, which really didn't happen until late June, early July.\\nDan Stauder -- JMP Securities -- Analyst\\nGreat. Thank you guys.\\nOperator\\nOur next question comes from the line of Richard Newitter with SVB Leerink. Please proceed with your question.\\nJamie -- SVB Leerink -- Analyst\\nHi, this is Jamie on for Rich.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nHi, Jamie.\\nPeter J. Mariani -- Chief Financial Officer\\nHey Jamie.\\nJamie -- SVB Leerink -- Analyst\\nHi guys. This is Jamie [Phonetic] on for Rich. So I just wanted to kind of come back to just the trends and what you're seeing. Could you potentially comment on, I guess, one way to think about it would be, is there a potential that you could hit that second tranche for the new financing agreement with Oberland in 3Q? Kind of help us think if that's something that could be a possibility. And then as you look into 4Q, is it reasonable to think that there could be year-over-year stability or potential growth? Or just based on what you see with the resurgence, you're not thinking that, that could be something that's on the table at this point?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nWe're still seeing or estimating. And again, this is trying to create our own crystal ball around the impact of COVID on nerve repair cases that we would remain below our prior year Q3 and Q4, which is right about where that Oberland oh, the $20 million sorry, the $20 million, we're already above and that would not be unreasonable to think that we'll be above that. The next tranche at $28 million is would be aspirational.\\nJamie -- SVB Leerink -- Analyst\\nGot it. Okay. And then just we've been hearing from a lot of other companies, COVID seems to be accelerating the trend to ASCs. And I think we've kind of talked about this in the past, but can you just comment on how or potentially when you guys believe this could impact your business and how you guys are what you guys are potentially doing to capitalize on this now?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nSure. Well, as we talked about before, there was a change in the Medicare reimbursement rate of OPPS rates for both outpatient surgery and ambulatory surgery centers that was favorable for nerve repair in general and in particular, nerve repair with implants, either a connector or an allograft. And so we see that as a benefit for the long term, the majority of nerve repair is not actually Medicare patients, so it'll have to roll through commercial payers as they as surgery centers adjust their contract with commercial payers. And we think that will take a couple of years to roll through the system.\\nWe're seeing good interest in that. But I would not say we've seen a material shift at this point. There's been certainly distractions in this quarter that may have put that as a lower priority. Having said that, one interesting thing that we did see, again, with the emphasis that surgeons really wanted to get their nerve repair patients in, in those locations where they were locked out-of-hospital ORs. So in places, for example, in Texas, as the resurgence happened, they shut down elective procedures in hospitals.\\nAnd what we saw was a very rapid shift of surgeons moving those patients to outpatient centers or to ambulatory surgery centers and still completing cases where they felt that was reasonable and the right option for their patients. And so we do see them leveraging that avenue, and we think that bodes well for the future as the payment schedules are adjusted as well.\\nPeter J. Mariani -- Chief Financial Officer\\nOkay, Devin?\\nOperator\\nOur final question comes from the line of Brandon Folkes with Cantor Fitzgerald. Proceed with your question.\\nBrandon Folkes -- Cantor Fitzgerald -- Analyst\\nHi. Thanks for taking my questions and congratulations on the success during the quarter. Maybe firstly, could you just elaborate a little bit on the funnel of patients you have been seeing post the quarter within [Indecipherable]? And then secondly, can you just again elaborate on some of the positive shifts that have happened during COVID that you do think will be tailwinds to your business when we come out but in terms of realized world.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nYes, Brandon, I just want to make sure I got your question because in the first part, it broke up a little bit. The second part that I heard was positive shifts that will be tailwinds for us, but I didn't hear the first part.\\nBrandon Folkes -- Cantor Fitzgerald -- Analyst\\nCan you just elaborate on the funnel of patients you are seeing in July?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nOkay. Well, what we have seen and have been really pleased with is that the surgeons who were active users have almost all, frankly, returned back to using AxoGen products. And so we don't have a leaky bucket in that respect of users continue to be users. And as their practices ramped back up, they ramped up in and using it at the same rate or, in some cases, even higher because there are we talk about benefits. There are benefits in a COVID environment to do an allograft or Avance as compared to an autograft. It is a much shorter surgical procedure time, there's less exposure.\\nYou can do wide-awake surgery versus surgery requiring anesthesia, in some cases, depending on the patient. All of those are healthy benefits for the hospital workers while providing good care for the patient. So we think there's real benefits in doing an allograft repair or an Avance repair in this environment. In terms of our funnel overall, to go back to your first part, we also had new users start to use our products, particularly in our active centers. So that's where we have our reps mostly focused is developing our footprint in places that we already have a strong surgeon user.\\nWe want to go deeper with that user and add in their partners. We are still adding some new active centers. So we'll see some of that in our pipeline, but the majority of our emphasis is going deeper in the centers that we're already in. And so we feel that the pipeline is good. And there remains strong interest in it. And we certainly saw that with the virtual education programs that we set up with new and developing surgeons and actually really outstanding engagement from surgeons wanting to be a part of that educational program.\\nIn terms of going forward and some of the benefits that we see from the environment we have here, I mentioned before the benefits of using Avance Nerve Graft as compared on autograft. It is there are safety benefits to the hospital staff because of reducing OR time and in some cases, being able to do wide-awake surgery. There are also the learned benefits that we talked about in terms of the digital marketing, the remote coverage. We think that those are really going to help us continue to expand our productivity of our existing sales team. And that they will pay benefits for the long term, allowing us to continue to grow in a cost-effective manner.\\nBrandon Folkes -- Cantor Fitzgerald -- Analyst\\nThank you very much. That was very helpful.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nGreat. Thank you.\\nOperator\\nAs there are no further questions left in the queue, I would like to turn the call back over to Karen Zaderej for any closing remarks.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nThank you, Devin. I want to thank everyone for joining us on today's call. We look forward to speaking with many of you at the upcoming virtual conferences we're attending, including the Canaccord Genuity Growth Conference, August 11 through the 13th; the Morgan Stanley Global Healthcare Conference, September 14 through the 16th; and the Cantor Fitzgerald Global Healthcare Conference, September 15 through the 17th. Thank you.\\nOperator\\n[Operator Closing Remarks]\\nDuration: 40 minutes\\nCall participants:\\nPeter J. Mariani -- Chief Financial Officer\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nRaj Denhoy -- Jefferies -- Analyst\\nDan Stauder -- JMP Securities -- Analyst\\nJamie -- SVB Leerink -- Analyst\\nBrandon Folkes -- Cantor Fitzgerald -- Analyst\\nMore AXGN analysis\\nAll earnings call transcripts\\n\\n\\n\\n\\n\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Timestamp\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 4751,\n        \"samples\": [\n          \"2022-08-18 08:00:00\",\n          \"2023-01-05 09:30:00\",\n          \"2021-01-26 09:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Date_only\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 804,\n        \"samples\": [\n          \"2022-02-17\",\n          \"2022-01-21\",\n          \"2020-07-20\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"word_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2520,\n        \"min\": 571,\n        \"max\": 32540,\n        \"num_unique_values\": 7264,\n        \"samples\": [\n          2920,\n          9656,\n          5206\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Price_change\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.08033506333874547,\n        \"min\": -0.7976,\n        \"max\": 0.7156863065922738,\n        \"num_unique_values\": 14057,\n        \"samples\": [\n          -0.1235294342041015,\n          -0.010693407694988,\n          0.001805411461732\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Target_Class\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"Neutral\",\n          \"Gain\",\n          \"Loss\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"DateOfWeek\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1,\n        \"min\": 0,\n        \"max\": 6,\n        \"num_unique_values\": 7,\n        \"samples\": [\n          3,\n          2,\n          4\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Month\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 3,\n        \"min\": 1,\n        \"max\": 12,\n        \"num_unique_values\": 12,\n        \"samples\": [\n          12,\n          5,\n          8\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Quarter\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1,\n        \"min\": 1,\n        \"max\": 4,\n        \"num_unique_values\": 4,\n        \"samples\": [\n          4,\n          2,\n          3\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Ticker_gain_prob\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.04774464722746024,\n        \"min\": 0.0720660848238917,\n        \"max\": 0.6140548859393732,\n        \"num_unique_values\": 97,\n        \"samples\": [\n          0.239932309301413,\n          0.2136549913582316,\n          0.3502333413093936\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Ticker_loss_prob\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.05390583019565528,\n        \"min\": 0.0028409712223198,\n        \"max\": 0.6357691661112397,\n        \"num_unique_values\": 100,\n        \"samples\": [\n          0.3385133460506979,\n          0.2973841945037564,\n          0.1892666126448741\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"FinBERT_Positive\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.3164153188473483,\n        \"min\": 0.008341541513800621,\n        \"max\": 0.9573535919189453,\n        \"num_unique_values\": 14091,\n        \"samples\": [\n          0.17113450169563293,\n          0.841820240020752,\n          0.019909732043743134\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"FinBERT_Negative\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.15204690754807296,\n        \"min\": 0.007195898797363043,\n        \"max\": 0.9723434448242188,\n        \"num_unique_values\": 14091,\n        \"samples\": [\n          0.011472414247691631,\n          0.013853976503014565,\n          0.02732784114778042\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"FinBERT_Neutral\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.33126945587937723,\n        \"min\": 0.013258830644190311,\n        \"max\": 0.9523656368255615,\n        \"num_unique_values\": 14067,\n        \"samples\": [\n          0.457214891910553,\n          0.16305600106716156,\n          0.06764431297779083\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 4
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_analysis.columns"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ceNBpJirLzrN",
        "outputId": "3ad0536f-3085-418f-f397-a27aaf695b40"
      },
      "execution_count": 5,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Index(['Unnamed: 0', 'date', 'exchange', 'q', 'ticker', 'transcript',\n",
              "       'Timestamp', 'Date_only', 'word_count', 'Price_change', 'Target_Class',\n",
              "       'DateOfWeek', 'Month', 'Quarter', 'Ticker_gain_prob',\n",
              "       'Ticker_loss_prob', 'FinBERT_Positive', 'FinBERT_Negative',\n",
              "       'FinBERT_Neutral'],\n",
              "      dtype='object')"
            ]
          },
          "metadata": {},
          "execution_count": 5
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_analysis.drop(columns=['Unnamed: 0',\"Ticker_gain_prob\",\"Ticker_loss_prob\"],inplace=True)\n",
        "df_analysis.head(5)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 660
        },
        "id": "lXWIMM4eMiz4",
        "outputId": "86f80ef6-5125-4f63-9a40-ddc1abd80428"
      },
      "execution_count": 7,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                         date      exchange        q ticker  \\\n",
              "0  Aug 27, 2020, 9:00 p.m. ET  NASDAQ: BILI  2020-Q2   BILI   \n",
              "1  Jul 30, 2020, 4:30 p.m. ET     NYSE: GFF  2020-Q3    GFF   \n",
              "2  Oct 23, 2019, 5:00 p.m. ET  NASDAQ: LRCX  2020-Q1   LRCX   \n",
              "3  Nov 6, 2019, 12:00 p.m. ET  NASDAQ: BBSI  2019-Q3   BBSI   \n",
              "4   Aug 7, 2019, 8:30 a.m. ET  NASDAQ: CSTE  2019-Q2   CSTE   \n",
              "\n",
              "                                          transcript            Timestamp  \\\n",
              "0  Prepared Remarks:\\nOperator\\nGood day, and wel...  2020-08-27 21:00:00   \n",
              "1  Prepared Remarks:\\nOperator\\nThank you for sta...  2020-07-30 16:30:00   \n",
              "2  Prepared Remarks:\\nOperator\\nGood day and welc...  2019-10-23 17:00:00   \n",
              "3  Prepared Remarks:\\nOperator\\nGood day, everyon...  2019-11-06 12:00:00   \n",
              "4  Prepared Remarks:\\nOperator\\nGreetings and wel...  2019-08-07 08:30:00   \n",
              "\n",
              "    Date_only  word_count  Price_change Target_Class  DateOfWeek  Month  \\\n",
              "0  2020-08-27        5623      0.035078      Neutral           3      8   \n",
              "1  2020-07-30        4755      0.116154         Gain           3      7   \n",
              "2  2019-10-23        8917      0.142022         Gain           2     10   \n",
              "3  2019-11-06        8286      0.029891      Neutral           2     11   \n",
              "4  2019-08-07        4611      0.249623         Gain           2      8   \n",
              "\n",
              "   Quarter  FinBERT_Positive  FinBERT_Negative  FinBERT_Neutral  \n",
              "0        3          0.146988          0.012653         0.840358  \n",
              "1        3          0.910005          0.010605         0.079389  \n",
              "2        4          0.878131          0.012376         0.109493  \n",
              "3        4          0.727205          0.122016         0.150779  \n",
              "4        3          0.755221          0.136653         0.108126  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-19438422-c50d-4599-89a6-9cc59fea3d2a\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>date</th>\n",
              "      <th>exchange</th>\n",
              "      <th>q</th>\n",
              "      <th>ticker</th>\n",
              "      <th>transcript</th>\n",
              "      <th>Timestamp</th>\n",
              "      <th>Date_only</th>\n",
              "      <th>word_count</th>\n",
              "      <th>Price_change</th>\n",
              "      <th>Target_Class</th>\n",
              "      <th>DateOfWeek</th>\n",
              "      <th>Month</th>\n",
              "      <th>Quarter</th>\n",
              "      <th>FinBERT_Positive</th>\n",
              "      <th>FinBERT_Negative</th>\n",
              "      <th>FinBERT_Neutral</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Aug 27, 2020, 9:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BILI</td>\n",
              "      <td>2020-Q2</td>\n",
              "      <td>BILI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, and wel...</td>\n",
              "      <td>2020-08-27 21:00:00</td>\n",
              "      <td>2020-08-27</td>\n",
              "      <td>5623</td>\n",
              "      <td>0.035078</td>\n",
              "      <td>Neutral</td>\n",
              "      <td>3</td>\n",
              "      <td>8</td>\n",
              "      <td>3</td>\n",
              "      <td>0.146988</td>\n",
              "      <td>0.012653</td>\n",
              "      <td>0.840358</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Jul 30, 2020, 4:30 p.m. ET</td>\n",
              "      <td>NYSE: GFF</td>\n",
              "      <td>2020-Q3</td>\n",
              "      <td>GFF</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nThank you for sta...</td>\n",
              "      <td>2020-07-30 16:30:00</td>\n",
              "      <td>2020-07-30</td>\n",
              "      <td>4755</td>\n",
              "      <td>0.116154</td>\n",
              "      <td>Gain</td>\n",
              "      <td>3</td>\n",
              "      <td>7</td>\n",
              "      <td>3</td>\n",
              "      <td>0.910005</td>\n",
              "      <td>0.010605</td>\n",
              "      <td>0.079389</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Oct 23, 2019, 5:00 p.m. ET</td>\n",
              "      <td>NASDAQ: LRCX</td>\n",
              "      <td>2020-Q1</td>\n",
              "      <td>LRCX</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day and welc...</td>\n",
              "      <td>2019-10-23 17:00:00</td>\n",
              "      <td>2019-10-23</td>\n",
              "      <td>8917</td>\n",
              "      <td>0.142022</td>\n",
              "      <td>Gain</td>\n",
              "      <td>2</td>\n",
              "      <td>10</td>\n",
              "      <td>4</td>\n",
              "      <td>0.878131</td>\n",
              "      <td>0.012376</td>\n",
              "      <td>0.109493</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Nov 6, 2019, 12:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BBSI</td>\n",
              "      <td>2019-Q3</td>\n",
              "      <td>BBSI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, everyon...</td>\n",
              "      <td>2019-11-06 12:00:00</td>\n",
              "      <td>2019-11-06</td>\n",
              "      <td>8286</td>\n",
              "      <td>0.029891</td>\n",
              "      <td>Neutral</td>\n",
              "      <td>2</td>\n",
              "      <td>11</td>\n",
              "      <td>4</td>\n",
              "      <td>0.727205</td>\n",
              "      <td>0.122016</td>\n",
              "      <td>0.150779</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Aug 7, 2019, 8:30 a.m. ET</td>\n",
              "      <td>NASDAQ: CSTE</td>\n",
              "      <td>2019-Q2</td>\n",
              "      <td>CSTE</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGreetings and wel...</td>\n",
              "      <td>2019-08-07 08:30:00</td>\n",
              "      <td>2019-08-07</td>\n",
              "      <td>4611</td>\n",
              "      <td>0.249623</td>\n",
              "      <td>Gain</td>\n",
              "      <td>2</td>\n",
              "      <td>8</td>\n",
              "      <td>3</td>\n",
              "      <td>0.755221</td>\n",
              "      <td>0.136653</td>\n",
              "      <td>0.108126</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-19438422-c50d-4599-89a6-9cc59fea3d2a')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-19438422-c50d-4599-89a6-9cc59fea3d2a button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-19438422-c50d-4599-89a6-9cc59fea3d2a');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-240847e0-ea15-4a7a-99b7-a4924782fa0c\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-240847e0-ea15-4a7a-99b7-a4924782fa0c')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-240847e0-ea15-4a7a-99b7-a4924782fa0c button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df_analysis",
              "summary": "{\n  \"name\": \"df_analysis\",\n  \"rows\": 15055,\n  \"fields\": [\n    {\n      \"column\": \"date\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 5142,\n        \"samples\": [\n          \"May 19, 2022, 11:00 a.m. ET\",\n          \"Oct 25, 2021, 3:30 p.m. ET\",\n          \"May 30, 2019, 3:00 p.m. ET\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"exchange\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2272,\n        \"samples\": [\n          \"NASDAQ: EGRX\",\n          \"NYSE: ASB\",\n          \"NYSE: HLF\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"q\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 19,\n        \"samples\": [\n          \"2020-Q2\",\n          \"2021-Q2\",\n          \"2021-Q4\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2271,\n        \"samples\": [\n          \"EGRX\",\n          \"ES\",\n          \"APD\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"transcript\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 14122,\n        \"samples\": [\n          \"Prepared Remarks:\\nOperator\\nLadies and gentlemen, thank you for standing by, and welcome to Sangamo Therapeutics Inc Q3 2020 webcast. [Operator Instructions] After the speaker presentation there will be a question and answer session. [Operator Instructions]\\nI would now like to hand the conference over to your host head of Corporate Communications McDavid Stilwell, please go ahead.\\nMcDavid Stilwell -- Head of Corporate Communications\\nGood afternoon. And thank you for joining us today. With me this afternoon on this call are several members of the same demo executive leadership team, including Sandy Macrae, Chief Executive Officer. Sung Lee Chief Financial Officer, Mark McClung, Chief Business Officer, Jason Fontenot, Interim Head of Research and Bettina Cockroft Chief Medical Officer. Slides from our corporate presentation can be found at our website, sangamo.com, under the Investors and Media section in the Events and Presentations page. This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to, statements relating to our pipeline of genomic medicine product candidates; our ability to develop, obtain regulatory approvals for and commercialize therapies to treat certain diseases and the timing, availability and cost of such therapies; plans and time lines for Sangamo and to conduct clinical trials and share clinical data and the potential for data to demonstrate clinical benefit to patients; the potential to use certain technologies to develop AR therapies, our collaboration strategy and the potential to earn fees, milestone payments and royalties from our collaboration; plans and time lines for building and opening manufacturing facilities, the effects of the evolving COVID-19 pandemic; the anticipated benefits of our organizational changes; our expectations regarding our financial performance and resources and other statements that are not historical fact. Actual results may differ substantially from what we discuss today.\\nIn addition, these statements are not guarantees of future performance and are subject to certain risks and uncertainties that are discussed in documents that we file with the securities and Exchange Commission, specifically in our quarterly report on Form 10-Q for the quarter ended September 30, 2020. The forward-looking statements stated today are made as of this date, and we undertake no duty to update such information, except as required under applicable law. On this call, we discuss a non-GAAP financial measure. We believe this measure is helpful in understanding our past financial performance and our potential future results. This is not meant to be considered in isolation or as a substitute for the comparable GAAP measure. The comparable GAAP measures and reconciliations of GAAP to the non-GAAP measures discussed on this call are included in today's press release, which is available on our website.\\nNow, I'd like to turn the call over to our CEO, Sandy Macrae.\\nSandy Macrae -- Chief Executive Officer\\nThank you, and good afternoon to everyone on the call. This quarter. We advanced our r&d activities as we continue to adapt to the conditions brought on by the evolving Covid-19 pandemic. We are moving forward on clinical execution. And we're optimistic we're plans to continue to doors patients and initiate new trials. We also completed our research activities associated with our als control collaboration with slide and are continuing to move our research projects with Biogen and Novartis forward and are progressing and work with our other partners. Pfizer has dosed the first participant in the phase three of fine study of JIRA tokujin, fetal Purbeck or SP five to five or investigational gene therapy for Haemophilia a patients. This event triggered a $13 million milestone achievement for sango, which we expect to receive in the current quarter, further strengthening our cash position. Pfizer previously communicated that they expect a pivotal data readout from the final study in 2022. During the mid September investor day, Pfizer provided an update from the phase one to alter study showing encouraging data garnering tolerability clinically meaningful factor levels, bleeding rates and factor use in the highest dose cohort up to 85 weeks in the longest treated patients. Pfizer and sanken will believe that these data support a potentially differentiated Haemophilia a gene therapy product candidate in August and September, in close collaboration with principal investigators monitoring safe conditions for patients with the within the context of COVID-19 single dose the first two patients in the phase one two star study evaluating STM 20 gene therapy in Fabry disease. Those are the first cohort of this study is no complete. And enrollment is ongoing for Cohort Two.\\nWe expect to share data on this study by the end of next year. During the quarter, we received additional regulatory approvals for the first in human Phase One Two clinical study evaluating car regulatory T cell or car t reg, candidate tx 200 and kidney transplantation. We believe we are on track to initiate the study next year. initiating the study may allow us to be the first company to explore the potential of car T cells in humans. We are hopeful that this will provide broader proof of concept for genetically engineered cell therapy using T rex beyond transplantation. We intend to further evaluate current T Rex, including zinc finger nucleases edited allergenic t reg therapies in autoimmune diseases with high unmet medical need. Also, this quarter we completed our research activities associated with our ongoing Pfizer collaboration to develop gene regulation therapy. Using zinc finger technology for the treatment of C nine or 72 related als in this program are safe finger proteins are designed to selectively target disease alio repeats a remarkable demonstration. Yet another way our versatile technology may be able to have a disease modifying impact on challenging CNS diseases. We recently earned a 5 million milestone payment from Pfizer so stay with this program, which we expect to receive later this quarter. It is a testament to our r&d momentum. We look forward to continue to work closely with Pfizer to support their research and development in this program.\\nWith that, I will turn the call over to our chief medical officer Bettina, who will provide additional details on our clinical accomplishments.\\nBettina Cockroft -- Senior Vice President and Chief Medical Officer\\nGood afternoon. As Sandy mentioned, our clinical operations have adapted to the challenges of the evolving covid 19 pandemic. And we are pleased with our progress in executing on our partner and wholly owned programs. Pfizer those the first patient in the assigned study of director gene fetal Popovic or SB five to five, our first acid in a registrational trial. A fine is a global phase three open label multicenter single arm study evaluating the efficacy and safety of SB five to five. in patients with moderately severe to severe Haemophilia a. The primary endpoint is annualized bleeding rates or APR through 12 months following treatment. This will be compared to ABR while in fact eight Replacement Therapy collected in the phase three lead and study, which will provide a baseline for phase three study participants. The secondary endpoints include factor eight activity level after the onset of steady state over 12 months. Participants will be analyzed throughout the five year study period following the single infusion to further assess your ability of efficacy and safety.\\nFive has shared updated phase one two data at a Pfizer investor events in September, which demonstrated that sb 525 was generally well tolerated. Each of the five patients in the high dose cohort sustained a clinically meaningful level effect great activity without leads or the need for prophylactic factor up to 85 weeks for the longest treated patient. Both companies are encouraged by these results and plan to present further follow up data from the altia study in the next few months. When all five patients in the 313 vector genomes per kilogram dose cohort have been followed for at least one year. We have those the first two patients comprising the first cohort in the phase one to start study evaluating SPSS 20 in Fabry disease. The goal of this gene therapy candidate is to provide a predictable and durable expression of the alpha gal a enzyme, which is deficient and Fabry disease due to mutations in the GLA gene, resulting in the accumulation of the substrates GP three, and it's soluble derivative lyso Gp three. This can cause challenging symptoms and morbidities including impaired renal and cardiac function, pain and gastrointestinal symptoms. The star trial is a multicenter open label those ranging study evaluating the safety and tolerability of St. 920 and classical Fabry patients 18 years and older study participants will receive a single intravenous infusion of St. 920, followed by one year of observation and monitoring of clinical endpoints, such as alpha gelei activity and assessment of GB three and laser GB three levels. A long term follow up study will allow patients to be monitored for an additional four years. enrollment for the second cohort is ongoing. We expect that data will be shared toward the end of 2021 after we have identified adults code for cohort expansion.\\nWe believe that sc 920 offers a potentially differentiated treatment for Fabry disease, with the potential to deliver efficacy with preserved renal function and reduced cardiac morbidity and neuropathy. preclinical studies evaluating STI 20 demonstrated strong expression of alpha Galle and G v3 substrate reduction across tissue types. As delivered directed gene therapy, Sc 920 is delivered by a one time intravenous infusion that does not require any preconditioning regimen for patients. We are also working closely with our oncology collaborator Kate Gilliard company, as it advances code 037 and allergenic and PCV 19 Carty therapy into clinical trial tight expects to submit an investigational new drug application by the end of 2020 and to initiate a clinical trial evaluating kite 037 in 2021.Throughout the third quarter, we have continued to receive additional regulatory approvals that support the phase one to steadfast clinical study evaluating the first inhuman car t reg cell therapy tx 200 in HLA to mismatched renal transplantation, we expect to initiate the study next year. The goal for this study is the prevention of transplant rejection through the engineering of T regs to express an HLA to kemmerich antigen receptor or car, allowing them to localize to the renal graft and activate upon recognition of the HLA to antigen. The Carty regs may prevent immune mediated rejection through the inhibition and modulation of inflammatory immune cells and the release of anti inflammatory cytokines to induce a tolerogenic environment within the preclinical data supporting the steadfast study presented last month showed that the TX 200 HLA to Carty regs efficiently prevented rejection in both graft versus host disease and skin transplantation model.\\nThey were also shown to be safe and well tolerated in our in vivo studies. Similar to other genetically engineered cell therapy approaches, patients will undergo a Luca phoresis procedure from which their t reg cells will be isolated and engineered then cryopreserved. The HLA to negative patient will subsequently undergo transplantation surgery and following a recovery period will receive their personalized pX 200 drug candidate.As a result of this detailed process, we expect those patients will occur several months after their enrollment. recent publications show that the regulatory cell therapy space is gaining momentum and excitement in the scientific community. In particular, the one study a large international clinical study gathering seven investigator led trials across five countries showed that immune regulatory cell therapy as a whole were safe, and that immune cell therapy is a potentially useful therapeutic approach in renal transplant recipients allowing immune cell composition restoration to normal healthy level of minimization of the burden of general immune suppression. This is very promising and supports our plan to evaluate Carty regs in renal transplant patient populations.\\nWill now turn the call over to some for an overview of the financial results.\\nSung Lee -- Executive Vice President and Chief Financial Officer\\nThank you, Bettina and good afternoon everyone. We're pleased to share our financial results for the third quarter of 2020. We reported a net loss of $1.6 million, or one cent per share compared to a net loss of $27.3 million or 24 cents per share for the same period in 2019. total revenues were $57.8 million, compared to $22 million for the same period in 2019. The increase was primarily attributable to a $30 million milestone achieved. For SP five to five or Haemophilia, a candidate partnered with Pfizer, and a $5 million milestone achieved for our C nine or 72 collaboration with Pfizer. Turning to expensive non GAAP operating expenses, which include stock based compensation expense were $54.8 million, compared to $46.5 million for the same period in 2019. The increase in operating expense reflects our headcount growth and facilities expansion to support the advancement of our therapeutic pipeline, and manufacturing capabilities.\\nThese increases were partially offset by a decrease in clinical and manufacturing supply expenses. Moving to the balance sheet, we ended the quarter with $695 million in cash, cash equivalents and marketable securities. This balance includes the $75 million upfront license fee payment received from Novartis. Additionally, in the current quarter, we expect to receive the $35 million milestone payments from Pfizer mentioned earlier. We believe our balance sheet remains strong and will allow us to reach several important r&d milestones, including the potential filing of the Vla for sp 525. For hemophilia a. Turning to 2024 year guides, we're updating our financial guidance for non GAAP operating expenses, which exclude estimated stock compensation expense of $25 million from an estimated range of 210 million to $225 million to now be in the estimated range of 210 million to $220 million.\\nI'll now turn it back to Sandy for closing remarks.\\nSandy Macrae -- Chief Executive Officer\\nThank you. So we're focused on clinical execution and building momentum. As we adapt to the conditions of COVID-19 and head toward the end of the year. We're pleased with our progress in clinical operations and with our partner programs. Our strong balance sheet enables us to advance our r&d pipeline. We believe these accomplishments are put single in a strong position to achieve several important milestones and catalysts heading into next year. We believe we remain on track for a V manufacturing facility in Brisbane to be operation at the end of this year, and offeror cell therapy facilities in Brisbane and football to be operational by year end 2021. We anticipate continued enrollment in Pfizer's phase three a fine study with a pivotal data readout expected by Pfizer in 2022. And also expect one year and two year phase one two data presentations over the next year and a half. We expect continued enrollment in the phase one two star study and the data read data readout toward the end of 2021.\\nSanta Fe has guided that the first data readout from the phase one to sickle cell disease study is expected next year. We anticipate presenting pull up sp 400 beta thalassemia data at the same time. And lastly, we expect the clinical trial initiation. So the phase one two first inhuman Carty reg status study will occur in 2021. And Kate expects that this study of allogeneic anti cd 19 Carty product candidate count or three seven will also commence in 2021. We look forward to delivering on these milestones in the coming year.\\nOperator, please open the line for questions.\\nQuestions and Answers:\\nOperator\\n[Operator Instructions] Our first question comes from the line of Geoff Meacham With Bank of America.\\nGeoff Meacham -- Bank of America -- Analyst\\nHey guys, thanks for the question and congrats on all the pipeline progress. I had a couple on the first one is on the Haemophilia a study just with the 12 month analyze bleed rate endpoint, I want to kind of get your feedback on on what FDA is, is looking for just relative to, you know, the feedback that biomarin received. And that's obviously subject of a lot of investor conversations of late. And then the second question is just a broader one on the strategy for the car t regs just wanted to maybe give us a little bit more, you know, context for, you know, how you see that differentiating and maybe what successes you see what the best probability of success, you see, and, and for example, solid tumors versus the liquid tumor say. Thank you.\\nSandy Macrae -- Chief Executive Officer\\nThank you for your questions. On the first one around Haemophilia a, we are limited in what we can see, because this is known Pfizer sounds, we are so pleased with their progress into phase three, with their enthusiasm for the program, and that all the way up and down their organization right up to their CEO, how valuable they see this asset for them. The you can be assured that they will be having regular conversations with the regulatory authorities. And I'm certain that Pfizer will know how to navigate that landscape. As regards to T regs, I'm going to pass over to Jason who is a real expert in this area.\\nGeoff Meacham -- Bank of America -- Analyst\\nAnd Jason, can you talk to us about how you see your T reg strategy?\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nThanks, Sandy. And thanks for the question. Um, so first, I'll start off by by pointing out that our programs and regulatory T cells, engineered regulatory T cells are directed in the autoimmune and inflammatory disease space, these are drugs for cancer. So we're really excited about our engineered regulatory T cell platform and the programs that we're bringing forward. We're excited about the progress and regulatory approvals we've received so far. And about our first inhuman. Carty reg study, Tx 200. We're leaders in this field. And, you know, we're developing and refining our understanding of cartoon t reg biology and rapidly advancing our ability to engineer and manufacture that cell. And our tx 200 study will be the first inhuman test of engineered regulatory T cells of car t regs, and this will be further demonstration of our leadership.\\nThe goal with that study is the prevention of renal transplant rejection in the setting of an MHC mismatch transplant. So this is a setting where and HLA a two negative patient will receive an HLA a two positive kidney transplant. And our therapy is comprised of T regs that are engineered to recognize the a two antigen through a Comerica antigen receptor and that car that will drive the accumulation and activation of the T regs in the renal graft and suppress the rejection of the graft by the patient's immune system. And what's important about that study is that as I mentioned, this is going to be the first test of this therapeutic hypothesis around core t regs. And this study will be important for us to understand the safety and efficacy and the therapeutic potential of car t regs. And we'll be informing programs that we're actively pursuing enlarger autoimmune and inflammatory indications such as multiple sclerosis and Crohn's disease.\\nGeoff Meacham -- Bank of America -- Analyst\\nOkay, great. Thank you.\\nOperator\\nThank you. Our next question comes from the line of Maurice Raycroft with Jefferies.\\nMaurice Raycroft -- Jefferies -- Analyst\\nHi, Everyone, thanks for taking my questions. I had one on the T reg program as well. So I guess for getting the getting that study started. Can you talk more about what factors have led to pushing the study start to 2021? Is it due to COVID or the autologous cell manufacturing process or anything else that you can comment on? And can you talk more about what else needs to be completed before starting the study?\\nSandy Macrae -- Chief Executive Officer\\nMaurice, thank you very much for your question. We are we're very pleased with the progress of the T reg for HLA to mismatch. We're very pleased with the approval From the regulatory authorities, we call for dis epic where COVID is in. In is impacting the hospitals, we will go to the the laboratories, the manufacturing. So there's a general COVID impact, but we are confident that we'll be able to move forward with this program.\\nMaurice Raycroft -- Jefferies -- Analyst\\nAnd from a manufacturing and process development standpoint, is that all figured out? Or is there any other perspective you can provide on that?\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nOne of the reasons that we acquired t excel in 2018, was their understanding of how to look after T Rex, which is different from how people look after T cells. And so we're very pleased with the progress that they've made.\\nMaurice Raycroft -- Jefferies -- Analyst\\nGot it. Okay. And then the other question I had was just on the preamp program that you guys have, which is sort of under the radar, I'm just wondering if you can provide a status update on that program, any timeline, update on that program, and then maybe talk about the strategic importance of that one, as well.\\nSandy Macrae -- Chief Executive Officer\\nJason, can you hear me talk about prions and what we think of them?\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nSure, Sandy, thank you. Um, you know, the prion program is in preclinical development. So I think, you know, we'll be looking forward to sharing updates at the appropriate time. I think that there is a great opportunity there to to demonstrate the power of our platform, similar to the approaches that we're taking with our partners in CNS, both Biogen and Novartis. These are both of these partnerships are driven by by what our partners see in our platform. And the prion program is yet to get another example of that, and we'll be excited to, to talk about it as we move forward. And we've done some of the initial work with the Broad Institute in Boston. And they have a real deep x the group we're working with as a real deep expertise in this. And so we have that biological expertise to match with our technological expertise.\\nMaurice Raycroft -- Jefferies -- Analyst\\nGot it. Thank you for the perspective. Thanks for taking the questions.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nThank you, Marie.\\nOperator\\nThank you. Next question comes from the line of Jim Burchinal with Wells Fargo.\\nJim Burchinal -- Wells Fargo. -- Analyst\\nHi, thanks for taking my question. This is a yen and on for Tim, some perhaps a question on the T reg program as as well. It, Could you confirm whether this is a gene additive product? Because I think it's autologous. So, it you know, the obviously the HLA two is put in with a gene audition approach. So if if you can comment on whether it's a gene edited product, and then for your, you know, future product, the genetic regulatory car T cells. How do you see the issue of persistence? I guess it's for this program, GTX 200, as well. How do you see the issue of persistence? And for renal transplant, would you require long term persistence? And would you explore repeated dosing for your animal genetic programs? Thanks.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nSo thank you for your question. They they're very sensible, scientific questions. And let me try and lay out the path that we've chosen, which is to start with a topic of sorts, we can understand the effectiveness of T regs. And one of the advantages of renal transplant is that the transplanted kidney can be biopsied because it's it's implanted close to the surface. So, we can look at things like persistence which as you can see is an important feature that would be required of any good treatment, we will gradually switch to allergenic and, and we can either develop our genetics, t regs by editing down from healthy donor volunteers, or by studying IPS, C's and other forms of stem cells to develop them up to be T Rex. So this is really at the very cutting edge of regulatory cellular science and we are lucky to have many options as possible to take us into those areas.\\nJim Burchinal -- Wells Fargo. -- Analyst\\nGot it? And a quick follow up in tx 200. Is there a gene editing component?\\nSandy Macrae -- Chief Executive Officer\\nTx 200 isn't a tall Lucas form and therefore doesn't have gene editing component? Jason, I'm correct on that.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nYes, that's correct. tx 200. We introduced the car with a lentivirus for that first, for that first program. But obviously, you know, our platform, one of the one of the assets we have etang. Mo is our platforms ability to do genomic engineering and the T rex are our future future products. And that was why the marriage of sanguine to excel was so sensible. They they brought the TV experience and we brought editing that they read, they needed to take the platform forward.\\nJim Burchinal -- Wells Fargo. -- Analyst\\nGot it, then maybe a question on zinc finger transcription factors. Just wondering about the origin origin of the transcription transcription factor, whether it is Foley Schumann, or is there any synthetic component in those transcript transcription factors? And how do you think how should we think about immunogenicity? Thanks.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nSure, so, so the base components of the zinc finger transcription factors are all human. Obviously, in order to direct those transcription factors to a desired sequence, we have to design a synthetic protein that is specific for a specific sequence in the genome. And, and by nature of the fact that they are fully human, we expect that the immunogenicity should, should be inherently lower. And we haven't made any observations today to suggest that immunogenicity can be a problem.\\nJim Burchinal -- Wells Fargo. -- Analyst\\nGreat, thank you so much for taking the question and congrats on your progress.\\nSandy Macrae -- Chief Executive Officer\\nThank you very much.\\nOperator\\nThank you. And our next question comes from the line of Gena Wang with Barclays.\\nGena Wang -- Barclays -- Analyst\\nThank you for taking my questions. I have three questions. Now. First is regarding Haemophilia a. Just wondering, certainly I know this is already tech transferred to Pfizer given the ball milling experience, phase one two data did not three data dinner had quite different from the least one two. So you know, any thoughts you can share with us regarding your face one two data and regarding. you know, also the phase three data and one hypothesis was the manufacturing part. In essence, you know, this manufacturing Phase One, two is from your side. And now we'll transfer to the Pfizer in any thoughts you can help us understand in terms of our potential predict ability from phase one to data to phase three.\\nAnd then the second question is regarding Pfizer Partner Program, the ALS didn't single protein transcription gene regulation program. So wondering if you can share any color regarding the efficiency from this initial r&d study. And the last question is regarding the February program, you already enrolled second cohort and what will be their determination that you think you reach the optimal cohort that you can extend the cohort regarding the biomarker data like a plasma lecture with GD three, you know, as a reference, Avro showed 30 to 40% further reduction versus the baseline er T. Any thoughts you have regarding what is your boss in order to determine the optimal dose?\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nI'm afraid I may disappoint you in my answers the visor the face two of the ultra study and the progression of of this with Pfizer is really in their hands, no to talk about. And the announced or the abstracts for ash were announced today. And so there'll be talking about that at ash and so I would go to to to wait for those results. The convertibility between phase two and phase three, really we we mustn't see anything until we see the three results. As regards the SR north. All I can tell you is Pfizer very pleased with the product that we produce for them. And they have transferred into their research organization and paid the necessary milestone. As regards fabri, I'm going to pass on to Bettina Bettina. Can you talk about fabri? And what we're looking for and what this study will measure?\\nBettina Cockroft -- Senior Vice President and Chief Medical Officer\\nAbsolutely. So, yes, thank you for the question. So as I've mentioned earlier, we don't the first cohort of two patients, and enrollment is ongoing. And the study goal really is to provide a predictable and durable expression of the alpha Galle enzyme, which is the enzyme deficient in Fabry disease due to mutations in the GLA gene. And so we are going to be measuring this parameter as one of the more more important parameters. But as you point out, we're also looking at substrates. GB, three and Lysa, GB, three, these are the basis of some of the challenges in terms of morbidity in patients with fabri. So we're going to be monitoring all of this data along with other data. Remember, this is first and foremost, the safety and tolerability study to start off with. And we have a safety monitoring committee that will be will be involved in the decisions as we move on to escalate, goes to the optimum dose, think it is, is with the totality of the data, and the data that we are monitoring from other studies with with other products, of course, as well that we will be making our ultimate decisions on the dollars that we bring forward in our cohort expansion.\\nGena Wang -- Barclays -- Analyst\\nOkay, thank you.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nThank you very much for your question.\\nOperator\\nThank you. Our next question comes from the line of Eric Joseph with JPmorgan.\\nEric Joseph -- JPmorgan -- Analyst\\nHi, thanks for taking the question. Maybe just perhaps this cheated. One. I'm curious to get a sense of whether there are? Well, how we should be thinking about the potential for additional, largely wholly owned programs coming for the clinic over the next 12 to 18 months, relative to I guess what we've seen over the past year, a fair amount of, you know, leveraging up the platform through partnering activities.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nNext. Thank you for your question, Eric. Mark, this feels like one for you, please.\\nMark McClung -- Executive Vice President and Chief Business Officer\\nHi, Eric, thanks for the question. You know, so if you take a look at the, the deals that we've done, including those most recently, really the driver of that is is twofold. And in some cases, they've come to us on, you know, obviously in the the charging case intersect and in the couple of the candidates that we had progressing toward the the end. But they came to us with a view taxi, expanding the number of CMS targets that we weren't otherwise considering. So we looked at that as being really an extension of our, our potential pipeline. he second way we sort of took take a look at partnerships is whether they're bringing a specific expertise and the resources necessary to accelerate the products assuming they're successful to patients, and in that particular case, as well as the Novartis case. Both of those really fit those type of criteria. We fully intend and we to to become a genomic medicine company. And we are continually looking to advance wholly owned assets, which we would take into the clinic and I think a good example of that is is what you heard in terms of tx 200 as well as the follow on programs that we're intending to take forward into the clinic for our car t reg programs.\\nEric Joseph -- JPmorgan -- Analyst\\nGot it I guess in addition to T reg, are there certain disease states over targets that you have essentially walled off and are prioritizing for internal development.\\nMark McClung -- Executive Vice President and Chief Business Officer\\nWe'd not disclose that. I mean, we're we're taking a look at, obviously, we've got interest in the autoimmune spaces, as we talked about, with her Carty read programs. And Jason touched on earlier. You know, naturally, we're working heavily within the CNS area with our partners in Biogen and partnership with Novartis. And so, you know, there may be targets that we choose in that particular space, but we've not made any decisions on that as yet. We don't believe you can really stick areas and go after it, we need to let the science drive us toward things that we believe are important to develop for patients.\\nEric Joseph -- JPmorgan -- Analyst\\nGod, that's a tough one. Thanks for taking the question.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nSure.\\nOperator\\nThank you. Our next question comes from the line of Ritu Baral with Cowen.\\nRitu Baral -- Cowen -- Analyst\\nHi, guys, thank you for taking the question. This is while on for two, just two quick questions from me. First, on the star fabri study, are you still seeing impacts from COVID on enrollment? I know you've completed the first cohort, but are all the sites up and running? And then as a quick follow up, regarding the Pfizer collaboration with the ALS program, you know, what are the next steps for the program? Specifically, what's the next opportunity for a milestone to reach is that contingent on them initiating a clinical trial? and unicolor on this would be helpful. Thank you.\\nSandy Macrae -- Chief Executive Officer\\nThank you for your question. We haven't we or Pfizer haven't commented on the LS program and when the mouse ones will come? I would say again, reiterate what I said in the call script. It's a remarkable piece of science to be able to suppress the transcription of one Leal and leave the other one, on touched is why Pfizer, Kim does and we have achieved what they requested of us, and it's move forward to them. So let's hope because it's such a dreadful disease, let's hope it gets to patients as soon as possible. For the Fabry disease, I'm going to refer you to Bettina who will answer that question?\\nBettina Cockroft -- Senior Vice President and Chief Medical Officer\\nYes, and thank you for that question. So on the clinical operations side, I have to say, we have an excellent clinical operations team working very hard on maintaining the relationship with all the sites on during the pandemic, we've also been able to initiate sites qualify other sites as we expand our footprint for the study. Of course, COVID has had an impact worldwide, some regions more than others, we are confident that we can keep going with following the enrollment and dozing of the first two patients to keep going with our enrollment, despite the pandemic at this stage where the the things we've put in place from an operational perspective with home visits with virtual assistants have really helped us make sure that but we, together with the sites manage to to guide the patients through the enrollment and screening procedures to ultimately get us to dosing. Very pleased. I'm very, very pleased with the way the clinical to have navigated. We feel we have a responsibility to do this. Well, to make sure that the patient comes first whether they're being treated for coffered in which case we should not be taking up doctors times. But we've been ready to doors as soon as the window was open. And I think Bettina and her team have done remarkable job together.\\nRitu Baral -- Cowen -- Analyst\\nThank you for the color.\\nOperator\\nThank you. Our next question comes from the line of the Nicole Germino with Securities.\\nNicole Germino -- Securities -- Analyst\\nGood evening, everyone. Hi, thanks for taking my question. On February, given the competition in this space, what is it more specifically about saying the most a decapitated or the promoter that make it differentiated and better than your peers? And how have you made that determination? And then does how does sc 920 impacts the renal and cardiac tissue?\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nSo let me take that one. We are encouraged by the data we've seen from AV six in hemophilia. But until we those patients with Fabry disease, we really can't and shouldn't comment on what it's going to look like. The animal data looks very encouraging. We see supramaximal dozing and supramaximal effect. And in the animal dosing that we recently published, we're able to show benefit to both the heart and the kidney. But I'm, I'm just prudent in telling people to wait and let's see what the clinical results are. Were guiding that will show the clinical results to RCM just next year when the Deus Ex escalation phase is completed.\\nNicole Germino -- Securities -- Analyst\\nOkay, great. Thank you so much.\\nOperator\\nThank you. Next question comes from the line of Boran Wang with Guggenheim securities.\\nBoran Wang -- Guggenheim securities -- Analyst\\nHi, guys, thanks for taking my question. I had to one on PMA and other on the Albuquerque program on him a what's the plan going forward to share data on the Phase One, two, I know you'll have the updated app. But are there any specific time points provide a complete picture of the data and without requiring of all patients require cross that time point. And on the alto Carty program?\\nSandy Macrae -- Chief Executive Officer\\nYeah, we've seen some data, early data from other Allo programs from allergy and CRISPR. No any thoughts on the initial data generated so far, and any kind of learnings you can take, especially given some of the deaths we've seen in those trials? So let me do the humane and then passes to Jason to comment on aloe. So the I'm gonna say again, why piercing through Pfizer will are in control of the release of data on hemophilia. The there is an abstract has been accepted for ash and they will use whatever conference schedule in the future to continue to demonstrate the benefit to patients or reduce absent bleeding events and no requirement for factor. Jason, can you talk about the allergy alginate question, please.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nSure. Thank you, Sandy. So I believe that you're referring to aloe Carty programs in in oncology and not we have a partnership with Gilead to support their allogeneic Carty programs. kite has has guided that we're expecting to begin the studies on on their alpha genetics cd 19 targeted Carty therapy next year. And we believe that the data that we've seen so far from from others are consistent with, with these with these therapies having real therapeutic potential and we're excited about it and and we're excited to see Kai get the get the therapies into patients.\\nBoran Wang -- Guggenheim securities -- Analyst\\nOkay, thank you.\\nOperator\\nThank you. I will now turn the call back over to head of corporate communications. Sandy Macrae for any further remarks.\\nSandy Macrae -- Chief Executive Officer\\nThank you once again for joining us today and for your questions. We look forward to keeping you updated on our future developments.\\nOperator\\n[Operator Closing Remarks]\\nDuration: 49 minutes\\nCall participants:\\nMcDavid Stilwell -- Head of Corporate Communications\\nSandy Macrae -- Chief Executive Officer\\nBettina Cockroft -- Senior Vice President and Chief Medical Officer\\nSung Lee -- Executive Vice President and Chief Financial Officer\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nMark McClung -- Executive Vice President and Chief Business Officer\\nGeoff Meacham -- Bank of America -- Analyst\\nMaurice Raycroft -- Jefferies -- Analyst\\nJim Burchinal -- Wells Fargo. -- Analyst\\nGena Wang -- Barclays -- Analyst\\nEric Joseph -- JPmorgan -- Analyst\\nRitu Baral -- Cowen -- Analyst\\nNicole Germino -- Securities -- Analyst\\nBoran Wang -- Guggenheim securities -- Analyst\\nMore SGMO analysis\\nAll earnings call transcripts\\n\\n\\n\\n\\n\",\n          \"Prepared Remarks:\\nOperator\\nGood morning, and thank you for standing by. Welcome to today's International Paper's First Quarter 2021 Investor Earnings Day Conference Call. [Operator Instructions]\\nI'd now like to turn today's conference call over to Guillermo Gutierrez, Vice President, Investor Relations.\\nGuillermo Gutierrez -- Vice President of Investor Relations\\nThank you, Maria. Good morning, and thank you for joining International Paper's First Quarter 2021 Earnings Call. Our speakers this morning are Mark Sutton, Chairman and Chief Executive Officer; and Tim Nicholls, Senior Vice President and Chief Financial Officer. There's important information at the beginning of our presentation on Slide two, including certain legal disclaimers. For example, during this call, we will make forward-looking statements that are subject to risks and uncertainties, including the impact of COVID-19. We will also present certain non-U.S. GAAP financial information.\\nA reconciliation of those figures to U.S. GAAP financial measures is available on our website. Our website also contains copies of our first quarter 2021 earnings press release and today's presentation slides. Relative to the Ilim joint venture and Graphic Packaging investment, Slide two provides context around the financial information and measures presented on those entities.\\nI will now turn the call over to Mark Sutton.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nThank you, Guillermo, and good morning, everyone. We will begin our discussion on Slide three. International Paper delivered solid earnings and strong cash generation in the first quarter. Our mill and converting system performed well to mitigate the significant impact of the winter storm and support a strong customer demand across all of our packaging channels. Input costs and transportation were a headwind in the first quarter, especially for energy, which was impacted by the duration of the severe cold temperatures in the Southern U.S.\\nWe see momentum building, continuing to build across our three businesses with very strong demand for corrugated packaging and containerboard and solid demand for absorbent pulp. And in papers, we're seeing an improved supply demand backdrop in all of our key geographies. Our capital allocation in the first quarter, we repaid $108 million of debt and we returned $331 million to shareholders, including $129 million of share repurchases. Our performance again demonstrates the agility and resilience of International Paper to perform well across many different circumstances.\\nWe're passing the 1-year mark of the global pandemic, and I could not be any prouder of the commitment of our employees to take care of each other and take care of our customers. The vast majority of our 48,000 team members work in our mills and conversion plants each and every day, and their health and safety remains our most important responsibility. We also made solid progress on the spin-off of our Printing Papers business, which we expect to complete late in the third quarter this year. Our team is also making strong progress to develop and deliver multiple streams of earnings initiatives to achieve the $350 million to $400 million in incremental earnings and accelerated growth by the end of 2023.\\nAs we work to build a better IP, we remain laser-focused on delivering superior solutions to our customers, executing well and meeting our commitments to our shareowners and our other stakeholders. Turning now to Slide four, which shows our first quarter results. We delivered EBITDA of $730 million and free cash flow of $423 million despite the $80 million pre-tax earnings impact from the winter storm in the Southern U.S. Revenue increased by more than $100 million sequentially, primarily driven by price realization in our Packaging and Global Cellulose Fibers businesses. And again, free cash flow is strong with a continued focus on running our businesses well, controlling our cost and actively managing our working capital.\\nNow I'll turn it over to Tim, who will cover our business performance and our second quarter outlook. Tim?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nThank you, Mark, and good morning. I'll start with the quarter-over-quarter earnings bridge on Slide five. First quarter operating earnings were $0.76. The winter storm impacted pre-tax earnings by $80 million or a $0.15 impact to operating EPS. We're still in the very early stages of the insurance process and do not have a recovery estimate at this time. Looking at the bridge, price/mix was strong driven by prior period price flow-through and packaging and cellulose fibers. Volume was essentially flat with continued strong demand for corrugated packaging and absorbent pulp.\\nOverall papers volume continues to recover even though we saw the expected seasonal decline for papers in Brazil in the first quarter. Operations and costs were favorable. Mill and box system performance was solid and helped mitigate the impact of the winter storm, which was a cost headwind of $55 million to operations. Maintenance costs increased sequentially, and we expect to complete about 65% of our maintenance outages in the first half of the year. Input costs were unfavorable, which included a $20 million cost impact from the storm, mostly for energy and raw materials such as starch and adhesives.\\nOverall, we're seeing higher costs for recovered fiber, energy, chemicals and distribution, which we expect to continue in the second quarter. Transportation conditions are challenging, and we're experiencing significant rail, truck and ocean transportation congestion. Higher corporate expenses were driven by a noncash foreign exchange loss on intercompany loans, and lower equity earnings are partly attributed to the reduced ownership position in GPK. Turning to the segments, and starting with Industrial Packaging on Slide six. We continue to see strong demand across all of our channels, including box, sheets and containerboard.\\nFor the quarter, volume was essentially flat. We lost 145,000 tons of containerboard production due to the winter storm. Although our mills and box plants in the region recovered quickly, the storm did impact sales in the quarter. We had nearly 30 box plants in Texas, Louisiana and Mississippi affected by the storm, which impacted our box shipments in the quarter. Price and mix was strong. Our November increase is essentially implemented fully with the $131 million first quarter realization. And I would add, this is one of the fastest implementations that we've seen.\\nOperations and cost includes about $55 million impact from the winter storm, about half of which is due to unabsorbed fixed costs and the balance is related to repairs and higher distribution costs. Overall, mill and box plant performance was solid, and we leveraged our system to support strong customer demand across all of our channels. Maintenance outage costs increased sequentially. We did defer about $30 million of maintenance outages from the first to the second quarter due to the significant production loss resulting from the winter storm. We expect to complete about 75% of our planned maintenance outages for packaging in the first half of the year.\\nInput costs were a significant headwind in the quarter, including about $20 million related to the winter storm due to higher energy, distribution and raw materials in our mill system and box plants. Higher recovered fiber costs were another significant headwind in the quarter. We expect continued cost pressure for recovered fiber, energy distribution in the second quarter, and we're still seeing the lingering effects in certain chemicals produced in Texas and Louisiana as suppliers recover from the winter storm. Turning to Slide eight.\\nAs we enter the second quarter, we're seeing continued strong demand across all of our channels. U.S. and export containerboard demand is strong with low inventories in all regions. Our first quarter shipments were impacted by the significant production loss resulting from the storm. We're working with our customers to recover from extensive backlogs. In our U.S. box system demand remains robust as more states start lifting restrictions. E-commerce, again grew at a strong double-digit pace in the first quarter, and we believe the majority of the accelerated consumer adoption in this channel is permanent.\\nWith states starting to reopen, we're also seeing improved demand in segments with greater exposure to restaurant and foodservice channels, such as produce and protein, although we're still not back to pre-COVID levels. Nondurables, excluding food and beverage, represents about 30% of U.S. box demand across a wide range of consumer and industrial products. This segment is benefiting from strong consumer demand in the broad manufacturing sector recovery. And lastly, demand for durable goods, which had the immediate pullback due to COVID is benefiting from a healthy housing market.\\nWe're well positioned and have the scale and footprint to serve just about every corrugated segment in a meaningful way, and our packaging team continues to focus on delivering superior packaging solutions to help our customers succeed. Turning to Slide eight. I'll provide an update on the progress we're making in our EMEA packaging business. Our objective is to bring this business back to sustainable mid-teen margins and generate returns above our cost of capital. We're well on our way to achieving our goal. In the first quarter, we improved adjusted EBITDA by nearly $20 million compared with last year.\\nThe Madrid mill is fully ramped, and we have more integration and cost opportunities available. We're integrating our world-class lightweight recycled containerboard with our box network in Southern Europe to provide customers with a broader array of packaging solutions. We've improved our footprint in the Iberian Peninsula through selective acquisitions, including two box plants in Spain acquired at the end of the first quarter. These acquisitions provide additional integration opportunities with the Madrid mill. And more importantly, they enhance our commercial capabilities in the region. We continue to make progress with our box system performance and have more opportunity ahead.\\nAll our plants have clear commercial and operational plans, and we're leveraging the skills and resources from across the company to deliver on our commitments.\\nThe map on the slide shows our packaging footprint in Europe after the sale of our Turkey packaging business, which we expect to close in the second quarter. After the sale, the EMEA packaging business will have two recycled containerboard mills, 21 box plants and two sheet plants. And again, our commitment is to bring this business to sustainable returns above our cost of capital. Moving to Global Cellulose Fibers on Slide nine.\\nPrice and mix was favorable with price realization accelerating across all pulp segments in the first quarter. Volume was moderately lower due to the shipping delays related to port congestion. Demand for fluff is solid and we have healthy backlogs. Operations and costs improved sequentially, driven by the nonrepeat of the $20 million write-off in the fourth quarter as well as solid operations and good cost management. These improvements were partially offset by about $10 million of higher seasonal energy consumption and an FX loss at our mill in Canada.\\nMaintenance outage costs decreased as expected, and input costs increased due to higher wood costs in the Mid-Atlantic region as well as higher energy costs. Demand improved as we entered the year and the end-use demand signals for absorbent hygiene products is healthy. Turning to Printing Papers on Slide 10. Our business -- our papers business has demonstrated outstanding resilience throughout the past year. Our performance reflects the talent and commitment of our team, the scale and capabilities of our global footprint and the strength of our highly valued brands.\\nWe continue to see steady recovery in demand across all regions, which we expect will accelerate with broader return to office and return-to-school activity. I'd also add that we've seen significant improvement in supply demand dynamics both within the U.S. and outside the U.S. Looking at our first quarter performance, price and mix was stable across the segment. Volume decreased sequentially due to the lower seasonal demand in Brazil and Russia as expected. It also meant that the export supply chains are stretched in most regions. Operations and costs improved on solid operations and good cost management, as well as a favorable FX in Brazil of about $10 million.\\nFixed cost absorption improved with economic downtime decreasing by 40,000 tons sequentially across the system. Maintenance outages increased modestly, as expected, and input costs increased primarily due to higher wood and energy costs in North America. Looking at Ilim on Slide 11. The joint venture delivered $49 million in equity earnings in the first quarter with an EBITDA margin of nearly 35%, driven by higher average pricing. Volume decreased sequentially, primarily due to fewer shipping days because of the Chinese New Year, as well as the impact of tight shipping capacity in China. Underlying demand remained strong as we enter the second quarter.\\nAnd lastly, in April, we saved a $144 million dividend payment from Ilim, which is $44 million higher than the estimate we provided last quarter. Now we can turn to the outlook on Slide 12, and starting with Industrial Packaging. We expect price and mix to improve by $75 million on realization of our March 2021 price increase. Volume is expected to decrease by $10 million on lower seasonal demand in Spain and Morocco as the citrus season winds down. Operations and costs are expected to improve by $15 million, with the full recovery of the winter storm impact partially offset by higher incentive compensation accruals related to a stronger outlook.\\nStaying with Industrial Packaging, maintenance outage expense is expected to increase by $77 million. And input costs are expected to increase by $20 million due to higher OCC, energy, raw materials and distribution costs. In Global Cellulose Fibers, we expect price and mix to increase by $100 million on realization of prior price movements. Volume is expected to increase by $5 million. Operations and costs are expected to decrease earnings by $10 million. Maintenance outage expense is expected to decrease by $10 million, and input costs are expected to be stable. Turning to Printing Papers. We expect price and mix to increase by $25 million.\\nVolume is expected to increase by $5 million. Operations and costs are expected to decrease earnings by $10 million due to the nonrepeat of foreign currency gain in Brazil during the first quarter. Maintenance outage expense is expected to increase by $22 million, and input costs are expected to increase by $5 million. And under equity earnings, you'll see the outlook for our Ilim joint venture. Turning to Slide 13. I want to take a moment to update you on our capital allocation actions in the first quarter. We're committed to maintaining a strong balance sheet. We have no significant near-term maturities. And in the first quarter, we reduced debt by $108 million.\\nWe also returned $331 million to shareholders, including $129 million of share repurchases, which represented about 2.6 million shares at an average price of $50.28. We acquired two box plants in Spain at the end of the first quarter. You can expect M&A to continue to focus primarily on bolt-on opportunities in North America and Europe. And lastly, in the first quarter, we monetized about $400 million of our stake in Graphic Packaging. After that transaction, we now hold about 7.4% ownership in the partnership.\\nAnd with that, I'll turn it back over to Mark.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nThank you, Tim. Turning to Slide 14. As we enter the second quarter, I'm mindful that we're still in the midst of a global pandemic, and there is still significant uncertainty in the geographies and markets that we operate. Having said that, we see momentum building in our three businesses. We continue to see very strong demand for corrugated packaging and containerboard in North America and Europe. We're also seeing solid demand for absorbent pulp with more favorable supply and demand dynamics as paper-grade pulp demand recovers. In Printing Papers, we're seeing a steady recovery in demand.\\nAnd in areas where schools and offices have reopened, we're seeing a step change improvement. Overall, we're seeing a much better supply/demand backdrop. We expect price flow-through from prior price increases across our three businesses. We expect margins to improve, even as we manage through the impact of higher input costs for recovered fiber, energy and transportation. In addition, we expect productivity and other cost initiatives to offset general inflation. All of this contributes to a more favorable outlook for 2021.\\nAnd I'll end our prepared remarks on Slide 15. I just want to take a moment to reflect on what has now been a full year of living and working in a global pandemic environment. When we shared our first quarter performance last year, we talked about all the protocols we quickly put in place to keep our employees and contractors safe so that we could continue taking care of our customers. We stayed diligent about adhering to those protocols, and we will remain steadfast for as long as it takes to get fully and safely past the pandemic.\\nWe continue to operate in this environment with a view toward the short-term and long-term success and sustainability of International Paper for all of our stakeholders, with an unwavering commitment to the health and safety of our employees and contractors, to understanding and taking care of our customers' needs as they also adapt to rapid change, to supporting the critical needs in our communities and to building a better IP for all of our stakeholders.\\nSince the pandemic began, not a day goes by that I don't think about the commitment of our employees, and especially our frontline teams for their ability to adapt well and perform at a high level across circumstances and geographies. And once again, I want to take this time to thank each of our employees for their role in making our company strong and resilient.\\nAnd with that, Tim and I are happy to take your questions.\\nQuestions and Answers:\\nOperator\\nThank you. [Operator Instructions] Our first question comes from the line of Mark Wilde of Bank of Montreal.\\nMark Wilde -- Bank of Montreal -- Analyst\\nGood morning, Mark. Good morning, Tim.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nGood morning.\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nGood morning.\\nMark Wilde -- Bank of Montreal -- Analyst\\nMark, I'm just curious, it does seem like the containerboard business really has accelerated globally, not just containerboard, but corrugated. And that the market is quite tight. And I'm just curious about how that might be impacting your thinking about a potential conversion of that second line down at Selma?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nThat's a good question, Mark. We obviously have looked at that and what product we might need in the future. If you just play out the current conditions, you'd probably look at using some of that from a packaging standpoint sooner. But outside of interruptions like we talked about with the winter storm and one-offs, we have largely the containerboard we need when you look at all of our channels, domestic and our own box, domestic open market and export for what we believe is the foreseeable future. But that's a good option for us in the future. And it depends on the type of grades, whether it's medium or linerboard that we need. One is quicker and less expensive than the other. But it's on our radar screen.\\nWe don't feel the need to immediately do that right now. When we operate well and we don't have interruptions like we had in the first quarter, we feel quite confident in our containerboard quality, type of grade and overall capacity.\\nMark Wilde -- Bank of Montreal -- Analyst\\nOkay. And just as a follow-on, if I could, Mark. I know that both European producers and North American producers have been sort of pulling out of the export market and kind of rechanneling volume to their domestic businesses and domestic customers. I just -- I'm curious about how you think about this in the context of taking care of long-term export customers because I think there's some real concern by converters in places like Latin America that have always relied on imported board.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nYes. It's definitely important to us. IP is probably the largest provider of kraftliner board in Latin America and Europe for long-term customers who use it because it's needed. And that's critically important to us, and we've talked about the importance of our channels to market, especially for kraftliner. Things are very tight right now. Disruptions make that further -- more difficult for the supply chain. I think where we are right now is inventories are very low through the system with our customers and our own processes.\\nAnd we are working individually with each of our customers, I can't speak for others, obviously, to make sure we can provide as much of their needs as possible in the time that they need it. But I think we're looking at a tight supply chain, especially for kraftliner for the foreseeable future.\\nMark Wilde -- Bank of Montreal -- Analyst\\nOkay. Great. I'll turn it over. Thank you, Mark.\\nOperator\\nOur next question comes from the line of George Staphos of Bank of America.\\nGeorge Staphos -- Bank of America -- Analyst\\nHi, everyone. Good morning. Hope you're doing well. Thanks for the details. I guess my first question is really around corrugated volume. And Mark, you mentioned that from what you're seeing and the acceleration from e-commerce, that you think the -- and I'm paraphrasing, the new consumption levels and new usage of corrugated, they're more or less here to stay. You don't intend or don't expect that to recede. So can you tell us why -- what evidence you're seeing that suggests that and how your volumes have looked to the extent that you can comment early in the second quarter?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nSo it's a great question, George. I think one of the things we look at is what our customers look at. And on the e-commerce part of your question, we're seeing really important winning customers, investing more in their capability, putting real dollars and real equipment and real capability and hiring employees. Their data analytics around customer repeat buying and all that gives them confidence to believe that a good portion of this shift to an e-commerce way of retail is permanent. It may not be 100% permanent, but it is the majority of it. So we look for clues from our customers instead of trying to wish it or guess at it.\\nWhat's uncertain is as things return to a more \\\"normal environment\\\", what does traditional retail do? Is it a net loss to e-commerce? Or is it a hybrid? Were there still going to be some normal return to in-store brick-and-mortar type retail, and you can look at a lot of information, studies and listen to company's earnings reports that are in those businesses, and it's hard to conclude from that. So our box volumes in April for our own make box -- the boxes we make, looks -- the trends look like they're continuing from the first quarter.\\nBut I'll remind you, we serve multiple channels. So we're in the box market, whether we make the box, whether we have a long-term strategic partner using our containerboard and making specialty boxes or whether it's a pure open market, and we're seeing those volumes up close to double digit for the overall exposure we have for the North American box market. So it looks like more of the same. We do see some channel shifting, which is good news. We see obviously some foodservice and restaurant supply picking up.\\nWhere that shows up for IP, and we're overweight in this area is fresh food produce, the type of things restaurants buy twice weekly, 3 times weekly basis, which really got hit hard in the pandemic. So we're encouraged by what we're seeing in the demand trends and the segment exposure that we have.\\nGeorge Staphos -- Bank of America -- Analyst\\nThanks, Mark. Just a point of clarification. The close to double-digit reference that you just made, what was that referring to?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nIt's all in channels to market that we look to provide to the U.S. box market. So our vertical channel in our own box business, we have some strategic partnerships where we have either partial ownership or majority ownership downstream in the converting. And usually, that's specialty type products. And then we have just the pure open market where we have long-term arrangements. When we look at the activity and -- that we participate in the U.S. box market, it's really strong.\\nGeorge Staphos -- Bank of America -- Analyst\\nOkay. Thanks for that. My other question, recognizing this was a very different first quarter from a storm and outage standpoint. And clearly, we can understand why you saw such a pickup in energy costs in the quarter. Looking back over time, it looks like IP's consumption of energy has been relatively constant. Are there -- given what we've seen in the last quarter and given that experience, what are the areas that you see where perhaps IP can become even more efficient within its mill network in terms of energy consumption? Thanks, guys, and good luck in the quarter.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nThanks, George. It's a good question. On energy, the main thing we can do on the mill system side is maximize our own make energy in our fully integrated kraftliner mills, where we make anywhere from 75% to 85% of our energy with carbon-neutral biomass. There's more we can do there. Sometimes it takes investment. As you know, what we've done with our capital investment program over the last couple of years is to navigate some strategic projects like Riverdale and then the pandemic and managing our entire liquidity situation. We -- those are the type of projects that you can go back and get later.\\nSometimes, it's unfortunate, but we delay them even though they have really good returns. So we've got more investment we can make. Fuel switching, we've done a lot of to natural gas from other higher-cost fuels. And in the converting plants, we don't make our own energy. So part of it's geographical exposure to the grid, but part of it's energy efficiency through the uses of energy in the plant. Most all of that, where we are now in our company in terms of consumption, most all of that is part of our investment profile. And usually, George, those projects have the highest returns. And we plan to invest -- increase our investments in those areas now that all phases of our financial condition are much stronger.\\nGeorge Staphos -- Bank of America -- Analyst\\nThank you, Mark.\\nOperator\\nOur next question comes from the line of Mark Weintraub of Seaport Global.\\nMark Weintraub -- Seaport Global -- Analyst\\nThank you. First question was you really did have a lot more pricing in the Industrial Packaging business flow-through than I think your original guidance had been. And you mentioned, Tim, that this was one of the fastest pass-throughs or your ability to get price turned out to be very good. Can you give us more color on what happened and what it tells you?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nIt's a difficult question, Mark, because there's so many customers and so many unique commercial agreements. I think the general answer is when you have this type of demand, and a lot of our customers are dealing with multiple supply chain challenges. It's not just the packaging that they get but the other inputs. I think the discussion time about the gray area in every commercial relationship about how fast or how slow, no one loves price increases, obviously. That dynamic just lends itself, so let's get this done and get our material in and get it in as quickly as possible because I've got 17 problems and the box is only one of them.\\nThat's just a general answer. The dynamic out there right now is things are very tight in multiple parts of the supply chain for a lot of our customers. And everything at the final minute of when you implement tends to be a human team in negotiation and it just went faster.\\nMark Weintraub -- Seaport Global -- Analyst\\nGreat. And can you give us a sense -- I recognize that certainly by the end of the quarter, it was all in. Is there still some carryover impact that's included in that $75 million that you're looking for in the second quarter versus the first quarter? Or is that actually genuinely all from the new initiatives?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nYes. It's small, Mark. There's probably just a little bit from the first price increase, but virtually all of it's in. And so we're looking forward now to the March increase implementation.\\nMark Weintraub -- Seaport Global -- Analyst\\nAnd one last one, sort of in the same vein, but in the pulp business, where great to see that, hopefully, second quarter will actually be a little bit in the black. I imagine though, because of the way those contracts are laid out, that even based on the prices -- price increases you've already implemented that there should presumably be more to come in the second half of the year. A, is that valid? And b, do you have pretty -- do you begin to have pretty good visibility on that? Or is that going to be negotiations and conversations yet to come?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nIt's for the -- we gave an outlook. I think the number was $100 million in price in the second quarter. That's as far as we're going to go on that. But we like -- as I said in my closing prepared remarks, we really like the momentum in Cellulose Fibers right now. A big part of that like is the movement in pricing. But I don't want to go out into the third -- or into the third quarter and fourth quarter. But if you just take the confidence we have in the trajectory, I think you can make some conclusions.\\nMark Weintraub -- Seaport Global -- Analyst\\nThank you.\\nOperator\\nOur next question comes from the line of Adam Josephson of KeyBanc.\\nAdam Josephson -- KeyBanc -- Analyst\\nHope you're well. Well, Tim, one question on the guide -- the 2021 momentum building slide. I asked the same basic question on the last call, but -- so everything seems to be getting better as you go through the year. Why not resume providing guidance at this point? I know about all the -- there are many uncertainties, as there always are. So did you -- how much consideration did you get to doing that? And why did you reach the conclusion, at least for now that you don't want to resume doing so?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nYes. It's a good question, Adam. I mean, technically, we don't provide guidance as such. We give an outlook. It's true that in prior periods, we had talked about a full year outlook and expectations sometimes within a range. It's something that we look at every quarter. I think we're -- some of the uncertainty around COVID is -- seems to be diminishing. But I think maybe as we get to the middle of the year, we'll have a better feel for vaccination rates and what's reopening and what's not. And so it was just not enough in our view at this point in time to start talking about full year guidance. But we do have a lot of optimism about how we see the year playing out.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nAdam, this is Mark. Just to add. It's -- look, it's a good question. We have given the investment community, as Tim said, at least an EBITDA range, a couple of other numbers for full year expectations. I think what's missing is that EBITDA number. We did talk about our capital expenditures, for example. But as we get into this year, a full year guidance given in the middle of the year, I think was maybe less valuable than if we would have given at the beginning of the year. Look, I'm an optimistic person. You know me personally, Adam, I am feeling really good about where we are.\\nBut just as soon as I say that, I think about our employees in Poland right now or our employees in Brazil, and they are where we were during the Christmas holidays and in January with pandemic and its effect on their economy and their lives. So I just don't want to get out over our skis and say things that imply this is all behind us only to have to come back and say, what, that was too quick. So I know it's a little frustrating, but we're trying to get this transparent outlook, as Tim walked through methodically all those numbers on the outlook slide. And hopefully, that gives people a sense of the big picture, which is things are really strong and improving.\\nAnd we have, as Tim said, on the capital allocation slide, a balance sheet that's headed very quickly to the low end of our range and good cash generation, flowing cash through the capital allocation framework, dividend share repurchases like we committed to, albeit interrupted for a program not casually. And so that's the message I really want investors to take away and analysts to work with. But your point is well taken. It's information you used to have, but you don't have right now.\\nAdam Josephson -- KeyBanc -- Analyst\\nNo, I really appreciate that, Mark. And just one other question for you on -- back to the e-commerce and the whole box demand issue. You used to talk about the relationship between box demand and GDP, and between box demand and nondurable industrial production. And you have that really good slide in your roadshow handout to that effect. How do you think those relationships have changed, if at all, given this new information you have about the presumed permanence of this e-commerce growth.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nWell, that's a really good question. I know our team is looking at the resiliency of that model that creates that slide you're talking about in our roadshow where we have the nondurable and transportation index and a number of other metrics. I don't know if we've decided that there's a shift in it yet, but I know our team is looking at it. As soon as we have something that we feel good about and that it's legitimate and statistically valid, we like to share that in our investor material, and we'll do that in the future.\\nAdam Josephson -- KeyBanc -- Analyst\\nThanks so much, Mark. Best of luck in the quarter.\\nOperator\\nOur next question comes from the line of Phil Ng of Jefferies.\\nPhil Ng -- Jefferies -- Analyst\\nHey, guys. Appreciating there's a greater lag in the flow-through on pricing. But with fluff pulp prices approaching 2018 levels, and commercial initiatives you guys are implementing, how quickly do you think that earnings power for cellulose to kind of return back to 2018 levels?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nWell, we gave the outlook for the second quarter, and you can look at the trend there on just the pricing comment of $100 million. I think we are in that part of the pulp market dynamic. And we're also trying, as I mentioned multiple times, we're trying to change the business model commercially, primarily on how we go to market and how we interact with our customers so that we put more sustainability and less volatility in the business. And that's a lot of work, about work I can comment on because it's customer-specific, but we feel good about where we are right now. And we think the business can get back to. And then, if we can invest in the cost side, improve upon what numbers you're talking about from '18.\\nPhil Ng -- Jefferies -- Analyst\\nThat's great. I appreciate that color. It seems like a solid game plan. The 145,000 lost tons in containerboard from the winter storms, is your view you would essentially sell pretty much all that? Or would that have been kind of an effort behind to build inventory? The reason I'm asking, I'm just trying to gauge if you view that as pent-up demand for 2Q. And then more broadly, just given how tight things are, do you have bandwidth to kind of supply your customers given how strong demand is right now?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nYes. We're working hand in glove with customers across all of our channels, trying to make sure that we're meeting their needs as quickly as possible. Having said that, it's a challenge. 145,000 tons, a big portion of that was available for sale and ready to go. In some cases, as we go into the second quarter, it's a heavier maintenance outage quarter. And so part of it is preparing for that as well. But definitely missed opportunities on the containerboard side. But as, if not more importantly on the box side, with 30 plants down and significant exposure. So our estimates around that exposure is that the growth that we had in the quarter would be closer to overall industry growth if we haven't had that disruption.\\nPhil Ng -- Jefferies -- Analyst\\nBut you see that demand still there? Or your customers kind of went elsewhere to kind of get supply just given how tight things are?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nWell, some of it's there. Some of them are still working through, as I mentioned in the prepared comments, working through backlogs. All of these channels have different lead times on orders and when customers are expecting them. And so we're working through it customer by customer on that basis.\\nPhil Ng -- Jefferies -- Analyst\\nOkay. Super helpful, guys. Appreciate it.\\nOperator\\nOur next question is from Mark Connelly of Stephens.\\nMark Connelly -- Stephens -- Analyst\\nFollowing on Phil's question. If we remove the storm impact that held back first quarter, is there any reason to think that IP can't match the industry shipments in 2021 or even exceed it? I'm thinking about the outages and the maintenance timing shifts and that sort of stuff. Because obviously, there was a lag or a lag in performance in 4Q too. So I just want to make sure we're not missing anything.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nNo, it's a good question, Mark. There's no reason to believe we can't match or exceed. Now given our size exceeds means some basis points, not multiples. But there's no reason you can't match the market. Fourth quarter, we did have some operational issues, if you recall. And then not an excuse, but this geography and the winter storm matched right on top of us. But no reason you shouldn't expect us to perform at or better than the market.\\nMark Connelly -- Stephens -- Analyst\\nOkay. And -- thank you, that's helpful. Just on EMEA, following on Tim's comments, how does the push to mid-teens margins in EMEA breakout between converting and mill opportunities? I'm just wondering if there's spending opportunities at those mills or if most of the incremental investment and improvement is coming on the converting side.\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nYes. It's a good question, Mark. We think we have additional opportunities, not that so many of them require capital in the mill operations, but just in terms of how we're managing cost as we get fully up the ramp curve and integrated, and it's both mill and supply chain. So we see more opportunity for the mill in Spain. The other mill is a more mature mill that's been there for a while. And so it's probably running at an optimal level. But in Spain, given the integration play, we see more opportunity.\\nMark Connelly -- Stephens -- Analyst\\nSo bringing some of the strengths in the integration that you have in the U.S. over to there. Okay. That's very helpful. Thank you.\\nOperator\\nOur next question comes from the line of Cleve Rueckert of UBS.\\nCleve Rueckert -- UBS -- Analyst\\nHi. Good morning, everybody. Thanks for taking my questions.\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nMorning.\\nCleve Rueckert -- UBS -- Analyst\\nJust first off, I wanted to follow up on the $350 million to $400 million of incremental EBITDA. I think $300 million of that was supposed to be from cost savings. And I realized Q1 was kind of challenging, but I didn't hear an update on how much of that you've achieved to date or how much you expect to achieve this year headed toward that 2023 exit rate?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nYes. Well, you -- we didn't provide one. So we're working through our plans right now, and we're in the process of beginning the implementation of all that. We pointed on the last quarterly call to some of the benefits that we saw coming through, more of the process automation and using data analytics and technology. And as we go through this year, we're looking forward to probably the third quarter where we provide a robust update in terms of all of the plans that are being executed and achievement this year, but also run rate expectations for 2022.\\nCleve Rueckert -- UBS -- Analyst\\nOkay. All right. That's clear. And then, I guess, just a follow-up on the containerboard and corrugated box business. Could you give us just a sense of where your inventories stand, given the disruptions kind of, I guess, where you are today at an inventory level versus where you like to be or where you've been historically on average? And kind of what the trajectory is there on the inventory side given the outages in the second quarter?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nWell, the easy answer is we're lower than we'd like to be. And that's the source of the hand to glove comment Tim just made. So we need to rebuild, while we serve our customers' active demand, we need to be very efficient in rebuilding important roll stock inventories across the wide range of boxes that we have to make. So there's more for us to do. It's not unexpected when you have this type of demand, coupled with the one-off interruption of the storm we talked about and then just the timing of outage schedules. But the good news is we have a really big system, and it's very flexible and it recovers very quickly.\\nSo we feel like we could do it. But our inventories are lower than we would like, all things considered. And the main thing I'm concerned with right now is our ability to support our customers through their dynamic demand changes. And that's what our focus is right now.\\nCleve Rueckert -- UBS -- Analyst\\nThat's clear. I guess just quickly, given what you know about the second quarter, would you expect to be in a position to build inventories?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nEvery effort is going to be made to try to restore inventory levels, but it's a heavy maintenance outage quarter. And so you're triaging and prioritizing and trying to satisfy all of the needs across the channels. So now the good news is, most of the outages are behind us by the time we get to the middle of the year. But these supply chains are very long, and they take a long time to recover.\\nCleve Rueckert -- UBS -- Analyst\\nThat's very clear. Thanks, guys. Appreciate it.\\nOperator\\n[Operator Instructions] Our next question comes from the line of Gabe Hajde of Wells Fargo Securities.\\nGabe Hajde -- Wells Fargo Securities -- Analyst\\nMark, Tim, good morning. I hope you guys are well.\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nMorning.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nMorning, Gabe.\\nGabe Hajde -- Wells Fargo Securities -- Analyst\\nI'm thinking about integration levels in the corrugated operations or Industrial Packaging North America and kind of whether or not you kind of still view this as the right destination? I mean, you have some competitors that are maybe trying to bump that up for different reasons. And I also appreciate that maybe looking back in the rearview mirror, you're kind of playing a little bit more defense and/or kind of making some asset changes along the way. Now you've got some kind of more, I'll call it, disposable cash to go on offense with and you made these two small box plant acquisitions. Is that part of the strategy that maybe get that closer to something, I don't know, 90%? Or you feel good at that 80% level kind of over a longer-term basis?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nYes. So we think what's important about integration is how we go about building it. Our most profitable channel is our North American domestically integrated channel containerboard to box and to the customer. And we want to grow that part of the business by delivering superior solutions on the packaging side to our customers. So that we're building long-term sustainable relationships where we can through small M&A or some of these more creative arrangements that we've started implementing to grow that channel. So higher over time, but done in a very sustainable way.\\nGabe Hajde -- Wells Fargo Securities -- Analyst\\nOkay. And then, I guess, kind of to revisit the cost reduction or the $300 million to $350 million of savings and trying to marry up the comments that you made about Europe. Are those sort of mutual exclusive, meaning the $20 million or so that you saw an improvement in profitability this quarter and I think what you talked about kind of getting back to mid-teens implies maybe another $100 million of improvement in aggregate for European Industrial Packaging. Is that more related to the mill conversion over there and that starting to contribute? Or is that, again, kind of included in that $300 million to $350 million of savings?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nYes. Part of it is included, but it's across commercial, operational supply chain. It's all the things that we touch in terms of delivering a packaging solution to a customer. So we've got improvement plans across all aspects of the business.\\nGabe Hajde -- Wells Fargo Securities -- Analyst\\nThank you, guys.\\nOperator\\nOur next question comes from the line of Paul Quinn of RBC Capital Markets.\\nPaul Quinn -- RBC Capital Markets -- Analyst\\nYes. Thanks very much. Good morning, guys.\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nGood morning.\\nPaul Quinn -- RBC Capital Markets -- Analyst\\nJust had a question on Global Cellulose Fibers. Just when I look at the quarter, I mean, it's an improvement, but it's still a disappointing result, especially when I compare it to your European peers. Where do you see this business being mid-cycle? Can you get up to the profitability of your peers? And when you -- how long do you think that's going to take?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nWell, as I mentioned on the last call, we -- last quarter call, Paul, we see the business improving quarter after quarter after quarter. And we think it'll be in very good shape. I don't have all those European numbers in my head -- off the top of my head, but we think it'll be in very good shape as we leave '21 and head into '22.\\nPaul Quinn -- RBC Capital Markets -- Analyst\\nAlright. That's all I had. Best of luck, guys.\\nOperator\\nOur next question comes from the line of Neel Kumar of Morgan Stanley.\\nNeel Kumar -- Morgan Stanley -- Analyst\\nGreat. Thank you. For corrugated, can you just talk about the cadence of volume growth through the first quarter by month? And then, can you just give us a sense of what you're seeing in terms of box shipments so far in April?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nApril is running very close to maybe a little bit ahead of how we exited the quarter, just looking -- it was pretty steady throughout the quarter -- yes. I mean, it started really strong in January. Now we think a big part of that is our exposure to e-commerce because you not only have the Christmas push around the holidays, but January with returns and in specialty sales and whatnot. It tends to be a strong month as well. But I think it was solid throughout the quarter.\\nNeel Kumar -- Morgan Stanley -- Analyst\\nOkay. That's helpful. And then in terms of your recent asset sales, I was wondering if you can just touch on how you're thinking about allocating proceeds between buybacks versus inorganic and organic investments? And then more generally, where are you in the process of evaluating your portfolio of assets. Could there be additional asset sale announcements? Or is it generally complete at this point?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nWell, when we talked about on the acquisition side is look at what we've been doing for the past couple of years. They've tended to be one-off operations, sometimes 2, bolt-on in nature and filling gaps in capability or exposure that we want. And most of them, to be honest, that's happened in Europe at this point. In terms of the cash coming in, we have a fairly robust capital allocation framework that we have talked about over time, including the strong balance sheet, target ranges of debt. The fact that we're on a path of share repurchases before COVID hit and out of prudence we took a pause last year, but we're back in the market. But the goal is to be thoughtful about the cash coming in and making sure that we're doing everything in our power to maximize value through the actions that we take.\\nOperator\\nAnd our last question comes from the line of Kyle White of Deutsche Bank.\\nKyle White -- Deutsche Bank -- Analyst\\nHey, good morning. Thanks for taking the question. On Global Cellulose Fibers, I just want to talk about the port congestion that you're experiencing and maybe how that is impacting your volumes or your supply chain in that business?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nIt's a good question, Kyle. It's a big issue. We're not losing orders because of it because we're spec-ed in, in a lot of the customers. It's just creating a long, long supply chain. So customers are trying to figure out the new duration between placing an order and actually receiving it and in some cases, trying to get our help to understand whether they should change their order cycle. So there's a lot of order management changes being talked about and figured out between IP as the supplier and our customers. But it affects more than our pulp business.\\nIt affects our export containerboard, and we're even seeing it in our export paper business in Brazil. I don't think there's an immediate fix to it. So it's a velocity mission on the supply chain than it looks like, we're going to have to adapt to for some period of time.\\nKyle White -- Deutsche Bank -- Analyst\\nGot it. That's helpful. And then switching to EMEA Industrial Packaging. Can you guys provide some of your integration rate for just that region and kind of where do you see it going with these recent acquisitions in Spain? And then maybe just a longer-term target for integration there as you continue kind of bolt-ons in that region?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nWe typically don't give a number because it's not as clean. We're integrated on our kraftliner from our U.S. mill system to our European box plants. We have world-class mill. We just started up a couple of years ago in Madrid. That's almost at its full ramp, which is a lot of our high-performance lightweight liner. But we buy most of our medium -- the corrugated medium from the open market. So we typically haven't given an absolute number. But as Tim said, building an integrated model regionally is where we have the most success commercially and on the financial metrics. And so that's kind of the approach we're taking in Europe is regional density.\\nAnd so right now, it's Iberian Peninsula surrounding our new mill and supported with kraftliner from our U.S. system. And then we have some very important suppliers in the European market for grades that we don't make or just that make geographic sense because of grade. So we're still a large customer for some key European containerboard producers and those are long-term relationships.\\nKyle White -- Deutsche Bank -- Analyst\\nGot it. Thank you. Good luck in the quarter.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nThank you. So I appreciate everyone's questions. Again, thank you for your interest in International Paper, and we look forward to talking with you again next quarter.\\nOperator\\n[Operator Closing Remarks]\\nDuration: 90 minutes\\nCall participants:\\nGuillermo Gutierrez -- Vice President of Investor Relations\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nMark Wilde -- Bank of Montreal -- Analyst\\nGeorge Staphos -- Bank of America -- Analyst\\nMark Weintraub -- Seaport Global -- Analyst\\nAdam Josephson -- KeyBanc -- Analyst\\nPhil Ng -- Jefferies -- Analyst\\nMark Connelly -- Stephens -- Analyst\\nCleve Rueckert -- UBS -- Analyst\\nGabe Hajde -- Wells Fargo Securities -- Analyst\\nPaul Quinn -- RBC Capital Markets -- Analyst\\nNeel Kumar -- Morgan Stanley -- Analyst\\nKyle White -- Deutsche Bank -- Analyst\\nMore IP analysis\\nAll earnings call transcripts\\n\\n\\n\\n\\n\",\n          \"Prepared Remarks:\\nOperator\\nWelcome to AxoGen, Inc. Second Quarter 2020 Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.\\nI would now like to turn the conference over to your host, Pete Mariani, AxoGen's Chief Financial Officer. Please begin, Mr. Mariani.\\nPeter J. Mariani -- Chief Financial Officer\\nThank you, Devin, and good afternoon, everyone. Joining me on today's call is Karen Zaderej, AxoGen's Chairman, Chief Executive Officer and President. Karen will begin today's call with an overview of our second quarter performance and an update on the ongoing recovery in our markets, followed by a review of the recent announcement of our RECON study enrollment and our path to a BLA submission. I will then provide an analysis of our second quarter performance, along with a summary of our recently announced debt deal with Oberland capital.\\nToday's call is being broadcast live via webcast, which is available on the Investors section of AxoGen's website. Within an hour following the end of the live call, a replay will be available in the Investors section of the company's website at www.axogeninc.com. Before we get started, I'd like to remind you that during this conference call, the company will make projections and forward-looking statements regarding future events.\\nWe encourage you to review the company's past and future filings with the SEC, including, without limitation, the company's forms 10-K and 10-Q, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements related to the expected impact of COVID-19 on our business, statements regarding product acquisition and/or development, product potential, the regulatory environment, sales and marketing strategies, capital resources or operating performance.\\nAnd with that, I'd like to turn the call over to Karen. Karen?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nThank you, Pete, and good afternoon, everyone. Our total revenue for the quarter was $22.1 million, representing a 17% decline to the prior year period. While COVID-19 had a material negative impact on total revenue, we saw steady improvement across the quarter as our customers reopen their surgical schedules. Our second quarter performance reflects the recovery in our markets that was stronger than we anticipated. As well as the priority that surgeons and hospitals have placed on nerve repair with AxoGen products in the early stages of the recovery. Our recovery also reflects the hard work and creativity of the entire AxoGen team to support our customers and their patients in this difficult environment.\\nThe recovery varied regionally based on the intensity and trends of COVID-19 in local markets. As elective surgeries resumed, we experienced short-term regional surges in nerve repair cases, reflecting the completion of deferred procedures. These recovery surges were typically followed by a return to more normalized levels for the territory. Certain interviews that we conducted confirmed that nearly all surgeons had experienced significant disruption to their practice and a reduction in surgical procedures due to COVID-19, but many surgeons believed that they were already caught up with their current backlog of deferred procedures, while most others believe they would catch up by the end of the summer.\\nIn addition to regional variation, our recovery also varies by nerve repair applications with our core trauma business leading our recovery. The recovery of procedures in our breast and OMF applications as well as our emerging business in the surgical treatment of pain began later in the quarter. Overall, we're encouraged by the execution of our team and the priority hospitals and surgeons are giving to nerve repair with AxoGen products during the recovery. However, we remain measured in our outlook for the remainder of the year as most currently deferred procedures will likely be completed by the end of the summer, and COVID-19 may continue to negatively impact the incidence of trauma, and regional surgical procedure volumes.\\nWe, therefore, expect third and fourth quarter revenue to remain below prior year levels. In the area of sales execution, we continue to strategically focus our sales representatives on extremity trauma and on driving deeper penetration with our existing surgeon customers, although COVID-19 required us to adjust our approach. During April, healthcare facilities broadly restricted vendor access, and we directed our sales team to enter facilities only when requested and necessary. Our sales representatives remained in frequent contact with our customers virtually. And they work together to provide effective case support remotely.\\nWe also used restricted time to provide six weeks of extensive product and skills training for our sales team, which we believe provided the benefits of keeping the sales team positively engaged and improve their ability to support our customers. On May 1, we released our sales team to begin reentering healthcare facilities following local, regional and national guidelines and using contact tracing. While our access to healthcare facilities have improved, the ability to effectively support our customers remotely continues to be an important learned capability that our team has embraced, and we believe our customers have appreciated.\\nWe ended the second quarter with 112 direct sales representatives, an increase of three representatives added early in the quarter. With our slowing of sales headcount expansion this year, we have minimized change and disruption to stabilize our sales territories and provide consistency of support to our customers. Our direct sales channel was supplemented by 19 independent sales agencies who generally cover geographies that are less impacted by COVID-19 during the quarter. These geographies delivered better year-over-year performance than those covered by our direct sales representatives. As a result, the indirect channel represented approximately 15% of our total revenue in the second quarter compared to an approximately 10% in the first quarter.\\nWe had 789 active accounts in the second quarter, an increase of 4% from 752 one year ago and down 4% versus the first quarter. We have always reported our number of active accounts as an average for the quarter. And the significant decrease in the number of orders from accounts in April and early May had a material impact on the average for the second quarter. Our active accounts have continued to increase each month, such that for the three months ending July 31, our average active accounts has increased and is more consistent with our Q1 average of 825.\\nWe were pleased that a large majority of our top surgeons and hospitals continue to use and order AxoGen products for their patients despite the challenges of COVID-19. The top 10% of our active accounts continue to represent approximately 35% of our revenue. Our sales team remains focused on our strategy of going deeper with current certain customers and exited the second quarter well prepared for the second half of the year. We continue to focus on building market awareness of AxoGen and our products despite reduced in-person access to surgeons and restrictions on certain travel to scientific conferences.\\nIn June, we expanded our digital marketing capabilities, allowing us to more fully engage with surgeons electronically. These digital efforts provide an enhanced long-term capability to supplement the efforts of our sales team. And help our sales reps engage with surgeons where access to hospitals remains limited. Our efforts to educate surgeons and develop advocates continued in the second quarter. In March, we canceled the remainder of our 2020 schedule of in-person surgeon and fellows education programs, and we've since developed several virtual education programs led by surgeon experts in nerve repair. In June, we launched an invitation-only program for early career upper extremity surgeons who are passionate about advancing the field of nerve repair. The program is an interactive 6-part series, led by an expert faculty.\\nSimilarly, we launched a surgeon-led extremity trauma webinar series open to all of our surgeon customers. We're also continuing our commitment to educating hand and microsurgery fellows and are launching an updated training program for the second half of 2020. We previously discussed our plans to introduce new products and expand the application of our portfolio into the surgical treatment of pain, focused on symptomatic neuroma. We launched AxoGuard Nerve Cap in February, and are pleased with our early results as we focus on expanding the nerve repair algorithm of our current surgeon customers.\\nNerve Cap, an important addition to our solutions portfolio, designed to protect the peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. With the addition of Nerve Cap, we now have a full portfolio of products for nerve connection, nerve protection and nerve termination. Increasing surgeon adoption of our product portfolio continues to be supported by a large and expanding body of clinical data. We recently announced our RECON clinical study had reached its targeted enrollment of 220 subjects in July.\\nRECON is our Phase III pivotal study supporting our biologics license application, or BLA, which will transition our Avance Nerve Graft from a Section 361 tissue product to a Section 351 biologic products. We're pleased to have reached this important milestone despite a challenging environment for clinical studies, and we appreciate the dedication and commitment of our participating study teams as well as our internal team of clinical professionals. The RECON clinical study protocol requires a one year follow-up assessment with the allowance for an additional three months visit window. With the final subjects enrolled in July of 2020, the last subject is expected to complete the study no later than October of 2021.\\nWe've increased our efforts to support completion of subject follow-up visits during the COVID-19 crisis by implementing an expanded home health visit program to allow follow-up visits to be conducted by a trained healthcare professional outside of the clinic environment and with appropriate safety precautions. We are working closely with our research centers to monitor follow visit windows and minimize any potential disruption. We anticipate providing a preliminary report of trial data in the second quarter of 2022 and expect to file the BLA in 2023. In addition to the completion of enrollment of the RECON study, our RANGER Registry now has over 2,200 nerve injuries enrolled.\\nAnd we expect data from the study to be presented at clinical conferences and published in the second half of the year. Enrollment in our REPOSE study is ongoing. REPOSE is a prospective randomized controlled study evaluating the use of AxoGuard Nerve Cap in the management of painful neuroma as compared to a standard neurectomy procedure. Preliminary outcomes from the pilot phase of the REPOSE study found that at six months, subjects reported meaningful improvements in pain and quality of life scales. We've completed the last subject follow-up visits and data analysis is under way to support our REPOSE study pilot phase manuscript.\\nWhile this is a small pilot study, we remain encouraged by the positive impact reported to date and will continue enrollment of the comparative phase of the study as centers reopen to research subjects. As we noted in our call in May, we've paused enrollment of our Sensation-NOW clinical registry for the remainder of 2020, given the COVID-19-related restrictions in our study centers. We're pleased with the enrollment of 600 subjects in the registry and believe this will create a significant body of evidence around the breast neurotization technique. Similarly, we've paused enrollment in our RETHINK PAIN registry and our Avive ASSIST study.\\nWe continue to monitor the recovery of activities at study centers and will prioritize the potential restart of the clinical programs based on our business needs. We remain committed to providing meaningful and impactful clinical evidence on the utility of our nerve repair portfolio. Despite ongoing COVID-related challenges in the market, we're encouraged by the performance of our AxoGen team to creatively adapt and adjust to these challenges. We've learned new skills in supporting our customers and continue to advance our strategy focused on extremity trauma and driving deeper penetration with our existing surgeon customers. We remain as excited as ever with the opportunity in front of us, and we believe we are well positioned to drive continued growth as we emerge from the pandemic.\\nNow I'll turn it over to Pete for a review of financial highlights. Pete?\\nPeter J. Mariani -- Chief Financial Officer\\nThanks, Karen. Second quarter revenue declined 17% to $22.1 million. Our revenue decline for the quarter was the result of a 19% decrease in unit volume, partially offset by a 2% net benefit from changes in pricing and product mix. Gross profit for the second quarter was $16.5 million compared to $22.5 million in the prior year. Gross margin was 74.7% for Q2 compared to 84.1% in the prior year second quarter. Gross margin was negatively impacted in Q2 as a result of increased period and variance cost, associated with the suspension of tissue processing during the quarter of $1.6 million and increases to inventory reserves.\\nWe began a gradual restart of our tissue processing in June, are continuing that ramp in the third quarter and anticipate that gross margins will return to normalized levels as sales and production levels recover. Total operating expenses in the second quarter declined 18% to $24.8 million compared to $30.1 million in the prior year. Total operating expenses in the second quarter included $2.2 million in noncash stock compensation compared to $2.7 million in the prior year. Sales and marketing expense in the second quarter declined 23% to $14.3 million compared to $18.5 million in the prior year.\\nThis decrease was primarily due to reduced compensation expenses including lower commissions, a reduction in our surgeon education expenses after canceling in-person education programs and lower travel expense as a result of the travel restrictions and canceled programs. As a percentage of total revenue, sales and marketing expense decreased or decreased to 65% for the three months ended June 30, 2020, as compared to 69% for the previous year. Research and development spending in the second quarter decreased 5% to $4.1 million compared to $4.3 million in the prior year.\\nResearch and development costs include product development, including expenses in support of the BLA for the Avance Nerve Graft and clinical research. Product development expenses represented approximately 50% of total R&D in the second quarter compared to 58% in the prior year. While clinical expenses represented the other 50% in the second quarter of 2020 compared to 42% in the prior year. As a percent of total revenues, research and development expenses were 18.4% in Q2 and compared to 16% in the prior year. General and administrative expenses in the second quarter decreased 13% to $6.4 million or 29% of revenue, compared to $7.4 million or 27.6% of revenue in the prior year.\\nHe decrease is primarily related to the reduction in litigation and professional fees as well as lower compensation and travel expenses. Net loss in the second quarter was $8.1 million or $0.20 per share compared to $7 million or $0.18 per share in the prior year. Excluding the impact of noncash stock compensation as well as litigation and related charges, adjusted net loss and net loss per share in Q2 of this year was $5.9 million and $0.15 per share compared to $3.7 million and $0.10 per share in the prior year. Adjusted EBITDA loss in the quarter, which also excludes the impact of stock compensation, litigation and related charges, was $5.7 million compared to an adjusted EBITDA loss of $4.1 million in the prior year.\\nTurning to our balance sheet. The balance of cash, cash equivalents and investments on June 30 was $109.9 million, compared to a balance of $89 million in March of 2020. The net change reflects the receipt of net debt proceeds of $34.7 million, partially offset by capital expenditures totaling $7.7 million and net operating cash burn of $6 million during the quarter. Capital expenditures in the quarter included $6.5 million related to cost incurred for our Dayton biologic processing center prior to the suspension of construction in April, and $1.2 million related to our new office and lab facility in Tampa.\\nWe anticipate completing our new Tampa facility in the third quarter and restarting construction on our Dayton biologics processing center in early 2021. On June 30, we announced a new seven year interest-only financing agreement with Oberland Capital, which provides up to $75 million in total financing commitments with $35 million drawn at close. The second tranche of $15 million can be drawn at the company's option upon achieving two consecutive quarters with revenue of at least $20 million. And this second tranche can also be put to the company at any time by Oberland. The third tranche of $25 million can be drawn by the company or at the company's option upon achieving two consecutive quarters with revenue of $28 million.\\nOberland cannot put third tranche to AxoGen. Under the terms of the agreement, the option to draw both the second and third tranche expires on December 31, 2021. Interest from this facility is calculated a 7.5% plus the greater of LIBOR or 2%, leading to an interest rated closing of 9.5%. An additional quarterly royalty payment calculated on up to $70 million of annual revenue will begin on September 30, 2021. This royalty structure results in approximately 1% per year of additional payment on the outstanding loan amount. We believe the terms of this debt agreement allow us to strengthen our balance sheet and support the completion of the Dayton and Tampa facilities.\\nThe financing provides a manageable and flexible covenant structure, and we believe the interest-only provision for the full seven years provides a sufficient liquidity extension without diluting our shareholders that can support our continued growth through an uncertain environment and as we drive toward long-term profitability. On April 23, we announced a cost mitigation initiative designed to defer and reduce certain expenses and capital expenditures in response to the anticipated reduction of revenue caused by the ongoing COVID-19 pandemic.\\nThis initiative preserved our ability to support customers and patients in the second quarter and through the recovery and put us on a more efficient spending run rate. The initiative included the reduction of executive cash compensation and Board fees by 20%, and reduced cash compensation for all other exempt salary employees by 10% to 15%. We have restored pay levels for most employees as of August, although our officers and the Board have continued with a 20% pay cut for the time being.\\nAdditionally, we were able to defer approximately $25 million to complete our Dayton, Ohio facility for up to a year. While the path and pace of our business recovery continues to be uncertain, we are encouraged by the execution of our team and the trends in our markets that we observed during the second quarter. We also believe that the strength of our balance sheet, our cost-mitigation initiatives and our continued commercial execution will allow us to emerge from this pandemic-related downturn, a stronger, leaner organization and a lot of path to profitability.\\nAnd with that, I'd like to hand the call back over to Karen.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nThank you, Pete. We're encouraged by the performance of our commercial team during the pandemic, and believe that our renewed focus on the core trauma opportunity has supported the pace of our recovery and has positioned us well as we enter the second half of the year and continue to develop the nerve repair market. We believe that the regional surges we experienced as surgical cases reopened indicates that nerve repair with AxoGen products ranks high among surgeon priorities. And provides additional evidence of our products, clinical benefit and value proposition to patients, surgeons and hospitals. At this point, I'd like to open up the line for questions. Devin?\\nQuestions and Answers:\\nOperator\\n[Operator Instructions] Our first question comes from the line of Raj Denhoy with Jefferies. Please proceed with your question.\\nRaj Denhoy -- Jefferies -- Analyst\\nHi, good afternoon.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nGood afternoon, Raj.\\nPeter J. Mariani -- Chief Financial Officer\\nHi, Raj.\\nRaj Denhoy -- Jefferies -- Analyst\\nI wonder if I could start with the revenue lines. Pretty encouraging to see only down, I think it was 17% for the quarter after the negative 70%, I think you talked about in April. And so it does imply that very strong recovery in the second couple of quarters second couple of months of the quarter, but you're still, I guess, pointing to that being mostly recovered procedures as opposed to underlying demand. And so what I'm trying to get at is what is that underlying demand right now? And you did talk about it being still below 2019 levels in the back half of the year. And so maybe you could just ground us in terms of where you think we are on that metric?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nYes. So the recovery in the quarter was both. It was both deferred procedures from the March time period that got rolled over into the Q2 time period as well as current trauma that just happens day-to-day as surgical ORs opened up, surgeons were able to do in real time. And so we saw both of those occurring and driving the demand. We definitely saw a surge or a spike as various regions opened up. And of course, those happened at different times as regions had different time periods of the recovery.\\nAs you can imagine, some of the Northeast recovered either late June or even into July, and other parts of the country started to recover in May, balanced by some of the pullback that we've seen in some of the regions as COVID starts up again. So from a impact to us overall. We feel that incidence overall of trauma is still down somewhat, not as much as it was during the full shutdown, but we believe that the overall incident is somewhat depressed. We believe that from a deferred procedures, actually, many of them were completed in the second quarter.\\nSo those March procedure that didn't happen, got rolled over into March excuse me, in the second quarter. There are some deferred procedures that will still get wrapped up toward the end of summer. But really, we think that, again, given the priority that surgeons placed on nerve repair, they moved those procedures pretty quickly into the OR. And so we won't see a big surge from deferred procedures, but we do see the underlying demand continuing to stabilize.\\nRaj Denhoy -- Jefferies -- Analyst\\nI guess I'm trying to understand at what level? I know you're not giving guidance, and I appreciate that you're operating under a pretty limited information. But is that down 10%? Is it down 20%? What level of lower demand are we talking about at this point? And I appreciate you also have the ability to speak to July. So I don't know if you want to comment on that as well.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nWell, I think we saw good solid trends as we moved into the third quarter and in July. We're encouraged by that. But our and I'll just tell you my hesitation on giving you a depression of the incidence of trauma and the surgical repair of those procedures is because I still don't know what's going to happen regionally around COVID as it resurges in different places. And that's going to affect the trauma rate. And so I really I just I don't feel like it's fair to give you a guidance number because it's going to be based on the resurgence of COVID. The underlying demand for the products remains strong, and surgeons certainly are prioritizing getting those nerve repairs done.\\nRaj Denhoy -- Jefferies -- Analyst\\nUnderstood. On a separate topic, you were, I guess, pretty encouraged by what you're seeing on your transition to more kind of digital or virtual training and even case support efforts. And I guess what I'm asking about is how permanent do you think some of these might be? I mean is something you could see playing out even once COVID ebbs and you can get back into the hospital? Does this represent some potential cost savings for you longer term? And how do you see this playing out over the next couple of years?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nYes. I think that we have learned. We've been really nimble. We've learned some new skills and build some new capabilities. And I'm pretty optimistic that these are permanent additions to our skill sets and capabilities. And so when we think about the remote case coverage, some of the virtual education work that we've developed, and the digital marketing tools that we've developed, we think we're going to keep those in our tool belt for the long term. We think they really are beneficial to us.\\nRaj Denhoy -- Jefferies -- Analyst\\nBut I guess, do those replace things you were doing? Or are those really additive in a sense? I mean is there the potential that you could see a permanent reduction in your selling costs, for instance, from where you were pre COVID?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nYes. I think that they contribute to sales rep productivity and overall commercialization productivity. So I think they are added tools that improve our overall productivity and make us more efficient.\\nRaj Denhoy -- Jefferies -- Analyst\\nOkay, understood. Thank you.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nThanks Raj.\\nOperator\\nOur next question comes from the line of David Turkaly with JMP Securities. Please proceed with your question.\\nDan Stauder -- JMP Securities -- Analyst\\nYes, hi, this is actually Dan Stauder on for Dave. How is it going?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nHi, Dan.\\nPeter J. Mariani -- Chief Financial Officer\\nHi, Dan.\\nDan Stauder -- JMP Securities -- Analyst\\nGreat. It's actually Dan Stauder on for Dave. So I guess just going back to Raj's question. You mentioned that sales consisted of both deferred procedures as well as some current trauma demand. Could you give us any more color on that? How much contributed from both? Was it mainly from recoup cases? Or any amount of detail you can go into that would be great.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nWell, by far, the majority is day-to-day trauma. The deferred cases that rolled in were what was delayed in March. So we saw procedures start to drop in the early part of March, and some of those obviously rolled in and were deferred procedures. But trauma overall in the peak of April, we estimate it was down about 20% and it has come back up from that. Again, it's highly affected by activity and activities affected by COVID and the lockdowns in various regions associated with that. But we've come up materially from where we were at the low point, both in, we believe, the incidence of trauma. As well as patients' willingness to come into either hospitals or surgery centers to get that traumatic injury repaired.\\nDan Stauder -- JMP Securities -- Analyst\\nGreat. And then just a follow-up on that. As different regions reopened, how much of that headwind from the state home orders really waned off? Was it really pretty immaterial in June as construction and other activities we're able to resume? Or do you think that's probably here for the back half as well?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nWe still see high regional variations. It definitely waned across much of the country, but we saw impacts in Texas, in South Florida and Southern California in the June time period, given the incidence of COVID that was happening there. It is tough to tell for us at this point, whether it's the incidence of trauma or whether it's people's willingness to come or ability to come in to get surgery completed. But that's counterbalanced by the opening up of places in the Northeast, which really didn't happen until late June, early July.\\nDan Stauder -- JMP Securities -- Analyst\\nGreat. Thank you guys.\\nOperator\\nOur next question comes from the line of Richard Newitter with SVB Leerink. Please proceed with your question.\\nJamie -- SVB Leerink -- Analyst\\nHi, this is Jamie on for Rich.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nHi, Jamie.\\nPeter J. Mariani -- Chief Financial Officer\\nHey Jamie.\\nJamie -- SVB Leerink -- Analyst\\nHi guys. This is Jamie [Phonetic] on for Rich. So I just wanted to kind of come back to just the trends and what you're seeing. Could you potentially comment on, I guess, one way to think about it would be, is there a potential that you could hit that second tranche for the new financing agreement with Oberland in 3Q? Kind of help us think if that's something that could be a possibility. And then as you look into 4Q, is it reasonable to think that there could be year-over-year stability or potential growth? Or just based on what you see with the resurgence, you're not thinking that, that could be something that's on the table at this point?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nWe're still seeing or estimating. And again, this is trying to create our own crystal ball around the impact of COVID on nerve repair cases that we would remain below our prior year Q3 and Q4, which is right about where that Oberland oh, the $20 million sorry, the $20 million, we're already above and that would not be unreasonable to think that we'll be above that. The next tranche at $28 million is would be aspirational.\\nJamie -- SVB Leerink -- Analyst\\nGot it. Okay. And then just we've been hearing from a lot of other companies, COVID seems to be accelerating the trend to ASCs. And I think we've kind of talked about this in the past, but can you just comment on how or potentially when you guys believe this could impact your business and how you guys are what you guys are potentially doing to capitalize on this now?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nSure. Well, as we talked about before, there was a change in the Medicare reimbursement rate of OPPS rates for both outpatient surgery and ambulatory surgery centers that was favorable for nerve repair in general and in particular, nerve repair with implants, either a connector or an allograft. And so we see that as a benefit for the long term, the majority of nerve repair is not actually Medicare patients, so it'll have to roll through commercial payers as they as surgery centers adjust their contract with commercial payers. And we think that will take a couple of years to roll through the system.\\nWe're seeing good interest in that. But I would not say we've seen a material shift at this point. There's been certainly distractions in this quarter that may have put that as a lower priority. Having said that, one interesting thing that we did see, again, with the emphasis that surgeons really wanted to get their nerve repair patients in, in those locations where they were locked out-of-hospital ORs. So in places, for example, in Texas, as the resurgence happened, they shut down elective procedures in hospitals.\\nAnd what we saw was a very rapid shift of surgeons moving those patients to outpatient centers or to ambulatory surgery centers and still completing cases where they felt that was reasonable and the right option for their patients. And so we do see them leveraging that avenue, and we think that bodes well for the future as the payment schedules are adjusted as well.\\nPeter J. Mariani -- Chief Financial Officer\\nOkay, Devin?\\nOperator\\nOur final question comes from the line of Brandon Folkes with Cantor Fitzgerald. Proceed with your question.\\nBrandon Folkes -- Cantor Fitzgerald -- Analyst\\nHi. Thanks for taking my questions and congratulations on the success during the quarter. Maybe firstly, could you just elaborate a little bit on the funnel of patients you have been seeing post the quarter within [Indecipherable]? And then secondly, can you just again elaborate on some of the positive shifts that have happened during COVID that you do think will be tailwinds to your business when we come out but in terms of realized world.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nYes, Brandon, I just want to make sure I got your question because in the first part, it broke up a little bit. The second part that I heard was positive shifts that will be tailwinds for us, but I didn't hear the first part.\\nBrandon Folkes -- Cantor Fitzgerald -- Analyst\\nCan you just elaborate on the funnel of patients you are seeing in July?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nOkay. Well, what we have seen and have been really pleased with is that the surgeons who were active users have almost all, frankly, returned back to using AxoGen products. And so we don't have a leaky bucket in that respect of users continue to be users. And as their practices ramped back up, they ramped up in and using it at the same rate or, in some cases, even higher because there are we talk about benefits. There are benefits in a COVID environment to do an allograft or Avance as compared to an autograft. It is a much shorter surgical procedure time, there's less exposure.\\nYou can do wide-awake surgery versus surgery requiring anesthesia, in some cases, depending on the patient. All of those are healthy benefits for the hospital workers while providing good care for the patient. So we think there's real benefits in doing an allograft repair or an Avance repair in this environment. In terms of our funnel overall, to go back to your first part, we also had new users start to use our products, particularly in our active centers. So that's where we have our reps mostly focused is developing our footprint in places that we already have a strong surgeon user.\\nWe want to go deeper with that user and add in their partners. We are still adding some new active centers. So we'll see some of that in our pipeline, but the majority of our emphasis is going deeper in the centers that we're already in. And so we feel that the pipeline is good. And there remains strong interest in it. And we certainly saw that with the virtual education programs that we set up with new and developing surgeons and actually really outstanding engagement from surgeons wanting to be a part of that educational program.\\nIn terms of going forward and some of the benefits that we see from the environment we have here, I mentioned before the benefits of using Avance Nerve Graft as compared on autograft. It is there are safety benefits to the hospital staff because of reducing OR time and in some cases, being able to do wide-awake surgery. There are also the learned benefits that we talked about in terms of the digital marketing, the remote coverage. We think that those are really going to help us continue to expand our productivity of our existing sales team. And that they will pay benefits for the long term, allowing us to continue to grow in a cost-effective manner.\\nBrandon Folkes -- Cantor Fitzgerald -- Analyst\\nThank you very much. That was very helpful.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nGreat. Thank you.\\nOperator\\nAs there are no further questions left in the queue, I would like to turn the call back over to Karen Zaderej for any closing remarks.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nThank you, Devin. I want to thank everyone for joining us on today's call. We look forward to speaking with many of you at the upcoming virtual conferences we're attending, including the Canaccord Genuity Growth Conference, August 11 through the 13th; the Morgan Stanley Global Healthcare Conference, September 14 through the 16th; and the Cantor Fitzgerald Global Healthcare Conference, September 15 through the 17th. Thank you.\\nOperator\\n[Operator Closing Remarks]\\nDuration: 40 minutes\\nCall participants:\\nPeter J. Mariani -- Chief Financial Officer\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nRaj Denhoy -- Jefferies -- Analyst\\nDan Stauder -- JMP Securities -- Analyst\\nJamie -- SVB Leerink -- Analyst\\nBrandon Folkes -- Cantor Fitzgerald -- Analyst\\nMore AXGN analysis\\nAll earnings call transcripts\\n\\n\\n\\n\\n\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Timestamp\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 4751,\n        \"samples\": [\n          \"2022-08-18 08:00:00\",\n          \"2023-01-05 09:30:00\",\n          \"2021-01-26 09:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Date_only\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 804,\n        \"samples\": [\n          \"2022-02-17\",\n          \"2022-01-21\",\n          \"2020-07-20\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"word_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2520,\n        \"min\": 571,\n        \"max\": 32540,\n        \"num_unique_values\": 7264,\n        \"samples\": [\n          2920,\n          9656,\n          5206\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Price_change\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.08033506333874547,\n        \"min\": -0.7976,\n        \"max\": 0.7156863065922738,\n        \"num_unique_values\": 14057,\n        \"samples\": [\n          -0.1235294342041015,\n          -0.010693407694988,\n          0.001805411461732\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Target_Class\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"Neutral\",\n          \"Gain\",\n          \"Loss\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"DateOfWeek\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1,\n        \"min\": 0,\n        \"max\": 6,\n        \"num_unique_values\": 7,\n        \"samples\": [\n          3,\n          2,\n          4\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Month\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 3,\n        \"min\": 1,\n        \"max\": 12,\n        \"num_unique_values\": 12,\n        \"samples\": [\n          12,\n          5,\n          8\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Quarter\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1,\n        \"min\": 1,\n        \"max\": 4,\n        \"num_unique_values\": 4,\n        \"samples\": [\n          4,\n          2,\n          3\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"FinBERT_Positive\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.3164153188473483,\n        \"min\": 0.008341541513800621,\n        \"max\": 0.9573535919189453,\n        \"num_unique_values\": 14091,\n        \"samples\": [\n          0.17113450169563293,\n          0.841820240020752,\n          0.019909732043743134\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"FinBERT_Negative\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.15204690754807296,\n        \"min\": 0.007195898797363043,\n        \"max\": 0.9723434448242188,\n        \"num_unique_values\": 14091,\n        \"samples\": [\n          0.011472414247691631,\n          0.013853976503014565,\n          0.02732784114778042\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"FinBERT_Neutral\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.33126945587937723,\n        \"min\": 0.013258830644190311,\n        \"max\": 0.9523656368255615,\n        \"num_unique_values\": 14067,\n        \"samples\": [\n          0.457214891910553,\n          0.16305600106716156,\n          0.06764431297779083\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 7
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def clean_ticker(ticker_str):\n",
        "  t=str(ticker_str).upper().strip()\n",
        "  if \":\" in t:    #if ticker is NASDAQ:AAPL\n",
        "    t=t.split(\":\")[1].strip()\n",
        "  t=t.replace(\"$\",\"\")\n",
        "  return t\n",
        "df_analysis[\"ticker_clean\"]=df_analysis['ticker'].apply(clean_ticker)\n",
        "print(f\"unique tickers: {df_analysis[\"ticker_clean\"].unique().tolist()}\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "lyo2cj_XOCJi",
        "outputId": "cd5ee1d1-799a-42ae-dafd-89cf710e0b40"
      },
      "execution_count": 8,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "unique tickers: ['BILI', 'GFF', 'LRCX', 'BBSI', 'CSTE', 'GDOT', 'KAR', 'EPAC', 'ABM', 'SGHC', 'SJM', 'URBN', 'HESM', 'SPOK', 'TSM', 'GNW', 'WPP', 'DXCM', 'EME', 'EEFT', 'ARAY', 'ZBRA', 'ROST', 'STZ', 'NET', 'HZO', 'LZB', 'USPH', 'MRNA', 'MELI', 'CDNS', 'VIV', 'NTCT', 'U', 'RUSHA', 'DTM', 'VCEL', 'MSTR', 'CSIQ', 'AAPL', 'CENT', 'FLNT', 'ACLS', 'GEO', 'DFIN', 'GOTU', 'MT', 'SHOP', 'EL', 'LGIH', 'EBS', 'REGN', 'EAF', 'META', 'HRB', 'STRS', 'TTE', 'FCNCA', 'OTIS', 'DHI', 'HLT', 'TLRY', 'ALGN', 'F', 'ADNT', 'PPG', 'AL', 'MKL', 'INBK', 'LILAK', 'SXC', 'CNI', 'BX', 'CMC', 'GNRC', 'BABA', 'OPRX', 'MOD', 'LAMR', 'TRV', 'LOPE', 'OCFT', 'HUN', 'TGT', 'SBSW', 'DB', 'MRCY', 'AI', 'FCN', 'PSMT', 'LITE', 'HCAT', 'KO', 'CMLS', 'OOMA', 'MVIS', 'BJRI', 'AGNC', 'TTWO', 'AMZN', 'IMOS', 'ROKU', 'CGEN', 'ONTO', 'MNKD', 'HR', 'CLF', 'SITM', 'OLED', 'COHR', 'ABR', 'WGO', 'APAM', 'CASH', 'MSA', 'GPI', 'CYD', 'ZEUS', 'WFC', 'NGD', 'PRI', 'CB', 'ANET', 'ARRY', 'SEER', 'KMB', 'GPRO', 'VVV', 'SNAP', 'OKTA', 'NUE', 'DIS', 'MED', 'UNM', 'CRTO', 'CCK', 'PODD', 'SPOT', 'PAYS', 'APPS', 'CHDN', 'VIRT', 'SYK', 'IHG', 'SE', 'AMWL', 'IRS', 'SIRI', 'EQIX', 'CARS', 'CACI', 'FOSL', 'GOGO', 'SABR', 'SDGR', 'HGV', 'TWO', 'MAX', 'LULU', 'CWBHF', 'TGNA', 'OGI', 'CF', 'CCO', 'RTX', 'TSLA', 'BGFV', 'PLNT', 'PFGC', 'PLD', 'KMX', 'QRVO', 'BNGO', 'NSA', 'DOV', 'SBRA', 'PRGO', 'BZUN', 'CRVL', 'MTSI', 'PBYI', 'UPS', 'ETSY', 'SCL', 'ESS', 'INTC', 'LLY', 'CBT', 'EGRX', 'VUZI', 'SBH', 'FOXF', 'NKE', 'ACM', 'AON', 'PBR', 'CDXS', 'CVLG', 'LBTYA', 'CVGW', 'PINS', 'PAG', 'SUI', 'PTC', 'IBM', 'PM', 'MODG', 'KOS', 'ERIE', 'SYF', 'LVS', 'ICUI', 'MAN', 'XGN', 'OMC', 'NOW', 'VLO', 'MASI', 'EOG', 'PLTR', 'C', 'BOX', 'BCRX', 'BLND', 'USB', 'MNST', 'GRPN', 'PKE', 'WIX', 'XPO', 'BAC', 'JOUT', 'SNDL', 'BALL', 'IDXX', 'LX', 'BWXT', 'CHD', 'GOOGL', 'MAIN', 'RC', 'PCH', 'NVO', 'MSCI', 'GERN', 'TNDM', 'FRO', 'CHE', 'GWW', 'OCFC', 'KEX', 'MAT', 'TCEHY', 'NDAQ', 'NAVI', 'ARGX', 'ATHM', 'NMIH', 'MSM', 'K', 'FSM', 'DOMO', 'CLX', 'GVA', 'KWR', 'COST', 'VRNT', 'ANGI', 'CSGP', 'REYN', 'UAA', 'TRMK', 'BFH', 'GTY', 'ESE', 'CNA', 'BP', 'GEOS', 'BZH', 'ENB', 'ISRG', 'TTD', 'RDWR', 'BUD', 'OII', 'UBER', 'STAG', 'HLX', 'CLDT', 'BCS', 'ADM', 'CLFD', 'SO', 'ADPT', 'ING', 'ATI', 'VNET', 'OCGN', 'GEF', 'REX', 'APO', 'TXT', 'GEL', 'IT', 'TENB', 'HMC', 'SIFY', 'JCI', 'EEX', 'GE', 'HCA', 'FTHM', 'GSHD', 'RACE', 'TREX', 'ILPT', 'ORGO', 'PTON', 'ATOM', 'FROG', 'GFI', 'ONTF', 'HST', 'SWBI', 'AAP', 'LILA', 'NVDA', 'CNX', 'SNY', 'EVC', 'AIR', 'TK', 'EZPW', 'CCEP', 'GIS', 'CBRL', 'MIDD', 'CORT', 'ORCL', 'LOW', 'FCEL', 'INCY', 'NOC', 'DLB', 'NYT', 'OCSL', 'PGNY', 'ALNY', 'MGPI', 'ICL', 'UCTT', 'WMS', 'CLNE', 'MTZ', 'NOK', 'COTY', 'CC', 'CHKP', 'ACMR', 'EXPI', 'NGVT', 'HLIT', 'UEIC', 'ACEL', 'NJR', 'KTB', 'SPB', 'RERE', 'T', 'NKTR', 'LFUS', 'CRWD', 'DCOM', 'MCD', 'NIO', 'HIMX', 'AVT', 'TXRH', 'UL', 'TX', 'LASR', 'PNC', 'WM', 'DOCU', 'AQN', 'DOW', 'FANG', 'AR', 'MTDR', 'SCHL', 'CYRX', 'UPWK', 'PTEN', 'BB', 'MTH', 'SWKS', 'AMSC', 'RKT', 'GCO', 'AER', 'GRWG', 'WPC', 'AIT', 'SBAC', 'EGBN', 'IPG', 'SSRM', 'HD', 'TCOM', 'ALE', 'CVNA', 'HNI', 'RLX', 'KRC', 'IR', 'HAS', 'KR', 'GBDC', 'PLAY', 'KEY', 'BIO', 'SITC', 'RRC', 'OTEX', 'ALL', 'TMCI', 'ZVIA', 'SLM', 'BMRN', 'HL', 'AMBC', 'AMRC', 'ECL', 'TRMB', 'RY', 'RDN', 'PLAB', 'NVT', 'EXTR', 'ALV', 'SFBS', 'INTU', 'DAR', 'EQNR', 'EXEL', 'CLB', 'OZK', 'CYH', 'ASR', 'AMRX', 'HUBS', 'MRVL', 'JBL', 'TILE', 'GS', 'CTSH', 'GAIN', 'NVCR', 'FUTU', 'AEM', 'A', 'MGRC', 'INO', 'AVB', 'CXW', 'NWN', 'MMM', 'STX', 'BAX', 'AGIO', 'LMT', 'FSLY', 'TIGO', 'LCII', 'STNG', 'RITM', 'NEE', 'DGICA', 'NEO', 'CHCT', 'TSE', 'LII', 'LGND', 'BYND', 'GLNG', 'CINF', 'IMXI', 'TFC', 'SPNS', 'PCYO', 'RGS', 'PBI', 'ALKS', 'VOD', 'CPS', 'JBSS', 'SYY', 'MLCO', 'NTR', 'JLL', 'NDLS', 'MTCH', 'JNJ', 'CVS', 'UPLD', 'CAH', 'FHB', 'DQ', 'UHAL', 'HSY', 'LAD', 'CANG', 'EQX', 'PHG', 'PANW', 'FIBK', 'NEM', 'IIPR', 'CMTL', 'VECO', 'FDS', 'BJ', 'DT', 'FIVE', 'FE', 'RUN', 'ASML', 'SBS', 'NFLX', 'FLGT', 'TBI', 'FRPT', 'VST', 'RF', 'CRIS', 'UNH', 'ZS', 'ITW', 'OIS', 'AVGO', 'VNOM', 'DAL', 'CLAR', 'GD', 'OPRA', 'SXT', 'OI', 'GL', 'QDEL', 'XXII', 'AMTB', 'SSD', 'AMRN', 'LOVE', 'WYNN', 'BNED', 'AAOI', 'QTRX', 'KAI', 'NWSA', 'MESA', 'JG', 'DPZ', 'XP', 'MGNI', 'AXP', 'CCRN', 'CRC', 'TXN', 'TMUS', 'MO', 'WPRT', 'PAC', 'LEN', 'BLK', 'EM', 'MEI', 'NBR', 'CMG', 'SQNS', 'CIGI', 'ETD', 'CNS', 'ALLE', 'FTV', 'TTSH', 'PATK', 'CARR', 'BDSX', 'JAZZ', 'SF', 'HII', 'HAL', 'KNDI', 'SU', 'INSG', 'GSK', 'HSBC', 'NCLH', 'AMD', 'MPC', 'WDAY', 'LPLA', 'DSGX', 'SPG', 'TISI', 'TSEM', 'NTGR', 'WRLD', 'VIPS', 'MSGS', 'BLDP', 'VIAV', 'AEIS', 'VERU', 'DVN', 'BIRD', 'WSM', 'AMPL', 'DKNG', 'LQDT', 'TRUP', 'AIRG', 'LCTX', 'ACIW', 'TXMD', 'DG', 'KPTI', 'CVEO', 'MYRG', 'BLMN', 'EXLS', 'PDM', 'ESI', 'FNF', 'INMB', 'RELY', 'DUK', 'ICE', 'BIOX', 'ET', 'MKTX', 'SON', 'VERX', 'EIG', 'CCL', 'XRAY', 'HIW', 'SHEN', 'BG', 'GBX', 'BKR', 'GATX', 'BMBL', 'EVLO', 'CIM', 'WSBC', 'JELD', 'BOOM', 'CHRS', 'SSSS', 'AROC', 'FUN', 'AWK', 'HDB', 'SKYW', 'G', 'CMP', 'EGO', 'NXPI', 'VZ', 'PSTG', 'RPAY', 'MAC', 'FOUR', 'GLOB', 'ASC', 'OXM', 'PDD', 'SMSI', 'PACB', 'EXK', 'DBX', 'MSI', 'TDS', 'JAGX', 'GM', 'LMAT', 'FCPT', 'LSTR', 'COMP', 'HCC', 'PRTS', 'DVA', 'STM', 'NXST', 'ACGL', 'BIIB', 'SPCE', 'TLYS', 'ANF', 'STNE', 'OHI', 'CDNA', 'TELA', 'IPHA', 'HAE', 'SBLK', 'WDFC', 'FOLD', 'NTST', 'SERA', 'LRN', 'TT', 'SGU', 'SCI', 'CNR', 'OGE', 'AHCO', 'IRM', 'MUR', 'BCH', 'FLR', 'ST', 'SIG', 'RDHL', 'EBAY', 'PHR', 'VNO', 'MDU', 'TEX', 'FPI', 'DAC', 'SONY', 'LAW', 'WRB', 'ENR', 'WB', 'VSH', 'GKOS', 'AGCO', 'PEN', 'PAA', 'JPM', 'NX', 'PLUG', 'AMAT', 'PRLB', 'JACK', 'GDRX', 'WST', 'UNFI', 'ENPH', 'SM', 'LYTS', 'DASTY', 'SLG', 'SNEX', 'EH', 'AXTI', 'DBRG', 'PERI', 'NRP', 'RMD', 'VITL', 'AXTA', 'JMIA', 'ALK', 'HUBB', 'LIND', 'COO', 'VOYA', 'LOB', 'ABT', 'VRSK', 'HPQ', 'LXP', 'BDC', 'APPN', 'LNG', 'MKC', 'PGR', 'SNOW', 'RBLX', 'ON', 'TCBI', 'CTRN', 'VFF', 'APEI', 'ULTA', 'EPAM', 'AX', 'FWONA', 'VRSN', 'AYI', 'OSPN', 'ARMK', 'IPGP', 'HQY', 'ALSN', 'AVD', 'SPH', 'OMCL', 'CTS', 'OPK', 'AZN', 'PR', 'GPRE', 'IPI', 'BEP', 'WEN', 'MTB', 'TW', 'APOG', 'ASIX', 'GES', 'L', 'AMGN', 'CRMD', 'MANH', 'SND', 'AMT', 'STN', 'KALU', 'QSR', 'KOP', 'WOR', 'MCK', 'IQV', 'CVX', 'PCG', 'FC', 'E', 'IONS', 'URI', 'ALGM', 'EVER', 'RNG', 'BNR', 'STIM', 'AMBA', 'MPLX', 'RMR', 'TEAM', 'OTTR', 'BIDU', 'EW', 'VRA', 'LNC', 'HBM', 'CWT', 'CARG', 'ALLY', 'SRPT', 'DLR', 'RRGB', 'LAND', 'KMI', 'AJG', 'DBI', 'ADSK', 'MDT', 'BYSI', 'TTC', 'MPWR', 'CGNX', 'RIG', 'IQ', 'VRNS', 'MYGN', 'DRH', 'WPM', 'VERI', 'SSYS', 'CPT', 'WMT', 'HRZN', 'BA', 'CAAS', 'BSX', 'SLP', 'PARR', 'SHW', 'LDI', 'LBRT', 'AXL', 'TWLO', 'EXAS', 'TRUE', 'AMG', 'COP', 'PAR', 'HUYA', 'HRI', 'NTLA', 'NPO', 'HON', 'BEN', 'UTZ', 'GMED', 'LUV', 'BCPC', 'NLY', 'ALT', 'NTES', 'SNV', 'ESRT', 'SEDG', 'ENTG', 'ATUS', 'EA', 'WAL', 'TFII', 'GLW', 'DECK', 'HELE', 'NBN', 'CWEN', 'DDOG', 'VALE', 'RS', 'RRR', 'WAT', 'SONO', 'CROX', 'MATX', 'JBLU', 'HOLX', 'CSGS', 'BOH', 'TDG', 'SKT', 'NOAH', 'WSO', 'CHTR', 'CBZ', 'OXY', 'CODI', 'H', 'CL', 'TASK', 'AUDC', 'DHC', 'RCL', 'GTN', 'CNP', 'JD', 'GLPI', 'ESLT', 'RBA', 'MCO', 'CHWY', 'CME', 'ZM', 'IDCC', 'ARCO', 'RM', 'TMO', 'ESTC', 'TPH', 'MBUU', 'WHD', 'DKL', 'CPRX', 'LIN', 'XHR', 'IVR', 'NTNX', 'XERS', 'CTAS', 'FNV', 'SFM', 'ABNB', 'NDSN', 'SIMO', 'MTRN', 'BBBY', 'POOL', 'BCO', 'QCOM', 'MCHP', 'HTGC', 'PETS', 'TEF', 'ADCT', 'LECO', 'AN', 'FSLR', 'LOCO', 'ZUMZ', 'ACN', 'SBGI', 'SAM', 'UTL', 'LEA', 'SQM', 'FIVN', 'KLAC', 'DOX', 'CYBR', 'ICHR', 'DLTR', 'MFA', 'D', 'TRN', 'NVGS', 'ALB', 'MOH', 'MGM', 'APG', 'AUPH', 'GHG', 'TIGR', 'RL', 'ORLY', 'CNO', 'EHTH', 'ZD', 'CAG', 'TDC', 'FLEX', 'AZO', 'YEXT', 'PNR', 'BRC', 'VEON', 'WDC', 'LSPD', 'ZTS', 'IBKR', 'WELL', 'CNDT', 'GEVO', 'ICLR', 'NBIX', 'HOPE', 'DKS', 'BHE', 'APA', 'CLPT', 'GILD', 'CUBE', 'GME', 'STAA', 'LSCC', 'PMT', 'IRBT', 'TRGP', 'FOXA', 'AHH', 'CE', 'FN', 'COHU', 'SSP', 'VMI', 'TECH', 'LH', 'PRGS', 'PPL', 'AFIB', 'GDS', 'CRUS', 'IMAX', 'URGN', 'HBAN', 'TITN', 'WEX', 'V', 'WVE', 'YETI', 'LMND', 'VRE', 'AXGN', 'EXPE', 'CM', 'POWL', 'ASPN', 'IOSP', 'MDB', 'ENS', 'SMP', 'OKE', 'CPB', 'ENSG', 'ACCO', 'BFAM', 'BMY', 'JJSF', 'IDT', 'CLS', 'COF', 'GCI', 'KBR', 'COIN', 'VICI', 'ERJ', 'NOV', 'BR', 'FGEN', 'TRIP', 'CRI', 'BRKR', 'AGYS', 'DCI', 'ROG', 'TTEC', 'VFC', 'NNBR', 'TWST', 'XPEV', 'QFIN', 'LNN', 'ECVT', 'GBCI', 'LW', 'PFE', 'LYFT', 'NSC', 'MTX', 'DAO', 'DDD', 'BBY', 'FCX', 'AXSM', 'CASY', 'ELF', 'PEP', 'SBUX', 'CRON', 'MNSO', 'FDP', 'MA', 'AFL', 'MEDP', 'HTH', 'PG', 'ARCC', 'CAE', 'RVLV', 'ASO', 'ARCB', 'ARWR', 'PWR', 'PHM', 'DHT', 'STWD', 'TNET', 'MOS', 'GTLS', 'CACC', 'PSO', 'CFLT', 'ASTE', 'AAL', 'CMA', 'HRMY', 'SAFE', 'BDN', 'EPD', 'BKNG', 'BRY', 'DGX', 'ORA', 'VNT', 'ABBV', 'NRG', 'DVAX', 'MRCC', 'PYPL', 'RCI', 'TJX', 'DLTH', 'CABO', 'FATE', 'LE', 'SII', 'GNSS', 'PENN', 'RMNI', 'COOP', 'WWW', 'KOPN', 'PAYX', 'ABEV', 'MMC', 'DRI', 'VSTA', 'EVH', 'CCI', 'XYL', 'AA', 'SMG', 'NVS', 'KEYS', 'MMS', 'TSN', 'UNP', 'COLM', 'BWA', 'WTFC', 'IEP', 'TBBK', 'HRL', 'GOCO', 'MGNX', 'WSC', 'EPM', 'BMO', 'SLAB', 'YUM', 'KMPR', 'ESPR', 'RHP', 'JAMF', 'CRS', 'ANDE', 'NATR', 'HSTM', 'TDOC', 'VRTX', 'AMC', 'EXP', 'RH', 'BBDC', 'ARLP', 'HOOD', 'BDX', 'CEVA', 'ADP', 'CBOE', 'CNC', 'IRT', 'TD', 'SUN', 'CFG', 'LFST', 'PSX', 'EVCM', 'PEG', 'ALDX', 'MITK', 'AIV', 'DOC', 'WLK', 'BEDU', 'SSTK', 'ODFL', 'WING', 'PLXS', 'AKAM', 'DXC', 'INMD', 'YOU', 'TPR', 'AOS', 'QLYS', 'KBH', 'ADC', 'PRCT', 'SLGN', 'MTN', 'AGEN', 'CRNT', 'NTRS', 'CW', 'RGP', 'LEVI', 'VEEV', 'ZENV', 'PRU', 'CAMT', 'CRH', 'KTOS', 'ACB', 'OMI', 'FLXS', 'FTCI', 'ELAN', 'CWAN', 'QGEN', 'RBBN', 'NEU', 'CRM', 'HAIN', 'NMFC', 'AVAV', 'YQ', 'GSL', 'SIGI', 'HUBG', 'DV', 'HLNE', 'BELFB', 'PII', 'NTB', 'XOM', 'SLB', 'WEC', 'CCAP', 'JKHY', 'IEX', 'PAYC', 'NWE', 'ATO', 'BZ', 'HY', 'TECK', 'ABUS', 'MITT', 'DAN', 'MAR', 'HUM', 'FDX', 'MDLZ', 'SEE', 'TRU', 'THRM', 'GGB', 'PBF', 'W', 'SPGI', 'CSCO', 'KSS', 'TEVA', 'ENVA', 'CZR', 'EYE', 'VREX', 'AEO', 'VTR', 'BRBR', 'EPR', 'LI', 'ABCL', 'PLYM', 'LUNG', 'BBVA', 'ABG', 'PNW', 'USNA', 'CTVA', 'GPN', 'AQST', 'HSIC', 'MRK', 'LPSN', 'HBI', 'CUBI', 'HOG', 'EWBC', 'UNF', 'VSAT', 'SRDX', 'JKS', 'CHH', 'ARR', 'UXIN', 'OPI', 'AHT', 'SAP', 'MGY', 'GNL', 'EAT', 'SNN', 'ADAP', 'AIG', 'CALA', 'DSP', 'IBEX', 'PCRX', 'BILL', 'ACI', 'INNV', 'RARE', 'EVTC', 'BXMT', 'QIWI', 'MTW', 'FRME', 'TTI', 'GIII', 'FINV', 'YI', 'BAP', 'NCNO', 'CBRE', 'JRVR', 'DLX', 'NIU', 'FFIV', 'CRMT', 'NNN', 'CVBF', 'ALRS', 'AVO', 'REKR', 'SNA', 'ATRO', 'HPE', 'SHG', 'SNBR', 'EXR', 'MSFT', 'KRT', 'ROCK', 'AMWD', 'UAL', 'CENX', 'SUZ', 'PRAA', 'GLPG', 'KN', 'NOMD', 'CMCM', 'FSS', 'CX', 'FITB', 'AFG', 'KVHI', 'TXG', 'CSTM', 'UFI', 'FSV', 'SVC', 'LAZ', 'AZZ', 'RJF', 'AIN', 'ELV', 'RUSHB', 'COMM', 'CPNG', 'ZION', 'SEM', 'COLB', 'PAAS', 'CDLX', 'IAC', 'BMA', 'EBR', 'CMRE', 'RIO', 'CHEF', 'MRVI', 'ODC', 'HE', 'BHF', 'CELH', 'SGC', 'SNCR', 'CERS', 'HALO', 'UTHR', 'CP', 'PAGS', 'RPM', 'LKQ', 'KRG', 'FIGS', 'GHM', 'REVG', 'CSX', 'OVV', 'GFL', 'PDS', 'MCRB', 'RYN', 'MTD', 'CRK', 'CTO', 'INGR', 'ADI', 'SMWB', 'BAK', 'ITGR', 'ULCC', 'TRI', 'AVNT', 'WNC', 'PFBC', 'AKBA', 'LCUT', 'AFYA', 'TIPT', 'TER', 'JHX', 'TPC', 'SATS', 'KMT', 'WES', 'FAF', 'BHC', 'LAKE', 'MHO', 'SCOR', 'RYAM', 'PBA', 'AVDL', 'MQ', 'FTI', 'UIS', 'STKL', 'SNX', 'TEL', 'BCE', 'TFX', 'SMCI', 'HAYW', 'UVSP', 'FORR', 'SOPH', 'KODK', 'AZTA', 'CMCSA', 'YELP', 'BXP', 'RGEN', 'BC', 'CYTK', 'INN', 'CSWC', 'SFIX', 'ALGT', 'SAIC', 'LESL', 'XEL', 'EQT', 'SUPV', 'XNET', 'TUSK', 'YSG', 'FNB', 'AGO', 'ATR', 'AMH', 'SRE', 'ROAD', 'EMN', 'LTC', 'LNTH', 'COR', 'IFF', 'NWG', 'RMBS', 'SNDR', 'CNXN', 'RAMP', 'SMTC', 'MPW', 'AXS', 'GPK', 'MEG', 'WAB', 'OPCH', 'CIEN', 'GT', 'ROP', 'TBPH', 'WU', 'RXT', 'BNS', 'MAS', 'CWCO', 'HASI', 'GAMB', 'EQH', 'FTNT', 'RELX', 'BYD', 'TWI', 'CSL', 'MTRX', 'PRDO', 'MPAA', 'KGC', 'KOF', 'TOL', 'RPRX', 'MXL', 'LNT', 'SFL', 'ASGN', 'IVZ', 'CGC', 'CRSR', 'FIS', 'WMG', 'CNNE', 'KFY', 'AMKR', 'PKG', 'TREE', 'MGIC', 'HYFM', 'BL', 'OC', 'TS', 'UPST', 'CPRT', 'GMAB', 'KHC', 'GSM', 'BANR', 'GTE', 'WCC', 'GDDY', 'CIO', 'VC', 'DEI', 'FISV', 'NGL', 'GTES', 'ANGO', 'TM', 'ADT', 'CATY', 'CNF', 'SOHU', 'DEA', 'CI', 'DAKT', 'PNNT', 'PDFS', 'USFD', 'TGS', 'SPSC', 'UCL', 'CNK', 'GGG', 'HEI', 'KELYA', 'ATRA', 'WRBY', 'MWA', 'MSGM', 'TKC', 'VKTX', 'SLQT', 'EDIT', 'CPF', 'POWI', 'SLF', 'FPH', 'FELE', 'MYE', 'PLTK', 'KB', 'DNOW', 'AVIR', 'CWST', 'GRBK', 'AWR', 'ARLO', 'CMI', 'SWIM', 'NVST', 'ECPG', 'GORO', 'ALEX', 'IDN', 'FRT', 'AMCR', 'DNUT', 'KUKE', 'ICFI', 'FLWS', 'CTSO', 'DIN', 'YMM', 'LHX', 'SUPN', 'DD', 'MNDY', 'RLI', 'CDE', 'APD', 'WCN', 'DOOO', 'BBCP', 'STC', 'SGHT', 'FSP', 'SNPS', 'MERC', 'INSM', 'XPOF', 'DOLE', 'HLI', 'ACTG', 'KLIC', 'SAR', 'IP', 'ROOT', 'ORI', 'CLW', 'CVAC', 'UGP', 'RDNT', 'TSCO', 'NTAP', 'PCAR', 'BRX', 'INFY', 'AVXL', 'LPRO', 'IHRT', 'LPX', 'BSY', 'SAMG', 'CULP', 'RWT', 'FWRD', 'YRD', 'POST', 'FTDR', 'NWL', 'HWC', 'CERT', 'INSW', 'BCC', 'FMS', 'CWK', 'RGNX', 'ONEW', 'BBU', 'FBP', 'CNTY', 'MUSA', 'FBK', 'TCMD', 'M', 'VIOT', 'DZSI', 'CHRW', 'PK', 'IIIN', 'WMB', 'LMNR', 'ALX', 'MAA', 'DXPE', 'BGS', 'RNST', 'WSR', 'HAFC', 'ATNI', 'AEYE', 'AUB', 'SAIA', 'CCOI', 'VRTS', 'R', 'SPT', 'MATW', 'AMCX', 'INSP', 'VICR', 'WY', 'EXC', 'SXI', 'HCM', 'QNST', 'NSP', 'DIOD', 'WD', 'VRRM', 'BBD', 'SR', 'HP', 'EPRT', 'CVLT', 'ZYXI', 'CPA', 'MKSI', 'SGMO', 'SWX', 'GIB', 'WWD', 'WERN', 'CMCO', 'WH', 'UGI', 'DGII', 'CPRI', 'SHAK', 'KIM', 'JHG', 'NI', 'RPD', 'PFS', 'SITE', 'IRWD', 'WIT', 'PNTG', 'AVA', 'AM', 'NVMI', 'SHOO', 'PEB', 'GOLF', 'REG', 'LU', 'MTLS', 'ASB', 'PPC', 'ALG', 'AGRO', 'ACHC', 'OMF', 'MFC', 'SPR', 'DENN', 'USAC', 'VLY', 'UVE', 'BV', 'CHMI', 'ITUB', 'ANIK', 'AEP', 'SMPL', 'GPC', 'DX', 'APPF', 'BKH', 'INGN', 'SFNC', 'IRTC', 'PLMR', 'LIVN', 'VAC', 'NFG', 'AKR', 'GSBC', 'IIIV', 'OSIS', 'FTAI', 'FIX', 'ABCB', 'RSG', 'POR', 'FLS', 'CAL', 'FDUS', 'TNC', 'VBTX', 'EQR', 'STRA', 'FULT', 'ASPS', 'NEXA', 'OFG', 'CUZ', 'PUMP', 'PBH', 'AMN', 'RNR', 'TTGT', 'CIVB', 'RHI', 'MMSI', 'UFCS', 'DTE', 'KREF', 'HCI', 'THS', 'ASND', 'GWRE', 'BAH', 'COLL', 'YUMC', 'MHK', 'HVT', 'AMPH', 'HIG', 'BANC', 'JBHT', 'GIL', 'FORM', 'AAT', 'BPOP', 'PSA', 'VNDA', 'IART', 'ATRC', 'CNQ', 'THG', 'ARW', 'APH', 'FCF', 'EB', 'INVH', 'TDY', 'ITRI', 'RPT', 'TV', 'MMYT', 'TTMI', 'SHO', 'RBC', 'AVNS', 'BSM', 'LPG', 'API', 'CVCO', 'OGS', 'ONB', 'PTCT', 'CVI', 'FMC', 'UMBF', 'CHT', 'TMHC', 'FUL', 'EVRG', 'KURA', 'ITT', 'ENTA', 'FLO', 'HSII', 'CLLS', 'AME', 'AGI', 'PRA', 'MEOH', 'GPMT', 'TALO', 'BOKF', 'PH', 'HFWA', 'EFSC', 'BOOT', 'SLN', 'CALX', 'SKY', 'GEN', 'ELP', 'ZIM', 'HPP', 'ACA', 'TRS', 'AIZ', 'MET', 'FR', 'TAC', 'ODP', 'CRL', 'ACRE', 'ARES', 'MLM', 'TSLX', 'MTG', 'NMRK', 'CTMX', 'AVY', 'J', 'TLS', 'SANM', 'STXS', 'LDOS', 'CVGI', 'XNCR', 'IBP', 'WOOF', 'AFRM', 'RMAX', 'CCJ', 'SEIC', 'ANIP', 'NXRT', 'CDW', 'FTS', 'CFR', 'OSUR', 'AAON', 'NUS', 'THRY', 'BLFS', 'EIX', 'DY', 'PAHC', 'WHR', 'OFIX', 'WTRG', 'CNMD', 'TEN', 'AEE', 'SSNC', 'OSCR', 'OXLC', 'CTRE', 'IPAR', 'LEG', 'RGLD', 'THC', 'PGEN', 'NBHC', 'SPXC', 'EPC', 'ESNT', 'REXR', 'LYV', 'CG', 'PCTY', 'SYNA', 'AVTR', 'REZI', 'PEGA', 'NHI', 'EFC', 'SAND', 'BLKB', 'TCPC', 'CBU', 'MMI', 'RES', 'PNFP', 'NICE', 'MCS', 'LYG', 'ASPU', 'DUO', 'HMN', 'FHN', 'OSK', 'UHS', 'HOUS', 'ARI', 'OR', 'PHI', 'ADTN', 'ZBH', 'WSFS', 'IMMR', 'B', 'EXPO', 'SID', 'NMR', 'OMAB', 'SAH', 'ATGE', 'IRDM', 'AEG', 'HWM', 'VCTR', 'BLD', 'CAC', 'CCS', 'LYB', 'UVV', 'KKR', 'SBCF', 'PINC', 'EGP', 'FHI', 'MNRO', 'BSAC', 'NVEC', 'KDP', 'NBTB', 'EFX', 'UDR', 'CEPU', 'CPK', 'FMX', 'FRBA', 'BKD', 'ATEC', 'PB', 'EHC', 'SGRY', 'OLN', 'MD', 'BE', 'SAN', 'IDA', 'ADMA', 'ALC', 'APP', 'TYL', 'FICO', 'FND', 'TNL', 'AMSF', 'ES', 'EVR', 'UMC', 'OUT', 'GNE', 'CLH', 'EMR', 'EC', 'ROL', 'ADUS', 'LNW', 'MESO', 'CVE', 'ASX', 'ETR', 'APTV', 'NEOG', 'SCSC', 'INDB', 'IAG', 'RGR', 'MDRX', 'ETN', 'SSL', 'PFG', 'PZZA', 'VYNE', 'ADBE', 'PJT', 'BRO', 'VMC', 'IMAB', 'KT', 'NSIT', 'GP', 'HLF', 'GHLD', 'UNIT', 'APLE', 'LBRDK', 'NWS', 'RGA', 'DRVN', 'MC', 'TIXT', 'QMCO', 'TSHA', 'HI', 'AES', 'MATV', 'OESX', 'PD', 'CIG', 'SKYT', 'IOVA', 'OM', 'S', 'NOTE', 'PAY', 'ADV', 'O', 'PUBM', 'KLTR', 'AXON', 'NNOX', 'VALN', 'BVS', 'EBET', 'PACK', 'DIBS', 'PCOR', 'LZ', 'FUBO', 'PAX', 'CXM', 'XMTR', 'TUYA', 'GO', 'ERIC', 'MASS', 'SRAD', 'TPG', 'ZIMV', 'CAR', 'DLO', 'EWCZ', 'NVAX', 'PRVA', 'ABOS', 'EE', 'BFLY', 'ALTO', 'MXCT', 'RDY', 'BLNK', 'ZETA', 'DUOL', 'EBC', 'FSBC', 'AFCG', 'KARO', 'AVAH', 'PROF', 'CSAN', 'CENTA', 'DASH', 'SHLS', 'SHC', 'GLBE', 'INTA', 'MCW', 'IAS', 'AOMR', 'PRG', 'ABSI', 'FRSH', 'PATH', 'RXST', 'RSKD', 'HNST', 'CEG', 'BLFY', 'SNCY', 'STVN', 'CRDO', 'OTLY', 'LUMN', 'TFIN', 'TLIS', 'XPRO', 'CMPS', 'BRLT', 'PRO', 'ZIP', 'MLNK', 'COUR', 'ALHC', 'ALKT', 'TTEK', 'FYBR', 'PSN', 'HEPS', 'QS', 'FLYW', 'ADN', 'SKLZ', 'DOCS', 'EGHT', 'EDU', 'NPCE', 'ACAD', 'VTOL', 'NTRA', 'VTRS', 'RPID', 'COOK', 'AXAHY', 'PECO', 'VTEX', 'BNL', 'WDH', 'TPL', 'TCRT', 'TOST', 'BROS', 'ACVA', 'NYXH', 'KW', 'ESTA', 'DH', 'AKA', 'ARE', 'AEVA', 'LC', 'TIMB', 'BLCO', 'DDI', 'AGL', 'FAST', 'ALLO', 'STE', 'DE', 'MP', 'BAND', 'CRGY', 'MOLN', 'NRGV']\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_analysis.head(5)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 660
        },
        "id": "2E4BpGg2OWKs",
        "outputId": "36b3566c-363a-49df-c1c4-10d4c3a6ddc7"
      },
      "execution_count": 9,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                         date      exchange        q ticker  \\\n",
              "0  Aug 27, 2020, 9:00 p.m. ET  NASDAQ: BILI  2020-Q2   BILI   \n",
              "1  Jul 30, 2020, 4:30 p.m. ET     NYSE: GFF  2020-Q3    GFF   \n",
              "2  Oct 23, 2019, 5:00 p.m. ET  NASDAQ: LRCX  2020-Q1   LRCX   \n",
              "3  Nov 6, 2019, 12:00 p.m. ET  NASDAQ: BBSI  2019-Q3   BBSI   \n",
              "4   Aug 7, 2019, 8:30 a.m. ET  NASDAQ: CSTE  2019-Q2   CSTE   \n",
              "\n",
              "                                          transcript            Timestamp  \\\n",
              "0  Prepared Remarks:\\nOperator\\nGood day, and wel...  2020-08-27 21:00:00   \n",
              "1  Prepared Remarks:\\nOperator\\nThank you for sta...  2020-07-30 16:30:00   \n",
              "2  Prepared Remarks:\\nOperator\\nGood day and welc...  2019-10-23 17:00:00   \n",
              "3  Prepared Remarks:\\nOperator\\nGood day, everyon...  2019-11-06 12:00:00   \n",
              "4  Prepared Remarks:\\nOperator\\nGreetings and wel...  2019-08-07 08:30:00   \n",
              "\n",
              "    Date_only  word_count  Price_change Target_Class  DateOfWeek  Month  \\\n",
              "0  2020-08-27        5623      0.035078      Neutral           3      8   \n",
              "1  2020-07-30        4755      0.116154         Gain           3      7   \n",
              "2  2019-10-23        8917      0.142022         Gain           2     10   \n",
              "3  2019-11-06        8286      0.029891      Neutral           2     11   \n",
              "4  2019-08-07        4611      0.249623         Gain           2      8   \n",
              "\n",
              "   Quarter  FinBERT_Positive  FinBERT_Negative  FinBERT_Neutral ticker_clean  \n",
              "0        3          0.146988          0.012653         0.840358         BILI  \n",
              "1        3          0.910005          0.010605         0.079389          GFF  \n",
              "2        4          0.878131          0.012376         0.109493         LRCX  \n",
              "3        4          0.727205          0.122016         0.150779         BBSI  \n",
              "4        3          0.755221          0.136653         0.108126         CSTE  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-94858e1f-6b9b-4e62-b6b3-70f9de8ae786\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>date</th>\n",
              "      <th>exchange</th>\n",
              "      <th>q</th>\n",
              "      <th>ticker</th>\n",
              "      <th>transcript</th>\n",
              "      <th>Timestamp</th>\n",
              "      <th>Date_only</th>\n",
              "      <th>word_count</th>\n",
              "      <th>Price_change</th>\n",
              "      <th>Target_Class</th>\n",
              "      <th>DateOfWeek</th>\n",
              "      <th>Month</th>\n",
              "      <th>Quarter</th>\n",
              "      <th>FinBERT_Positive</th>\n",
              "      <th>FinBERT_Negative</th>\n",
              "      <th>FinBERT_Neutral</th>\n",
              "      <th>ticker_clean</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Aug 27, 2020, 9:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BILI</td>\n",
              "      <td>2020-Q2</td>\n",
              "      <td>BILI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, and wel...</td>\n",
              "      <td>2020-08-27 21:00:00</td>\n",
              "      <td>2020-08-27</td>\n",
              "      <td>5623</td>\n",
              "      <td>0.035078</td>\n",
              "      <td>Neutral</td>\n",
              "      <td>3</td>\n",
              "      <td>8</td>\n",
              "      <td>3</td>\n",
              "      <td>0.146988</td>\n",
              "      <td>0.012653</td>\n",
              "      <td>0.840358</td>\n",
              "      <td>BILI</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Jul 30, 2020, 4:30 p.m. ET</td>\n",
              "      <td>NYSE: GFF</td>\n",
              "      <td>2020-Q3</td>\n",
              "      <td>GFF</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nThank you for sta...</td>\n",
              "      <td>2020-07-30 16:30:00</td>\n",
              "      <td>2020-07-30</td>\n",
              "      <td>4755</td>\n",
              "      <td>0.116154</td>\n",
              "      <td>Gain</td>\n",
              "      <td>3</td>\n",
              "      <td>7</td>\n",
              "      <td>3</td>\n",
              "      <td>0.910005</td>\n",
              "      <td>0.010605</td>\n",
              "      <td>0.079389</td>\n",
              "      <td>GFF</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Oct 23, 2019, 5:00 p.m. ET</td>\n",
              "      <td>NASDAQ: LRCX</td>\n",
              "      <td>2020-Q1</td>\n",
              "      <td>LRCX</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day and welc...</td>\n",
              "      <td>2019-10-23 17:00:00</td>\n",
              "      <td>2019-10-23</td>\n",
              "      <td>8917</td>\n",
              "      <td>0.142022</td>\n",
              "      <td>Gain</td>\n",
              "      <td>2</td>\n",
              "      <td>10</td>\n",
              "      <td>4</td>\n",
              "      <td>0.878131</td>\n",
              "      <td>0.012376</td>\n",
              "      <td>0.109493</td>\n",
              "      <td>LRCX</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Nov 6, 2019, 12:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BBSI</td>\n",
              "      <td>2019-Q3</td>\n",
              "      <td>BBSI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, everyon...</td>\n",
              "      <td>2019-11-06 12:00:00</td>\n",
              "      <td>2019-11-06</td>\n",
              "      <td>8286</td>\n",
              "      <td>0.029891</td>\n",
              "      <td>Neutral</td>\n",
              "      <td>2</td>\n",
              "      <td>11</td>\n",
              "      <td>4</td>\n",
              "      <td>0.727205</td>\n",
              "      <td>0.122016</td>\n",
              "      <td>0.150779</td>\n",
              "      <td>BBSI</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Aug 7, 2019, 8:30 a.m. ET</td>\n",
              "      <td>NASDAQ: CSTE</td>\n",
              "      <td>2019-Q2</td>\n",
              "      <td>CSTE</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGreetings and wel...</td>\n",
              "      <td>2019-08-07 08:30:00</td>\n",
              "      <td>2019-08-07</td>\n",
              "      <td>4611</td>\n",
              "      <td>0.249623</td>\n",
              "      <td>Gain</td>\n",
              "      <td>2</td>\n",
              "      <td>8</td>\n",
              "      <td>3</td>\n",
              "      <td>0.755221</td>\n",
              "      <td>0.136653</td>\n",
              "      <td>0.108126</td>\n",
              "      <td>CSTE</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-94858e1f-6b9b-4e62-b6b3-70f9de8ae786')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-94858e1f-6b9b-4e62-b6b3-70f9de8ae786 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-94858e1f-6b9b-4e62-b6b3-70f9de8ae786');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-5076e60b-19ad-43a3-9833-878deb4fa38f\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-5076e60b-19ad-43a3-9833-878deb4fa38f')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-5076e60b-19ad-43a3-9833-878deb4fa38f button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df_analysis",
              "summary": "{\n  \"name\": \"df_analysis\",\n  \"rows\": 15055,\n  \"fields\": [\n    {\n      \"column\": \"date\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 5142,\n        \"samples\": [\n          \"May 19, 2022, 11:00 a.m. ET\",\n          \"Oct 25, 2021, 3:30 p.m. ET\",\n          \"May 30, 2019, 3:00 p.m. ET\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"exchange\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2272,\n        \"samples\": [\n          \"NASDAQ: EGRX\",\n          \"NYSE: ASB\",\n          \"NYSE: HLF\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"q\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 19,\n        \"samples\": [\n          \"2020-Q2\",\n          \"2021-Q2\",\n          \"2021-Q4\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2271,\n        \"samples\": [\n          \"EGRX\",\n          \"ES\",\n          \"APD\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"transcript\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 14122,\n        \"samples\": [\n          \"Prepared Remarks:\\nOperator\\nLadies and gentlemen, thank you for standing by, and welcome to Sangamo Therapeutics Inc Q3 2020 webcast. [Operator Instructions] After the speaker presentation there will be a question and answer session. [Operator Instructions]\\nI would now like to hand the conference over to your host head of Corporate Communications McDavid Stilwell, please go ahead.\\nMcDavid Stilwell -- Head of Corporate Communications\\nGood afternoon. And thank you for joining us today. With me this afternoon on this call are several members of the same demo executive leadership team, including Sandy Macrae, Chief Executive Officer. Sung Lee Chief Financial Officer, Mark McClung, Chief Business Officer, Jason Fontenot, Interim Head of Research and Bettina Cockroft Chief Medical Officer. Slides from our corporate presentation can be found at our website, sangamo.com, under the Investors and Media section in the Events and Presentations page. This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to, statements relating to our pipeline of genomic medicine product candidates; our ability to develop, obtain regulatory approvals for and commercialize therapies to treat certain diseases and the timing, availability and cost of such therapies; plans and time lines for Sangamo and to conduct clinical trials and share clinical data and the potential for data to demonstrate clinical benefit to patients; the potential to use certain technologies to develop AR therapies, our collaboration strategy and the potential to earn fees, milestone payments and royalties from our collaboration; plans and time lines for building and opening manufacturing facilities, the effects of the evolving COVID-19 pandemic; the anticipated benefits of our organizational changes; our expectations regarding our financial performance and resources and other statements that are not historical fact. Actual results may differ substantially from what we discuss today.\\nIn addition, these statements are not guarantees of future performance and are subject to certain risks and uncertainties that are discussed in documents that we file with the securities and Exchange Commission, specifically in our quarterly report on Form 10-Q for the quarter ended September 30, 2020. The forward-looking statements stated today are made as of this date, and we undertake no duty to update such information, except as required under applicable law. On this call, we discuss a non-GAAP financial measure. We believe this measure is helpful in understanding our past financial performance and our potential future results. This is not meant to be considered in isolation or as a substitute for the comparable GAAP measure. The comparable GAAP measures and reconciliations of GAAP to the non-GAAP measures discussed on this call are included in today's press release, which is available on our website.\\nNow, I'd like to turn the call over to our CEO, Sandy Macrae.\\nSandy Macrae -- Chief Executive Officer\\nThank you, and good afternoon to everyone on the call. This quarter. We advanced our r&d activities as we continue to adapt to the conditions brought on by the evolving Covid-19 pandemic. We are moving forward on clinical execution. And we're optimistic we're plans to continue to doors patients and initiate new trials. We also completed our research activities associated with our als control collaboration with slide and are continuing to move our research projects with Biogen and Novartis forward and are progressing and work with our other partners. Pfizer has dosed the first participant in the phase three of fine study of JIRA tokujin, fetal Purbeck or SP five to five or investigational gene therapy for Haemophilia a patients. This event triggered a $13 million milestone achievement for sango, which we expect to receive in the current quarter, further strengthening our cash position. Pfizer previously communicated that they expect a pivotal data readout from the final study in 2022. During the mid September investor day, Pfizer provided an update from the phase one to alter study showing encouraging data garnering tolerability clinically meaningful factor levels, bleeding rates and factor use in the highest dose cohort up to 85 weeks in the longest treated patients. Pfizer and sanken will believe that these data support a potentially differentiated Haemophilia a gene therapy product candidate in August and September, in close collaboration with principal investigators monitoring safe conditions for patients with the within the context of COVID-19 single dose the first two patients in the phase one two star study evaluating STM 20 gene therapy in Fabry disease. Those are the first cohort of this study is no complete. And enrollment is ongoing for Cohort Two.\\nWe expect to share data on this study by the end of next year. During the quarter, we received additional regulatory approvals for the first in human Phase One Two clinical study evaluating car regulatory T cell or car t reg, candidate tx 200 and kidney transplantation. We believe we are on track to initiate the study next year. initiating the study may allow us to be the first company to explore the potential of car T cells in humans. We are hopeful that this will provide broader proof of concept for genetically engineered cell therapy using T rex beyond transplantation. We intend to further evaluate current T Rex, including zinc finger nucleases edited allergenic t reg therapies in autoimmune diseases with high unmet medical need. Also, this quarter we completed our research activities associated with our ongoing Pfizer collaboration to develop gene regulation therapy. Using zinc finger technology for the treatment of C nine or 72 related als in this program are safe finger proteins are designed to selectively target disease alio repeats a remarkable demonstration. Yet another way our versatile technology may be able to have a disease modifying impact on challenging CNS diseases. We recently earned a 5 million milestone payment from Pfizer so stay with this program, which we expect to receive later this quarter. It is a testament to our r&d momentum. We look forward to continue to work closely with Pfizer to support their research and development in this program.\\nWith that, I will turn the call over to our chief medical officer Bettina, who will provide additional details on our clinical accomplishments.\\nBettina Cockroft -- Senior Vice President and Chief Medical Officer\\nGood afternoon. As Sandy mentioned, our clinical operations have adapted to the challenges of the evolving covid 19 pandemic. And we are pleased with our progress in executing on our partner and wholly owned programs. Pfizer those the first patient in the assigned study of director gene fetal Popovic or SB five to five, our first acid in a registrational trial. A fine is a global phase three open label multicenter single arm study evaluating the efficacy and safety of SB five to five. in patients with moderately severe to severe Haemophilia a. The primary endpoint is annualized bleeding rates or APR through 12 months following treatment. This will be compared to ABR while in fact eight Replacement Therapy collected in the phase three lead and study, which will provide a baseline for phase three study participants. The secondary endpoints include factor eight activity level after the onset of steady state over 12 months. Participants will be analyzed throughout the five year study period following the single infusion to further assess your ability of efficacy and safety.\\nFive has shared updated phase one two data at a Pfizer investor events in September, which demonstrated that sb 525 was generally well tolerated. Each of the five patients in the high dose cohort sustained a clinically meaningful level effect great activity without leads or the need for prophylactic factor up to 85 weeks for the longest treated patient. Both companies are encouraged by these results and plan to present further follow up data from the altia study in the next few months. When all five patients in the 313 vector genomes per kilogram dose cohort have been followed for at least one year. We have those the first two patients comprising the first cohort in the phase one to start study evaluating SPSS 20 in Fabry disease. The goal of this gene therapy candidate is to provide a predictable and durable expression of the alpha gal a enzyme, which is deficient and Fabry disease due to mutations in the GLA gene, resulting in the accumulation of the substrates GP three, and it's soluble derivative lyso Gp three. This can cause challenging symptoms and morbidities including impaired renal and cardiac function, pain and gastrointestinal symptoms. The star trial is a multicenter open label those ranging study evaluating the safety and tolerability of St. 920 and classical Fabry patients 18 years and older study participants will receive a single intravenous infusion of St. 920, followed by one year of observation and monitoring of clinical endpoints, such as alpha gelei activity and assessment of GB three and laser GB three levels. A long term follow up study will allow patients to be monitored for an additional four years. enrollment for the second cohort is ongoing. We expect that data will be shared toward the end of 2021 after we have identified adults code for cohort expansion.\\nWe believe that sc 920 offers a potentially differentiated treatment for Fabry disease, with the potential to deliver efficacy with preserved renal function and reduced cardiac morbidity and neuropathy. preclinical studies evaluating STI 20 demonstrated strong expression of alpha Galle and G v3 substrate reduction across tissue types. As delivered directed gene therapy, Sc 920 is delivered by a one time intravenous infusion that does not require any preconditioning regimen for patients. We are also working closely with our oncology collaborator Kate Gilliard company, as it advances code 037 and allergenic and PCV 19 Carty therapy into clinical trial tight expects to submit an investigational new drug application by the end of 2020 and to initiate a clinical trial evaluating kite 037 in 2021.Throughout the third quarter, we have continued to receive additional regulatory approvals that support the phase one to steadfast clinical study evaluating the first inhuman car t reg cell therapy tx 200 in HLA to mismatched renal transplantation, we expect to initiate the study next year. The goal for this study is the prevention of transplant rejection through the engineering of T regs to express an HLA to kemmerich antigen receptor or car, allowing them to localize to the renal graft and activate upon recognition of the HLA to antigen. The Carty regs may prevent immune mediated rejection through the inhibition and modulation of inflammatory immune cells and the release of anti inflammatory cytokines to induce a tolerogenic environment within the preclinical data supporting the steadfast study presented last month showed that the TX 200 HLA to Carty regs efficiently prevented rejection in both graft versus host disease and skin transplantation model.\\nThey were also shown to be safe and well tolerated in our in vivo studies. Similar to other genetically engineered cell therapy approaches, patients will undergo a Luca phoresis procedure from which their t reg cells will be isolated and engineered then cryopreserved. The HLA to negative patient will subsequently undergo transplantation surgery and following a recovery period will receive their personalized pX 200 drug candidate.As a result of this detailed process, we expect those patients will occur several months after their enrollment. recent publications show that the regulatory cell therapy space is gaining momentum and excitement in the scientific community. In particular, the one study a large international clinical study gathering seven investigator led trials across five countries showed that immune regulatory cell therapy as a whole were safe, and that immune cell therapy is a potentially useful therapeutic approach in renal transplant recipients allowing immune cell composition restoration to normal healthy level of minimization of the burden of general immune suppression. This is very promising and supports our plan to evaluate Carty regs in renal transplant patient populations.\\nWill now turn the call over to some for an overview of the financial results.\\nSung Lee -- Executive Vice President and Chief Financial Officer\\nThank you, Bettina and good afternoon everyone. We're pleased to share our financial results for the third quarter of 2020. We reported a net loss of $1.6 million, or one cent per share compared to a net loss of $27.3 million or 24 cents per share for the same period in 2019. total revenues were $57.8 million, compared to $22 million for the same period in 2019. The increase was primarily attributable to a $30 million milestone achieved. For SP five to five or Haemophilia, a candidate partnered with Pfizer, and a $5 million milestone achieved for our C nine or 72 collaboration with Pfizer. Turning to expensive non GAAP operating expenses, which include stock based compensation expense were $54.8 million, compared to $46.5 million for the same period in 2019. The increase in operating expense reflects our headcount growth and facilities expansion to support the advancement of our therapeutic pipeline, and manufacturing capabilities.\\nThese increases were partially offset by a decrease in clinical and manufacturing supply expenses. Moving to the balance sheet, we ended the quarter with $695 million in cash, cash equivalents and marketable securities. This balance includes the $75 million upfront license fee payment received from Novartis. Additionally, in the current quarter, we expect to receive the $35 million milestone payments from Pfizer mentioned earlier. We believe our balance sheet remains strong and will allow us to reach several important r&d milestones, including the potential filing of the Vla for sp 525. For hemophilia a. Turning to 2024 year guides, we're updating our financial guidance for non GAAP operating expenses, which exclude estimated stock compensation expense of $25 million from an estimated range of 210 million to $225 million to now be in the estimated range of 210 million to $220 million.\\nI'll now turn it back to Sandy for closing remarks.\\nSandy Macrae -- Chief Executive Officer\\nThank you. So we're focused on clinical execution and building momentum. As we adapt to the conditions of COVID-19 and head toward the end of the year. We're pleased with our progress in clinical operations and with our partner programs. Our strong balance sheet enables us to advance our r&d pipeline. We believe these accomplishments are put single in a strong position to achieve several important milestones and catalysts heading into next year. We believe we remain on track for a V manufacturing facility in Brisbane to be operation at the end of this year, and offeror cell therapy facilities in Brisbane and football to be operational by year end 2021. We anticipate continued enrollment in Pfizer's phase three a fine study with a pivotal data readout expected by Pfizer in 2022. And also expect one year and two year phase one two data presentations over the next year and a half. We expect continued enrollment in the phase one two star study and the data read data readout toward the end of 2021.\\nSanta Fe has guided that the first data readout from the phase one to sickle cell disease study is expected next year. We anticipate presenting pull up sp 400 beta thalassemia data at the same time. And lastly, we expect the clinical trial initiation. So the phase one two first inhuman Carty reg status study will occur in 2021. And Kate expects that this study of allogeneic anti cd 19 Carty product candidate count or three seven will also commence in 2021. We look forward to delivering on these milestones in the coming year.\\nOperator, please open the line for questions.\\nQuestions and Answers:\\nOperator\\n[Operator Instructions] Our first question comes from the line of Geoff Meacham With Bank of America.\\nGeoff Meacham -- Bank of America -- Analyst\\nHey guys, thanks for the question and congrats on all the pipeline progress. I had a couple on the first one is on the Haemophilia a study just with the 12 month analyze bleed rate endpoint, I want to kind of get your feedback on on what FDA is, is looking for just relative to, you know, the feedback that biomarin received. And that's obviously subject of a lot of investor conversations of late. And then the second question is just a broader one on the strategy for the car t regs just wanted to maybe give us a little bit more, you know, context for, you know, how you see that differentiating and maybe what successes you see what the best probability of success, you see, and, and for example, solid tumors versus the liquid tumor say. Thank you.\\nSandy Macrae -- Chief Executive Officer\\nThank you for your questions. On the first one around Haemophilia a, we are limited in what we can see, because this is known Pfizer sounds, we are so pleased with their progress into phase three, with their enthusiasm for the program, and that all the way up and down their organization right up to their CEO, how valuable they see this asset for them. The you can be assured that they will be having regular conversations with the regulatory authorities. And I'm certain that Pfizer will know how to navigate that landscape. As regards to T regs, I'm going to pass over to Jason who is a real expert in this area.\\nGeoff Meacham -- Bank of America -- Analyst\\nAnd Jason, can you talk to us about how you see your T reg strategy?\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nThanks, Sandy. And thanks for the question. Um, so first, I'll start off by by pointing out that our programs and regulatory T cells, engineered regulatory T cells are directed in the autoimmune and inflammatory disease space, these are drugs for cancer. So we're really excited about our engineered regulatory T cell platform and the programs that we're bringing forward. We're excited about the progress and regulatory approvals we've received so far. And about our first inhuman. Carty reg study, Tx 200. We're leaders in this field. And, you know, we're developing and refining our understanding of cartoon t reg biology and rapidly advancing our ability to engineer and manufacture that cell. And our tx 200 study will be the first inhuman test of engineered regulatory T cells of car t regs, and this will be further demonstration of our leadership.\\nThe goal with that study is the prevention of renal transplant rejection in the setting of an MHC mismatch transplant. So this is a setting where and HLA a two negative patient will receive an HLA a two positive kidney transplant. And our therapy is comprised of T regs that are engineered to recognize the a two antigen through a Comerica antigen receptor and that car that will drive the accumulation and activation of the T regs in the renal graft and suppress the rejection of the graft by the patient's immune system. And what's important about that study is that as I mentioned, this is going to be the first test of this therapeutic hypothesis around core t regs. And this study will be important for us to understand the safety and efficacy and the therapeutic potential of car t regs. And we'll be informing programs that we're actively pursuing enlarger autoimmune and inflammatory indications such as multiple sclerosis and Crohn's disease.\\nGeoff Meacham -- Bank of America -- Analyst\\nOkay, great. Thank you.\\nOperator\\nThank you. Our next question comes from the line of Maurice Raycroft with Jefferies.\\nMaurice Raycroft -- Jefferies -- Analyst\\nHi, Everyone, thanks for taking my questions. I had one on the T reg program as well. So I guess for getting the getting that study started. Can you talk more about what factors have led to pushing the study start to 2021? Is it due to COVID or the autologous cell manufacturing process or anything else that you can comment on? And can you talk more about what else needs to be completed before starting the study?\\nSandy Macrae -- Chief Executive Officer\\nMaurice, thank you very much for your question. We are we're very pleased with the progress of the T reg for HLA to mismatch. We're very pleased with the approval From the regulatory authorities, we call for dis epic where COVID is in. In is impacting the hospitals, we will go to the the laboratories, the manufacturing. So there's a general COVID impact, but we are confident that we'll be able to move forward with this program.\\nMaurice Raycroft -- Jefferies -- Analyst\\nAnd from a manufacturing and process development standpoint, is that all figured out? Or is there any other perspective you can provide on that?\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nOne of the reasons that we acquired t excel in 2018, was their understanding of how to look after T Rex, which is different from how people look after T cells. And so we're very pleased with the progress that they've made.\\nMaurice Raycroft -- Jefferies -- Analyst\\nGot it. Okay. And then the other question I had was just on the preamp program that you guys have, which is sort of under the radar, I'm just wondering if you can provide a status update on that program, any timeline, update on that program, and then maybe talk about the strategic importance of that one, as well.\\nSandy Macrae -- Chief Executive Officer\\nJason, can you hear me talk about prions and what we think of them?\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nSure, Sandy, thank you. Um, you know, the prion program is in preclinical development. So I think, you know, we'll be looking forward to sharing updates at the appropriate time. I think that there is a great opportunity there to to demonstrate the power of our platform, similar to the approaches that we're taking with our partners in CNS, both Biogen and Novartis. These are both of these partnerships are driven by by what our partners see in our platform. And the prion program is yet to get another example of that, and we'll be excited to, to talk about it as we move forward. And we've done some of the initial work with the Broad Institute in Boston. And they have a real deep x the group we're working with as a real deep expertise in this. And so we have that biological expertise to match with our technological expertise.\\nMaurice Raycroft -- Jefferies -- Analyst\\nGot it. Thank you for the perspective. Thanks for taking the questions.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nThank you, Marie.\\nOperator\\nThank you. Next question comes from the line of Jim Burchinal with Wells Fargo.\\nJim Burchinal -- Wells Fargo. -- Analyst\\nHi, thanks for taking my question. This is a yen and on for Tim, some perhaps a question on the T reg program as as well. It, Could you confirm whether this is a gene additive product? Because I think it's autologous. So, it you know, the obviously the HLA two is put in with a gene audition approach. So if if you can comment on whether it's a gene edited product, and then for your, you know, future product, the genetic regulatory car T cells. How do you see the issue of persistence? I guess it's for this program, GTX 200, as well. How do you see the issue of persistence? And for renal transplant, would you require long term persistence? And would you explore repeated dosing for your animal genetic programs? Thanks.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nSo thank you for your question. They they're very sensible, scientific questions. And let me try and lay out the path that we've chosen, which is to start with a topic of sorts, we can understand the effectiveness of T regs. And one of the advantages of renal transplant is that the transplanted kidney can be biopsied because it's it's implanted close to the surface. So, we can look at things like persistence which as you can see is an important feature that would be required of any good treatment, we will gradually switch to allergenic and, and we can either develop our genetics, t regs by editing down from healthy donor volunteers, or by studying IPS, C's and other forms of stem cells to develop them up to be T Rex. So this is really at the very cutting edge of regulatory cellular science and we are lucky to have many options as possible to take us into those areas.\\nJim Burchinal -- Wells Fargo. -- Analyst\\nGot it? And a quick follow up in tx 200. Is there a gene editing component?\\nSandy Macrae -- Chief Executive Officer\\nTx 200 isn't a tall Lucas form and therefore doesn't have gene editing component? Jason, I'm correct on that.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nYes, that's correct. tx 200. We introduced the car with a lentivirus for that first, for that first program. But obviously, you know, our platform, one of the one of the assets we have etang. Mo is our platforms ability to do genomic engineering and the T rex are our future future products. And that was why the marriage of sanguine to excel was so sensible. They they brought the TV experience and we brought editing that they read, they needed to take the platform forward.\\nJim Burchinal -- Wells Fargo. -- Analyst\\nGot it, then maybe a question on zinc finger transcription factors. Just wondering about the origin origin of the transcription transcription factor, whether it is Foley Schumann, or is there any synthetic component in those transcript transcription factors? And how do you think how should we think about immunogenicity? Thanks.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nSure, so, so the base components of the zinc finger transcription factors are all human. Obviously, in order to direct those transcription factors to a desired sequence, we have to design a synthetic protein that is specific for a specific sequence in the genome. And, and by nature of the fact that they are fully human, we expect that the immunogenicity should, should be inherently lower. And we haven't made any observations today to suggest that immunogenicity can be a problem.\\nJim Burchinal -- Wells Fargo. -- Analyst\\nGreat, thank you so much for taking the question and congrats on your progress.\\nSandy Macrae -- Chief Executive Officer\\nThank you very much.\\nOperator\\nThank you. And our next question comes from the line of Gena Wang with Barclays.\\nGena Wang -- Barclays -- Analyst\\nThank you for taking my questions. I have three questions. Now. First is regarding Haemophilia a. Just wondering, certainly I know this is already tech transferred to Pfizer given the ball milling experience, phase one two data did not three data dinner had quite different from the least one two. So you know, any thoughts you can share with us regarding your face one two data and regarding. you know, also the phase three data and one hypothesis was the manufacturing part. In essence, you know, this manufacturing Phase One, two is from your side. And now we'll transfer to the Pfizer in any thoughts you can help us understand in terms of our potential predict ability from phase one to data to phase three.\\nAnd then the second question is regarding Pfizer Partner Program, the ALS didn't single protein transcription gene regulation program. So wondering if you can share any color regarding the efficiency from this initial r&d study. And the last question is regarding the February program, you already enrolled second cohort and what will be their determination that you think you reach the optimal cohort that you can extend the cohort regarding the biomarker data like a plasma lecture with GD three, you know, as a reference, Avro showed 30 to 40% further reduction versus the baseline er T. Any thoughts you have regarding what is your boss in order to determine the optimal dose?\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nI'm afraid I may disappoint you in my answers the visor the face two of the ultra study and the progression of of this with Pfizer is really in their hands, no to talk about. And the announced or the abstracts for ash were announced today. And so there'll be talking about that at ash and so I would go to to to wait for those results. The convertibility between phase two and phase three, really we we mustn't see anything until we see the three results. As regards the SR north. All I can tell you is Pfizer very pleased with the product that we produce for them. And they have transferred into their research organization and paid the necessary milestone. As regards fabri, I'm going to pass on to Bettina Bettina. Can you talk about fabri? And what we're looking for and what this study will measure?\\nBettina Cockroft -- Senior Vice President and Chief Medical Officer\\nAbsolutely. So, yes, thank you for the question. So as I've mentioned earlier, we don't the first cohort of two patients, and enrollment is ongoing. And the study goal really is to provide a predictable and durable expression of the alpha Galle enzyme, which is the enzyme deficient in Fabry disease due to mutations in the GLA gene. And so we are going to be measuring this parameter as one of the more more important parameters. But as you point out, we're also looking at substrates. GB, three and Lysa, GB, three, these are the basis of some of the challenges in terms of morbidity in patients with fabri. So we're going to be monitoring all of this data along with other data. Remember, this is first and foremost, the safety and tolerability study to start off with. And we have a safety monitoring committee that will be will be involved in the decisions as we move on to escalate, goes to the optimum dose, think it is, is with the totality of the data, and the data that we are monitoring from other studies with with other products, of course, as well that we will be making our ultimate decisions on the dollars that we bring forward in our cohort expansion.\\nGena Wang -- Barclays -- Analyst\\nOkay, thank you.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nThank you very much for your question.\\nOperator\\nThank you. Our next question comes from the line of Eric Joseph with JPmorgan.\\nEric Joseph -- JPmorgan -- Analyst\\nHi, thanks for taking the question. Maybe just perhaps this cheated. One. I'm curious to get a sense of whether there are? Well, how we should be thinking about the potential for additional, largely wholly owned programs coming for the clinic over the next 12 to 18 months, relative to I guess what we've seen over the past year, a fair amount of, you know, leveraging up the platform through partnering activities.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nNext. Thank you for your question, Eric. Mark, this feels like one for you, please.\\nMark McClung -- Executive Vice President and Chief Business Officer\\nHi, Eric, thanks for the question. You know, so if you take a look at the, the deals that we've done, including those most recently, really the driver of that is is twofold. And in some cases, they've come to us on, you know, obviously in the the charging case intersect and in the couple of the candidates that we had progressing toward the the end. But they came to us with a view taxi, expanding the number of CMS targets that we weren't otherwise considering. So we looked at that as being really an extension of our, our potential pipeline. he second way we sort of took take a look at partnerships is whether they're bringing a specific expertise and the resources necessary to accelerate the products assuming they're successful to patients, and in that particular case, as well as the Novartis case. Both of those really fit those type of criteria. We fully intend and we to to become a genomic medicine company. And we are continually looking to advance wholly owned assets, which we would take into the clinic and I think a good example of that is is what you heard in terms of tx 200 as well as the follow on programs that we're intending to take forward into the clinic for our car t reg programs.\\nEric Joseph -- JPmorgan -- Analyst\\nGot it I guess in addition to T reg, are there certain disease states over targets that you have essentially walled off and are prioritizing for internal development.\\nMark McClung -- Executive Vice President and Chief Business Officer\\nWe'd not disclose that. I mean, we're we're taking a look at, obviously, we've got interest in the autoimmune spaces, as we talked about, with her Carty read programs. And Jason touched on earlier. You know, naturally, we're working heavily within the CNS area with our partners in Biogen and partnership with Novartis. And so, you know, there may be targets that we choose in that particular space, but we've not made any decisions on that as yet. We don't believe you can really stick areas and go after it, we need to let the science drive us toward things that we believe are important to develop for patients.\\nEric Joseph -- JPmorgan -- Analyst\\nGod, that's a tough one. Thanks for taking the question.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nSure.\\nOperator\\nThank you. Our next question comes from the line of Ritu Baral with Cowen.\\nRitu Baral -- Cowen -- Analyst\\nHi, guys, thank you for taking the question. This is while on for two, just two quick questions from me. First, on the star fabri study, are you still seeing impacts from COVID on enrollment? I know you've completed the first cohort, but are all the sites up and running? And then as a quick follow up, regarding the Pfizer collaboration with the ALS program, you know, what are the next steps for the program? Specifically, what's the next opportunity for a milestone to reach is that contingent on them initiating a clinical trial? and unicolor on this would be helpful. Thank you.\\nSandy Macrae -- Chief Executive Officer\\nThank you for your question. We haven't we or Pfizer haven't commented on the LS program and when the mouse ones will come? I would say again, reiterate what I said in the call script. It's a remarkable piece of science to be able to suppress the transcription of one Leal and leave the other one, on touched is why Pfizer, Kim does and we have achieved what they requested of us, and it's move forward to them. So let's hope because it's such a dreadful disease, let's hope it gets to patients as soon as possible. For the Fabry disease, I'm going to refer you to Bettina who will answer that question?\\nBettina Cockroft -- Senior Vice President and Chief Medical Officer\\nYes, and thank you for that question. So on the clinical operations side, I have to say, we have an excellent clinical operations team working very hard on maintaining the relationship with all the sites on during the pandemic, we've also been able to initiate sites qualify other sites as we expand our footprint for the study. Of course, COVID has had an impact worldwide, some regions more than others, we are confident that we can keep going with following the enrollment and dozing of the first two patients to keep going with our enrollment, despite the pandemic at this stage where the the things we've put in place from an operational perspective with home visits with virtual assistants have really helped us make sure that but we, together with the sites manage to to guide the patients through the enrollment and screening procedures to ultimately get us to dosing. Very pleased. I'm very, very pleased with the way the clinical to have navigated. We feel we have a responsibility to do this. Well, to make sure that the patient comes first whether they're being treated for coffered in which case we should not be taking up doctors times. But we've been ready to doors as soon as the window was open. And I think Bettina and her team have done remarkable job together.\\nRitu Baral -- Cowen -- Analyst\\nThank you for the color.\\nOperator\\nThank you. Our next question comes from the line of the Nicole Germino with Securities.\\nNicole Germino -- Securities -- Analyst\\nGood evening, everyone. Hi, thanks for taking my question. On February, given the competition in this space, what is it more specifically about saying the most a decapitated or the promoter that make it differentiated and better than your peers? And how have you made that determination? And then does how does sc 920 impacts the renal and cardiac tissue?\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nSo let me take that one. We are encouraged by the data we've seen from AV six in hemophilia. But until we those patients with Fabry disease, we really can't and shouldn't comment on what it's going to look like. The animal data looks very encouraging. We see supramaximal dozing and supramaximal effect. And in the animal dosing that we recently published, we're able to show benefit to both the heart and the kidney. But I'm, I'm just prudent in telling people to wait and let's see what the clinical results are. Were guiding that will show the clinical results to RCM just next year when the Deus Ex escalation phase is completed.\\nNicole Germino -- Securities -- Analyst\\nOkay, great. Thank you so much.\\nOperator\\nThank you. Next question comes from the line of Boran Wang with Guggenheim securities.\\nBoran Wang -- Guggenheim securities -- Analyst\\nHi, guys, thanks for taking my question. I had to one on PMA and other on the Albuquerque program on him a what's the plan going forward to share data on the Phase One, two, I know you'll have the updated app. But are there any specific time points provide a complete picture of the data and without requiring of all patients require cross that time point. And on the alto Carty program?\\nSandy Macrae -- Chief Executive Officer\\nYeah, we've seen some data, early data from other Allo programs from allergy and CRISPR. No any thoughts on the initial data generated so far, and any kind of learnings you can take, especially given some of the deaths we've seen in those trials? So let me do the humane and then passes to Jason to comment on aloe. So the I'm gonna say again, why piercing through Pfizer will are in control of the release of data on hemophilia. The there is an abstract has been accepted for ash and they will use whatever conference schedule in the future to continue to demonstrate the benefit to patients or reduce absent bleeding events and no requirement for factor. Jason, can you talk about the allergy alginate question, please.\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nSure. Thank you, Sandy. So I believe that you're referring to aloe Carty programs in in oncology and not we have a partnership with Gilead to support their allogeneic Carty programs. kite has has guided that we're expecting to begin the studies on on their alpha genetics cd 19 targeted Carty therapy next year. And we believe that the data that we've seen so far from from others are consistent with, with these with these therapies having real therapeutic potential and we're excited about it and and we're excited to see Kai get the get the therapies into patients.\\nBoran Wang -- Guggenheim securities -- Analyst\\nOkay, thank you.\\nOperator\\nThank you. I will now turn the call back over to head of corporate communications. Sandy Macrae for any further remarks.\\nSandy Macrae -- Chief Executive Officer\\nThank you once again for joining us today and for your questions. We look forward to keeping you updated on our future developments.\\nOperator\\n[Operator Closing Remarks]\\nDuration: 49 minutes\\nCall participants:\\nMcDavid Stilwell -- Head of Corporate Communications\\nSandy Macrae -- Chief Executive Officer\\nBettina Cockroft -- Senior Vice President and Chief Medical Officer\\nSung Lee -- Executive Vice President and Chief Financial Officer\\nJason Fontenot -- Senior Vice President of Cell Therapy; Interim Head of Research\\nMark McClung -- Executive Vice President and Chief Business Officer\\nGeoff Meacham -- Bank of America -- Analyst\\nMaurice Raycroft -- Jefferies -- Analyst\\nJim Burchinal -- Wells Fargo. -- Analyst\\nGena Wang -- Barclays -- Analyst\\nEric Joseph -- JPmorgan -- Analyst\\nRitu Baral -- Cowen -- Analyst\\nNicole Germino -- Securities -- Analyst\\nBoran Wang -- Guggenheim securities -- Analyst\\nMore SGMO analysis\\nAll earnings call transcripts\\n\\n\\n\\n\\n\",\n          \"Prepared Remarks:\\nOperator\\nGood morning, and thank you for standing by. Welcome to today's International Paper's First Quarter 2021 Investor Earnings Day Conference Call. [Operator Instructions]\\nI'd now like to turn today's conference call over to Guillermo Gutierrez, Vice President, Investor Relations.\\nGuillermo Gutierrez -- Vice President of Investor Relations\\nThank you, Maria. Good morning, and thank you for joining International Paper's First Quarter 2021 Earnings Call. Our speakers this morning are Mark Sutton, Chairman and Chief Executive Officer; and Tim Nicholls, Senior Vice President and Chief Financial Officer. There's important information at the beginning of our presentation on Slide two, including certain legal disclaimers. For example, during this call, we will make forward-looking statements that are subject to risks and uncertainties, including the impact of COVID-19. We will also present certain non-U.S. GAAP financial information.\\nA reconciliation of those figures to U.S. GAAP financial measures is available on our website. Our website also contains copies of our first quarter 2021 earnings press release and today's presentation slides. Relative to the Ilim joint venture and Graphic Packaging investment, Slide two provides context around the financial information and measures presented on those entities.\\nI will now turn the call over to Mark Sutton.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nThank you, Guillermo, and good morning, everyone. We will begin our discussion on Slide three. International Paper delivered solid earnings and strong cash generation in the first quarter. Our mill and converting system performed well to mitigate the significant impact of the winter storm and support a strong customer demand across all of our packaging channels. Input costs and transportation were a headwind in the first quarter, especially for energy, which was impacted by the duration of the severe cold temperatures in the Southern U.S.\\nWe see momentum building, continuing to build across our three businesses with very strong demand for corrugated packaging and containerboard and solid demand for absorbent pulp. And in papers, we're seeing an improved supply demand backdrop in all of our key geographies. Our capital allocation in the first quarter, we repaid $108 million of debt and we returned $331 million to shareholders, including $129 million of share repurchases. Our performance again demonstrates the agility and resilience of International Paper to perform well across many different circumstances.\\nWe're passing the 1-year mark of the global pandemic, and I could not be any prouder of the commitment of our employees to take care of each other and take care of our customers. The vast majority of our 48,000 team members work in our mills and conversion plants each and every day, and their health and safety remains our most important responsibility. We also made solid progress on the spin-off of our Printing Papers business, which we expect to complete late in the third quarter this year. Our team is also making strong progress to develop and deliver multiple streams of earnings initiatives to achieve the $350 million to $400 million in incremental earnings and accelerated growth by the end of 2023.\\nAs we work to build a better IP, we remain laser-focused on delivering superior solutions to our customers, executing well and meeting our commitments to our shareowners and our other stakeholders. Turning now to Slide four, which shows our first quarter results. We delivered EBITDA of $730 million and free cash flow of $423 million despite the $80 million pre-tax earnings impact from the winter storm in the Southern U.S. Revenue increased by more than $100 million sequentially, primarily driven by price realization in our Packaging and Global Cellulose Fibers businesses. And again, free cash flow is strong with a continued focus on running our businesses well, controlling our cost and actively managing our working capital.\\nNow I'll turn it over to Tim, who will cover our business performance and our second quarter outlook. Tim?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nThank you, Mark, and good morning. I'll start with the quarter-over-quarter earnings bridge on Slide five. First quarter operating earnings were $0.76. The winter storm impacted pre-tax earnings by $80 million or a $0.15 impact to operating EPS. We're still in the very early stages of the insurance process and do not have a recovery estimate at this time. Looking at the bridge, price/mix was strong driven by prior period price flow-through and packaging and cellulose fibers. Volume was essentially flat with continued strong demand for corrugated packaging and absorbent pulp.\\nOverall papers volume continues to recover even though we saw the expected seasonal decline for papers in Brazil in the first quarter. Operations and costs were favorable. Mill and box system performance was solid and helped mitigate the impact of the winter storm, which was a cost headwind of $55 million to operations. Maintenance costs increased sequentially, and we expect to complete about 65% of our maintenance outages in the first half of the year. Input costs were unfavorable, which included a $20 million cost impact from the storm, mostly for energy and raw materials such as starch and adhesives.\\nOverall, we're seeing higher costs for recovered fiber, energy, chemicals and distribution, which we expect to continue in the second quarter. Transportation conditions are challenging, and we're experiencing significant rail, truck and ocean transportation congestion. Higher corporate expenses were driven by a noncash foreign exchange loss on intercompany loans, and lower equity earnings are partly attributed to the reduced ownership position in GPK. Turning to the segments, and starting with Industrial Packaging on Slide six. We continue to see strong demand across all of our channels, including box, sheets and containerboard.\\nFor the quarter, volume was essentially flat. We lost 145,000 tons of containerboard production due to the winter storm. Although our mills and box plants in the region recovered quickly, the storm did impact sales in the quarter. We had nearly 30 box plants in Texas, Louisiana and Mississippi affected by the storm, which impacted our box shipments in the quarter. Price and mix was strong. Our November increase is essentially implemented fully with the $131 million first quarter realization. And I would add, this is one of the fastest implementations that we've seen.\\nOperations and cost includes about $55 million impact from the winter storm, about half of which is due to unabsorbed fixed costs and the balance is related to repairs and higher distribution costs. Overall, mill and box plant performance was solid, and we leveraged our system to support strong customer demand across all of our channels. Maintenance outage costs increased sequentially. We did defer about $30 million of maintenance outages from the first to the second quarter due to the significant production loss resulting from the winter storm. We expect to complete about 75% of our planned maintenance outages for packaging in the first half of the year.\\nInput costs were a significant headwind in the quarter, including about $20 million related to the winter storm due to higher energy, distribution and raw materials in our mill system and box plants. Higher recovered fiber costs were another significant headwind in the quarter. We expect continued cost pressure for recovered fiber, energy distribution in the second quarter, and we're still seeing the lingering effects in certain chemicals produced in Texas and Louisiana as suppliers recover from the winter storm. Turning to Slide eight.\\nAs we enter the second quarter, we're seeing continued strong demand across all of our channels. U.S. and export containerboard demand is strong with low inventories in all regions. Our first quarter shipments were impacted by the significant production loss resulting from the storm. We're working with our customers to recover from extensive backlogs. In our U.S. box system demand remains robust as more states start lifting restrictions. E-commerce, again grew at a strong double-digit pace in the first quarter, and we believe the majority of the accelerated consumer adoption in this channel is permanent.\\nWith states starting to reopen, we're also seeing improved demand in segments with greater exposure to restaurant and foodservice channels, such as produce and protein, although we're still not back to pre-COVID levels. Nondurables, excluding food and beverage, represents about 30% of U.S. box demand across a wide range of consumer and industrial products. This segment is benefiting from strong consumer demand in the broad manufacturing sector recovery. And lastly, demand for durable goods, which had the immediate pullback due to COVID is benefiting from a healthy housing market.\\nWe're well positioned and have the scale and footprint to serve just about every corrugated segment in a meaningful way, and our packaging team continues to focus on delivering superior packaging solutions to help our customers succeed. Turning to Slide eight. I'll provide an update on the progress we're making in our EMEA packaging business. Our objective is to bring this business back to sustainable mid-teen margins and generate returns above our cost of capital. We're well on our way to achieving our goal. In the first quarter, we improved adjusted EBITDA by nearly $20 million compared with last year.\\nThe Madrid mill is fully ramped, and we have more integration and cost opportunities available. We're integrating our world-class lightweight recycled containerboard with our box network in Southern Europe to provide customers with a broader array of packaging solutions. We've improved our footprint in the Iberian Peninsula through selective acquisitions, including two box plants in Spain acquired at the end of the first quarter. These acquisitions provide additional integration opportunities with the Madrid mill. And more importantly, they enhance our commercial capabilities in the region. We continue to make progress with our box system performance and have more opportunity ahead.\\nAll our plants have clear commercial and operational plans, and we're leveraging the skills and resources from across the company to deliver on our commitments.\\nThe map on the slide shows our packaging footprint in Europe after the sale of our Turkey packaging business, which we expect to close in the second quarter. After the sale, the EMEA packaging business will have two recycled containerboard mills, 21 box plants and two sheet plants. And again, our commitment is to bring this business to sustainable returns above our cost of capital. Moving to Global Cellulose Fibers on Slide nine.\\nPrice and mix was favorable with price realization accelerating across all pulp segments in the first quarter. Volume was moderately lower due to the shipping delays related to port congestion. Demand for fluff is solid and we have healthy backlogs. Operations and costs improved sequentially, driven by the nonrepeat of the $20 million write-off in the fourth quarter as well as solid operations and good cost management. These improvements were partially offset by about $10 million of higher seasonal energy consumption and an FX loss at our mill in Canada.\\nMaintenance outage costs decreased as expected, and input costs increased due to higher wood costs in the Mid-Atlantic region as well as higher energy costs. Demand improved as we entered the year and the end-use demand signals for absorbent hygiene products is healthy. Turning to Printing Papers on Slide 10. Our business -- our papers business has demonstrated outstanding resilience throughout the past year. Our performance reflects the talent and commitment of our team, the scale and capabilities of our global footprint and the strength of our highly valued brands.\\nWe continue to see steady recovery in demand across all regions, which we expect will accelerate with broader return to office and return-to-school activity. I'd also add that we've seen significant improvement in supply demand dynamics both within the U.S. and outside the U.S. Looking at our first quarter performance, price and mix was stable across the segment. Volume decreased sequentially due to the lower seasonal demand in Brazil and Russia as expected. It also meant that the export supply chains are stretched in most regions. Operations and costs improved on solid operations and good cost management, as well as a favorable FX in Brazil of about $10 million.\\nFixed cost absorption improved with economic downtime decreasing by 40,000 tons sequentially across the system. Maintenance outages increased modestly, as expected, and input costs increased primarily due to higher wood and energy costs in North America. Looking at Ilim on Slide 11. The joint venture delivered $49 million in equity earnings in the first quarter with an EBITDA margin of nearly 35%, driven by higher average pricing. Volume decreased sequentially, primarily due to fewer shipping days because of the Chinese New Year, as well as the impact of tight shipping capacity in China. Underlying demand remained strong as we enter the second quarter.\\nAnd lastly, in April, we saved a $144 million dividend payment from Ilim, which is $44 million higher than the estimate we provided last quarter. Now we can turn to the outlook on Slide 12, and starting with Industrial Packaging. We expect price and mix to improve by $75 million on realization of our March 2021 price increase. Volume is expected to decrease by $10 million on lower seasonal demand in Spain and Morocco as the citrus season winds down. Operations and costs are expected to improve by $15 million, with the full recovery of the winter storm impact partially offset by higher incentive compensation accruals related to a stronger outlook.\\nStaying with Industrial Packaging, maintenance outage expense is expected to increase by $77 million. And input costs are expected to increase by $20 million due to higher OCC, energy, raw materials and distribution costs. In Global Cellulose Fibers, we expect price and mix to increase by $100 million on realization of prior price movements. Volume is expected to increase by $5 million. Operations and costs are expected to decrease earnings by $10 million. Maintenance outage expense is expected to decrease by $10 million, and input costs are expected to be stable. Turning to Printing Papers. We expect price and mix to increase by $25 million.\\nVolume is expected to increase by $5 million. Operations and costs are expected to decrease earnings by $10 million due to the nonrepeat of foreign currency gain in Brazil during the first quarter. Maintenance outage expense is expected to increase by $22 million, and input costs are expected to increase by $5 million. And under equity earnings, you'll see the outlook for our Ilim joint venture. Turning to Slide 13. I want to take a moment to update you on our capital allocation actions in the first quarter. We're committed to maintaining a strong balance sheet. We have no significant near-term maturities. And in the first quarter, we reduced debt by $108 million.\\nWe also returned $331 million to shareholders, including $129 million of share repurchases, which represented about 2.6 million shares at an average price of $50.28. We acquired two box plants in Spain at the end of the first quarter. You can expect M&A to continue to focus primarily on bolt-on opportunities in North America and Europe. And lastly, in the first quarter, we monetized about $400 million of our stake in Graphic Packaging. After that transaction, we now hold about 7.4% ownership in the partnership.\\nAnd with that, I'll turn it back over to Mark.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nThank you, Tim. Turning to Slide 14. As we enter the second quarter, I'm mindful that we're still in the midst of a global pandemic, and there is still significant uncertainty in the geographies and markets that we operate. Having said that, we see momentum building in our three businesses. We continue to see very strong demand for corrugated packaging and containerboard in North America and Europe. We're also seeing solid demand for absorbent pulp with more favorable supply and demand dynamics as paper-grade pulp demand recovers. In Printing Papers, we're seeing a steady recovery in demand.\\nAnd in areas where schools and offices have reopened, we're seeing a step change improvement. Overall, we're seeing a much better supply/demand backdrop. We expect price flow-through from prior price increases across our three businesses. We expect margins to improve, even as we manage through the impact of higher input costs for recovered fiber, energy and transportation. In addition, we expect productivity and other cost initiatives to offset general inflation. All of this contributes to a more favorable outlook for 2021.\\nAnd I'll end our prepared remarks on Slide 15. I just want to take a moment to reflect on what has now been a full year of living and working in a global pandemic environment. When we shared our first quarter performance last year, we talked about all the protocols we quickly put in place to keep our employees and contractors safe so that we could continue taking care of our customers. We stayed diligent about adhering to those protocols, and we will remain steadfast for as long as it takes to get fully and safely past the pandemic.\\nWe continue to operate in this environment with a view toward the short-term and long-term success and sustainability of International Paper for all of our stakeholders, with an unwavering commitment to the health and safety of our employees and contractors, to understanding and taking care of our customers' needs as they also adapt to rapid change, to supporting the critical needs in our communities and to building a better IP for all of our stakeholders.\\nSince the pandemic began, not a day goes by that I don't think about the commitment of our employees, and especially our frontline teams for their ability to adapt well and perform at a high level across circumstances and geographies. And once again, I want to take this time to thank each of our employees for their role in making our company strong and resilient.\\nAnd with that, Tim and I are happy to take your questions.\\nQuestions and Answers:\\nOperator\\nThank you. [Operator Instructions] Our first question comes from the line of Mark Wilde of Bank of Montreal.\\nMark Wilde -- Bank of Montreal -- Analyst\\nGood morning, Mark. Good morning, Tim.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nGood morning.\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nGood morning.\\nMark Wilde -- Bank of Montreal -- Analyst\\nMark, I'm just curious, it does seem like the containerboard business really has accelerated globally, not just containerboard, but corrugated. And that the market is quite tight. And I'm just curious about how that might be impacting your thinking about a potential conversion of that second line down at Selma?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nThat's a good question, Mark. We obviously have looked at that and what product we might need in the future. If you just play out the current conditions, you'd probably look at using some of that from a packaging standpoint sooner. But outside of interruptions like we talked about with the winter storm and one-offs, we have largely the containerboard we need when you look at all of our channels, domestic and our own box, domestic open market and export for what we believe is the foreseeable future. But that's a good option for us in the future. And it depends on the type of grades, whether it's medium or linerboard that we need. One is quicker and less expensive than the other. But it's on our radar screen.\\nWe don't feel the need to immediately do that right now. When we operate well and we don't have interruptions like we had in the first quarter, we feel quite confident in our containerboard quality, type of grade and overall capacity.\\nMark Wilde -- Bank of Montreal -- Analyst\\nOkay. And just as a follow-on, if I could, Mark. I know that both European producers and North American producers have been sort of pulling out of the export market and kind of rechanneling volume to their domestic businesses and domestic customers. I just -- I'm curious about how you think about this in the context of taking care of long-term export customers because I think there's some real concern by converters in places like Latin America that have always relied on imported board.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nYes. It's definitely important to us. IP is probably the largest provider of kraftliner board in Latin America and Europe for long-term customers who use it because it's needed. And that's critically important to us, and we've talked about the importance of our channels to market, especially for kraftliner. Things are very tight right now. Disruptions make that further -- more difficult for the supply chain. I think where we are right now is inventories are very low through the system with our customers and our own processes.\\nAnd we are working individually with each of our customers, I can't speak for others, obviously, to make sure we can provide as much of their needs as possible in the time that they need it. But I think we're looking at a tight supply chain, especially for kraftliner for the foreseeable future.\\nMark Wilde -- Bank of Montreal -- Analyst\\nOkay. Great. I'll turn it over. Thank you, Mark.\\nOperator\\nOur next question comes from the line of George Staphos of Bank of America.\\nGeorge Staphos -- Bank of America -- Analyst\\nHi, everyone. Good morning. Hope you're doing well. Thanks for the details. I guess my first question is really around corrugated volume. And Mark, you mentioned that from what you're seeing and the acceleration from e-commerce, that you think the -- and I'm paraphrasing, the new consumption levels and new usage of corrugated, they're more or less here to stay. You don't intend or don't expect that to recede. So can you tell us why -- what evidence you're seeing that suggests that and how your volumes have looked to the extent that you can comment early in the second quarter?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nSo it's a great question, George. I think one of the things we look at is what our customers look at. And on the e-commerce part of your question, we're seeing really important winning customers, investing more in their capability, putting real dollars and real equipment and real capability and hiring employees. Their data analytics around customer repeat buying and all that gives them confidence to believe that a good portion of this shift to an e-commerce way of retail is permanent. It may not be 100% permanent, but it is the majority of it. So we look for clues from our customers instead of trying to wish it or guess at it.\\nWhat's uncertain is as things return to a more \\\"normal environment\\\", what does traditional retail do? Is it a net loss to e-commerce? Or is it a hybrid? Were there still going to be some normal return to in-store brick-and-mortar type retail, and you can look at a lot of information, studies and listen to company's earnings reports that are in those businesses, and it's hard to conclude from that. So our box volumes in April for our own make box -- the boxes we make, looks -- the trends look like they're continuing from the first quarter.\\nBut I'll remind you, we serve multiple channels. So we're in the box market, whether we make the box, whether we have a long-term strategic partner using our containerboard and making specialty boxes or whether it's a pure open market, and we're seeing those volumes up close to double digit for the overall exposure we have for the North American box market. So it looks like more of the same. We do see some channel shifting, which is good news. We see obviously some foodservice and restaurant supply picking up.\\nWhere that shows up for IP, and we're overweight in this area is fresh food produce, the type of things restaurants buy twice weekly, 3 times weekly basis, which really got hit hard in the pandemic. So we're encouraged by what we're seeing in the demand trends and the segment exposure that we have.\\nGeorge Staphos -- Bank of America -- Analyst\\nThanks, Mark. Just a point of clarification. The close to double-digit reference that you just made, what was that referring to?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nIt's all in channels to market that we look to provide to the U.S. box market. So our vertical channel in our own box business, we have some strategic partnerships where we have either partial ownership or majority ownership downstream in the converting. And usually, that's specialty type products. And then we have just the pure open market where we have long-term arrangements. When we look at the activity and -- that we participate in the U.S. box market, it's really strong.\\nGeorge Staphos -- Bank of America -- Analyst\\nOkay. Thanks for that. My other question, recognizing this was a very different first quarter from a storm and outage standpoint. And clearly, we can understand why you saw such a pickup in energy costs in the quarter. Looking back over time, it looks like IP's consumption of energy has been relatively constant. Are there -- given what we've seen in the last quarter and given that experience, what are the areas that you see where perhaps IP can become even more efficient within its mill network in terms of energy consumption? Thanks, guys, and good luck in the quarter.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nThanks, George. It's a good question. On energy, the main thing we can do on the mill system side is maximize our own make energy in our fully integrated kraftliner mills, where we make anywhere from 75% to 85% of our energy with carbon-neutral biomass. There's more we can do there. Sometimes it takes investment. As you know, what we've done with our capital investment program over the last couple of years is to navigate some strategic projects like Riverdale and then the pandemic and managing our entire liquidity situation. We -- those are the type of projects that you can go back and get later.\\nSometimes, it's unfortunate, but we delay them even though they have really good returns. So we've got more investment we can make. Fuel switching, we've done a lot of to natural gas from other higher-cost fuels. And in the converting plants, we don't make our own energy. So part of it's geographical exposure to the grid, but part of it's energy efficiency through the uses of energy in the plant. Most all of that, where we are now in our company in terms of consumption, most all of that is part of our investment profile. And usually, George, those projects have the highest returns. And we plan to invest -- increase our investments in those areas now that all phases of our financial condition are much stronger.\\nGeorge Staphos -- Bank of America -- Analyst\\nThank you, Mark.\\nOperator\\nOur next question comes from the line of Mark Weintraub of Seaport Global.\\nMark Weintraub -- Seaport Global -- Analyst\\nThank you. First question was you really did have a lot more pricing in the Industrial Packaging business flow-through than I think your original guidance had been. And you mentioned, Tim, that this was one of the fastest pass-throughs or your ability to get price turned out to be very good. Can you give us more color on what happened and what it tells you?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nIt's a difficult question, Mark, because there's so many customers and so many unique commercial agreements. I think the general answer is when you have this type of demand, and a lot of our customers are dealing with multiple supply chain challenges. It's not just the packaging that they get but the other inputs. I think the discussion time about the gray area in every commercial relationship about how fast or how slow, no one loves price increases, obviously. That dynamic just lends itself, so let's get this done and get our material in and get it in as quickly as possible because I've got 17 problems and the box is only one of them.\\nThat's just a general answer. The dynamic out there right now is things are very tight in multiple parts of the supply chain for a lot of our customers. And everything at the final minute of when you implement tends to be a human team in negotiation and it just went faster.\\nMark Weintraub -- Seaport Global -- Analyst\\nGreat. And can you give us a sense -- I recognize that certainly by the end of the quarter, it was all in. Is there still some carryover impact that's included in that $75 million that you're looking for in the second quarter versus the first quarter? Or is that actually genuinely all from the new initiatives?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nYes. It's small, Mark. There's probably just a little bit from the first price increase, but virtually all of it's in. And so we're looking forward now to the March increase implementation.\\nMark Weintraub -- Seaport Global -- Analyst\\nAnd one last one, sort of in the same vein, but in the pulp business, where great to see that, hopefully, second quarter will actually be a little bit in the black. I imagine though, because of the way those contracts are laid out, that even based on the prices -- price increases you've already implemented that there should presumably be more to come in the second half of the year. A, is that valid? And b, do you have pretty -- do you begin to have pretty good visibility on that? Or is that going to be negotiations and conversations yet to come?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nIt's for the -- we gave an outlook. I think the number was $100 million in price in the second quarter. That's as far as we're going to go on that. But we like -- as I said in my closing prepared remarks, we really like the momentum in Cellulose Fibers right now. A big part of that like is the movement in pricing. But I don't want to go out into the third -- or into the third quarter and fourth quarter. But if you just take the confidence we have in the trajectory, I think you can make some conclusions.\\nMark Weintraub -- Seaport Global -- Analyst\\nThank you.\\nOperator\\nOur next question comes from the line of Adam Josephson of KeyBanc.\\nAdam Josephson -- KeyBanc -- Analyst\\nHope you're well. Well, Tim, one question on the guide -- the 2021 momentum building slide. I asked the same basic question on the last call, but -- so everything seems to be getting better as you go through the year. Why not resume providing guidance at this point? I know about all the -- there are many uncertainties, as there always are. So did you -- how much consideration did you get to doing that? And why did you reach the conclusion, at least for now that you don't want to resume doing so?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nYes. It's a good question, Adam. I mean, technically, we don't provide guidance as such. We give an outlook. It's true that in prior periods, we had talked about a full year outlook and expectations sometimes within a range. It's something that we look at every quarter. I think we're -- some of the uncertainty around COVID is -- seems to be diminishing. But I think maybe as we get to the middle of the year, we'll have a better feel for vaccination rates and what's reopening and what's not. And so it was just not enough in our view at this point in time to start talking about full year guidance. But we do have a lot of optimism about how we see the year playing out.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nAdam, this is Mark. Just to add. It's -- look, it's a good question. We have given the investment community, as Tim said, at least an EBITDA range, a couple of other numbers for full year expectations. I think what's missing is that EBITDA number. We did talk about our capital expenditures, for example. But as we get into this year, a full year guidance given in the middle of the year, I think was maybe less valuable than if we would have given at the beginning of the year. Look, I'm an optimistic person. You know me personally, Adam, I am feeling really good about where we are.\\nBut just as soon as I say that, I think about our employees in Poland right now or our employees in Brazil, and they are where we were during the Christmas holidays and in January with pandemic and its effect on their economy and their lives. So I just don't want to get out over our skis and say things that imply this is all behind us only to have to come back and say, what, that was too quick. So I know it's a little frustrating, but we're trying to get this transparent outlook, as Tim walked through methodically all those numbers on the outlook slide. And hopefully, that gives people a sense of the big picture, which is things are really strong and improving.\\nAnd we have, as Tim said, on the capital allocation slide, a balance sheet that's headed very quickly to the low end of our range and good cash generation, flowing cash through the capital allocation framework, dividend share repurchases like we committed to, albeit interrupted for a program not casually. And so that's the message I really want investors to take away and analysts to work with. But your point is well taken. It's information you used to have, but you don't have right now.\\nAdam Josephson -- KeyBanc -- Analyst\\nNo, I really appreciate that, Mark. And just one other question for you on -- back to the e-commerce and the whole box demand issue. You used to talk about the relationship between box demand and GDP, and between box demand and nondurable industrial production. And you have that really good slide in your roadshow handout to that effect. How do you think those relationships have changed, if at all, given this new information you have about the presumed permanence of this e-commerce growth.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nWell, that's a really good question. I know our team is looking at the resiliency of that model that creates that slide you're talking about in our roadshow where we have the nondurable and transportation index and a number of other metrics. I don't know if we've decided that there's a shift in it yet, but I know our team is looking at it. As soon as we have something that we feel good about and that it's legitimate and statistically valid, we like to share that in our investor material, and we'll do that in the future.\\nAdam Josephson -- KeyBanc -- Analyst\\nThanks so much, Mark. Best of luck in the quarter.\\nOperator\\nOur next question comes from the line of Phil Ng of Jefferies.\\nPhil Ng -- Jefferies -- Analyst\\nHey, guys. Appreciating there's a greater lag in the flow-through on pricing. But with fluff pulp prices approaching 2018 levels, and commercial initiatives you guys are implementing, how quickly do you think that earnings power for cellulose to kind of return back to 2018 levels?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nWell, we gave the outlook for the second quarter, and you can look at the trend there on just the pricing comment of $100 million. I think we are in that part of the pulp market dynamic. And we're also trying, as I mentioned multiple times, we're trying to change the business model commercially, primarily on how we go to market and how we interact with our customers so that we put more sustainability and less volatility in the business. And that's a lot of work, about work I can comment on because it's customer-specific, but we feel good about where we are right now. And we think the business can get back to. And then, if we can invest in the cost side, improve upon what numbers you're talking about from '18.\\nPhil Ng -- Jefferies -- Analyst\\nThat's great. I appreciate that color. It seems like a solid game plan. The 145,000 lost tons in containerboard from the winter storms, is your view you would essentially sell pretty much all that? Or would that have been kind of an effort behind to build inventory? The reason I'm asking, I'm just trying to gauge if you view that as pent-up demand for 2Q. And then more broadly, just given how tight things are, do you have bandwidth to kind of supply your customers given how strong demand is right now?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nYes. We're working hand in glove with customers across all of our channels, trying to make sure that we're meeting their needs as quickly as possible. Having said that, it's a challenge. 145,000 tons, a big portion of that was available for sale and ready to go. In some cases, as we go into the second quarter, it's a heavier maintenance outage quarter. And so part of it is preparing for that as well. But definitely missed opportunities on the containerboard side. But as, if not more importantly on the box side, with 30 plants down and significant exposure. So our estimates around that exposure is that the growth that we had in the quarter would be closer to overall industry growth if we haven't had that disruption.\\nPhil Ng -- Jefferies -- Analyst\\nBut you see that demand still there? Or your customers kind of went elsewhere to kind of get supply just given how tight things are?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nWell, some of it's there. Some of them are still working through, as I mentioned in the prepared comments, working through backlogs. All of these channels have different lead times on orders and when customers are expecting them. And so we're working through it customer by customer on that basis.\\nPhil Ng -- Jefferies -- Analyst\\nOkay. Super helpful, guys. Appreciate it.\\nOperator\\nOur next question is from Mark Connelly of Stephens.\\nMark Connelly -- Stephens -- Analyst\\nFollowing on Phil's question. If we remove the storm impact that held back first quarter, is there any reason to think that IP can't match the industry shipments in 2021 or even exceed it? I'm thinking about the outages and the maintenance timing shifts and that sort of stuff. Because obviously, there was a lag or a lag in performance in 4Q too. So I just want to make sure we're not missing anything.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nNo, it's a good question, Mark. There's no reason to believe we can't match or exceed. Now given our size exceeds means some basis points, not multiples. But there's no reason you can't match the market. Fourth quarter, we did have some operational issues, if you recall. And then not an excuse, but this geography and the winter storm matched right on top of us. But no reason you shouldn't expect us to perform at or better than the market.\\nMark Connelly -- Stephens -- Analyst\\nOkay. And -- thank you, that's helpful. Just on EMEA, following on Tim's comments, how does the push to mid-teens margins in EMEA breakout between converting and mill opportunities? I'm just wondering if there's spending opportunities at those mills or if most of the incremental investment and improvement is coming on the converting side.\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nYes. It's a good question, Mark. We think we have additional opportunities, not that so many of them require capital in the mill operations, but just in terms of how we're managing cost as we get fully up the ramp curve and integrated, and it's both mill and supply chain. So we see more opportunity for the mill in Spain. The other mill is a more mature mill that's been there for a while. And so it's probably running at an optimal level. But in Spain, given the integration play, we see more opportunity.\\nMark Connelly -- Stephens -- Analyst\\nSo bringing some of the strengths in the integration that you have in the U.S. over to there. Okay. That's very helpful. Thank you.\\nOperator\\nOur next question comes from the line of Cleve Rueckert of UBS.\\nCleve Rueckert -- UBS -- Analyst\\nHi. Good morning, everybody. Thanks for taking my questions.\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nMorning.\\nCleve Rueckert -- UBS -- Analyst\\nJust first off, I wanted to follow up on the $350 million to $400 million of incremental EBITDA. I think $300 million of that was supposed to be from cost savings. And I realized Q1 was kind of challenging, but I didn't hear an update on how much of that you've achieved to date or how much you expect to achieve this year headed toward that 2023 exit rate?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nYes. Well, you -- we didn't provide one. So we're working through our plans right now, and we're in the process of beginning the implementation of all that. We pointed on the last quarterly call to some of the benefits that we saw coming through, more of the process automation and using data analytics and technology. And as we go through this year, we're looking forward to probably the third quarter where we provide a robust update in terms of all of the plans that are being executed and achievement this year, but also run rate expectations for 2022.\\nCleve Rueckert -- UBS -- Analyst\\nOkay. All right. That's clear. And then, I guess, just a follow-up on the containerboard and corrugated box business. Could you give us just a sense of where your inventories stand, given the disruptions kind of, I guess, where you are today at an inventory level versus where you like to be or where you've been historically on average? And kind of what the trajectory is there on the inventory side given the outages in the second quarter?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nWell, the easy answer is we're lower than we'd like to be. And that's the source of the hand to glove comment Tim just made. So we need to rebuild, while we serve our customers' active demand, we need to be very efficient in rebuilding important roll stock inventories across the wide range of boxes that we have to make. So there's more for us to do. It's not unexpected when you have this type of demand, coupled with the one-off interruption of the storm we talked about and then just the timing of outage schedules. But the good news is we have a really big system, and it's very flexible and it recovers very quickly.\\nSo we feel like we could do it. But our inventories are lower than we would like, all things considered. And the main thing I'm concerned with right now is our ability to support our customers through their dynamic demand changes. And that's what our focus is right now.\\nCleve Rueckert -- UBS -- Analyst\\nThat's clear. I guess just quickly, given what you know about the second quarter, would you expect to be in a position to build inventories?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nEvery effort is going to be made to try to restore inventory levels, but it's a heavy maintenance outage quarter. And so you're triaging and prioritizing and trying to satisfy all of the needs across the channels. So now the good news is, most of the outages are behind us by the time we get to the middle of the year. But these supply chains are very long, and they take a long time to recover.\\nCleve Rueckert -- UBS -- Analyst\\nThat's very clear. Thanks, guys. Appreciate it.\\nOperator\\n[Operator Instructions] Our next question comes from the line of Gabe Hajde of Wells Fargo Securities.\\nGabe Hajde -- Wells Fargo Securities -- Analyst\\nMark, Tim, good morning. I hope you guys are well.\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nMorning.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nMorning, Gabe.\\nGabe Hajde -- Wells Fargo Securities -- Analyst\\nI'm thinking about integration levels in the corrugated operations or Industrial Packaging North America and kind of whether or not you kind of still view this as the right destination? I mean, you have some competitors that are maybe trying to bump that up for different reasons. And I also appreciate that maybe looking back in the rearview mirror, you're kind of playing a little bit more defense and/or kind of making some asset changes along the way. Now you've got some kind of more, I'll call it, disposable cash to go on offense with and you made these two small box plant acquisitions. Is that part of the strategy that maybe get that closer to something, I don't know, 90%? Or you feel good at that 80% level kind of over a longer-term basis?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nYes. So we think what's important about integration is how we go about building it. Our most profitable channel is our North American domestically integrated channel containerboard to box and to the customer. And we want to grow that part of the business by delivering superior solutions on the packaging side to our customers. So that we're building long-term sustainable relationships where we can through small M&A or some of these more creative arrangements that we've started implementing to grow that channel. So higher over time, but done in a very sustainable way.\\nGabe Hajde -- Wells Fargo Securities -- Analyst\\nOkay. And then, I guess, kind of to revisit the cost reduction or the $300 million to $350 million of savings and trying to marry up the comments that you made about Europe. Are those sort of mutual exclusive, meaning the $20 million or so that you saw an improvement in profitability this quarter and I think what you talked about kind of getting back to mid-teens implies maybe another $100 million of improvement in aggregate for European Industrial Packaging. Is that more related to the mill conversion over there and that starting to contribute? Or is that, again, kind of included in that $300 million to $350 million of savings?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nYes. Part of it is included, but it's across commercial, operational supply chain. It's all the things that we touch in terms of delivering a packaging solution to a customer. So we've got improvement plans across all aspects of the business.\\nGabe Hajde -- Wells Fargo Securities -- Analyst\\nThank you, guys.\\nOperator\\nOur next question comes from the line of Paul Quinn of RBC Capital Markets.\\nPaul Quinn -- RBC Capital Markets -- Analyst\\nYes. Thanks very much. Good morning, guys.\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nGood morning.\\nPaul Quinn -- RBC Capital Markets -- Analyst\\nJust had a question on Global Cellulose Fibers. Just when I look at the quarter, I mean, it's an improvement, but it's still a disappointing result, especially when I compare it to your European peers. Where do you see this business being mid-cycle? Can you get up to the profitability of your peers? And when you -- how long do you think that's going to take?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nWell, as I mentioned on the last call, we -- last quarter call, Paul, we see the business improving quarter after quarter after quarter. And we think it'll be in very good shape. I don't have all those European numbers in my head -- off the top of my head, but we think it'll be in very good shape as we leave '21 and head into '22.\\nPaul Quinn -- RBC Capital Markets -- Analyst\\nAlright. That's all I had. Best of luck, guys.\\nOperator\\nOur next question comes from the line of Neel Kumar of Morgan Stanley.\\nNeel Kumar -- Morgan Stanley -- Analyst\\nGreat. Thank you. For corrugated, can you just talk about the cadence of volume growth through the first quarter by month? And then, can you just give us a sense of what you're seeing in terms of box shipments so far in April?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nApril is running very close to maybe a little bit ahead of how we exited the quarter, just looking -- it was pretty steady throughout the quarter -- yes. I mean, it started really strong in January. Now we think a big part of that is our exposure to e-commerce because you not only have the Christmas push around the holidays, but January with returns and in specialty sales and whatnot. It tends to be a strong month as well. But I think it was solid throughout the quarter.\\nNeel Kumar -- Morgan Stanley -- Analyst\\nOkay. That's helpful. And then in terms of your recent asset sales, I was wondering if you can just touch on how you're thinking about allocating proceeds between buybacks versus inorganic and organic investments? And then more generally, where are you in the process of evaluating your portfolio of assets. Could there be additional asset sale announcements? Or is it generally complete at this point?\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nWell, when we talked about on the acquisition side is look at what we've been doing for the past couple of years. They've tended to be one-off operations, sometimes 2, bolt-on in nature and filling gaps in capability or exposure that we want. And most of them, to be honest, that's happened in Europe at this point. In terms of the cash coming in, we have a fairly robust capital allocation framework that we have talked about over time, including the strong balance sheet, target ranges of debt. The fact that we're on a path of share repurchases before COVID hit and out of prudence we took a pause last year, but we're back in the market. But the goal is to be thoughtful about the cash coming in and making sure that we're doing everything in our power to maximize value through the actions that we take.\\nOperator\\nAnd our last question comes from the line of Kyle White of Deutsche Bank.\\nKyle White -- Deutsche Bank -- Analyst\\nHey, good morning. Thanks for taking the question. On Global Cellulose Fibers, I just want to talk about the port congestion that you're experiencing and maybe how that is impacting your volumes or your supply chain in that business?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nIt's a good question, Kyle. It's a big issue. We're not losing orders because of it because we're spec-ed in, in a lot of the customers. It's just creating a long, long supply chain. So customers are trying to figure out the new duration between placing an order and actually receiving it and in some cases, trying to get our help to understand whether they should change their order cycle. So there's a lot of order management changes being talked about and figured out between IP as the supplier and our customers. But it affects more than our pulp business.\\nIt affects our export containerboard, and we're even seeing it in our export paper business in Brazil. I don't think there's an immediate fix to it. So it's a velocity mission on the supply chain than it looks like, we're going to have to adapt to for some period of time.\\nKyle White -- Deutsche Bank -- Analyst\\nGot it. That's helpful. And then switching to EMEA Industrial Packaging. Can you guys provide some of your integration rate for just that region and kind of where do you see it going with these recent acquisitions in Spain? And then maybe just a longer-term target for integration there as you continue kind of bolt-ons in that region?\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nWe typically don't give a number because it's not as clean. We're integrated on our kraftliner from our U.S. mill system to our European box plants. We have world-class mill. We just started up a couple of years ago in Madrid. That's almost at its full ramp, which is a lot of our high-performance lightweight liner. But we buy most of our medium -- the corrugated medium from the open market. So we typically haven't given an absolute number. But as Tim said, building an integrated model regionally is where we have the most success commercially and on the financial metrics. And so that's kind of the approach we're taking in Europe is regional density.\\nAnd so right now, it's Iberian Peninsula surrounding our new mill and supported with kraftliner from our U.S. system. And then we have some very important suppliers in the European market for grades that we don't make or just that make geographic sense because of grade. So we're still a large customer for some key European containerboard producers and those are long-term relationships.\\nKyle White -- Deutsche Bank -- Analyst\\nGot it. Thank you. Good luck in the quarter.\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nThank you. So I appreciate everyone's questions. Again, thank you for your interest in International Paper, and we look forward to talking with you again next quarter.\\nOperator\\n[Operator Closing Remarks]\\nDuration: 90 minutes\\nCall participants:\\nGuillermo Gutierrez -- Vice President of Investor Relations\\nMark S. Sutton -- Chairman and Chief Executive Officer\\nTim S. Nicholls -- Senior Vice President and Chief Financial Officer\\nMark Wilde -- Bank of Montreal -- Analyst\\nGeorge Staphos -- Bank of America -- Analyst\\nMark Weintraub -- Seaport Global -- Analyst\\nAdam Josephson -- KeyBanc -- Analyst\\nPhil Ng -- Jefferies -- Analyst\\nMark Connelly -- Stephens -- Analyst\\nCleve Rueckert -- UBS -- Analyst\\nGabe Hajde -- Wells Fargo Securities -- Analyst\\nPaul Quinn -- RBC Capital Markets -- Analyst\\nNeel Kumar -- Morgan Stanley -- Analyst\\nKyle White -- Deutsche Bank -- Analyst\\nMore IP analysis\\nAll earnings call transcripts\\n\\n\\n\\n\\n\",\n          \"Prepared Remarks:\\nOperator\\nWelcome to AxoGen, Inc. Second Quarter 2020 Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.\\nI would now like to turn the conference over to your host, Pete Mariani, AxoGen's Chief Financial Officer. Please begin, Mr. Mariani.\\nPeter J. Mariani -- Chief Financial Officer\\nThank you, Devin, and good afternoon, everyone. Joining me on today's call is Karen Zaderej, AxoGen's Chairman, Chief Executive Officer and President. Karen will begin today's call with an overview of our second quarter performance and an update on the ongoing recovery in our markets, followed by a review of the recent announcement of our RECON study enrollment and our path to a BLA submission. I will then provide an analysis of our second quarter performance, along with a summary of our recently announced debt deal with Oberland capital.\\nToday's call is being broadcast live via webcast, which is available on the Investors section of AxoGen's website. Within an hour following the end of the live call, a replay will be available in the Investors section of the company's website at www.axogeninc.com. Before we get started, I'd like to remind you that during this conference call, the company will make projections and forward-looking statements regarding future events.\\nWe encourage you to review the company's past and future filings with the SEC, including, without limitation, the company's forms 10-K and 10-Q, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements related to the expected impact of COVID-19 on our business, statements regarding product acquisition and/or development, product potential, the regulatory environment, sales and marketing strategies, capital resources or operating performance.\\nAnd with that, I'd like to turn the call over to Karen. Karen?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nThank you, Pete, and good afternoon, everyone. Our total revenue for the quarter was $22.1 million, representing a 17% decline to the prior year period. While COVID-19 had a material negative impact on total revenue, we saw steady improvement across the quarter as our customers reopen their surgical schedules. Our second quarter performance reflects the recovery in our markets that was stronger than we anticipated. As well as the priority that surgeons and hospitals have placed on nerve repair with AxoGen products in the early stages of the recovery. Our recovery also reflects the hard work and creativity of the entire AxoGen team to support our customers and their patients in this difficult environment.\\nThe recovery varied regionally based on the intensity and trends of COVID-19 in local markets. As elective surgeries resumed, we experienced short-term regional surges in nerve repair cases, reflecting the completion of deferred procedures. These recovery surges were typically followed by a return to more normalized levels for the territory. Certain interviews that we conducted confirmed that nearly all surgeons had experienced significant disruption to their practice and a reduction in surgical procedures due to COVID-19, but many surgeons believed that they were already caught up with their current backlog of deferred procedures, while most others believe they would catch up by the end of the summer.\\nIn addition to regional variation, our recovery also varies by nerve repair applications with our core trauma business leading our recovery. The recovery of procedures in our breast and OMF applications as well as our emerging business in the surgical treatment of pain began later in the quarter. Overall, we're encouraged by the execution of our team and the priority hospitals and surgeons are giving to nerve repair with AxoGen products during the recovery. However, we remain measured in our outlook for the remainder of the year as most currently deferred procedures will likely be completed by the end of the summer, and COVID-19 may continue to negatively impact the incidence of trauma, and regional surgical procedure volumes.\\nWe, therefore, expect third and fourth quarter revenue to remain below prior year levels. In the area of sales execution, we continue to strategically focus our sales representatives on extremity trauma and on driving deeper penetration with our existing surgeon customers, although COVID-19 required us to adjust our approach. During April, healthcare facilities broadly restricted vendor access, and we directed our sales team to enter facilities only when requested and necessary. Our sales representatives remained in frequent contact with our customers virtually. And they work together to provide effective case support remotely.\\nWe also used restricted time to provide six weeks of extensive product and skills training for our sales team, which we believe provided the benefits of keeping the sales team positively engaged and improve their ability to support our customers. On May 1, we released our sales team to begin reentering healthcare facilities following local, regional and national guidelines and using contact tracing. While our access to healthcare facilities have improved, the ability to effectively support our customers remotely continues to be an important learned capability that our team has embraced, and we believe our customers have appreciated.\\nWe ended the second quarter with 112 direct sales representatives, an increase of three representatives added early in the quarter. With our slowing of sales headcount expansion this year, we have minimized change and disruption to stabilize our sales territories and provide consistency of support to our customers. Our direct sales channel was supplemented by 19 independent sales agencies who generally cover geographies that are less impacted by COVID-19 during the quarter. These geographies delivered better year-over-year performance than those covered by our direct sales representatives. As a result, the indirect channel represented approximately 15% of our total revenue in the second quarter compared to an approximately 10% in the first quarter.\\nWe had 789 active accounts in the second quarter, an increase of 4% from 752 one year ago and down 4% versus the first quarter. We have always reported our number of active accounts as an average for the quarter. And the significant decrease in the number of orders from accounts in April and early May had a material impact on the average for the second quarter. Our active accounts have continued to increase each month, such that for the three months ending July 31, our average active accounts has increased and is more consistent with our Q1 average of 825.\\nWe were pleased that a large majority of our top surgeons and hospitals continue to use and order AxoGen products for their patients despite the challenges of COVID-19. The top 10% of our active accounts continue to represent approximately 35% of our revenue. Our sales team remains focused on our strategy of going deeper with current certain customers and exited the second quarter well prepared for the second half of the year. We continue to focus on building market awareness of AxoGen and our products despite reduced in-person access to surgeons and restrictions on certain travel to scientific conferences.\\nIn June, we expanded our digital marketing capabilities, allowing us to more fully engage with surgeons electronically. These digital efforts provide an enhanced long-term capability to supplement the efforts of our sales team. And help our sales reps engage with surgeons where access to hospitals remains limited. Our efforts to educate surgeons and develop advocates continued in the second quarter. In March, we canceled the remainder of our 2020 schedule of in-person surgeon and fellows education programs, and we've since developed several virtual education programs led by surgeon experts in nerve repair. In June, we launched an invitation-only program for early career upper extremity surgeons who are passionate about advancing the field of nerve repair. The program is an interactive 6-part series, led by an expert faculty.\\nSimilarly, we launched a surgeon-led extremity trauma webinar series open to all of our surgeon customers. We're also continuing our commitment to educating hand and microsurgery fellows and are launching an updated training program for the second half of 2020. We previously discussed our plans to introduce new products and expand the application of our portfolio into the surgical treatment of pain, focused on symptomatic neuroma. We launched AxoGuard Nerve Cap in February, and are pleased with our early results as we focus on expanding the nerve repair algorithm of our current surgeon customers.\\nNerve Cap, an important addition to our solutions portfolio, designed to protect the peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. With the addition of Nerve Cap, we now have a full portfolio of products for nerve connection, nerve protection and nerve termination. Increasing surgeon adoption of our product portfolio continues to be supported by a large and expanding body of clinical data. We recently announced our RECON clinical study had reached its targeted enrollment of 220 subjects in July.\\nRECON is our Phase III pivotal study supporting our biologics license application, or BLA, which will transition our Avance Nerve Graft from a Section 361 tissue product to a Section 351 biologic products. We're pleased to have reached this important milestone despite a challenging environment for clinical studies, and we appreciate the dedication and commitment of our participating study teams as well as our internal team of clinical professionals. The RECON clinical study protocol requires a one year follow-up assessment with the allowance for an additional three months visit window. With the final subjects enrolled in July of 2020, the last subject is expected to complete the study no later than October of 2021.\\nWe've increased our efforts to support completion of subject follow-up visits during the COVID-19 crisis by implementing an expanded home health visit program to allow follow-up visits to be conducted by a trained healthcare professional outside of the clinic environment and with appropriate safety precautions. We are working closely with our research centers to monitor follow visit windows and minimize any potential disruption. We anticipate providing a preliminary report of trial data in the second quarter of 2022 and expect to file the BLA in 2023. In addition to the completion of enrollment of the RECON study, our RANGER Registry now has over 2,200 nerve injuries enrolled.\\nAnd we expect data from the study to be presented at clinical conferences and published in the second half of the year. Enrollment in our REPOSE study is ongoing. REPOSE is a prospective randomized controlled study evaluating the use of AxoGuard Nerve Cap in the management of painful neuroma as compared to a standard neurectomy procedure. Preliminary outcomes from the pilot phase of the REPOSE study found that at six months, subjects reported meaningful improvements in pain and quality of life scales. We've completed the last subject follow-up visits and data analysis is under way to support our REPOSE study pilot phase manuscript.\\nWhile this is a small pilot study, we remain encouraged by the positive impact reported to date and will continue enrollment of the comparative phase of the study as centers reopen to research subjects. As we noted in our call in May, we've paused enrollment of our Sensation-NOW clinical registry for the remainder of 2020, given the COVID-19-related restrictions in our study centers. We're pleased with the enrollment of 600 subjects in the registry and believe this will create a significant body of evidence around the breast neurotization technique. Similarly, we've paused enrollment in our RETHINK PAIN registry and our Avive ASSIST study.\\nWe continue to monitor the recovery of activities at study centers and will prioritize the potential restart of the clinical programs based on our business needs. We remain committed to providing meaningful and impactful clinical evidence on the utility of our nerve repair portfolio. Despite ongoing COVID-related challenges in the market, we're encouraged by the performance of our AxoGen team to creatively adapt and adjust to these challenges. We've learned new skills in supporting our customers and continue to advance our strategy focused on extremity trauma and driving deeper penetration with our existing surgeon customers. We remain as excited as ever with the opportunity in front of us, and we believe we are well positioned to drive continued growth as we emerge from the pandemic.\\nNow I'll turn it over to Pete for a review of financial highlights. Pete?\\nPeter J. Mariani -- Chief Financial Officer\\nThanks, Karen. Second quarter revenue declined 17% to $22.1 million. Our revenue decline for the quarter was the result of a 19% decrease in unit volume, partially offset by a 2% net benefit from changes in pricing and product mix. Gross profit for the second quarter was $16.5 million compared to $22.5 million in the prior year. Gross margin was 74.7% for Q2 compared to 84.1% in the prior year second quarter. Gross margin was negatively impacted in Q2 as a result of increased period and variance cost, associated with the suspension of tissue processing during the quarter of $1.6 million and increases to inventory reserves.\\nWe began a gradual restart of our tissue processing in June, are continuing that ramp in the third quarter and anticipate that gross margins will return to normalized levels as sales and production levels recover. Total operating expenses in the second quarter declined 18% to $24.8 million compared to $30.1 million in the prior year. Total operating expenses in the second quarter included $2.2 million in noncash stock compensation compared to $2.7 million in the prior year. Sales and marketing expense in the second quarter declined 23% to $14.3 million compared to $18.5 million in the prior year.\\nThis decrease was primarily due to reduced compensation expenses including lower commissions, a reduction in our surgeon education expenses after canceling in-person education programs and lower travel expense as a result of the travel restrictions and canceled programs. As a percentage of total revenue, sales and marketing expense decreased or decreased to 65% for the three months ended June 30, 2020, as compared to 69% for the previous year. Research and development spending in the second quarter decreased 5% to $4.1 million compared to $4.3 million in the prior year.\\nResearch and development costs include product development, including expenses in support of the BLA for the Avance Nerve Graft and clinical research. Product development expenses represented approximately 50% of total R&D in the second quarter compared to 58% in the prior year. While clinical expenses represented the other 50% in the second quarter of 2020 compared to 42% in the prior year. As a percent of total revenues, research and development expenses were 18.4% in Q2 and compared to 16% in the prior year. General and administrative expenses in the second quarter decreased 13% to $6.4 million or 29% of revenue, compared to $7.4 million or 27.6% of revenue in the prior year.\\nHe decrease is primarily related to the reduction in litigation and professional fees as well as lower compensation and travel expenses. Net loss in the second quarter was $8.1 million or $0.20 per share compared to $7 million or $0.18 per share in the prior year. Excluding the impact of noncash stock compensation as well as litigation and related charges, adjusted net loss and net loss per share in Q2 of this year was $5.9 million and $0.15 per share compared to $3.7 million and $0.10 per share in the prior year. Adjusted EBITDA loss in the quarter, which also excludes the impact of stock compensation, litigation and related charges, was $5.7 million compared to an adjusted EBITDA loss of $4.1 million in the prior year.\\nTurning to our balance sheet. The balance of cash, cash equivalents and investments on June 30 was $109.9 million, compared to a balance of $89 million in March of 2020. The net change reflects the receipt of net debt proceeds of $34.7 million, partially offset by capital expenditures totaling $7.7 million and net operating cash burn of $6 million during the quarter. Capital expenditures in the quarter included $6.5 million related to cost incurred for our Dayton biologic processing center prior to the suspension of construction in April, and $1.2 million related to our new office and lab facility in Tampa.\\nWe anticipate completing our new Tampa facility in the third quarter and restarting construction on our Dayton biologics processing center in early 2021. On June 30, we announced a new seven year interest-only financing agreement with Oberland Capital, which provides up to $75 million in total financing commitments with $35 million drawn at close. The second tranche of $15 million can be drawn at the company's option upon achieving two consecutive quarters with revenue of at least $20 million. And this second tranche can also be put to the company at any time by Oberland. The third tranche of $25 million can be drawn by the company or at the company's option upon achieving two consecutive quarters with revenue of $28 million.\\nOberland cannot put third tranche to AxoGen. Under the terms of the agreement, the option to draw both the second and third tranche expires on December 31, 2021. Interest from this facility is calculated a 7.5% plus the greater of LIBOR or 2%, leading to an interest rated closing of 9.5%. An additional quarterly royalty payment calculated on up to $70 million of annual revenue will begin on September 30, 2021. This royalty structure results in approximately 1% per year of additional payment on the outstanding loan amount. We believe the terms of this debt agreement allow us to strengthen our balance sheet and support the completion of the Dayton and Tampa facilities.\\nThe financing provides a manageable and flexible covenant structure, and we believe the interest-only provision for the full seven years provides a sufficient liquidity extension without diluting our shareholders that can support our continued growth through an uncertain environment and as we drive toward long-term profitability. On April 23, we announced a cost mitigation initiative designed to defer and reduce certain expenses and capital expenditures in response to the anticipated reduction of revenue caused by the ongoing COVID-19 pandemic.\\nThis initiative preserved our ability to support customers and patients in the second quarter and through the recovery and put us on a more efficient spending run rate. The initiative included the reduction of executive cash compensation and Board fees by 20%, and reduced cash compensation for all other exempt salary employees by 10% to 15%. We have restored pay levels for most employees as of August, although our officers and the Board have continued with a 20% pay cut for the time being.\\nAdditionally, we were able to defer approximately $25 million to complete our Dayton, Ohio facility for up to a year. While the path and pace of our business recovery continues to be uncertain, we are encouraged by the execution of our team and the trends in our markets that we observed during the second quarter. We also believe that the strength of our balance sheet, our cost-mitigation initiatives and our continued commercial execution will allow us to emerge from this pandemic-related downturn, a stronger, leaner organization and a lot of path to profitability.\\nAnd with that, I'd like to hand the call back over to Karen.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nThank you, Pete. We're encouraged by the performance of our commercial team during the pandemic, and believe that our renewed focus on the core trauma opportunity has supported the pace of our recovery and has positioned us well as we enter the second half of the year and continue to develop the nerve repair market. We believe that the regional surges we experienced as surgical cases reopened indicates that nerve repair with AxoGen products ranks high among surgeon priorities. And provides additional evidence of our products, clinical benefit and value proposition to patients, surgeons and hospitals. At this point, I'd like to open up the line for questions. Devin?\\nQuestions and Answers:\\nOperator\\n[Operator Instructions] Our first question comes from the line of Raj Denhoy with Jefferies. Please proceed with your question.\\nRaj Denhoy -- Jefferies -- Analyst\\nHi, good afternoon.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nGood afternoon, Raj.\\nPeter J. Mariani -- Chief Financial Officer\\nHi, Raj.\\nRaj Denhoy -- Jefferies -- Analyst\\nI wonder if I could start with the revenue lines. Pretty encouraging to see only down, I think it was 17% for the quarter after the negative 70%, I think you talked about in April. And so it does imply that very strong recovery in the second couple of quarters second couple of months of the quarter, but you're still, I guess, pointing to that being mostly recovered procedures as opposed to underlying demand. And so what I'm trying to get at is what is that underlying demand right now? And you did talk about it being still below 2019 levels in the back half of the year. And so maybe you could just ground us in terms of where you think we are on that metric?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nYes. So the recovery in the quarter was both. It was both deferred procedures from the March time period that got rolled over into the Q2 time period as well as current trauma that just happens day-to-day as surgical ORs opened up, surgeons were able to do in real time. And so we saw both of those occurring and driving the demand. We definitely saw a surge or a spike as various regions opened up. And of course, those happened at different times as regions had different time periods of the recovery.\\nAs you can imagine, some of the Northeast recovered either late June or even into July, and other parts of the country started to recover in May, balanced by some of the pullback that we've seen in some of the regions as COVID starts up again. So from a impact to us overall. We feel that incidence overall of trauma is still down somewhat, not as much as it was during the full shutdown, but we believe that the overall incident is somewhat depressed. We believe that from a deferred procedures, actually, many of them were completed in the second quarter.\\nSo those March procedure that didn't happen, got rolled over into March excuse me, in the second quarter. There are some deferred procedures that will still get wrapped up toward the end of summer. But really, we think that, again, given the priority that surgeons placed on nerve repair, they moved those procedures pretty quickly into the OR. And so we won't see a big surge from deferred procedures, but we do see the underlying demand continuing to stabilize.\\nRaj Denhoy -- Jefferies -- Analyst\\nI guess I'm trying to understand at what level? I know you're not giving guidance, and I appreciate that you're operating under a pretty limited information. But is that down 10%? Is it down 20%? What level of lower demand are we talking about at this point? And I appreciate you also have the ability to speak to July. So I don't know if you want to comment on that as well.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nWell, I think we saw good solid trends as we moved into the third quarter and in July. We're encouraged by that. But our and I'll just tell you my hesitation on giving you a depression of the incidence of trauma and the surgical repair of those procedures is because I still don't know what's going to happen regionally around COVID as it resurges in different places. And that's going to affect the trauma rate. And so I really I just I don't feel like it's fair to give you a guidance number because it's going to be based on the resurgence of COVID. The underlying demand for the products remains strong, and surgeons certainly are prioritizing getting those nerve repairs done.\\nRaj Denhoy -- Jefferies -- Analyst\\nUnderstood. On a separate topic, you were, I guess, pretty encouraged by what you're seeing on your transition to more kind of digital or virtual training and even case support efforts. And I guess what I'm asking about is how permanent do you think some of these might be? I mean is something you could see playing out even once COVID ebbs and you can get back into the hospital? Does this represent some potential cost savings for you longer term? And how do you see this playing out over the next couple of years?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nYes. I think that we have learned. We've been really nimble. We've learned some new skills and build some new capabilities. And I'm pretty optimistic that these are permanent additions to our skill sets and capabilities. And so when we think about the remote case coverage, some of the virtual education work that we've developed, and the digital marketing tools that we've developed, we think we're going to keep those in our tool belt for the long term. We think they really are beneficial to us.\\nRaj Denhoy -- Jefferies -- Analyst\\nBut I guess, do those replace things you were doing? Or are those really additive in a sense? I mean is there the potential that you could see a permanent reduction in your selling costs, for instance, from where you were pre COVID?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nYes. I think that they contribute to sales rep productivity and overall commercialization productivity. So I think they are added tools that improve our overall productivity and make us more efficient.\\nRaj Denhoy -- Jefferies -- Analyst\\nOkay, understood. Thank you.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nThanks Raj.\\nOperator\\nOur next question comes from the line of David Turkaly with JMP Securities. Please proceed with your question.\\nDan Stauder -- JMP Securities -- Analyst\\nYes, hi, this is actually Dan Stauder on for Dave. How is it going?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nHi, Dan.\\nPeter J. Mariani -- Chief Financial Officer\\nHi, Dan.\\nDan Stauder -- JMP Securities -- Analyst\\nGreat. It's actually Dan Stauder on for Dave. So I guess just going back to Raj's question. You mentioned that sales consisted of both deferred procedures as well as some current trauma demand. Could you give us any more color on that? How much contributed from both? Was it mainly from recoup cases? Or any amount of detail you can go into that would be great.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nWell, by far, the majority is day-to-day trauma. The deferred cases that rolled in were what was delayed in March. So we saw procedures start to drop in the early part of March, and some of those obviously rolled in and were deferred procedures. But trauma overall in the peak of April, we estimate it was down about 20% and it has come back up from that. Again, it's highly affected by activity and activities affected by COVID and the lockdowns in various regions associated with that. But we've come up materially from where we were at the low point, both in, we believe, the incidence of trauma. As well as patients' willingness to come into either hospitals or surgery centers to get that traumatic injury repaired.\\nDan Stauder -- JMP Securities -- Analyst\\nGreat. And then just a follow-up on that. As different regions reopened, how much of that headwind from the state home orders really waned off? Was it really pretty immaterial in June as construction and other activities we're able to resume? Or do you think that's probably here for the back half as well?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nWe still see high regional variations. It definitely waned across much of the country, but we saw impacts in Texas, in South Florida and Southern California in the June time period, given the incidence of COVID that was happening there. It is tough to tell for us at this point, whether it's the incidence of trauma or whether it's people's willingness to come or ability to come in to get surgery completed. But that's counterbalanced by the opening up of places in the Northeast, which really didn't happen until late June, early July.\\nDan Stauder -- JMP Securities -- Analyst\\nGreat. Thank you guys.\\nOperator\\nOur next question comes from the line of Richard Newitter with SVB Leerink. Please proceed with your question.\\nJamie -- SVB Leerink -- Analyst\\nHi, this is Jamie on for Rich.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nHi, Jamie.\\nPeter J. Mariani -- Chief Financial Officer\\nHey Jamie.\\nJamie -- SVB Leerink -- Analyst\\nHi guys. This is Jamie [Phonetic] on for Rich. So I just wanted to kind of come back to just the trends and what you're seeing. Could you potentially comment on, I guess, one way to think about it would be, is there a potential that you could hit that second tranche for the new financing agreement with Oberland in 3Q? Kind of help us think if that's something that could be a possibility. And then as you look into 4Q, is it reasonable to think that there could be year-over-year stability or potential growth? Or just based on what you see with the resurgence, you're not thinking that, that could be something that's on the table at this point?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nWe're still seeing or estimating. And again, this is trying to create our own crystal ball around the impact of COVID on nerve repair cases that we would remain below our prior year Q3 and Q4, which is right about where that Oberland oh, the $20 million sorry, the $20 million, we're already above and that would not be unreasonable to think that we'll be above that. The next tranche at $28 million is would be aspirational.\\nJamie -- SVB Leerink -- Analyst\\nGot it. Okay. And then just we've been hearing from a lot of other companies, COVID seems to be accelerating the trend to ASCs. And I think we've kind of talked about this in the past, but can you just comment on how or potentially when you guys believe this could impact your business and how you guys are what you guys are potentially doing to capitalize on this now?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nSure. Well, as we talked about before, there was a change in the Medicare reimbursement rate of OPPS rates for both outpatient surgery and ambulatory surgery centers that was favorable for nerve repair in general and in particular, nerve repair with implants, either a connector or an allograft. And so we see that as a benefit for the long term, the majority of nerve repair is not actually Medicare patients, so it'll have to roll through commercial payers as they as surgery centers adjust their contract with commercial payers. And we think that will take a couple of years to roll through the system.\\nWe're seeing good interest in that. But I would not say we've seen a material shift at this point. There's been certainly distractions in this quarter that may have put that as a lower priority. Having said that, one interesting thing that we did see, again, with the emphasis that surgeons really wanted to get their nerve repair patients in, in those locations where they were locked out-of-hospital ORs. So in places, for example, in Texas, as the resurgence happened, they shut down elective procedures in hospitals.\\nAnd what we saw was a very rapid shift of surgeons moving those patients to outpatient centers or to ambulatory surgery centers and still completing cases where they felt that was reasonable and the right option for their patients. And so we do see them leveraging that avenue, and we think that bodes well for the future as the payment schedules are adjusted as well.\\nPeter J. Mariani -- Chief Financial Officer\\nOkay, Devin?\\nOperator\\nOur final question comes from the line of Brandon Folkes with Cantor Fitzgerald. Proceed with your question.\\nBrandon Folkes -- Cantor Fitzgerald -- Analyst\\nHi. Thanks for taking my questions and congratulations on the success during the quarter. Maybe firstly, could you just elaborate a little bit on the funnel of patients you have been seeing post the quarter within [Indecipherable]? And then secondly, can you just again elaborate on some of the positive shifts that have happened during COVID that you do think will be tailwinds to your business when we come out but in terms of realized world.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nYes, Brandon, I just want to make sure I got your question because in the first part, it broke up a little bit. The second part that I heard was positive shifts that will be tailwinds for us, but I didn't hear the first part.\\nBrandon Folkes -- Cantor Fitzgerald -- Analyst\\nCan you just elaborate on the funnel of patients you are seeing in July?\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nOkay. Well, what we have seen and have been really pleased with is that the surgeons who were active users have almost all, frankly, returned back to using AxoGen products. And so we don't have a leaky bucket in that respect of users continue to be users. And as their practices ramped back up, they ramped up in and using it at the same rate or, in some cases, even higher because there are we talk about benefits. There are benefits in a COVID environment to do an allograft or Avance as compared to an autograft. It is a much shorter surgical procedure time, there's less exposure.\\nYou can do wide-awake surgery versus surgery requiring anesthesia, in some cases, depending on the patient. All of those are healthy benefits for the hospital workers while providing good care for the patient. So we think there's real benefits in doing an allograft repair or an Avance repair in this environment. In terms of our funnel overall, to go back to your first part, we also had new users start to use our products, particularly in our active centers. So that's where we have our reps mostly focused is developing our footprint in places that we already have a strong surgeon user.\\nWe want to go deeper with that user and add in their partners. We are still adding some new active centers. So we'll see some of that in our pipeline, but the majority of our emphasis is going deeper in the centers that we're already in. And so we feel that the pipeline is good. And there remains strong interest in it. And we certainly saw that with the virtual education programs that we set up with new and developing surgeons and actually really outstanding engagement from surgeons wanting to be a part of that educational program.\\nIn terms of going forward and some of the benefits that we see from the environment we have here, I mentioned before the benefits of using Avance Nerve Graft as compared on autograft. It is there are safety benefits to the hospital staff because of reducing OR time and in some cases, being able to do wide-awake surgery. There are also the learned benefits that we talked about in terms of the digital marketing, the remote coverage. We think that those are really going to help us continue to expand our productivity of our existing sales team. And that they will pay benefits for the long term, allowing us to continue to grow in a cost-effective manner.\\nBrandon Folkes -- Cantor Fitzgerald -- Analyst\\nThank you very much. That was very helpful.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nGreat. Thank you.\\nOperator\\nAs there are no further questions left in the queue, I would like to turn the call back over to Karen Zaderej for any closing remarks.\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nThank you, Devin. I want to thank everyone for joining us on today's call. We look forward to speaking with many of you at the upcoming virtual conferences we're attending, including the Canaccord Genuity Growth Conference, August 11 through the 13th; the Morgan Stanley Global Healthcare Conference, September 14 through the 16th; and the Cantor Fitzgerald Global Healthcare Conference, September 15 through the 17th. Thank you.\\nOperator\\n[Operator Closing Remarks]\\nDuration: 40 minutes\\nCall participants:\\nPeter J. Mariani -- Chief Financial Officer\\nKaren Zaderej -- Chairman, Chief Executive Officer, and President\\nRaj Denhoy -- Jefferies -- Analyst\\nDan Stauder -- JMP Securities -- Analyst\\nJamie -- SVB Leerink -- Analyst\\nBrandon Folkes -- Cantor Fitzgerald -- Analyst\\nMore AXGN analysis\\nAll earnings call transcripts\\n\\n\\n\\n\\n\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Timestamp\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 4751,\n        \"samples\": [\n          \"2022-08-18 08:00:00\",\n          \"2023-01-05 09:30:00\",\n          \"2021-01-26 09:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Date_only\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 804,\n        \"samples\": [\n          \"2022-02-17\",\n          \"2022-01-21\",\n          \"2020-07-20\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"word_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2520,\n        \"min\": 571,\n        \"max\": 32540,\n        \"num_unique_values\": 7264,\n        \"samples\": [\n          2920,\n          9656,\n          5206\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Price_change\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.08033506333874547,\n        \"min\": -0.7976,\n        \"max\": 0.7156863065922738,\n        \"num_unique_values\": 14057,\n        \"samples\": [\n          -0.1235294342041015,\n          -0.010693407694988,\n          0.001805411461732\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Target_Class\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"Neutral\",\n          \"Gain\",\n          \"Loss\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"DateOfWeek\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1,\n        \"min\": 0,\n        \"max\": 6,\n        \"num_unique_values\": 7,\n        \"samples\": [\n          3,\n          2,\n          4\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Month\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 3,\n        \"min\": 1,\n        \"max\": 12,\n        \"num_unique_values\": 12,\n        \"samples\": [\n          12,\n          5,\n          8\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Quarter\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1,\n        \"min\": 1,\n        \"max\": 4,\n        \"num_unique_values\": 4,\n        \"samples\": [\n          4,\n          2,\n          3\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"FinBERT_Positive\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.3164153188473483,\n        \"min\": 0.008341541513800621,\n        \"max\": 0.9573535919189453,\n        \"num_unique_values\": 14091,\n        \"samples\": [\n          0.17113450169563293,\n          0.841820240020752,\n          0.019909732043743134\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"FinBERT_Negative\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.15204690754807296,\n        \"min\": 0.007195898797363043,\n        \"max\": 0.9723434448242188,\n        \"num_unique_values\": 14091,\n        \"samples\": [\n          0.011472414247691631,\n          0.013853976503014565,\n          0.02732784114778042\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"FinBERT_Neutral\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.33126945587937723,\n        \"min\": 0.013258830644190311,\n        \"max\": 0.9523656368255615,\n        \"num_unique_values\": 14067,\n        \"samples\": [\n          0.457214891910553,\n          0.16305600106716156,\n          0.06764431297779083\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker_clean\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2271,\n        \"samples\": [\n          \"EGRX\",\n          \"ES\",\n          \"APD\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 9
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_analysis.columns"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "0VTl8qy3Oiue",
        "outputId": "4fd5fb27-afef-4855-91e6-9f7db4fd3ae5"
      },
      "execution_count": 10,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Index(['date', 'exchange', 'q', 'ticker', 'transcript', 'Timestamp',\n",
              "       'Date_only', 'word_count', 'Price_change', 'Target_Class', 'DateOfWeek',\n",
              "       'Month', 'Quarter', 'FinBERT_Positive', 'FinBERT_Negative',\n",
              "       'FinBERT_Neutral', 'ticker_clean'],\n",
              "      dtype='object')"
            ]
          },
          "metadata": {},
          "execution_count": 10
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "path=\"/content/drive/MyDrive/Earnings Call Prediction/Dataframe_after_finbert.csv\"\n",
        "df_analysis.to_csv(path,index=False)"
      ],
      "metadata": {
        "id": "Yp7ZmVH0O4-L"
      },
      "execution_count": 11,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.model_selection import train_test_split\n",
        "cols_to_drop = [\n",
        "    \"Target_Class\",\n",
        "    \"Price_change\",\n",
        "    \"Date_only\",\n",
        "    \"date\",\n",
        "    \"Timestamp\",\n",
        "    \"transcript\",\n",
        "    \"exchange\",\n",
        "    \"q\",\n",
        "    \"ticker\",\n",
        "    \"word_count\"\n",
        "]\n",
        "\n",
        "X = df_analysis.drop(columns=[c for c in cols_to_drop if c in df_analysis.columns])\n",
        "y = df_analysis[\"Target_Class\"]\n",
        "\n",
        "X_train, X_test, y_train, y_test = train_test_split(\n",
        "    X,\n",
        "    y,\n",
        "    test_size=0.3,\n",
        "    random_state=42,\n",
        "    stratify=y\n",
        ")\n",
        "\n",
        "print(f\"Training data size: {len(X_train)}\")\n",
        "print(f\"Test data size: {len(X_test)}\")\n",
        "print(\"\\nFinal Features in X_train:\", X_train.columns.tolist())"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "S_2de7oMPQww",
        "outputId": "124f6480-a25a-40d2-bbf6-80c928c496a6"
      },
      "execution_count": 12,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Training data size: 10538\n",
            "Test data size: 4517\n",
            "\n",
            "Final Features in X_train: ['DateOfWeek', 'Month', 'Quarter', 'FinBERT_Positive', 'FinBERT_Negative', 'FinBERT_Neutral', 'ticker_clean']\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "train_df = pd.concat([X_train, y_train], axis=1)\n",
        "test_df = pd.concat([X_test, y_test], axis=1)\n",
        "train_path=\"/content/drive/MyDrive/Earnings Call Prediction/train_dataset.csv\"\n",
        "test_path=\"/content/drive/MyDrive/Earnings Call Prediction/test_dataset.csv\"\n",
        "train_df.to_csv(train_path, index=False)\n",
        "test_df.to_csv(test_path, index=False)\n",
        "\n",
        "print(\"Train and Test datasets saved successfully!\")\n",
        "print(f\"Train shape: {train_df.shape}\")\n",
        "print(f\"Test shape: {test_df.shape}\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "nwMH1tG1QsSK",
        "outputId": "4ae8ca2c-cd56-45d4-f617-4eb48394232c"
      },
      "execution_count": 14,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Train and Test datasets saved successfully!\n",
            "Train shape: (10538, 8)\n",
            "Test shape: (4517, 8)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install category_encoders\n",
        "from category_encoders import TargetEncoder\n",
        "\n",
        "gain_encoder = TargetEncoder(cols=['ticker_clean'])\n",
        "loss_encoder = TargetEncoder(cols=['ticker_clean'])\n",
        "\n",
        "y_train_gain = (y_train == 'Gain').astype(int)\n",
        "y_train_loss = (y_train == 'Loss').astype(int)\n",
        "\n",
        "# FITTING on X_train, TRANSFORM X_train\n",
        "X_train['Ticker_Gain_Prob'] = gain_encoder.fit_transform(X_train['ticker_clean'], y_train_gain)\n",
        "X_train['Ticker_Loss_Prob'] = loss_encoder.fit_transform(X_train['ticker_clean'], y_train_loss)\n",
        "\n",
        "# TRANSFORM X_test\n",
        "X_test['Ticker_Gain_Prob'] = gain_encoder.transform(X_test['ticker_clean'])\n",
        "X_test['Ticker_Loss_Prob'] = loss_encoder.transform(X_test['ticker_clean'])\n",
        "\n",
        "X_train.drop(columns=['ticker_clean'], inplace=True)\n",
        "X_test.drop(columns=['ticker_clean'], inplace=True)\n",
        "\n",
        "print(\"Target Encoding done correctly! No data leakage.\")\n",
        "print(\"X_train columns:\", X_train.columns.tolist())"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "wYjMXRmeKmcW",
        "outputId": "593f4263-cc1d-4643-a90e-30b4c78beda3"
      },
      "execution_count": 15,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting category_encoders\n",
            "  Downloading category_encoders-2.9.0-py3-none-any.whl.metadata (7.9 kB)\n",
            "Requirement already satisfied: numpy>=1.14.0 in /usr/local/lib/python3.12/dist-packages (from category_encoders) (2.0.2)\n",
            "Requirement already satisfied: pandas>=1.0.5 in /usr/local/lib/python3.12/dist-packages (from category_encoders) (2.2.2)\n",
            "Collecting patsy>=0.5.1 (from category_encoders)\n",
            "  Downloading patsy-1.0.2-py2.py3-none-any.whl.metadata (3.6 kB)\n",
            "Requirement already satisfied: scikit-learn>=1.6.0 in /usr/local/lib/python3.12/dist-packages (from category_encoders) (1.6.1)\n",
            "Requirement already satisfied: scipy>=1.0.0 in /usr/local/lib/python3.12/dist-packages (from category_encoders) (1.16.3)\n",
            "Collecting statsmodels>=0.9.0 (from category_encoders)\n",
            "  Downloading statsmodels-0.14.5-cp312-cp312-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl.metadata (9.5 kB)\n",
            "Requirement already satisfied: python-dateutil>=2.8.2 in /usr/local/lib/python3.12/dist-packages (from pandas>=1.0.5->category_encoders) (2.9.0.post0)\n",
            "Requirement already satisfied: pytz>=2020.1 in /usr/local/lib/python3.12/dist-packages (from pandas>=1.0.5->category_encoders) (2025.2)\n",
            "Requirement already satisfied: tzdata>=2022.7 in /usr/local/lib/python3.12/dist-packages (from pandas>=1.0.5->category_encoders) (2025.2)\n",
            "Requirement already satisfied: joblib>=1.2.0 in /usr/local/lib/python3.12/dist-packages (from scikit-learn>=1.6.0->category_encoders) (1.5.2)\n",
            "Requirement already satisfied: threadpoolctl>=3.1.0 in /usr/local/lib/python3.12/dist-packages (from scikit-learn>=1.6.0->category_encoders) (3.6.0)\n",
            "Requirement already satisfied: packaging>=21.3 in /usr/local/lib/python3.12/dist-packages (from statsmodels>=0.9.0->category_encoders) (25.0)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.12/dist-packages (from python-dateutil>=2.8.2->pandas>=1.0.5->category_encoders) (1.17.0)\n",
            "Downloading category_encoders-2.9.0-py3-none-any.whl (85 kB)\n",
            "\u001b[2K   \u001b[90m\u001b[0m \u001b[32m85.9/85.9 kB\u001b[0m \u001b[31m4.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading patsy-1.0.2-py2.py3-none-any.whl (233 kB)\n",
            "\u001b[2K   \u001b[90m\u001b[0m \u001b[32m233.3/233.3 kB\u001b[0m \u001b[31m13.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading statsmodels-0.14.5-cp312-cp312-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl (10.4 MB)\n",
            "\u001b[2K   \u001b[90m\u001b[0m \u001b[32m10.4/10.4 MB\u001b[0m \u001b[31m133.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: patsy, statsmodels, category_encoders\n",
            "Successfully installed category_encoders-2.9.0 patsy-1.0.2 statsmodels-0.14.5\n",
            "Target Encoding done correctly! No data leakage.\n",
            "X_train columns: ['DateOfWeek', 'Month', 'Quarter', 'FinBERT_Positive', 'FinBERT_Negative', 'FinBERT_Neutral', 'Ticker_Gain_Prob', 'Ticker_Loss_Prob']\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# **5.Feature Scaling**"
      ],
      "metadata": {
        "id": "24bQFuu8TVP1"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.preprocessing import StandardScaler\n",
        "import joblib\n",
        "\n",
        "scaler = StandardScaler()\n",
        "\n",
        "# Fitting on Train, Transforming Train\n",
        "X_train_scaled = scaler.fit_transform(X_train)\n",
        "# Transforming Test\n",
        "X_test_scaled = scaler.transform(X_test)\n",
        "\n",
        "X_train_scaled = pd.DataFrame(X_train_scaled, columns=X_train.columns)\n",
        "X_test_scaled = pd.DataFrame(X_test_scaled, columns=X_test.columns)\n",
        "print(\"Data Scaling Complete.\")\n",
        "\n",
        "# SAVING THE COMPONENTS for Streamlit ---\n",
        "# Save Encoders\n",
        "joblib.dump(gain_encoder, 'ticker_gain_encoder.joblib')\n",
        "joblib.dump(loss_encoder, 'ticker_loss_encoder.joblib')\n",
        "# Save Scaler (\n",
        "joblib.dump(scaler, 'standard_scaler.joblib')\n",
        "\n",
        "print(\"Encoders and Scaler saved to .joblib files.\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "GfclUf4XS6gO",
        "outputId": "db4770bc-9e3d-45d0-a160-43cb47ee803b"
      },
      "execution_count": 16,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Data Scaling Complete.\n",
            "Encoders and Scaler saved to .joblib files.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "\n",
        "train_final_df=X_train_scaled.copy()\n",
        "test_final_df=X_test_scaled.copy()\n",
        "\n",
        "# Adding the Target column to them to save\n",
        "train_final_df['Target_Class'] = y_train.reset_index(drop=True)\n",
        "test_final_df['Target_Class'] = y_test.reset_index(drop=True)\n",
        "\n",
        "train_final_df.to_csv(\"/content/drive/MyDrive/Earnings Call Prediction/train_scaled_ready.csv\", index=False)\n",
        "test_final_df.to_csv(\"/content/drive/MyDrive/Earnings Call Prediction/test_scaled_ready.csv\", index=False)\n",
        "\n",
        "print(\"Scaled data saved! You are safe to start Hyperparameter Tuning.\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "sDmZVUMQVJQh",
        "outputId": "aa10d6b5-1356-462e-d250-2d60a2692fb3"
      },
      "execution_count": 19,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Scaled data saved! You are safe to start Hyperparameter Tuning.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# **6 Model Training**"
      ],
      "metadata": {
        "id": "dIMxcka3W9zQ"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install xgboost\n",
        "from sklearn.preprocessing import LabelEncoder\n",
        "from sklearn.model_selection import RandomizedSearchCV\n",
        "from xgboost import XGBClassifier\n",
        "import joblib\n",
        "\n",
        "# Encoding Target Labels (Gain/Loss/Neutral -> 0/1/2)\n",
        "le = LabelEncoder()\n",
        "y_train_encoded = le.fit_transform(y_train)\n",
        "y_test_encoded = le.transform(y_test)\n",
        "\n",
        "# Saving the Label Encoder for streamlit\n",
        "joblib.dump(le, 'target_label_encoder.joblib')\n",
        "print(\"Target Labels encoded and encoder saved.\")\n",
        "\n",
        "# Hyperparameter Grid\n",
        "param_grid = {\n",
        "    'n_estimators': [100, 200, 300],\n",
        "    'learning_rate': [0.01, 0.05, 0.1, 0.2],\n",
        "    'max_depth': [3, 4, 5, 6, 8],\n",
        "    'min_child_weight': [1, 3, 5, 7],\n",
        "    'subsample': [0.6, 0.8, 1.0],\n",
        "    'colsample_bytree': [0.6, 0.8, 1.0],\n",
        "    'gamma': [0, 0.1, 0.2]\n",
        "}\n",
        "\n",
        "# Initializing the Model\n",
        "xgb = XGBClassifier(\n",
        "    objective='multi:softprob',\n",
        "    num_class=3,\n",
        "    random_state=42,\n",
        "    eval_metric='mlogloss'\n",
        ")\n",
        "\n",
        "#Randomized Search\n",
        "random_search = RandomizedSearchCV(\n",
        "    estimator=xgb,\n",
        "    param_distributions=param_grid,\n",
        "    n_iter=50,\n",
        "    scoring='f1_weighted',\n",
        "    cv=5,\n",
        "    verbose=1,\n",
        "    random_state=42,\n",
        "    n_jobs=-1\n",
        ")\n",
        "\n",
        "print(\"Starting Hyperparameter Tuning...\")\n",
        "random_search.fit(X_train_scaled, y_train_encoded)\n",
        "\n",
        "print(\"\\nTuning Complete!\")\n",
        "print(f\"Best Parameters: {random_search.best_params_}\")\n",
        "print(f\"Best Weighted F1-Score: {random_search.best_score_:.4f}\")\n",
        "\n",
        "# Saving the Best Model\n",
        "best_model = random_search.best_estimator_\n",
        "joblib.dump(best_model, 'final_xgb_model.joblib')\n",
        "print(\"Best model saved as 'final_xgb_model.joblib'\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "IWQJ2fC0UwIL",
        "outputId": "e113d276-70bc-45b7-d9d3-ce7523c2d1e1"
      },
      "execution_count": 21,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting xgboost\n",
            "  Downloading xgboost-3.1.2-py3-none-manylinux_2_28_x86_64.whl.metadata (2.1 kB)\n",
            "Requirement already satisfied: numpy in /usr/local/lib/python3.12/dist-packages (from xgboost) (2.0.2)\n",
            "Collecting nvidia-nccl-cu12 (from xgboost)\n",
            "  Downloading nvidia_nccl_cu12-2.28.9-py3-none-manylinux_2_18_x86_64.whl.metadata (2.0 kB)\n",
            "Requirement already satisfied: scipy in /usr/local/lib/python3.12/dist-packages (from xgboost) (1.16.3)\n",
            "Downloading xgboost-3.1.2-py3-none-manylinux_2_28_x86_64.whl (115.9 MB)\n",
            "\u001b[2K   \u001b[90m\u001b[0m \u001b[32m115.9/115.9 MB\u001b[0m \u001b[31m8.6 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading nvidia_nccl_cu12-2.28.9-py3-none-manylinux_2_18_x86_64.whl (296.8 MB)\n",
            "\u001b[2K   \u001b[90m\u001b[0m \u001b[32m296.8/296.8 MB\u001b[0m \u001b[31m1.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: nvidia-nccl-cu12, xgboost\n",
            "Successfully installed nvidia-nccl-cu12-2.28.9 xgboost-3.1.2\n",
            "Target Labels encoded and encoder saved.\n",
            "Starting Hyperparameter Tuning...\n",
            "Fitting 5 folds for each of 50 candidates, totalling 250 fits\n",
            "\n",
            "Tuning Complete!\n",
            "Best Parameters: {'subsample': 0.6, 'n_estimators': 200, 'min_child_weight': 5, 'max_depth': 5, 'learning_rate': 0.05, 'gamma': 0, 'colsample_bytree': 0.8}\n",
            "Best Weighted F1-Score: 0.6920\n",
            "Best model saved as 'final_xgb_model.joblib'\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "X_train_scaled.shape"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "qNkoCUpIYopL",
        "outputId": "b4d50586-10e1-4dcf-df93-96ff2fbc8094"
      },
      "execution_count": 22,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "(10538, 8)"
            ]
          },
          "metadata": {},
          "execution_count": 22
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# **7 Model Testing and Evaluation**"
      ],
      "metadata": {
        "id": "hzQhNlzJZLek"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.metrics import classification_report, confusion_matrix\n",
        "import seaborn as sns\n",
        "import matplotlib.pyplot as plt\n",
        "\n",
        "y_pred = best_model.predict(X_test_scaled)\n",
        "# Converting numerical predictions back to labels (0/1/2 -> Gain/Loss/Neutral)\n",
        "y_test_decoded = le.inverse_transform(y_test_encoded)\n",
        "y_pred_decoded = le.inverse_transform(y_pred)\n",
        "\n",
        "print(\"\\n--- FINAL CLASSIFICATION REPORT ---\")\n",
        "print(classification_report(y_test_decoded, y_pred_decoded))\n",
        "\n",
        "cm = confusion_matrix(y_test_decoded, y_pred_decoded, labels=['Gain', 'Loss', 'Neutral'])\n",
        "plt.figure(figsize=(8, 6))\n",
        "sns.heatmap(cm, annot=True, fmt='d', cmap='Blues',\n",
        "            xticklabels=['Gain', 'Loss', 'Neutral'],\n",
        "            yticklabels=['Gain', 'Loss', 'Neutral'])\n",
        "plt.xlabel('Predicted')\n",
        "plt.ylabel('Actual')\n",
        "plt.title('Confusion Matrix')\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 772
        },
        "id": "XPBQAgjhZJ6V",
        "outputId": "1f349d81-aed4-404d-8e74-f4394d63370a"
      },
      "execution_count": 23,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "--- FINAL CLASSIFICATION REPORT ---\n",
            "              precision    recall  f1-score   support\n",
            "\n",
            "        Gain       0.33      0.24      0.28       856\n",
            "        Loss       0.34      0.28      0.31       869\n",
            "     Neutral       0.70      0.79      0.74      2792\n",
            "\n",
            "    accuracy                           0.59      4517\n",
            "   macro avg       0.46      0.44      0.44      4517\n",
            "weighted avg       0.56      0.59      0.57      4517\n",
            "\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 800x600 with 2 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# **8 Feature Importance**"
      ],
      "metadata": {
        "id": "dvj7Tn_3fk3v"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "import matplotlib.pyplot as plt\n",
        "import seaborn as sns\n",
        "importances = best_model.feature_importances_\n",
        "\n",
        "# Mapping scores to column names\n",
        "feature_names = X_train.columns\n",
        "feature_importance_df = pd.DataFrame({\n",
        "    'Feature': feature_names,\n",
        "    'Importance': importances\n",
        "}).sort_values(by='Importance', ascending=False)\n",
        "\n",
        "# Visualize\n",
        "plt.figure(figsize=(10, 6))\n",
        "sns.barplot(x='Importance', y='Feature', data=feature_importance_df.head(10), palette='viridis')\n",
        "plt.title('Top 10 Most Important Features for Predicting Stock Movement')\n",
        "plt.xlabel('Importance Score')\n",
        "plt.ylabel('Feature Name')\n",
        "plt.show()\n",
        "\n",
        "# Printing the raw data\n",
        "print(feature_importance_df.head(10))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 792
        },
        "id": "f7y3LBsFaZui",
        "outputId": "4be61d0a-2c68-41bc-8039-5b112c0a2d21"
      },
      "execution_count": 25,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/tmp/ipython-input-895659390.py:15: FutureWarning: \n",
            "\n",
            "Passing `palette` without assigning `hue` is deprecated and will be removed in v0.14.0. Assign the `y` variable to `hue` and set `legend=False` for the same effect.\n",
            "\n",
            "  sns.barplot(x='Importance', y='Feature', data=feature_importance_df.head(10), palette='viridis')\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1000x600 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "            Feature  Importance\n",
            "7  Ticker_Loss_Prob    0.351759\n",
            "6  Ticker_Gain_Prob    0.328649\n",
            "2           Quarter    0.061243\n",
            "1             Month    0.052867\n",
            "3  FinBERT_Positive    0.052172\n",
            "4  FinBERT_Negative    0.051892\n",
            "5   FinBERT_Neutral    0.051033\n",
            "0        DateOfWeek    0.050384\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# **10 Threshold Tuning**"
      ],
      "metadata": {
        "id": "J83DSxaTgIU3"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import numpy as np\n",
        "import matplotlib.pyplot as plt\n",
        "from sklearn.metrics import precision_score, recall_score\n",
        "\n",
        "# Getting Probabilities instead of Class Labels\n",
        "# This returns an array with 3 columns: [Prob_Gain, Prob_Loss, Prob_Neutral]\n",
        "y_probs = best_model.predict_proba(X_test_scaled)\n",
        "\n",
        "print(f\"Class Order: {le.classes_}\")\n",
        "gain_index = np.where(le.classes_ == 'Gain')[0][0]\n",
        "\n",
        "# Testing Thresholds from 0.3 to 0.9\n",
        "thresholds = np.arange(0.3, 0.95, 0.05)\n",
        "precisions = []\n",
        "recalls = []\n",
        "\n",
        "# Ground truth for Gain (Binary: 1 if Gain, 0 if Loss/Neutral)\n",
        "y_test_gain_binary = (y_test_decoded == 'Gain').astype(int)\n",
        "\n",
        "for t in thresholds:\n",
        "    # If Prob_Gain > t, predict 1, else 0\n",
        "    custom_preds = (y_probs[:, gain_index] >= t).astype(int)\n",
        "    # Calculating scores\n",
        "    if np.sum(custom_preds) > 0: # Avoid division by zero\n",
        "        p = precision_score(y_test_gain_binary, custom_preds)\n",
        "        r = recall_score(y_test_gain_binary, custom_preds)\n",
        "    else:\n",
        "        p = 1.0\n",
        "        r = 0.0\n",
        "\n",
        "    precisions.append(p)\n",
        "    recalls.append(r)\n",
        "\n",
        "# Plotting the Trade-off of Precision and Recall\n",
        "plt.figure(figsize=(10, 6))\n",
        "plt.plot(thresholds, precisions, label='Precision (Win Rate)', marker='o', color='green')\n",
        "plt.plot(thresholds, recalls, label='Recall (Opportunity Capture)', marker='x', color='blue')\n",
        "plt.title('Impact of Confidence Threshold on Trading Performance')\n",
        "plt.xlabel('Probability Threshold required to predict \"Gain\"')\n",
        "plt.ylabel('Score')\n",
        "plt.legend()\n",
        "plt.grid(True)\n",
        "plt.show()\n",
        "\n",
        "\n",
        "for t, p, r in zip(thresholds, precisions, recalls):\n",
        "    print(f\"Threshold: {t:.2f} | Precision: {p:.2f} | Recall: {r:.2f}\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 807
        },
        "id": "_AkZs_Q5bXR5",
        "outputId": "b94e03ac-561c-4f83-b11e-d9a22cc78101"
      },
      "execution_count": 26,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Class Order: ['Gain' 'Loss' 'Neutral']\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1000x600 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Threshold: 0.30 | Precision: 0.30 | Recall: 0.40\n",
            "Threshold: 0.35 | Precision: 0.31 | Recall: 0.34\n",
            "Threshold: 0.40 | Precision: 0.33 | Recall: 0.28\n",
            "Threshold: 0.45 | Precision: 0.34 | Recall: 0.23\n",
            "Threshold: 0.50 | Precision: 0.37 | Recall: 0.18\n",
            "Threshold: 0.55 | Precision: 0.40 | Recall: 0.13\n",
            "Threshold: 0.60 | Precision: 0.43 | Recall: 0.11\n",
            "Threshold: 0.65 | Precision: 0.41 | Recall: 0.08\n",
            "Threshold: 0.70 | Precision: 0.43 | Recall: 0.06\n",
            "Threshold: 0.75 | Precision: 0.42 | Recall: 0.05\n",
            "Threshold: 0.80 | Precision: 0.43 | Recall: 0.04\n",
            "Threshold: 0.85 | Precision: 0.43 | Recall: 0.04\n",
            "Threshold: 0.90 | Precision: 0.46 | Recall: 0.03\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "**Download Files and get versions for Streamlit**"
      ],
      "metadata": {
        "id": "610EFqXNfRVo"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import os\n",
        "import zipfile\n",
        "from IPython.display import FileLink\n",
        "\n",
        "files_to_download = [\n",
        "    'final_xgb_model.joblib',\n",
        "    'standard_scaler.joblib',\n",
        "    'target_label_encoder.joblib',\n",
        "    'ticker_gain_encoder.joblib',\n",
        "    'ticker_loss_encoder.joblib',\n",
        "    'cleaned_stock_data.csv'\n",
        "]\n",
        "\n",
        "zip_filename = 'project_artifacts.zip'\n",
        "\n",
        "print(f\"Zipping {len(files_to_download)} files into '{zip_filename}'...\")\n",
        "missing_files = []\n",
        "\n",
        "with zipfile.ZipFile(zip_filename, 'w') as zipf:\n",
        "    for file in files_to_download:\n",
        "        if os.path.exists(file):\n",
        "            zipf.write(file)\n",
        "            print(f\"  - Added: {file}\")\n",
        "        else:\n",
        "            missing_files.append(file)\n",
        "            print(f\"Warning: '{file}' not found. Did you save it?\")\n",
        "\n",
        "if len(missing_files) == len(files_to_download):\n",
        "    print(\"\\nError: No files found to zip. Please re-run the saving steps.\")\n",
        "else:\n",
        "    print(f\"\\nZip file created: {zip_filename}\")\n",
        "    try:\n",
        "        from google.colab import files\n",
        "        files.download(zip_filename)\n",
        "        print(\"Downloading via Google Colab...\")\n",
        "    except ImportError:\n",
        "        print(\"Kaggle Detected. Click the link below to download:\")\n",
        "        display(FileLink(zip_filename))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 191
        },
        "id": "CwAC5ix5eNGa",
        "outputId": "1478ff75-5a51-4d85-9ef8-988af6ae96b6"
      },
      "execution_count": 28,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Zipping 6 files into 'project_artifacts.zip'...\n",
            "  - Added: final_xgb_model.joblib\n",
            "  - Added: standard_scaler.joblib\n",
            "  - Added: target_label_encoder.joblib\n",
            "  - Added: ticker_gain_encoder.joblib\n",
            "  - Added: ticker_loss_encoder.joblib\n",
            "Warning: 'cleaned_stock_data.csv' not found. Did you save it?\n",
            "\n",
            "Zip file created: project_artifacts.zip\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.Javascript object>"
            ],
            "application/javascript": [
              "\n",
              "    async function download(id, filename, size) {\n",
              "      if (!google.colab.kernel.accessAllowed) {\n",
              "        return;\n",
              "      }\n",
              "      const div = document.createElement('div');\n",
              "      const label = document.createElement('label');\n",
              "      label.textContent = `Downloading \"${filename}\": `;\n",
              "      div.appendChild(label);\n",
              "      const progress = document.createElement('progress');\n",
              "      progress.max = size;\n",
              "      div.appendChild(progress);\n",
              "      document.body.appendChild(div);\n",
              "\n",
              "      const buffers = [];\n",
              "      let downloaded = 0;\n",
              "\n",
              "      const channel = await google.colab.kernel.comms.open(id);\n",
              "      // Send a message to notify the kernel that we're ready.\n",
              "      channel.send({})\n",
              "\n",
              "      for await (const message of channel.messages) {\n",
              "        // Send a message to notify the kernel that we're ready.\n",
              "        channel.send({})\n",
              "        if (message.buffers) {\n",
              "          for (const buffer of message.buffers) {\n",
              "            buffers.push(buffer);\n",
              "            downloaded += buffer.byteLength;\n",
              "            progress.value = downloaded;\n",
              "          }\n",
              "        }\n",
              "      }\n",
              "      const blob = new Blob(buffers, {type: 'application/binary'});\n",
              "      const a = document.createElement('a');\n",
              "      a.href = window.URL.createObjectURL(blob);\n",
              "      a.download = filename;\n",
              "      div.appendChild(a);\n",
              "      a.click();\n",
              "      div.remove();\n",
              "    }\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.Javascript object>"
            ],
            "application/javascript": [
              "download(\"download_5dc053e3-bff5-4d44-ba63-27901d6efea6\", \"project_artifacts.zip\", 1504845)"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Downloading via Google Colab...\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import xgboost\n",
        "import sklearn\n",
        "import joblib\n",
        "print(f\"XGBoost Version: {xgboost.__version__}\")\n",
        "print(f\"Scikit-Learn Version: {sklearn.__version__}\")\n",
        "print(f\"Joblib Version: {joblib.__version__}\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "xvToeIZOaEtp",
        "outputId": "631c2ae7-c08e-41a4-a086-ade4d68c0d43"
      },
      "execution_count": 24,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "XGBoost Version: 3.1.2\n",
            "Scikit-Learn Version: 1.6.1\n",
            "Joblib Version: 1.5.2\n"
          ]
        }
      ]
    }
  ],
  "metadata": {
    "accelerator": "TPU",
    "colab": {
      "gpuType": "V5E1",
      "provenance": [],
      "toc_visible": true
    },
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "name": "python"
    },
    "widgets": {
      "application/vnd.jupyter.widget-state+json": {
        "e96c58d8348645f4beb6d3a2c2e60c3a": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_81cd2bfe800e4ea9a3abf8e57f50e032",
              "IPY_MODEL_2864e3bbf8b54e6c9ca0da602e4f4ebd",
              "IPY_MODEL_187aafbcb3ab4561ba717cea3af54c63"
            ],
            "layout": "IPY_MODEL_130cfb6d4d87487c9c1aa5ea54644be9"
          }
        },
        "81cd2bfe800e4ea9a3abf8e57f50e032": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_7112badf528a4bdea60a25064fb2cd5e",
            "placeholder": "",
            "style": "IPY_MODEL_bb55b537c03a4a43ab98dda45e8c5f79",
            "value": "100%"
          }
        },
        "2864e3bbf8b54e6c9ca0da602e4f4ebd": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_04779e4827774f58b58a579d0f779b01",
            "max": 471,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_9002657615ce465f9e55d076e27defd0",
            "value": 471
          }
        },
        "187aafbcb3ab4561ba717cea3af54c63": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_962093db2760463786e5a86a96d255a8",
            "placeholder": "",
            "style": "IPY_MODEL_71de8006d55c406c9222ad3f8dcecb14",
            "value": "471/471[08:45&lt;00:00,1.11it/s]"
          }
        },
        "130cfb6d4d87487c9c1aa5ea54644be9": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "7112badf528a4bdea60a25064fb2cd5e": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "bb55b537c03a4a43ab98dda45e8c5f79": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "04779e4827774f58b58a579d0f779b01": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "9002657615ce465f9e55d076e27defd0": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "962093db2760463786e5a86a96d255a8": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "71de8006d55c406c9222ad3f8dcecb14": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        }
      }
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}